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The purpose of this investigation was to evaluate the effects of smoking and 
gender on 1) tetrahydroisoquinolines (TIQs) and β-carbolines (BCs) in a population of 
healthy subjects and 2) TIQ’s in an alcohol-dependent population undergoing in-patient 
detoxification. Comparison in plasma TIQ’s between the populations was additionally 
conducted.  To support the clinical investigations, a HPLC-FD method was developed 
and validated to assess plasma concentrations of BCs, harman and norharman, while a 
HPLC-ESI-MS/MS method was validated to quantify the TIQ’s, R/S-salsolinol along 
xxxiv 
xxxv 
with dopamine.  Forty-one young volunteers were recruited including 19 nonsmokers 
(NS), 11 light smokers (LS) and 11 heavy smokers (HS), stratified by their smoking 
history.  Each group had, at least, 5 males and females.  Plasma samples were obtained 
for analyte measurement within 30 minutes of smoking for LS and HS groups.  Two–
way ANCOVA was performed on the log-transformed concentrations.  Significant 
differences were found between HS-NS and LS-NS in analyte concentrations.  A 
comparison to eighteen subjects (6 NS, LS and HS) abstaining from smoking for 15 
hours resulted in a difference only between NS and HS, suggesting that acute tobacco 
smoking has a major influence on circulating TIQs and BCs between smoking status 
groups.   In a study involving thirty-five alcohol dependent subjects (12 NS, 11 LS, and 
12 HS, balanced with gender), TIQ measurements were taken on day 1, 2, 3, 8 and 15 of 
inpatient detoxification.  A significant effect of time was observed, with TIQ 
concentrations slightly increasing from admission to day 15.  Both factors of smoking 
status and gender did not have a significant effect on plasma TIQ’s at any of the time 
points evaluated.   Although, measures of acute and chronic alcohol intake had no effect 
on TIQ levels, liver function showed moderate correlation with plasma TIQ’s.  
Comparison of both populations showed that alcoholics had a lower average TIQ 
concentration than healthy subjects.    The results indicate that smoking status 1) has an 
effect on plasma TIQs and BCs in healthy individuals and 2) does not have an effect in 
alcoholics during detoxification.  The alcoholics possessed lower TIQ concentrations 
than the healthy subjects.  No gender effect was observed in either study. 
 
  
 
 
 
 
 
 
CHAPTER 1  
INTRODUCTION AND BACKGROUND 
 
 
 
1.1. Introduction 
Alcohol and nicotine, the most frequently abused drugs, are likely also the most 
costly drugs in terms of health and societal costs.  It is estimated that there are 15.1 
million alcohol-abusing or alcohol-dependent individuals (approx 1 in 18 or 5.55%)  in 
the United States (Allen et al., 2004).    Alcoholism is a chronic, often progressive 
disease with symptoms that consist of a strong need to drink regardless of negative 
consequences.  Like many other diseases, it has a generally predictable course, has 
recognized symptoms, and is influenced by both genetic and environmental factors that 
are being increasingly well defined.  Although the prevalence is decreasing, 
approximately 20.8% of the US population aged 18 years or older, are current smokers. 
Tobacco use kills nearly half a million Americans each year, with one in every six U.S. 
deaths is the result of smoking (Volkow, 2006).  
1 
2 
The co-occurrence of alcohol and nicotine dependence in people are common 
and well documented (Istvan and Matarazzo, 1984; Bien and Burge, 1990; Miller and 
Gold, 1998).  Several studies have established that the vast majority (80-90%) of 
alcoholics smoke at a prevalence that is about three times higher than amongst the 
population as a whole (Dreher and Fraser, 1967; Crowley et al., 1974; Burling et al., 
1982).  Conversely, smokers consume twice as much alcohol as do non-smokers, and 
alcoholism has been estimated to be 10-14 times more familiar among smokers than 
nonsmokers (DiFranza and Guerrera, 1990).  Furthermore, alcoholics who smoke use 
more cigarettes per day than do non-alcoholic smokers (Dawson, 2000).   The close 
interrelationship between smoking and alcohol use is also exemplified by the 
observation that smoking cessation is more difficult to attain in previous or current 
alcohol abusers (Bobo et al., 1987) and that successful smoking or alcohol cessation 
improves the likelihood of alcohol intake reduction (Miller et al., 1983) or smoking 
cessation (Burling et al., 1982),  respectively.  Major reasons are that concurrent alcohol 
use, and/or prior alcohol exposure, may modify the reinforcing effects of nicotine, and 
vice-versa, and that each drug becomes a pharmacological cue for the expectation of the 
other.   Results of the investigations on the relation of nicotine addiction and alcoholism 
suggest a synergism in the reinforcing properties of dependence. 
 
 
 
 
3 
1.2  Background 
1.2.1 Current Biomarkers for Smoking Dependence and Alcoholism 
In the clinical management of these problems, a critical necessity are effective 
and accurate biological markers that will enable clinicians to identify the extent of 
alcohol abuse and smoking dependence, as well as to monitor progress in treatment.  
Clinical laboratory procedures are commonly used to corroborate results of subjective 
patient interviews and clinical examinations when assessing drug dependence.  In recent 
years, inherited components in the etiology of certain aspects of drug abuse are widely 
acknowledged and, as a consequence, the searches for biomarkers have gained 
importance.  The markers of alcohol and smoking dependence may offer objective 
evidence of excessive dependence, especially in patients who deny their problems. 
Abusers of alcohol and tobacco may exhibit several clinical and/or chemical 
changes.   The more frequent the use of screening tests, combined with the use of new 
biochemical markers in patients who are suspected of alcohol abuse or tobacco use, will 
improve detection and permit intervention earlier in the course of illness.  In the case of 
alcoholism, establishment of several biomarker candidates for excessive alcohol use has 
been attempted, including aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), erythrocyte mean corpuscular volume (MCV), γ-glutamyl transferase (GGT), 
and Carbohydrate-deficient transferrin (CDT) (Yersin et al., 1995; Allen et al., 2004). 
Unfortunately, these current markers have variable sensitivity and/or low specificity 
(Moravcova et al., 2004).  CDT  has been reported to be the best laboratory marker of 
4 
the chronic alcohol abuse, but there are conflicting data on its accuracy and sensitivity 
(Stibler, 1991; Anton and Sillanaukee, 1996).  
In the case of smoking, an array of biomarkers of tobacco smoke exposure have 
been proposed.  Chemicals in tobacco smoke such as carbon monoxide or cyanide (the 
latter metabolized in the body to thiocyanate) can be measured in blood.  However, the 
levels of these chemicals are nonspecific, i.e., there are significant sources of carbon 
monoxide and cyanide, including the body's own metabolism, other than tobacco smoke 
exposure (Benowitz, 1999). Thus, these markers are both nonspecific and insensitive 
markers of tobacco smoke exposure.  Other markers that have been proposed to 
quantitate tobacco exposure consist of adducts of benzo[a]pyrene carcinogens to DNA 
(Binkova et al., 1995), 4-aminobiphenyl adducts to hemoglobin (Bartsch et al., 1990), 
adducts of polycyclic aromatic hydrocarbons (Crawford et al., 1994), urinary excretion 
of nicotine-derived nitrosoamines (Adikofer et al., 1984), and others.  Specificity and 
sensitivity to these markers have yet to be acceptable for clinical use.  The measurement 
of cotinine concentrations in biologic fluids has been used most widely by scientists to 
evaluate tobacco smoke exposure because cotinine reflects exposure to nicotine, which 
is almost specific to tobacco (Benowitz, 1996).  The specificity of cotinine as a marker 
of tobacco exposure may come into question as food sources may contribute to overall 
exposure of cotinine.  Moreover, cotinine is not a suitable marker in persons undergoing 
treatment with nicotine replacement therapy (e.g., gum, inhaler, transdermal patch). 
Therefore, substances present in tobacco or endogenously formed upon inhalation of 
tobacco, measurable in biological fluids, but not derived metabolically from nicotine 
5 
would be valuable for validating tobacco abstinence in persons undergoing nicotine 
replacement therapy. Additional benefit would come about if the biochemical 
measurement has implications in the mechanism by which smoking dependence and 
reinforcement transpires (i.e., causal repercussions).  
 Issues pertaining to alcohol and tobacco smoke exposure biomarkers primarily 
consist of a lack of sensitivity and specificity for the measurements.   Importantly, the 
current candidates for biomarkers generally consist of molecules presenting as result of 
insult to the natural physiology.   These types of markers may present false positive 
rates due to organ pathophysiology and may have a delayed quantifiable presentation in 
the body.   Although some of the aforementioned markers attempt to relate to the acute 
and chronic exposure of alcohol and/or cigarette smoke, none of the markers show a 
mechanistic relationship to the reinforcing aspects of alcohol and nicotine.   An 
understanding of the mechanism by which these drugs of abuse produce a reinforcing 
effect is essential to elucidate a biomarker with this type of characteristic.  
 
1.2.2 The “Reward” pathway 
 
During the past few decades, investigations on the molecular basis of alcohol 
and nicotine dependence and its etiology, per se, have concentrated on the discovery 
and validation of endogenous neurochemical factors.  Drugs of abuse, such as ethanol 
(Thielen et al., 2004; Rodd et al., 2005) and nicotine (Balfour, 1989; Rausch et al., 
1989; Crooks and Dwoskin, 1997; Staley et al., 2001)  exert numerous pharmacological 
effects through their interactions with various neurotransmitter and neuromodulator 
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systems.  Acute central nervous system (CNS) effects are mediated by different proteins 
and receptors, classically, the nicotinic acetylcholine receptors for nicotine and N-
methyl-D-aspartate (NMDA) and γ-amino butyric acid (GABA) for ethanol (Gamberino 
and Gold, 1999).  Tobacco smoke and alcohol intake are known to cause major acute 
and chronic neurochemical adaptations in the brain, including a profound enhancement 
of dopamine (DA) and serotonin (5-HT) transmission.  The increased neurotransmission 
of these biogenic amines, particularly in the nucleus accumbens of the 
mesocorticolimbic system, is central to mechanisms regulating CNS effects of both 
nicotine and alcohol (Gamberino and Gold, 1999).  Activation of DA and 5-HT 
transmission within the mesocorticolimbic pathways (dopaminergic system) has also 
been implicated in the reinforcing aspect of reward from natural stimuli (Groenewegen 
et al., 1991; Philips et al., 1991).   It is suggested that compounds that interact with the 
nucleus accumbens and the dopaminergic neurons within these pathways plays a 
significant role in drug dependence and in drug-seeking behavior.  In essence, this 
paradigm states that the pharmacological effect of the drug along with increased levels 
of DA and 5-HT within this dopaminergic ‘reward’ pathway, give way to the 
reinforcing properties of substances of abuse. 
A primary means in which DA and 5-HT levels increase pertains to inhibition of 
monoamine oxidase (MAO) enzymes.  As the actions of catecholamines are terminated 
via MAO-metabolic transformation, inhibition of MAO (e.g., pargyline, nialamide) can 
cause an increase in the concentration of norepinephrine (NE), DA, and 5-HT in the 
postsynaptic membrane of the brain and other tissues accompanied by a variety of 
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pharmacological effects (Nicotra et al., 2004).   Both tobacco smokers and alcohol 
dependent subjects were reported to show a decrease in MAO activity in the brain and 
peripheral tissues. Several studies have illustrated that, in the alcoholic population, 
peripheral and central MAO-A and MAO-B activity is significantly decreased 
compared to control (Berggren et al., 2000; Coccini et al., 2002; Demir et al., 2002). In 
addition, researchers have found constituents in tobacco that inhibit both forms of 
monoamine oxidase, in-vitro (Berlin et al., 1995; Rose et al., 2001), and clinical studies 
have shown that ex-vivo MAO activity is lower in smokers than in nonsmokers 
(Norman et al., 1987; Ward et al., 1987; Berlin et al., 1995).  Both ethanol and nicotine, 
the pharmacologically active constituents of alcohol and tobacco, and corresponding 
immediate metabolites of both drugs, are not inhibitors of either MAO isoenzymes.   
Several studies exemplified that recently abstaining alcoholics produce higher 
circulating levels of acetaldehyde than control following ethanol administration 
(Collins, 1988).    In addition, peripheral levels of acetaldehyde in smokers are known 
to be higher than non-smokers and depend on the number of cigarettes smoked 
(McLaughlin et al., 1990).   Acetaldehyde is a highly reactive molecule that can react 
with many molecules via adduction, condensation and polymerization.   The by-
products of these reactions exert a wide variety of biological effects and 
neuropharmacological properties directly affecting psychological behavior.   It is 
plausible that levels of stable adducts, consequent from acetaldehyde condensation with 
biogenic amines, also may be increased in alcoholics and smokers consuming ethanol 
and smoking, thus serving in body fluids as biochemical markers that are more 
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persistent that acetaldehyde itself.    Moreover, these markers may provide a basis for 
the alcohol and nicotine seeking behavior seen in alcohol and smoking dependent 
individuals.   
Of note, two classes of endogenously-formed compounds, the 
tetrahydroisoquinolines (TIQ’s) and β-carbolines, have been indicted as chemicals that 
display MAO inhibition and are by-products associated with acetaldehyde from alcohol 
and tobacco smoke exposure.   There is also evidence that these classes of compounds 
are potent inhibitors of 5-HT, DA, and NE reuptake mechanisms, in-vitro (Airaksinen et 
al., 1980; Komulainen et al., 1980; McNaught et al., 1996).    Additional mechanisms 
that TIQ’s and β-carbolines may be implicated in dopaminergic system modulation 
include dopamine receptor regulation, enzyme activity inhibition (e.g., catechol-O-
methyl transferase), catecholamine biosynthesis (e.g., tyrosine hydroxylase) and 
mitochondrial metabolism (Bringmann et al., 2002; Toth et al., 2002)  In essence, these 
compounds may be responsible for the increase in biogenic amine transmission within 
the dopaminergic ‘reward’ pathway.    In addition, human exposure to TIQ’s and β-
carbolines via smoking and/or alcohol consumption may contribute to the 
pharmacological reinforcing effects.  
 
1.2.3 Tetrahydroisoquinolines (TIQ’s: R/S-Salsolinol) 
1.2.3a Chemistry and biosynthesis  
TIQ's are a class of partially aromatic alkaloids that include R/S-salsolinol, 1-
carboxysalsolinol, and tetrahydropapaveroline.   TIQ's are compounds that are formed 
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as a result of a condensation reaction between DA and acetaldehyde or pyruvate 
(Rommelspacher et al., 1991a) and are natural metabolites of DA produced in the brain 
as well as other organs (Rommelspacher et al., 1995).  Tetrahydropapaveroline (THP) is 
the dopamine - 3,4, -dihydroxyphenyl acetaldehyde condensation product whereas 
salsolinol  is the dopamine-acetaldehyde condensation product (Duncan and Dietrich, 
1980).   
Salsolinol (SAL), 1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, is an 
isoquinoline analogue consisting of a catechol ring and a secondary amine that is able to 
be protonated at physiological pH (primarily ionized).   Like many other TIQ’s, SAL 
has an asymmetric center at the C-1 position of the heterocycle, thus leading to two 
stereo-isomeric forms (+)-(R)-SAL and (-)-(S)-SAL.  The physicochemical properties of 
SAL have not been experimentally characterized.   According to calculated results, the 
primary ionizable moiety is the secondary amine that possesses a pKa of ~ 9.4.    SAL is 
very soluble in water possessing a log D of -1.68 (calculated from Advanced Chemistry 
Development, ACD/Labs, Software V 8.19 for Solaris © 1994-2008).    The structure of 
SAL is shown in the figure below. 
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Chemical:  Salsolinol (SAL) 
IUPAC name:  1-methyl-6,7-hydroxy-1,2,3,4-tetrahydroisoquinoline 
Mol Weight (g/mol)  179.22 
pKa     9.4 (secondary amine)   
logD (calc)  -1.68 
solubility   very soluble (1000g/L), slightly soluble in methanol 
 
Figure 1-1:  Structure and physicochemical characteristics of salsolinol.  Chiral center 
denoted with asterisk.  
 
SAL is present in various foods and beverages such as bananas, soy sauce, wine, 
and beer (Smythe and Duncan, 1985).    The enantiomeric ratio within these food 
sources is close to 1, especially in dried banana, a food source rich in R- and S-SAL 
(Strolin-Benedetti et al., 1989), while the R-SAL enantiomer predominates in port wine 
(Dostert et al., 1991).   The contribution of dietary SAL to the overall human exposure 
has not been extensively or well investigated.    Attempts have been made to classify 
each enantiomer in terms of exogenous contribution or endogenous synthesis, but 
further studies are needed.   In recent studies, it has been demonstrated that R-SAL 
predominates in human urine (Strolin-Benedetti et al., 1989).  Results showed that the 
S-SAL enantiomer seemed to be formed in individuals who drink significant amounts of 
alcohol regularly.   The differential enantiomer exposures are discussed to be affected 
by a genetic predisposition for an alcohol-induced SAL formation.  
One biosynthetic pathway of SAL is the non-enzymatic condensation of 
dopamine and acetaldehyde to yield the racemic mixture of both enantiomers.  The 
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Pictet-Spengler condensation reaction is known to form a 1:1 ratio of both R-SAL and 
S-SAL (Musshoff et al., 1999).  Other pathways of biosynthesis of SAL have been 
proposed including the enzymatic formation by salsolinol synthase or the reaction of 
dopamine to pyruvic acid via intermediate formation of salsolinol-1-carboxylic acid 
(Naoi et al., 1996).    Additional enzymes involved in this pathway have not been well 
characterized or further studied.  Recently, the nature of R-SAL biosynthesis may be 
due to stereospecific enzymatic condensation of dopamine with pyruvic acid but 
substantiated evidence is still missing.   A schematic depicting synthesis routes is shown 
in the figure below. 
 
 
Figure 1-2:  Biosynthetic pathway of Salsolinol.  In addition to the condensation 
reaction product between dopamine and acetaldehyde, enzymatic formation has been 
purported (? = unknown enzyme). (adapted from Naoi et al, 2002). 
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Although the few reports describe the synthesis of the SAL isoquinoline, the 
metabolic disposition of SAL has been less extensively evaluated.   It was thought that 
the metabolism of SAL yielded the neurotoxin 1,2-dimethyl-6,7-hydroxyisoquinolinium 
ion via N-methyl-transferase and amine oxidase (Naoi et al., 2002).    Further studies 
need to be performed to evaluate the metabolic disposition of SAL and the 
stereoselective nature of the metabolism.   Salsoline and isosalsoline are mono-O-
methylated metabolites of SAL.  Cateholamine-derived 6,7-dihydroxy-TIQs, such as 
SAL, serve as substrates for catechol-O-methyltransferase, in which SAL is O-
methylated at the 7-position in-vivo (Collins and Origitano, 1983).    
 
1.2.3b SAL in-vitro pharmacology 
The neurotoxic properties of SAL have been extensively studied due to similar 
structural characteristics of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 
which is known to induce selective neuronal cell death of dopaminergic neurons 
(Martinez-Alvarado et al., 2001; Maruyama and Naoi, 2002).  In-vitro studies have 
shown that incubation of dopaminergic neuroblastoma SH-SY5Y cells with N-methyl-
salsolinol caused cell apoptosis (Storch et al., 2000).    Other proposed catecholamine 
system dysfunctions invoked by SAL include autonomic dysfunction in Parkinson’s 
Disease and production of positive ionotropic effect on guinea pig myocardium and 
isolated perfused rat heart (Chavez-Lara et al., 1989).  
 It has been suggested that SAL, the condensation product of the alcohol 
metabolite acetaldehyde and dopamine, may be involved in the balance of the reward 
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systems.  It is well known that alcohol itself does not have any affinity for pre- or post-
synaptic receptors in the neurons of the brain (Myers, 1989).  The intra-cranial self-
administration technique has shown that SAL induced reinforcement in the nucleus 
accumbens shell of rats occurs at concentrations that are pharmacologically possible.  
The mechanisms by which SAL induces this effect have been thoroughly evaluated.   At 
relatively low concentrations (1 µmol/l), both enantiomers of SAL were able to 
antagonistically bind to dopamine receptors (D2 and D3), with the S-SAL form binding 
with higher affinity (Melzig et al., 1998).   In-vitro data exemplified a substantial 
decrease in pro-opiomelanocortin gene expression caused by SAL, suggesting possible 
involvement of SAL in the role of opioid deficiency in alcoholism and the rewarding 
effect the SAL may have on mu-opioid receptors.    
While R-SAL more specifically inhibits MAO-A (Ki = 31 μM) in vitro, 1,2,3,4-
tetrahydroisoquinoline (TIQ) is more specific to MAO-B (Ki = 15 μM) (Bembenek et 
al., 1990; Naoi et al., 2004).  S-SAL is an inhibitor of both MAO isoforms but less 
potent than that of the R-isomer (Naoi et al., 2004).  It is speculated that these 
condensation products may also interfere with biogenic amine uptake and release.  
These compounds were found to inhibit the extraneuronal uptake of biogenic amines in 
the vas deferens, and SAL injections released DA and large amounts of 5-HT from the 
striatum, in rats (Duncan and Dietrich, 1980).   In addition, SAL has shown to inhibit 
uptake and cause release of stored catecholamines via presynaptic α2- and postsynaptic 
β-adrenergic receptor binding, to be an inhibitor of catechols-O-methyl transferase, and 
tyrosine and tryptophan hydroxylases, in-vitro (Haber et al., 1996).   All sites of action 
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may lead to increased synaptic supply of dopamine within the dopaminergic “reward” 
pathway. 
 
1.2.3c SAL in-vivo animal and human studies 
In order to illustrate the drug reinforcing aspects of these compounds, several 
investigators showed that consumption of particular drugs of abuse (e.g. amphetamine, 
ethanol, cocaine) significantly increased upon exposure to TIQ’s (Vetulani et al., 2001).   
Previous studies have found that chronic injection of TIQ causes an increase in alcohol 
intake in rats (Melchior and Myers, 1977; Myers and Oblinger, 1977; Duncan and 
Dietrich, 1980).  Specifically, rats infused intraventricularly with 4.0 μg of salsolinol 
increased alcohol intake from 0.74 to 4.9 gm/kg/day.   In another study, single infusions 
of racemic salsolinol in doses ranging from 0.1 - 1.0 μg increased alcohol consumption 
from 0.62 to 4.38 g/kg/day in the non-alcohol-preferring strain of Sprague-Dawley rats 
(Melchior and Myers, 1977).  Animal studies have provided evidence that significant 
differences in SAL levels exist between alcohol-preferring (AP) and alcohol-non-
preferring rats, with the AP rats showing significantly lower SAL content in the 
striatum and adrenal glands (Haber and Dumaual, 1999). A recent study also illustrated 
that SAL produces reinforcing effects when administered directly into the shell of the 
nucleus accumbens of AP rats (Rodd et al., 2003).  Acute and chronic administration of 
selected TIQ’s have been reported to alter alcohol consumption significantly.    
In self-administration studies, it was exemplified that SAL exerts its reinforcing 
effect by stimulating receptors in the dopamine-rich nucleus accumbens (Rodd et al., 
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2003).  In conditioned fear stress tests, it was found that SAL induced a marked place 
preference in rats using doses ranging from 1-10 mg/kg i.p. (Matsuzawa et al., 2000).  It 
was concluded that the potentiation and inhibition of this effect by morphine and β-
funaltrexamine, respectively, indicate that SAL exerts its effect via the µ-opioid 
receptor.    
A novel study utilizing a microdialysis-HPLC technique evaluated the action of 
R-SAL on 5-HT and DA metabolism in the brain (Naoi et al., 1996).   It was concluded 
that R-SAL acts to stimulate a release of biogenic amines via inhibition of MAO and 
COMT.  R-SAL was shown to be a more potent inducer of 5-HT and DA release from 
synapses than amphetamine itself.  Additional animal studies have exemplified the in 
vivo formation of SAL upon high exposure of acetaldehyde (AcH), a primary 
metabolite of ethanol (Mostafa et al., 2003).  Using a microdialysis-HPLC technique 
into the striatum, rats were treated with cyanamide, a potent inhibitor of aldehyde 
dehydrogenase, and 4-methylpyrazole (4-MP, a strong inhibitor of alcohol 
dehydrogenase), followed by ethanol (1 g/kg).  High concentrations of SAL were 
detected in striatal dialysates and high AcH concentrations were found in the blood. The 
time course of changes in SAL concentrations correlated with blood AcH 
concentrations.  In the other experimental groups, SAL in the dialysates and high AcH 
concentrations in the blood were not detected.  It was concluded that high AcH 
concentrations induce the formation of SAL in the rat striatum.  The delineation of 
individual SAL enantiomer exposure was not assessed.    
16 
Preclinical in-vivo pharmacological effects of SAL have been studied in rats.  
SAL has shown to have a modulatory role on cerebral benzodiazepine receptor 
(Kuriyama et al., 1987).  The authors conclude that the decreased capacity of such a 
modulating mechanism may be involved in the exhibition of alcohol withdrawal 
syndrome, possibly by decreasing the function of endogenous ligands for 
benzodiazepine receptor in the brain. 
Initial in-vitro and animal studies stimulated several researchers to evaluate SAL 
exposure in an alcoholic population.   Of note, formal assessments of SAL effect on 
nicotine self-administration, or vice-versa, in rats have not been performed.  SAL has 
been identified in urine, cerebrospinal fluid and the brain of humans (Melzig et al., 
1998; Naoi et al., 2004).  It was also found that blood acetaldehyde is positively 
correlated with urinary SAL (r = 0.88, p < 0.001), which supports the hypothesis that 
SAL is produced in-vivo from acetaldehyde condensation with dopamine (Adachi et al., 
1986).  Numerous human studies investigating plasma and urine concentrations of SAL 
have been published with regards to ethanol abuse (See Table 1-1).  Baseline levels vary 
considerably within and between these studies.  This may be due to methodological 
differences but some confounding factors have been identified, such as foodstuffs and 
tobacco smoke (Pais and Knize, 2000).  The extent of these factors on SAL exposure 
levels has not been fully elucidated.  Moreover, a majority of the studies were 
unbalanced with regards to group sample size and the effect of gender has not been 
explored.  To date there are no clinical investigations that address the contribution of 
smoking to TIQ, and specifically SAL exposure, in the alcoholic and control 
17 
populations. SAL has not been reported as a cigarette smoke component.  Moreover, 
dopamine is not present in tobacco and therefore tobacco smoke acetaldehyde can 
therefore only react with endogenous dopamine to contribute to circulating SAL 
concentrations. 
 Of equal importance, robust time-course measurements of SAL exposure have 
not been evaluated after acute and chronic ethanol exposure.  Of the reports evaluated, 
sampling schedules only included a baseline measurements and, if assessed, one time 
point after ethanol exposure or after the start of detoxification, in the case for alcohol 
dependent subjects.    The pharmacokinetic profiles of SAL have not been explored 
after acute ethanol exposure.    Adequate sampling schedules after ethanol exposure 
would be needed in order to critically evaluate SAL concentrations between 
populations.  A study performed by Rommelspacher et al, 1995 attempted to investigate 
the time course of SAL exposure in alcoholic subjects undergoing detoxification. 
Significant baseline differences were seen between alcoholic and control plasma SAL 
and declined over a three-month period, exemplifying the importance of the temporal 
effects of SAL exposure.   The data suggests that alcohol dependent persons attempt to 
maintain particular physiological levels of SAL to possibly circumvent withdrawal 
effects or sustain a pleasurable “reward” feeling.   Although the time-course of 
enantiomeric SAL plasma concentrations was assessed, sampling schedule was sparse 
and inadequate.  Of important note, no formal preclinical or clinical pharmacokinetic 
investigations on the endogenous formation, exposure and elimination of R- and S-SAL 
have been performed to date. 
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1.2.4  β-carbolines (harman and norharman) 
 
1.2.4a Chemistry and biosynthesis 
 
β-carbolines, such as harman and norharman, are another class of aromatic 
compounds that are formed via the condensation of serotonin (5-HT) or other 
indolealkylamines with aldehydes (Airaksinen and Kari, 1981a).   This class of 
compound possesses aromatic, planar, conjugated ring structures.   The lipophilic nature 
of an array of β-carbolines has been studied, with harman (1-methyl-9H-pyrido-[3,4-
b]indole) and norharman (9H-pyrido-[3,4-b]indole) resulting in relatively high logD 
values (Biagi et al., 1989).  The pyridine nitrogen behaves as a base and is easily 
protonated, while the pyrrolic nitrogen is acidic and loses its proton in an alkaline 
environment, although outside its pH scale (pH>14).    
 
N
N
H
R
  
 
 
Chemical:   Harman                           Norharman 
R:          CH3             H 
Mol Weight (g/mol)       182.2                                           168.2 
pKa      7.37, 14.46                               7.26, 14.23 
logD (calc)        2.8                                             2.6 
solubility   insol in H2O, sol in dilute acids, methanol, and non-polar solvents 
 
Figure 1-3:  Structure and physicochemical characteristics of the β-carbolines, harman 
and norharman.  
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 There is substantial evidence suggesting that simple β-carbolines, may be 
biosynthesized from tryptophan, serotonin or its metabolites in animal cells, i.e., 
“mammalian alkaloids” (Melchior and Myers, 1977; Airaksinen and Kari, 1981a).  The 
key biosynthetic pathway is shown below.   
 
 
Figure 1-4:  Reaction pathways for the formation of heteroaromatic β-carbolines (βC), 
1,2,3,4 tetrahydro-β-carbolines (THβC) or 3,4 dihydro-β-carbolines (DHβC) via A) the 
Pictet-Spengler condensation or the B) N-acylation with cyclization.  Adapted from 
(Collins and Neafsey, 1998). 
 
 Indolealkylamines like tryptophan or serotonin can non-enzymatically condense 
with acetaldehyde to form the tetrahydro-β-carbolines and spontaneously oxidize to the 
heteroaromatic harman or norharman (βC).  Alternatively, biogenic amines may 
undergo enzymatic n-acylation and cyclization to yield dihydro-β-carbolines and to 
ultimately oxidize to form harman or norharman.   Fekkes and co-workers reported that 
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the ingestion of tryptophan resulted in a low increase of the plasma concentration of 
norharman, but concluded that the primary norharman content in the body was from 
other sources (Fekkes et al., 2001).  In general, the exact sequence of the specific steps 
in the pathways is yet to be established.  Indeed, other, more complicated, biosynthetic 
pathways are also conceivable. 
 Few reports have evaluated the metabolism of the β-carbolines.    The primary 
elimination route of norharman is the liver, where its half-life is approximately 20 
minutes (Fekkes et al., 2001).    Moreover, it has been reported that norharman binding 
in rat liver microsomes can be inhibited by CYP2E1 ligands and indole-3-carbinol 
(Stawowy et al., 1999), and is a known inhibitor of benzo[a]pyrene metabolism.  Both 
β-carbolines are methylated by S-adenosyl-L-methionine N-methyltransferase on both 
the pyridyl and indole nitrogens (Matsubara et al., 1993).  Driven by a combination of 
reported results, carboline based neurotoxic entities possibly involved in Parkinson’s 
disease  might be quarternary, cationic β-carbolines possessing methyl groups on both 
nitrogens (Matsubara et al., 1993).  The charged molecules could form via sequential 
methyl transfer reactions within the brain from hydrophobic, blood-brain barrier 
permeable β-carbolines of environmental as well as endogenous biosynthetic origins.   
 Exogenous food sources such as cheese, charred beef and chicken contain 
variable amounts of β-carbolines (Pfau and Skog, 2004), but the post-prandial 
contribution of these foods to circulating β-carbolines have not been evaluated.   
Alcoholic beverages including wine and beer, contain substantial amounts of norharman 
and harman ranging from 0.3 – 22.7 ng/ml (Rommelspacher et al., 1996; Adachi et al., 
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2000).    Certain hallucinogenic plants can also biosynthesize β-carbolines and, as a 
consequence, have been purported to contribute to psychogenic pharmacological effects 
(Airaksinen and Kari, 1981b).  Interestingly, the quantification of β-carbolines from 
tobacco smoke condensate and tobacco leaves have shown that harman and norharman 
are present in significant concentrations.  The smoke of one cigarette contains 0.1-5.8 
µg of harman and 1.3-6.2 μg of norharman (Poindexter and Carpenter, 1962; Herraiz 
and Chaparro, 2005).  Of note, additional β-carboline may be formed endogenously 
from acetaldehyde inhaled from cigarette smoke and condensation with biogenic 
amines.   
 
1.2.4b β-carbolines in-vitro pharmacology 
 
 Substantial data is available with regard to the harmala alkaloids and MAO 
inhibition, effects on membrane ion transport, blockade of the serotonin transporter, and 
antagonism of the GABA/benzodiazepine receptor complex (Collins and Neafsey, 
1998).  Speculations on the biological significance of harman and norharman consist of 
cytotoxic as well as neuroprotective properties. They have been proposed as 
endogenous ligands for benzodiazepine (Rommelspacher et al., 1980) and imidazoline 
(Hudson et al., 1999) receptors.  Apart from the actions at these receptors, other effects 
of harman and norharman at the cellular level have been identified.  These include 
activation of 5-HT2A and 5-HT2C receptors, potent inhibition of synaptosomal γ-
hydroxybutyrate (McCormick and Tunnicliff, 1998) re-uptake and impairment of 
sodium-hydrogen exchange (Glennon et al., 2000).  
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 Kinetic analysis revealed that β-carbolines from cigarette smoke were 
competitive, reversible, and potent inhibitors of MAO enzymes (Herraiz and Chaparro, 
2005).  It has been established that, in vitro, norharman and harman inhibit MAO B (Ki 
= 730 nM, brain tissue, rats) and MAO A (Ki = 220 nM), respectively (Rommelspacher 
et al., 2002).  These results suggest that β-carboline alkaloids from cigarette smoke 
acting as potent reversible inhibitors of MAO enzymes may contribute to the MAO-
reduced activity produced by tobacco smoke in smokers. Note that nicotine and 
corresponding metabolites (e.g., cotinine, thiocyanate) are not potent inhibitors of 
MAO, having inhibitory constants, (Ki’s) 1000-fold or more higher than β-carbolines 
(Oreland et al., 1981).  Moreover, the concentrations required to inhibit MAO by 
nicotine and its corresponding metabolites are not of physiological range (Volkow et al., 
2005).  In-vitro experimentation of harman and norharman effects on tyrosine 
hydroxylase and catechol-O-methyl transferase activity has not been explored.    
 
1.2.4c β-carbolines in-vivo animal and human studies 
 
Studies in animals have provided evidence of induction of ethanol intake by β-
carbolines.  When unanesthetized rats were infused with tryptoline, a β-carboline, the 
release of dopamine in the caudate nucleus and nucleus accumbens was significantly 
increased (Myers and Oblinger, 1977).   In addition, it was shown that norharman 
plasma levels were significantly elevated in rats that ingested ethanol for two-weeks.  
Authors suggest elevated plasma norharman was due to binding to enzymes of the 
cytochrome P450 superfamily (Stawowy et al., 1999).  A subsequent study involving 
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injections of a range of doses on norharman showed that administration of doses of 2.44 
μmol/kg and 43.97 μmol/kg induced an increase of dopamine efflux by 70% and 160% 
(Baum et al., 1995).  This was thought to indicate that norharman influences the 
mesolimbic dopaminergic neurons in a dose-response fashion, and the authors 
suggested that norharman is affecting the dopaminergic system via different receptors, 
namely MAO-A, MAO-B and non-MAO binding site. 
Harman has been shown to induce preference for ethanol in rats 
(Rommelspacher et al., 1987).   Increasing concentrations of ethanol were accessible to 
male Wistar rats for 21 days.  Between day 8 and day 21, the animals were treated with 
several doses of harman and tetrahydronorharman (tetrahydro-beta-carboline) by means 
of continuous intraventricular infusion.  Harman and tetrahydronorharman induced a 
significant preference for ethanol in a dose-dependent manner with harman being three 
times more potent than THN.  The amount of ethanol consumed during the second and 
third weeks of the experimental period correlated with the harman concentration in the 
brain after the cessation of the treatment (p-value < 0.01).  In an additional study, 
harman has been shown to induce volitional drinking of ethanol in the rat (Adell and 
Myers, 1994).   The results demonstrated that the long-term exposure of hippocampal 
neurons to harman induces a preference for high concentrations of alcohol even in a line 
of rats lacking such a genetic predisposition.  Harman administration increased the 
release of DA and 5-HT in the nucleus accumbens (Baum et al., 1996).  These results 
have been corroborated by the results of harman administration enhanced the brain 
levels of 5-HT up to four times (Adell, 1996).    No reports, to date, have investigated 
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the self administration of cigarette smoke and/or nicotine solution upon administration 
of harman or norharman to rats.   
Interestingly, norharman has been shown to attenuate the withdrawal effects of 
alcohol in rats.  Norharman injected intraperitoneally (6.3 mg/kg) attenuated the 
behavioral signs of alcohol withdrawal significantly in rats who were administered 
ethanol for 21 consecutive days and subsequently abstained (Fekkes et al., 2004).   
Conversely, Spies et al showed that norharman levels were significantly increased on 
days in patients who developed alcohol withdrawal syndrome compared with those who 
did not.  An increase in norharman levels preceded hallucinations or delirium with a 
median period of approximately 3 days (Spies et al., 1996).  The researchers suggested 
that norharman may be a possible substance that triggers convulsions and alcohol 
withdrawal syndrome. 
In humans, these compounds are formed endogenously under normal conditions 
with the highest natural concentrations found in the substantia nigra (16 nmol/kg 
tissue)(Matsubara et al., 1993).      Early investigations in humans exemplified that a 
high dose of ethanol (100g) resulted in an increase in urinary excretion of norharman.    
Moreover, it was shown that plasma levels of ethanol and acetaldehyde paralleled that 
of harman blood concentrations with a maximum concentration reached at ~1-2 hours 
after dosing (Rommelspacher et al., 1996).  No harman was detectable in blood when 
no ethanol was given.  Experimental studies showed that dosing with ethanol resulted in 
elevated harman levels while, conversely, elevated norharman levels were reported in 
alcoholics.     In all studies reported (See table 1-2 below), considerable variability exist 
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in the results for both harman and norharman.  In all studies involving alcoholics, the 
tobacco smoking of patients or control was not accounted for.    
Recently, clinical studies have investigated the of role acute cigarette 
consumption on the plasma levels of harman and norharman.   A clinical study 
determining the impact of smoking and drinking on norharman found that resumption of 
smoking after a period of abstinence generated elevated plasma levels of norharman 
among smokers (who did not drink alcohol excessively) as compared to the non-
smoking, non-drinking (control) group (Breyer-Pfaff et al., 1996).  It has been 
suggested that the acutely elevated plasma levels of β-carbolines in smokers may be due 
to recent cigarette consumption (Spijkerman et al., 2002).  However, a clinical study 
investigating ex-vivo MAO-B platelet inhibition by harman and norharman 
demonstrated a baseline difference of β-carbolines in plasma and platelets between non-
smokers (n=5) and smokers (n=19)(Rommelspacher et al., 2002).  In plasma, baseline 
levels were two-fold higher in smokers than non-smokers (smokers: harman = 8.7 
pg/ml, norharman = 19.2 pg/ml; nonsmokers: harman = 4.1 pg/ml, norharman = 9.5 
pg/ml).  After both groups consumed one and two cigarettes, harman and norharman 
levels were significantly higher in smokers than the nonsmokers at all time points. 
Only few studies have evaluated the pharmacokinetics of harman or norharman 
in man.  Oral administration of norharman was investigated in a small number of 
healthy subjects receiving doses of 7, 65, or 110 µg/kg body weight with considerable 
inter-individual differences in exposure (area under the curve)(Fekkes et al., 2001).   
Sublingual administration resulted in a maximum exposure after 5 minutes of 
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administration and was twenty-fold higher than oral administration.  Elimination half-
lives of 51 minutes (Breyer-Pfaff et al., 1996) and 25-30 minutes (Rommelspacher et 
al., 2002) for harman and norharman, respectively, have been estimated from human 
studies. 
 
1.3 TIQ’s and β-carbolines summary 
As it has been noted in the literature, the modulation of drug abuse behavior and 
the consequent interaction of TIQ's and β-carbolines with the dopaminergic system 
demonstrate that these compounds may have a role in drug dependence. Among the 
brain neurotransmitters, dopamine is by far the one, if not the only to have been 
implicated in the behavioral stimulus effects of nicotine and alcohol.
  
The dopaminergic 
system has been well established as the "reward system" in the brain. Therefore, 
compounds that interact with the nucleus accumbens and the dopaminergic neurons 
could have a significant role in drug dependence.   TIQ's and β-carbolines possess 
various significant pharmacological properties to modulate dopamine transmission 
within this pathway, namely MAO inhibition.  Furthermore, as the dopaminergic system 
has a significant role in the drug-seeking behavior, it is possible that other drugs of 
dependence such as nicotine or other ingredients of cigarette smoke may also interact 
with the TIQ's and β-carbolines.  Additionally, these compounds may mediate smoking 
behavior.
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A number of studies investigating the biological concentrations of the β-
carbolines and TIQ’s have been published.    Considerable variability in results between 
and within studies has been reported in alcohol dependent patients compared to control. 
Several confounding issues are present that may contribute to the variability.   For the 
most part, the majority of studies did not account for the effects of smoking on 
circulating β-carbolines and TIQ’s.    As the co-dependence of alcohol and smoking is 
prevalent, research involving the contribution of alcohol exposure on physiological 
concentrations of β-carbolines and TIQ’s need to account for the exposure of tobacco 
smoke within the control and alcohol-dependent patients.   
The information summarized above lead to the hypotheses that (1) TIQ’s and β-
carbolines may have implications in the etiology of smoking and alcohol dependence 
via the dopaminergic ‘reward pathway’, (2) TIQ’s and β-carbolines are elevated in 
plasma and urinary levels differ between smoking and alcohol dependent populations 
compared to control, and (3) smoking and alcohol consumption differentially alters the 
blood levels of TIQ’s and β-carbolines. All aforementioned points suggest that these 
compounds of interest possess tobacco-smoking and alcohol exposure biomarker 
characteristics.   To date there are only a few studies that address the contribution of 
smoking to TIQ’s and β-carbolines levels in the tobacco-smoking dependent population. 
In addition, the majority of the studies did not study the effect of gender. 
  
 
 
 
 
CHAPTER 2  
RESEARCH HYPOTHESES 
 
 
2.1 Hypothesis  
The hypotheses directing this research project are: 
1) Within a healthy, non-alcoholic population, smokers will have higher 
concentrations of TIQ’s and β-carbolines than non-smokers, in a dose-dependent 
manner (i.e., heavy-smokers > light-smokers > nonsmokers) (Figure 2-1).    
Concentrations in light- and heavy-smokers will be observed within thirty-
minutes of smoking a cigarette. 
2) The plasma concentrations of TIQ’s will decline over a two-week period in a 
population of alcoholics during detoxification (Figure 2-2).  
3) At all sampling times, smokers will have higher exposure of TIQ’s compared to 
nonsmokers in both abstinent non-alcoholic and alcoholic populations.  
Moreover, heavy smokers are expected to have higher levels of TIQ’s as 
compared to light-smokers (Figure 2-2). 
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4) The alcoholic population will have higher average exposure of TIQ’s, and at 
admission and discharge of detoxification, compared to the control non-
alcoholic population, regardless of smoking status. 
5) A time-dependent withdrawal assessment, the CIWA-AR (Clinical Institute 
Withdrawal Assessment-Alcohol Revised), will correlate with the levels of 
TIQ’s during detoxification of the alcoholic cohort.  
6) A positive relationship between the degrees of smoking and/or alcohol 
dependence with TIQ’s and/or β-carbolines will exist (e.g., the higher the degree 
of dependence, the higher the exposure).     
 
 This study was performed in two parts.  Study I was a pilot study in forty-one 
male and female volunteers to study the effects of smoking on TIQ and β-carboline 
exposure.  The outpatient study was non-interventional, designed to evaluate baseline 
measurements of plasma TIQ’s and β-carbolines.  Subjects were stratified according to 
smoking status of non-smokers (NS), light-smokers (LS) and heavy smokers (HS).    
Stratification was based on the number of cigarettes smoked per day and the Fagerström 
Test for Nicotine Dependence (FTND).     Subject participation involved two morning 
outpatient visits in which a single blood sample was taken on each visit for the 
quantification of plasma TIQ’s and β-carbolines.  This study was designed to evaluate 
the effects of smoking and gender in baseline plasma TIQ’s and β-carbolines in addition 
to the inter- and intra-individual variability that may be associated with the 
measurements.  
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 A comparison was made to a second study involving an alcohol-dependent 
cohort undergoing detoxification treatment at the National Institutes of Health - 
National Institute on Alcohol Abuse and Alcoholism.  This investigation proposed to 
evaluate detoxification-induced changes in plasma TIQ concentrations in n = 36 
alcoholics undergoing a four-week, inpatient alcohol abstinence program.   Subjects 
were stratified with respect to smoking status of NS, LS and HS and the analysis was 
balanced for gender.  Plasma samples were collected during the first two weeks of 
detoxification: on admission, day 2, 3, 8, and 15 days after enrollment.  A clinical 
endpoint, the Clinical Institute Withdrawal Assessment-Alcohol Revised (CIWA-AR), 
was used to assess a possible correlation of these levels to withdrawal symptoms.  
Plasma TIQ levels were assessed along with CIWA-AR, smoking history and exposure, 
and alcohol dependence measurements in order to assess their feasibility as a clinical 
biomarker for smoking and alcohol dependence.   Importantly, the time-course of these 
compounds during early abstinence in an alcohol-dependent cohort was assessed.  
Evaluation of the contribution of smoking to levels of these compounds and, ultimately, 
the time-course was the primary objective of this study. 
 
2.1.1 Study #1 Hypothesis 
 As nicotine is a drug of dependence interacting with the dopaminergic reward 
pathways in the brain, and cigarette smoking involves systemic exposure to aldehydes 
and/or TIQ and β-carbolines, we expect that smokers will have higher concentration as 
compared to control in a ‘dose-response’ fashion.  In other words smoking status will 
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have an effect on plasma TIQ and β-carbolines with NS < LS < HS.  A graphical 
representation of the research hypotheses are presented in the figure below. 
 
 
 
 
 
 
 
 
 
Figure 2-1:  Proposed hypothesis of TIQ and β-carbolines relative average baseline 
plasma exposure in healthy nonsmoking (NS), light-smoking (LS), and heavy smoking 
(HS) populations.  
 
 Upon statistical evaluation, significant difference will be seen with the 
circulating TIQ’s and β-carbolines when accounting for the factors of smoking and/or 
gender.    A statistically significant positive correlation between the degree of 
dependence, as measured by the Fagerström Test for Nicotine Dependence (FTND) and 
the number of cigarettes smoked per day will be observed.    
 
2.1.2 Study #2 Hypothesis 
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 On the foundation that smoking will have a significant effect on plasma TIQ, it 
is expected that smoking tobacco should have an influence on the time-course of the 
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compounds in alcohol dependent patients.    In these patients, the time course of the 
aldehydes adducts will differ at baseline and throughout the detoxification period, 
dependent on smoking status.   The average aldehyde adduct concentrations, throughout 
the detoxification period, will be dependent on smoking status, with HS > LS > NS.     
Moreover, this relationship will be observed on day 15 of the detoxification period.    
 A withdrawal scale, the Clinical Institute Withdrawal Assessment (CIWA-AR) 
will decline during the initial stages of the detoxification period.  Levels of circulating 
TIQ’s and β-carbolines are expected to decline along with the CIWA-AR.  A schematic 
representing the hypothesis for study #2 is shown below.   
 
  
Figure 2-2:  Proposed hypothesis of TIQ’s relative average plasma exposure in alcohol 
 
dependent nonsmoking (NS), light-smoking (LS), and heavy smoking (HS) populations 
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undergoing 3-weeks of detoxification.  CIWA-AR profile denotes the withdrawal scale 
used within the first week of alcohol abstinence. 
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 A statistically significant difference will be observed with regard to day 1, day 
and cigarette smoking involves 
stem
.2 Rationale and Significance 
neurochemical basis underlying the addictive 
propert
15 and average concentrations of plasma TIQ’s and β-carbolines upon accounting for 
the two factors of smoking status and gender.  A positive correlation between 
concentrations of TIQ’s and FTND or number of cigarettes smoked per day.    The 
CIWA-AR withdrawal scale will positively correlate with plasma TIQ’s in a 
concentration dependent fashion.  Overall a statistically significant difference will be 
seen between levels of smoking status and gender.    
  As the combination of alcohol drinking 
sy ic exposure to aldehydes and/or TIQ and β-carbolines, we expect that smokers 
and alcohol dependent patients will have higher concentration as compared to control.  
Upon comparison between the studies, the alcohol dependent cohort will possess higher 
circulating levels of TIQ’s with respect to the population observed in study #1, 
regardless of smoking status.   
 
2
The understanding of the 
ies of drugs of abuse is imperative for the rational development of new 
pharmacological treatments to reverse the addictive state, prevent relapse and/or reduce 
the intake of these drugs. The TIQ’s and β-carbolines have demonstrated to have a 
variety of neuropharmacological effects that may be related to the reinforcing aspects of 
drug and alcohol abuse.  However, sound evidence for the formation of these 
compounds and elevated concentrations after alcohol abuse and smoking is not yet 
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conclusive.  Due to great inter-individual variations is plasma/urinary TIQ’s and β-
carbolines exposure levels and excretion rate, these compounds remain an insufficient 
marker to distinguish between alcoholics and non-alcoholics.  The variability in the 
reported data might be a result of variables, including smoking status and gender, 
duration and amount of ethanol exposure, polymorphisms in metabolizing systems, and 
analytical problems associated with the quantification of the TIQ’s and β-carbolines, all 
of which have not been thoroughly explored.  
Currently, there are only a few studies reported in the literature that have studied 
the effe
overall research hypothesis of 
ct of alcohol and detoxification on exposure TIQ’s and β-carbolines.   Some of 
these investigations had questionable methodology, including not following the 
complete time-course of the levels, and not accounting for other variables influencing 
TIQ and β-carboline exposure, such as smoking.  This research provides new, hitherto 
unknown information about the baseline levels of these compounds in regards to 
smoking status.  In addition, this investigation assessed the effects of alcohol 
detoxification on the time-course of TIQ exposure in humans and attempted to establish 
a relationship to a clinical endpoint, the CIWA-AR.   
 These anticipated results will support the 
activation of the central dopaminergic pathways as a consequence of smoking and 
alcohol dependence.  Furthermore, if differences are found between NS, LS and HS, 
this would suggest that chronic exposure to TIQ’s affects the withdrawal response, 
possibly as a result of chronic tolerance (e.g., CNS receptor down regulation).  
Measurement and examination of covariates, such as smoking and drinking history, will 
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allow comprehensive evaluation of TIQ and β-carboline levels in the alcohol and 
nicotine-dependent populations versus controls.  Moreover, it will provide valuable 
information on its potential use as a state marker of alcohol and smoking dependence.  
Essentially, understanding TIQ and β-carboline exposure differences among individuals 
with smoking and/or alcohol dependence may provide clues about the dynamics of 
nicotine and alcohol seeking behavior and may provide a basis for enhanced treatment 
efficacy. 
  
 
 
 
 
CHAPTER 3  
BIOANALYTICAL ASSAY DEVELOPMENT FOR THE β-CARBOLINES, 
HARMAN AND NORHARMAN, IN HUMAN PLASMA 
 
 
3.1  Introduction – Selection of Analytical method 
 In order to adequately evaluate physiological concentrations of β-carbolines in 
human plasma, a sensitive and specific analytical method is required.  Several β-
carboline alkaloids have been analyzed in different matrices including plant extracts, 
foods and beverages (Pfau and Skog, 2004).   While the majority of these methods have 
been employed for quantification of the β-carbolines in foodstuffs (Pais and Knize, 
2000), few analytical methods have been published for the support of the investigation 
of harman and norharman in human pharmacological studies.   Applicability of 
transferring the assays for food sources to biological matrices have yet to be 
satisfactorily explored.   Since the physiological concentrations of β-carbolines are 
reported to be in the low nanogram/ml to low picogram/ml range, and the available 
samples from humans are complex matrices, multi-step enhancement and preparation 
techniques are necessary for ultimate detection and quantification.  In alcoholic patients 
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(Matsubara et al., 1986; Breyer-Pfaff et al., 1996; Rommelspacher et al., 1996; 
Tsuchiya et al., 1996; Wodarz et al., 1996) and patients undergoing elective tumor 
resection (Spies et al., 1995), the reported physiological concentrations ranged from ~5 
pg/ml to 2 ng/ml of plasma and/or urine.  In control subjects and smokers, similar 
plasma concentrations were seen immediately after smoking cigarettes (Breyer-Pfaff et 
al., 1996; Rommelspacher et al., 2002).  Due to the highly lipophilic nature and the 
strong intrinsic fluorophore of the β-carboline alkaloids, bioanalytical methods used for 
quantification included primarily reversed-phase high-pressure liquid chromatography 
coupled with fluorescence detection (FD).  The reported methodologies for 
quantification of harman and norharman in a biological matrix have been sensitive but 
several shortcomings exist for the published techniques.  A list of published records of 
norharman and harman analysis in a biological matrix is presented in the table below. 
 Further critique of the reported bioanalytical assays is warranted, as the 
inadequacies in the chromatography, extraction, and validation of the β-carboline assay 
methods are apparent.  Chromatographic baseline resolution for both harman and 
norharman has not been accomplished with majority of the assays presented, especially 
in reports that have supposed relatively low limits of quantification.  Separation or 
resolution is an essential requirement in quantitative HPLC analysis and a baseline 
resolutions of Rs > 1.5 favors maximum precision and accurate quantification in 
reported results (Snyder et al., 1997). 
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 With regard to quantification, several deficiencies are present in reported 
methods.  Firstly, internal standards have not been used for the greater part of reported 
assays.  Significant sample pretreatment and preparation steps utilized in these methods 
necessitate the use of an internal standard.  A properly chosen internal standard can 
compensate for changes in sample size or concentration due to instrumental variations 
as well as variation in extraction recovery.  
 Requirements for a proper internal standard include, but are not limited to, well 
resolved from the analytes of interest, similar retention to the analyte, should not be 
present in the  original sample, and stable and unreactive with sample or mobile phase 
(Snyder et al., 1997).    For the assays in which an internal standard was employed, 
endogenous levels of internal standards are present which may compromise accuracy 
and precision estimates.  For these methods, the concentrations of endogenous levels of 
internal standard in the plasma was not assessed or reported.  In biological samples such 
as plasma or tissue where even lower levels are detected, the fluorescent 1-ethyl-9H-
pyrido[3,4-b]indole or 1-propyl-9H-pyrido[3,4-b]indole have been used successfully as 
internal standards, but both require laborious organic synthesis (Bosin and Faull, 1988).
 Secondly, appropriate bioanalytical validation metrics (i.e., accuracy and 
precision) have either not been presented or assessed.  These aspects of method 
development are necessary to challenge the method and determine limits of allowed 
variability for the conditions needed to run the assay, both of which have significant 
bearing on suitable analyte quantitation in a biological matrix.   
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  Most importantly, the calibration matrix that has been used for quantitation in 
published assays has been via external calibration in buffer or mobile phase.  The 
premise behind the use of these matrices is the lack of a true blank matrix.  Approaches 
used to minimize background noise and interference, via data processing and 
chromatographic separation, have not solved the seemingly insurmountable problem of 
a significant background signal when the analyte itself is present in the blank matrix 
used to prepare calibration standards (Li and Cohen, 2003).  Calibration techniques used 
in reported β-carboline assays do not use the matrix the analyte(s) are intended to be 
measured in, but are quantitated via calibration curve in neat aqueous and/or organic 
solvents.   This practice of calibration completely disregards sample extraction 
efficiency or matrix effects that may occur during the analysis or detection.    
 In summary, the reported bioanalytical methodologies for quantification of the 
β-carbolines, harman and norharman, in human plasma are not adequate for clinical 
study use due to poor resolution of analytes, lack of internal standard use in samples 
that have significant pretreatment steps, and, of utmost importance, insufficient and 
inappropriate validation of the bioanalytical assay.  The current method developed for 
β-carboline quantification addresses the limitations associated with reported assay 
literature, whilst keeping the sensitivity needed for use in human pharmacology studies. 
 
3.2 Physico-chemical Characteristics of Harman and Norharman   
 β-carbolines, such as harman (1-methyl-9H-pyrido-[3,4-b]indole) and 
norharman (9H-pyrido-[3,4-b]indole), are a class of aromatic compounds that are 
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formed via the condensation of indolealkylamines (e.g., tryptophan, serotonin) with 
aldehydes. Recall the structure and physicochemical characteristics from figure 1-3.  
The β-carboline class of molecules show commonality in possessing aromatic, planar, 
conjugated ring structures with extended π-electron systems.   The lipophilic nature of 
an array of β-carbolines has been studied (Biagi et al., 1989), with harman and 
norharman resulting in relatively high logD values.    The pyridine nitrogen behaves as 
a base and is easily protonated, therefore, all β-carboline derivatives studied possess 
pKa values that vary from 6.2-9.5 (Draxler and Lippitsch, 1995).  Conversely, the 
pyrrolic nitrogen is acidic and loses its proton in alkaline environment, although outside 
the usual pH scale (pH>14).   Due to their structural properties, norharman and harman 
exhibit a notable native fluorescence and atypical acid-base behavior in the ground and 
excited states (Pardo et al., 1992).  Considering that β-carbolines are lipophilic and 
highly fluorescent, reversed-phase HPLC with fluorometric detection is a very useful 
technique to determine these compounds in a biological fluid.  Therefore, the following 
experiments for assay development were designed to optimize fluorescence detection 
and chromatographic separation.  The ultimate goal of the bioanalytical assay 
development was to quantify the β-carbolines, harman and norharman, in human plasma 
for the support of two clinical studies.  
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3.3  HPLC-Fluorescence Detection Method Development 
3.3.1 Fluorescence Detection (FD) Experiments 
 Owing to their strong fluorescence characteristics, the β-carbolines have been 
investigated by numerous photophysical methods (Carmona et al., 2000).  The 
fluorescent nature of these molecules may be due in part to their planar, conjugated ring 
structures, which possess extended π-electron systems.  These compounds, in particular 
norharman, have been proposed as fluorescence standards due to their high quantum 
yields and their inability to be quenched by halide ions (Pardo et al., 1992).  The pH- 
dependence of the absorption and fluorescence spectra of several naturally occurring β-
carboline derivatives have been thoroughly investigated (Balon et al., 1993), (Wolfbeis 
et al., 1982).  All reports infer that the polarity and acidity of the surrounding media 
greatly affect the fluorescence emission spectra, quantum yields and life-time of β-
carboline derivatives.  Unquestionably, much of the interesting photophysical properties 
of the β-carbolines arise from the polyfunctional hydrogen bonding nature of the β-
carboline ring.  Thus, the presence in this ring of the acidic pyrrolic and basic pyridinic 
acidic nitrogen atoms allows β-carbolines to act as hydrogen bond donor and acceptor 
molecules.  As the fluorescence of an aromatic compound with acidic and/or basic ring 
substituents is usually pH-dependent (Skoog et al., 1998), spectral characteristics are 
likely to be different for the ionized and unionized forms of the molecule.   The changes 
in the excitation and emission energy of ionizable species arise from the different 
number of resonance species that are associated with the acidic and basic forms of the 
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molecule.  These observations suggest that analytical procedures based on fluorescence 
detection frequently require control of pH.    
 As protonation of the amine groups results in a loss of electron-donating 
characteristics, the pH dependence of the fluorescence behavior of these aromatic 
amines was studied.     The aim of this investigation was to determine the most 
favorable λexcitation and λemission for fluorescent detection analysis and to evaluate the 
effect that pH may have on the fluorescence excitation and emission of both β-
carbolines, using standard applications for spectrofluorometric techniques.    
 Harman and norharman physiological concentrations are reported to be in the 
low picogram to nanogram per milliliter range, therefore optimization of fluorescence 
detection was based on: 
1. evaluation of the dependency of signal intensity on pH for both analytes; 
2. obtaining the most advantageous λexcitation and λemission for fluorescent detection 
analysis, along with an adequate Stokes’ shift for selective measurement; and 
3. determination of any deviations from linearity of fluorescence signal in the expected 
physiological concentration range of analytes at optimal λexcitation and λemission. 
 The Stokes shift is fundamental to the sensitivity and selectivity of fluorescence 
techniques because it allows emission photons to be detected against a low background, 
isolated from excitation photons (Skoog et al., 1998).  Optimal pH and λexcitation and 
λemission results will aid in selecting an appropriate mobile phase for sensitive and 
specific detection of harman and norharman after chromatographic separation.    
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3.3.1a Materials and Reagents 
 All chemicals were or analytical grade quality and obtained from commercial 
sources.  Solvents used for the spectrofluorometric measurements were of spectroscopic 
or HPLC grade and used without further purification.   
1. Harman, purum ≥ 98%  (Sigma-Aldrich Corp., St. Louis, MO) 
2. Norharman (Sigma-Aldrich Corp., St. Louis, MO) 
3. 0.05 M  H2SO4, pH 1  
  - H2SO4, double distilled (GFS Chemicals Columbia, OH), 18M 
4. Potassium phosphate buffer (for buffers between pH 2-3 and pH 7.2) 
 - monobasic potassium phosphate, KH2PO4 (Sigma-Aldrich Corp, St. Louis,  MO) 
 - dibasic potassium phosphate, K2HPO4 (Sigma-Aldrich Corp., St. Louis, MO) 
 - phosphoric acid, H3PO4 (Sigma-Aldrich Corp., St. Louis, MO), 14.8M 
5. Ammonium acetate buffer (for buffers pH 4 and 5.5) 
 - ammonium acetate (Fisher Chem, Fairlawn, NJ) 
 - glacial acetic acid (CMS Chempure Houston, TX) 
6. Ammonium chloride buffer pH 9, 10, 12 
 - ammonium chloride (Fisher Chem, Fairlawn, NJ) 
 - ammonia, anhydrous (Sigma-Aldrich, St. Louis, MO)  
7. 10 M NaOH (VWR, Westchester, PA) 
8. Methanol, HPLC Grade (Burdick and Jackson, Morristown, NJ) 
9. Acetonitrile (Burdick and Jackson, Morristown, NJ) 
10.  Milli-Q® water (Virginia Commonwealth University, Bioanalytical Laboratory) 
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3.3.1b Equipment   
1. Instrumentation:  Shimadzu RF-5301 Spectrofluorometer 
2. Data acquisition:   Shimadzu RF-5301PC Software 
3. Cuvettes, Silica quartz 10.0 mm Shimadzu Scientific  (Columbia, MD) 
4. Corning pH meter, Model 240 (Corning, NY) 
5. 10-μl, 100-μl, and 1000-μl VWR variable volume pipette and corresponding pipette 
tips.  
 
3.3.1c Preparation of Solutions and Standards 
1. 0.001 M Harman in methanol 
 Approximately 10.3 mg of harman was weighed and placed in a volumetric 
 flask of 50-ml methanol.  For additional concentration levels, serial dilutions 
 were performed using respective buffers. 
2. 0.001 M Norharman in methanol 
 Approximately 10.1 mg of norharman was weighed and placed in a volumetric 
 flask of 50-ml methanol.  For additional concentration levels, serial dilutions 
 were performed using respective buffers. 
3.  0.05 M H2SO4 (GFS Chemicals Columbia, OH), pH 1 
 In a 100 ml volumetric flask, 270 μl of 18M H2SO4 was added to 100 ml Milli-
 Q® water. 
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4.  Buffers - For each pH level, an appropriate amount of stock 0.5M base, stock 0.5M 
acid and Milli-Q® water was added to make a 100 ml 0.025M buffer at the respective 
pH.   
a) Potassium phosphate buffers (for buffers between pH 2-3 and pH 7.2) 
 - 0.5 M monobasic potassium phosphate (KH2PO4)- 6.804 g added to 100 ml of 
 Milli-Q® water in a 100 ml volumetric flask.  
 - 0.5M dibasic potassium phosphate (K2HPO4)- 8.708 g added to 100 ml of 
 Milli- Q water in a 100 ml volumetric flask.  
 - 0.5M phosphoric acid (H3PO4) - 3.3784 ml was added to a 100 ml of Milli-Q® 
 water. 
b) Ammonium acetate buffers (for buffers pH 4 and 5.5) 
 - 0.5M ammonium acetate – 3.854 mg was added to 100 ml of Milli-Q® water. 
 - 0.5M acetic acid  - 2.87 ml of glacial acetic acid, 17.4M was added to 100 ml 
 of Milli-Q® water.  
c) Ammonium chloride buffers  (for pH 9, 10, and 12 buffers) 
 - 0.5M ammonium chloride – 2.67g of NH4Cl was added to 100 ml of Milli-Q® 
 water.  
 - 0.5M ammonia solution - 373 μl of anhydrous ammonia (13.4M) was added to 
 100 ml of Milli-Q® water.  
5.  0.1 N NaOH – 5 ml of 10 M NaOH was added to 100ml of Milli-Q® water in a 100 
ml volumetric flask.   
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3.3.1d Methods  
 Freshly prepared methanolic stock solutions of H and NH were prepared at a 
concentration of 0.001 M.   Buffered solutions of various pH’s were prepared at a 
concentration of ~ 0.025 M in order to maintain a maximum buffer capacity of at least 
40%.   Initially, the pH’s (and respective buffers) that were evaluated for the 
optimization were the following:  pH 1 (0.05 M H2SO4); pH 2 and 3 (KH2PO4/H3PO4 
buffer); pH 4 and 5.5 (NH4C2H3O2/CH3COOH buffer); pH 7.2 (K2HPO4/KH2PO4 
buffer); pH 9, 10 and 12 (NH3/NH4Cl buffer); and pH 13 (0.1 N NaOH).   In order to 
determine the fluorescent properties of H and NH in common HPLC solvents, 
measurements were additionally made in 100% methanol and 100% acetonitrile.    
 Stationary excitation and emission spectra (uncorrected for instrument) were 
evaluated at each pH for the given concentration of H and NH.  Blank buffer or solvent 
was additionally assessed for matrix evaluation.  In order to obtain λmaxexcitation and 
λmaxemission at each respective pH for both H and NH, fluorescence scanning experiments 
were performed.  The excitation spectra were evaluated between the ranges of 220-400 
nm, at a fixed λemission of 500 nm.  Upon appraisal of the spectra, the λmaxexcitation was 
fixed, and the λemission was scanned from between 250-550 nm.   The excitation and 
emission slit width was set at 10 nm and 1.5 nm, respectively.  All recorded spectra 
were taken at room temperature (22± 2 °C) at a scan speed at the medium setting with a 
response time of 0.1 seconds.     
 To make solutions for spectral pH optimization measurements, a predetermined 
amount of stock solution was added to a buffered solution to make a desired 
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concentration of 250 pg/ml (~1.4 x 10-6 M) and 220 pg/ml (~1.3 x 10-6 M) for H and 
NH, respectively.  Dilution to this low of a concentration was necessary to avoid inner 
filter effects and reabsorption phenomena (Munoz et al., 2000). Final solvent for 
spectral measurement was 3:1 buffer to methanol mixture and was not degassed.    At 
each pH excitation and emission spectra were scanned and recorded for both analytes (n 
= 3 for each measurement).  Further pH optimization was performed at intervals of 0.1 
pH units around the most favorable pH from the prior experiment.   
 For the linearity assessment of response the optimal λmaxexcitation and λmaxemission 
with an optimal pH buffer was used.   An approximately 1000-fold concentration range 
from ~5 pg/ml (~2.8 x 10-8 M) to 2.7 ng/ml (7.9 x 10-6M) for both analytes was assessed 
and a calibration curve was plotted and evaluated for any deviations from linearity (10 
concentrations in triplicate).  The standards for the curve were prepared for the 0.001 M 
stock solution of H and NH and serial dilution was preformed to achieve the desired 
concentrations.  
 
3.3.1e Results 
 
 For both β-carbolines, the spectral λexcitation  and λemission varied, reliant on the pH 
of the solvent environment.  The λmaxexcitation  and λmaxemission for each analyte are 
presented in the table 3-2 below.  Of note, all solvents were checked for background 
fluorescence that yielded a negligible fluorescence signal.  Using the λmaxexcitation for 
each solvent in the respective pH, the signal intensity at the λmaxemission was recorded.    
For situations where two or more λmaxexcitation were observed, the longer wavelength 
52
52
 
an
 
N
or
ha
rm
n 
 
T
ab
le
 3
-2
: M
ax
im
um
 e
xc
ita
tio
n 
an
d 
em
is
si
on
 λ
 (n
m
) f
or
 H
 a
nd
 N
H
 a
t v
ar
yi
ng
 p
H
’s
 w
ith
 sp
ec
ul
at
ed
 io
ni
za
tio
n 
st
at
e.
 
 
H
ar
m
a
pH
, b
uf
fe
r 
E
x 
λ 
(n
m
) 
E
m
 λ
 m
ax
 (n
m
) 
E
x 
λ 
(n
m
) 
E
m
 λ
 m
ax
 (n
m
) 
 
M
aj
or
 Io
ni
za
tio
n 
St
at
e 
 1 
  0
.0
5M
 H
2S
O
4 
 
24
7,
 2
97
 
 
43
2 
 
24
8,
 2
96
 
 
44
9 
 
ca
tio
ni
c 
 2 
  K
H
2P
O
4/H
3P
O
4 
 
24
6,
 2
98
 
 
43
3 
 
24
7,
 2
97
 
 
44
8 
 
ca
tio
ni
c 
 3 
  K
H
2P
O
4/H
3P
O
4 
 
24
8,
 2
98
 
 
43
7 
 
24
7,
 2
97
 
 
44
9 
 
ca
tio
ni
c 
 4 
 N
H
4C
2H
3O
2/C
H
3C
O
O
H
 
 
24
0,
 3
03
 
 
43
0 
 
24
4,
 3
13
 
 
43
2 
 
ne
ut
ra
l 
 5.
5 
N
H
4C
2H
3O
2/C
H
3C
O
O
H
 
 
24
2,
 3
05
 
 
42
8 
 
24
2,
 3
05
 
 
43
0 
 
ne
ut
ra
l 
 7.
2 
 K
2H
PO
4/K
H
2P
O
4 
 
23
0,
 2
78
 
 
36
0 
 
24
7,
 2
78
 
 
38
0 
 
ne
ut
ra
l 
 9 
  N
H
3/N
H
4C
l 
 
24
1,
 2
79
 
 
37
8 
 
24
2,
 2
85
 
 
38
2 
 
an
io
ni
c*
 
 10
   
N
H
3/N
H
4C
l 
 
23
8,
 2
81
 
 
40
5 
 
23
8,
 2
81
 
 
40
0 
 
an
io
ni
c*
 
 12
   
N
H
3/N
H
4C
l 
 
23
2,
 2
80
 
 
47
9 
 
24
0,
 2
82
 
 
48
0 
 
an
io
ni
c*
 
 13
  0
.1
 M
 N
aO
H
 
 
23
4,
 2
83
 
 
47
9 
 
23
0,
 2
83
 
 
38
2,
 4
85
 
 
an
io
ni
c*
 
 M
et
ha
no
l 
 
24
7 
 
36
0,
 4
42
 
 
24
7 
 
36
7,
 4
40
 
 
ne
ut
ra
l 
 
ne
ut
ra
l 
 
36
0 
 
23
0 
 
35
5 
 
23
3 
 A
ce
to
ni
tri
le
 
*z
w
itt
er
io
ni
c 
sp
ec
ie
s m
ay
 b
e 
pr
es
en
t 
53 
(lower energy) was used for excitation to improve the selectivity of the detection.  
Fluorescence detection sensitivity can be severely compromised by background signals, 
which may originate from endogenous sample constituents.  Minimization of the 
background noise can be performed by selecting excitation energies at longer 
wavelengths.  Furthermore, at longer wavelengths, light scattering by dense media such 
as plasma is much reduced, resulting in greater penetration of the excitation light 
(Cullander, 1994).  Moreover, the fluorescence emission spectrum is independent of the 
excitation wavelength, due to the partial dissipation of excitation energy during the 
excited-state lifetime (Lakowicz, 2007).  
 The pH dependency of signal intensity at λmaxemission is presented in figure 3-1 
below for the pH range between pH 1 and 13.  An important experimental design 
criterion for a reversed-phase HPLC pertains to the pH stability of the solid phase of the 
column.  The majority of the manufactured HPLC columns are stable at a pH range 
between 2 and 9 with temperature control <50 ºC (Snyder et al., 1997).   For this reason, 
further evaluation for the optimal fluorescence signal of H and NH was performed 
between the stable pH ranges of commercially available HPLC columns.  
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Figure 3-1:  Harman and norharman fluorescence intensity and speculated ionization 
state as a function of pH at optimal excitation and emission wavelengths (mean ± SD, 
n=3). 
 
 Maximum fluorescent response was observed for H and NH at pH of ~3.0 in 
which H: λ  = 298 nm, λexcitation emission = 437 nm and NH: λ  = 299 nm, λexcitation emission = 
440 nm.  As the pH 3 solvent resulted in the most favorable fluorescence signal, 
supplementary experiments at 0.1 pH units below and above below pH 3 were appraised 
(range from pH 2.6-3.6).  Using a 0.025 M buffer solution of KH PO /H PO2 4 3 4, at the 
respective pH, fluorescent scanning experiments were performed (pH adjusted using 
1M H PO3 4).  The spectral characteristics of the excitation and emission did not vary 
much over small pH range, therefore the signal intensities were evaluated at λmaxexcitation 
max max max= 298 nm and λ =  437 nm for H and λemission  excitation  = 297 nm and λ =emission   449 
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nm for NH.   The results of the pH dependency on fluorescence intensity are presented 
in figure 3-2.  
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Figure 3-2:  Harman and norharman fluorescence intensity between pH 2.6 and 3.6 
(mean ± SD, n=3). 
 
In the methanol and acetonitrile solutions, the neutral molecule’s fluorescence is present 
within the UV range.   
 The additional pH experiments, at smaller pH intervals, resulted in an optimal 
fluorescence signal intensity at pH ~ 3.2, as deemed by the largest, most reproducible 
signal intensity for the given concentration of H and NH.    From the pH optimization 
experiments, the resultant wavelengths were used for calibration curve experiments at 
pH 3.2; H: λmax max max= 298 nm, λ = 437 nm; NH: λexcitation emission  excitation  = 297 nm, 
λmax = 449 nm.   The excitation and fluorescence spectra for H and NH are emission  
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exemplified in the figures below.  For reference, the structure of the presumed ionic 
state is represented in the spectra. 
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Figure 3-3:  Excitation and emission fluorescence spectrum of harman in the cationic 
state, pH = 3.2.      
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Figure 3-4:  Excitation and emission fluorescence spectrum of norharman in the 
cationic state, pH = 3.2. 
 
  
 From this investigation, it was concluded that H and NH show good 
photophysical properties with strong fluorescence, large Stokes shifts (>90 nm) and 
relatively long excitation (>278 nm) and emission (>360 nm) wavelengths for both 
analytes throughout the pH range, all of which can minimize the effects of the 
background fluorescence.   The difference in the wavelengths of maximum excitation 
and maximum emission is called the Stokes’ shift (λmax max- λemission excitation) (Gaigalas et 
al., 2001).  Stokes’ shifts that were observed as a function of pH are presented in the 
table below. 
 
 
 
 
58 
Table 3-3: Stokes shifts (nm) for harman and norharman at varying pH’s  
 
pH Harman  Norharman 
(nm) 
Speculated 
Ionization state 
 
(nm) 
1 135 153 cationic  
2 135 157 cationic 
3 139 152 cationic  
4 127 119 neutral 
5.5 123 125 neutral  
7.2 82 102 neutral 
9 99 97 neutral  
10 124 119 anionic* 
12 199 198 anionic*  
13 196 202 anionic* 
MeOH 113 120 neutral  
ACN 122 130 neutral 
 *zwitterionic species may be present 
 
 
 Larger stokes shifts were observed at pH’s >10 (presumed anionic state).  For 
practicality and utility of HPLC development, the acidic pH ranges between 1 and 3 
yielded the larger Stoke’s shifts.  As the pH of approximately 3 resulted in the highest 
fluorescent intensity for a given concentration of H and NH, and the Stoke’s shift at this 
pH was the largest, the pH 3.2, 0.025 M buffer solution of KH PO /H PO2 4 3 4, was used to 
maximize sensitivity and selectivity for spectrofluorometric quantification experiments.   
 Calibration curve experiments resulted in linear response throughout the 
concentration range for both H (R2 > 0.998) and NH (R2 > 0.997).  For each analyte, the 
inter-individual variability between slopes of the calibration curves was negligible and 
showed consistency for each analyte.  Moreover, the y-intercepts obtained from each 
calibration regression were insignificant and statistically not different from zero.  In this 
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spectrofluorometric system, the minimum concentration detected (LOD) for H and NH 
were 32 pg/ml and 25 pg/ml, respectively.  This LOD calculation was based on the 
standard deviation of the noise and slope of the calibration curve (3 times the standard 
deviation of the noise divided by the slope of the calibration curve)(ICH, December 18, 
1996).  The standard deviation was estimated based on n = 3 blank sample signals or 
can be extracted from the calibration curve.  Of note, the LOD is not a very stable 
characteristic because of its susceptibility to minor changes in the conditions of the 
analytical method, like temperature, purity of reagents, sample matrices, and 
instrumental system changes.    This measurement was expected to change upon 
analysis of, H and NH in a biological matrix and upon transfer onto an HPLC-FD 
system.  Additional experiments were conducted on additional, more concentrated 
solutions for testing fluorescence signal saturation.  Non-linearity of the instrument 
response occurred at concentrations above 10 ng/ml, likely due to insolubility issues, 
and implying that dilution may be required of any samples above this concentration.   
 
3.3.1f Discussion    
 The molecular resonance energy of a fluorophore in aqueous solutions are rather 
sensitive to the surrounding milieu that, in turn, tends to influence the energy of the 
electronic states.   Thus, changes in solution properties, such as pH, usually lead to 
shifts in the wavelength of maximum emission and large changes in the quantum yield.   
As seen in experimentation and previously reported literature, the β-carbolines, H and 
NH, have been extensively evaluated for their spectral properties in different solvents.   
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The pH, and consequently ionization state, significantly alters the fluorometric 
measurement of H and NH.  Owing to the acidic nitrogen moiety and the basic nitrogen 
atom in the pyridine nucleus, H and NH can exist in three differently charged ground 
state species.  Their respective equilibria, shown in the scheme below are governed by 
two pKa’s.  The zwitterionic species may also be present, especially in the excitation 
spectra observed in the pH range of greater than neutral.    
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Figure 3-5:  Structure and ionization states of the β-carbolines, governed by two pKa’s  
cation (conjugate acid)                      neutral species        anion (conjugate base) 
 
 According to the proton transfer dynamics of the β-carbolines in differing pH’s, 
the cationic form of H and NH yielded the maximal response for a given concentration 
(between pH 1-4), and the anionic and zwitterionic form (> pH 10).    This is consistent 
with reported literature in which it was found that the fluorescence yield of the cationic 
species of norharman was the largest and found to be constant at pH’s below 4.  It has 
been observed that the molar extinction coefficients (log ε) for the cationic forms are 
4.16 and 3.64 and the quantum yield (ΦF) is 0.56 and 0.83 for NH and H, respectively 
(Balon et al., 1993).  Within the 4-10 pH range the fluorescence signal, albeit 
reproducible, yielded the smallest response for the given concentration.  Within this pH 
range, the neutral species for both H and NH are seemingly predominant. 
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 For further HPLC method development, an initial pH of 3.2 was used for 
additional experimentation due to the following reasons: (1) at this pH, a relatively large 
fluorescence intensity was seen for a given concentration of H and NH; (2)  the cationic 
form of H and NH predominates at this pH and, in concordance with previous literature, 
has the highest quantum yield;  (3) for practical HPLC method development, the Stokes 
shift observed at this pH was relatively large, which was expected to improve selectivity 
and sensitivity of the method.   Furthermore, there is small overlap between excitation 
and fluorescence spectra and the spectrum are independent of exciting wavelength, 
which are characteristic of superior fluorescence standards (Pardo et al., 1992).  From 
these results, it was concluded that the 0.025 M buffer solution of KH2PO4/H3PO4 at pH 
= 3.2 was used for an initial mobile phase buffer for HPLC method optimization.  At 
this pH, the resulting wavelengths were used were: λmaxexcitation = 298 nm, λmaxemission = 
437 nm for harman and λmaxexcitation  = 297 nm, λmaxemission =  449 nm for norharman. 
 
3.3.2 Chromatographic Experiments and Optimization 
 The high-pressure liquid chromatography (HPLC) method was chosen due to the 
sensitivity of the method, its ready adaptability to accurate quantitative determinations, 
and its suitability for separating non-volatile species.  Moreover, the physicochemical 
properties of the β-carbolines, H and NH, make the HPLC method conducive for 
separation and quantification.   To address the concerns of previously reported assay 
methodologies, the following aims of chromatographic optimization were considered:  
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1. Baseline resolution of H and NH was paramount in order to ensure precision during 
quantification. 
2. Retention time, peak shape (e.g., tailing factor and symmetry), resolution of peaks, 
selectivity and system suitability parameters (e.g., reproducibility of replicate 
injections) were to be optimized in order to ascertain the effectiveness of the final 
operating system. 
3. In order to achieve adequate sensitivity to detect trace amount of H and NH in a 
minimal amount of human plasma, the chromatography was optimized to achieve 
the smallest amount of analyte(s) on column. 
4. Exploration of a chromatographically suitable internal standard for further 
extraction method development.  
 
 As the analytes are considered to be a mixture of small molecules and are highly 
lipophilic, reversed-phase HPLC optimization was performed.  Initial conditions of 
mobile phase pH were chosen based on the fluorescence detection optimization in 
which the cationic forms of H and NH yielded the optimal detection (in sensitivity and 
reproducibility).  The preferred initial experimental conditions (Snyder et al., 1997) 
HPLC separation for ionized analytes were based on the conditions listed in table 3-4.   
 Specifically, the optimization of the chromatographic conditions was based on 
the USP XXIV 621 requirements for chromatographic separation and system suitability 
(USPharmacopoeia, 1999). Separation of the β-carbolines was based on the most 
favorable capacity factor, resolution of the peaks, and injection precision.  Moreover, 
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peak shape for both H and NH were assessed for tailing factor, peak asymmetry, and 
number of theoretical plates.   
 
 
Table 3-4: Initial Experimental Conditions for RP-HPLC Separation of Ionized H and 
NH (Snyder et al., 1997) 
Separation variable   Initial Choice 
Column  
     Dimensions (length, ID) 15 x 0.46 cm 
     Particle Size 5 μm 
     Stationary phase C18 and C8
Mobile Phase  
     Solvents A and B Buffer and Methanol or Acetonitrile 
     % B 50% 
     Buffer (compound, pH, concentration) 25 mM potassium phosphate, pH 3 
Flow rate  Isocratic, 1.0 ml/min 
  
Temperature Room temperature 
 
 
Injection volume 50 μl 
 
 Capacity factor (k) describes the migration rates of the analytes on column and 
is related to retention time of the analyte: 
( )
0
0
t
ttk R −=    (Equation 3.1)     
 where tR is the band retention time and t0 is the column dead time.   The goal of the 
solvent strength adjustment and buffer pH optimization was to position the bands within 
a k range of roughly 0.5 to 20.  This range was based on the avoidance of initial 
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baseline disturbance overlapping the first band (early-eluting interferences) and to 
evade broadening of the last band that may be seen with long run times (Snyder et al., 
1997).    
 An inadequacy apparent from reported assays for H and NH quantification 
biological matrices is resolution, Rs, between β-carboline analytes. With baseline 
resolution, the HPLC data system is able to draw an accurate baseline under each band-
peak, thereby increasing the accuracy of the band-area measurements and resultant 
calculation of sample concentrations (Snyder et al., 1997).   The measurement of 
efficiency of the separation of H and NH in a mixture was determined by the equation: 
12
12 )(2
WW
ttRs −
−=      (Equation 3.2) 
whereby t  and t  are the retention times for the two components, H and NH, and W2 1 2 
and W1 are the corresponding widths of the bases of the peaks (bandwidth), obtained by 
extrapolating the relatively straight sides of the peaks to the baseline.   The goal 
baseline resolution that corresponds to Rs > 1.5 will allow for adjacent bands of 
dissimilar bands  and account for the usual deterioration of an HPLC method from day-
to-day use (Snyder et al., 1997).   
 Another useful parameter is the reproducibility of replicate injections of the 
analytical solution of H and NH.  The reproducibility of the replicate injection is best 
expressed by the injection precision, or percent relative standard deviation, %RSD.  The 
calculation is expressed by the equation:   
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xin which, %RSD is the relative standard deviation in percentage,  is the mean of a set 
of n measurements and xi is an individual measurement.  The x term refers to the peak 
area response corresponding to the reference standard.  The injection precision 
suggested limit is a %RSD < 3% for n ≥ 5 chromatographic measurements 
(USPharmacopoeia, 1999).   
 Additional information such as peak shape (i.e., tailing factor, peak asymmetry) 
and number of theoretical plates should also be assessed to evaluate the performance of 
the HPLC method.  More specifically, column performance can be defined in these 
terms for a test substance run under “optimal” conditions.   The column plate number, 
N, is an important characteristic of the column and is defined as the ability of the 
column to produce sharp narrow peaks for achieving good resolution between band 
pairs (Snyder et al., 1997).   A relationship used to measure plate number is:  
2'2 ⎟⎠
⎞⎜⎝
⎛=
A
htN Rπ   (Equation 3.4)     
where tR is the band retention time, and h’ and A are the peak height and area, 
respectively.     Equation 3.4 is often used in HPLC data systems to determine the value 
of N and is used for measuring column performance (Snyder et al., 1997).     
Representative values of an ideal N value for columns of differing lengths and particle 
sizes vary and are generally reported under ‘ideal conditions’.  For the purposes of 
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initial HPLC method development, an acceptance limit of N > 2000 was proposed as a 
criterion.   The plate number was evaluated primarily for the evaluation of column 
efficiency and evaluation of column lifetime throughout the HPLC method 
development.        
  While the column plate number is a useful measure of column quality and 
efficiency, the peak shape and tailing assessment is also important during development 
(Snyder et al., 1997).    Lack of symmetry in peak shape, As (exactly symmetrical peaks 
have a value of 1.0), can result in issues in imprecise quantitation, poor retention 
reproducibility, and degraded resolution (Snyder et al., 1997).  The peak symmetry is 
calculated at 10% of full peak height and samples of interest generally should have As 
values of <1.5 (Snyder et al., 1997).   
 Chromatographic optimization for H and NH separation in neat solution was 
based on the initial criteria and limits aforementioned.   These suggested limits were 
used as a reference to set up initial system suitability criteria during the early HPLC 
method development process. The goal of this chromatographic investigation was to 
obtain a range of HPLC system parameters (i.e., %B, pH of mobile phase, flow rate) 
from neat solution in order to further optimize the conditions from those of extracted 
human plasma matrix.  This safeguard provided initial HPLC parameters for further 
method chromatographic exploration from extracted plasma, especially in the case of 
selectivity issues that may arise.   The results of the optimization were carried further in 
subsequent validation and analysis with human plasma matrix.   
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3.3.2a Materials and Reagents 
 All chemicals were or analytical grade quality and obtained from commercial 
sources.  Solvents used for the chromatographic optimization measurements were of 
spectroscopic or HPLC grade and used after filtration with a 0.2 μm porosity filter 
(Corning, Corning, NY).   
1. Harman, purum ≥ 98%  (Sigma-Aldrich Corp., St. Louis, MO) 
2. Norharman (Sigma-Aldrich Corp., St. Louis, MO) 
3. Potassium phosphate buffer (for buffers between pH 2-5 and pH 7.2) 
 - monobasic potassium phosphate - KH2PO4 (Sigma-Aldrich Corp, St. Louis, MO) 
 - dibasic potassium phosphate, K2HPO4 (Sigma-Aldrich Corp., St. Louis, MO) 
 - phosphoric acid, H3PO4 (Sigma-Aldrich Corp., St. Louis, MO), 14.8M 
4. Methanol, HPLC Grade (Burdick and Jackson, Morristown, NJ) 
5. Acetonitrile (Burdick and Jackson, Morristown, NJ) 
6. Milli-Q® water (Virginia Commonwealth University, Bioanalytical Laboratory) 
 
3.3.2b Equipment   
1. Instrumentation: Waters HPLC, 600 Controller, 717+ Autosampler, 2475 
Fluorescence Detector, with In-line Degasser. 
2. Data acquisition:   Waters Empower® Software 
3. Corning pH meter, Model 240 (Corning, NY) 
4. 10-μl, 100-μl, and 1000-μl VWR variable volume pipette and corresponding pipette 
tips.  
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5. Columns (all end-capped): 
 - Waters Symmetry®, C18, 3.5 μm (150 x 4.6mm) 
 - Waters Symmetry®, C18, 5 μm (75 x 4.6mm) 
 - Agilent Zorbax Eclipse XDB®, C8, 5 μm (150 x 4.6mm)   
6. Vials/Caps/Septa:  Waters®, 1ml glass shell with polypropylene caps 
 
3.3.2c Preparation of Solutions and Standards 
1. 0.001 M Harman in methanol 
 Approximately 10.2 mg of harman was weighed and placed in a volumetric 
 flask of 50-ml methanol.  For additional concentration levels, serial dilutions 
 were performed using methanol. 
2. 0.001 M Norharman in methanol 
 Approximately 10.0 mg of norharman was weighed and placed in a volumetric 
 flask of 50-ml methanol.  For additional concentration levels, serial dilutions 
 were performed using methanol. 
3.  Buffers - For each pH level, an appropriate amount of stock 0.5M base, stock 0.5M 
acid and Milli-Q® water was added to make a 100 ml 0.025M buffer at the respective 
pH.  For the potassium phosphate buffers (for buffers between pH 2-5 and pH 7.2): 
 - 0.5 M monobasic potassium phosphate (KH2PO4)- 6.804 g added to 100 ml of 
 Milli-Q® water in a 100 ml volumetric flask.  
 - 0.5M dibasic potassium phosphate (K2HPO4)- 8.708 g added to 100 ml of 
 Milli- Q water in a 100 ml volumetric flask.  
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 - 0.5M phosphoric acid (H3PO4) - 3.3784 ml was added to a 100 ml of Milli-Q® 
 water. 
 
3.3.2d Methods 
 The steps taken during the optimization of chromatographic separation were 
based on current HPLC method development practice (Snyder et al., 1997).  Initial 
specific conditions were described previously, and the results of which were used in 
subsequent experiments.  Moreover, optimal analyte solvent (pH ~3) along with 
excitation and emission wavelengths at the most favorable pH were utilized for mobile 
phase pH and detection, respectively.  A systematic (along with a trial-and-error) 
process was continued until successful separation was achieved.  Based on the 
physicochemical characteristics of H and NH, the reversed phase separation conditions 
and parameters that were explored were column chemistry (packing) and configuration, 
mobile phase strength (%B), pH and concentration of buffer, flow rate, temperature of 
column, injection volume and sample plug solvent composition.  For all experiments, 
the conditions were evaluated via univariate experimental design.  
 Specifically, the types of columns that were evaluated ranged from a single C8 
column to two different C18 columns with differing column configurations (in length 
and particle size, see section 3.3.2.2 under “Columns”).   A C8 or C18 column made 
from specially purified, less acidic silica and designed specifically for the separation for 
basic compounds is generally suitable for all samples and is strongly recommended 
(Snyder et al., 1997).   An optimal column was chosen on the basis of the ability for H 
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and NH to be retained and eluted from the column, the retention time, and the resolution 
and peak shape of H and NH bands.   Isocratic methods were explored initially for 
method development simplicity.   
 With respect to the mobile phase composition, optimization experiments were 
performed with the following prioritization of conditions (most important to less 
important): (1) the percent organic, %B, (2) flow rate of mobile phase, (3) pH of buffer, 
and (4) concentration of buffer.  In particular, the %B was varied from 5% to 50% in 
increments of 5%.   Both methanol and acetonitrile, or a combination of both, were 
utilized to determine best retention and separation conditions.  The initial experiments 
used a H3PO4/KH2PO4 buffered mobile phase at ~ pH 3 at a concentration of 50 mM.  
These initial pH conditions were used to reflect the results from the spectrofluorometric 
experiments described earlier.  The initial concentration of the buffer was used to 
maintain adequate buffer capacity and, at the same time, to avoid salt precipitation upon 
introduction of larger %B.   The flow rate of the mobile phase was subsequently 
explored from between 0.5 ml/min to 1.5 ml/min.   Along with chromatographic 
evaluation, the pressure was evaluated for consistency within the chromatographic run 
and between injections.   
 As H and NH are expected to be in its cationic state at the initial pH conditions 
(pH ~ 3), the buffered aqueous composition was subsequently optimized.   Besides the 
notion that this pH yielded the largest signal intensity for a given concentration of H 
and NH, a low pH protonates column silanols and reduces their chromatographic 
activity (Snyder et al., 1997).  Secondly, the low pH is far enough from the pKa values 
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for the basic functional groups of H and NH to maintain its ionization.  Therefore, at the 
initial low pH conditions it was hypothesized that the retention of H and NH will not be 
affected by the small changes in pH and the reversed-phase HPLC method will be more 
rugged.  Optimization at pH 3.0, 3.2, 3.5, 4.0, 4.5, 5.0 and 7.2 was explored to evaluate 
effects of pH conditions on H and NH chromatography.    pH values lower than 3.0 
were not evaluated as the solid phase stability of the columns used may be 
compromised.    In conjunction with pH assessment, the concentration of the buffer was 
explored to maintain the pH.  This was performed to ensure the pH reproducibility and 
buffering capacity of the final mobile phase upon dilution.  The buffer concentrations 
that were explored were between 10 mM and 50 mM at increments of 10 mM.   Higher 
buffer concentrations, provide an increased buffer capacity but may not show favorable 
solubility in mobile phases with a high organic content (%B).   As the initial conditions 
for the HPLC separation were for the ionized form of H and NH, consideration of 
buffers with a marginal buffer capacity (i.e., low concentration) were avoided to 
circumvent less reproducible separations for the ionized H and NH.   A H3PO4/KH2PO4 
buffered mobile phase was adjusted accordingly with acid or base to achieve a desired 
pH and concentration.  
 Along with the column configurations and mobile phase compositions, the 
sample injection volume and composition of the sample solution (i.e., injected solution) 
was also evaluated.  The volume of sample introduced into the HPLC was constrained 
by the injection loop size (100 μl for the Waters HPLC system used).   Injection 
volumes < 10 μl were not used due to irreproducibility that may occur with sample 
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introduction from the sample loop and needle.  Sample volume was assessed upon 
chromatographic evaluation using the system suitability and peak shape requirements 
aforementioned.    The goal of the sample volume investigation was to avoid an 
undesirable change in separation due to a sample size that is too large (e.g., column 
overload) and to increase detection sensitivity for the trace analysis of H and NH by 
using the largest possible sample size.  The composition of the sample solvent was kept 
close (±5%) to the composition of the mobile phase to evade extra-column effects 
associated with the HPLC (e.g., band broadening or peak asymmetry).   It has been 
exemplified that injecting the sample in a solvent that is stronger than the mobile phase 
usually results in early bands that are distorted and tailing (Snyder et al., 1997).  
 The initial solution concentrations used for the chromatographic optimization 
were 406 pg/ml and 452 pg/ml for NH and H, respectively.   Injections for each 
optimization step (i.e., when a chromatographic condition was changed) were 
performed in triplicate.   Univariate optimization was performed in a step-wise fashion.    
This sequential single-factor approach requires all factors but one to be held constant 
while the univariate search was carried out on the factor of interest (Massart et al., 
1988). After optimization of the conditions, three levels of concentrations for both 
analytes were investigated for precision, system suitability requirements, and peak 
shape reproducibility.  The concentrations were 202 pg/ml and 260 pg/ml for the low 
level, 406 pg/ml and 452 pg/ml for the medium level, and 1.12 and 1.25 ng/ml for the 
high level for H and NH, respectively.  A total of n=6 injections were performed for 
each level using the optimized chromatographic conditions.       
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 For the calibration and sensitivity analyses for both analytes, a range of reported 
physiological concentrations for both analytes were used to determine the linearity of 
the response and to determine the lowest amount of analyte on column.  The 
concentrations (n=16) that were employed for both analytes ranged from 5 ng/ml down 
to 5 pg/ml for both β-carbolines.  Areas under the peak for both analytes were used for 
calibration quantitation.  Once the calibration range was established and assessed via 
linear regression, injections were run in triplicate for those injections giving an adequate 
signal-to-noise ratio for detection (S/N > 3).    The lowest detectable amount on column 
was defined as a S/N > 3 with %RSD < 2% for n=6 repeated injections.  
 
3.3.2e Results 
 Using a neat solution, the chromatography was optimized with respect to the 
column chemistry and configuration, the percent of organic modifier, pH and 
concentration of the buffer, flow rate and injection volume.    Chromatographic 
retention of both H and NH was seen for all columns investigated.   Although they were 
not baseline resolved, peak(s) were observed within one minute for each column when 
100% methanol or 100% acetonitrile was used for the mobile phase.   For these extreme 
conditions, the capacity factor (k) was < 0.2, resulting in the need to use a weaker, more 
polar mobile phase.    Adequate retention for the analytes, as defined by 0.5 < k < 20, 
was seen for a %B < 50%.    Although resolution of the analytes was not observed at 
various solvent strengths for both configurations of the C18 columns, the C8 column 
employed for investigation resulted in a sufficient capacity factor and resolution.  The 
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results of solvent strength (%B is 50:50 methanol:acetonitrile) on the capacity factor for 
both H and NH are exemplified in the figure below.  
  
Figure 3-6:  Capacity factor (k), on logarithmic scale, as a function of organic strength 
of mobile phase (%) for H (solid line) and NH (dashed line) on the C8 column.  Other 
HPLC parameters:  flow rate 1 ml/min, %A is pH = 3 H PO /KH PO3 4 2 4 buffer, 50 mM, 
and injection volume = 20 μl, column temp = RT.  (mean response on n=3 injections, 
%RSD < 2% for all) 
 
 Under these conditions, it can be seen that the organic strength of the mobile 
phase has a significant influence on the retention and the capacity factor for both H and 
NH.   As NH is slightly less lipophilic, the capacity factor is less than that of H at all 
%B.   Moreover, the separation (and resolution) between the analytes appear to increase 
with a decrease in %B.  At first approximation, the retention behavior of H and NH 
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decreases logarithmically with respect to mobile phase strength.  The dependence of 
RP-HPLC retention on %B has been studied exhaustively, and the retention behavior of 
H and NH is in agreement with other highly lipophilic compounds (Snyder et al., 1997).  
The successive reductions in %B from 50% to approximately 15% yielded results in the 
desired capacity factor range (0.5 < k < 20).  When the mobile phase strength was much 
weaker (%B <15%) the retention for both H and NH were unacceptably long.  
Moreover, the peak shape, albeit symmetrical, decreased in sharpness and, in turn, the 
S/N ratio. Superior resolution was obtained with the lower strengths of %B at the cost 
of a longer run time.   From the optimization results of organic strength, a range that 
was most favorable was between 15% - 35%.  Within this range of organic composition, 
the analytes showed baseline separation with the resolution increasing with a decrease 
in %B.  Moreover, at this concentration a sufficient S/N ratio was observed for both 
analytes.  This range was kept in mind in order to evaluate selectivity of the assay 
during method development in the biological matrix.     
 In the initial organic strength experimentation, the optimization was based on 
the separation of the cationic form of both H and NH (pH~3 buffered aqueous phase).    
For ionic compounds, a change in pH can result in a 10-fold or greater range in capacity 
factor (Snyder et al., 1997), but also have a profound effect on the resolution of the 
analytes.  Therefore, based on the initial isocratic conditions and using a %B of 30% 
methanol, the pH was adjusted to evaluate the effects on retention and resolution for H 
and NH.   As seen in figure 3-7, a systematic increase in the capacity factor is observed 
with increases in pH of the mobile phase.   Between the low pH range of 3.0 to 4.0, the 
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capacity factor is relatively consistent with sufficient resolution between H and NH.    
As the pH approaches the pKa of H and NH (i.e., ~7.3) the capacity factor increases and 
less resolution is observed between analytes, due to a shorter retention (see figure 
below).   
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Figure 3-7:  Capacity factor (k) and resolution (Rs) on Cartesian scale, as a function 
mobile phase pH (H PO /KH PO  buffer, 50 mM) for H (●) and NH (○) on the C3 4 2 4 8 
column.  Other HPLC parameters:  flow rate 1 ml/min, %B is 30% methanol, 50 mM, 
and injection volume = 20 μl, column temp = RT.  (mean response on n=3 injections, 
%RSD < 3% for all) 
 
 
At all pH measurements, H possessed a larger capacity factor than NH and the retention 
behavior became similar upon increasing pH towards the pKa.     
 Peak shape, asymmetry and peak tailing was evaluated at each pH.  Peak 
asymmetry was close to unity (As~1.4) for the mobile phase pH between 3.0-3.5.  An 
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increase to more neutral pH yielded less symmetric peaks, significant tailing, and less 
resolution.  For these experimental conditions, the peak shape of both H and NH 
deteriorates progressively as the pH is increased above 4, presumably due to a 
decreased buffer capacity of the phosphate buffer at this pH.   The buffer capacity at 
each pH was further explored by changing the concentration between 10-50 mM at pH 
values below 4.0.   Influence of the concentration of phosphate buffer (20 - 50 mM) on 
the peak separation and shape was negligible at pH values below 4.0.   Although 
separation with the 10 mM buffer concentration at low pH yielded adequate separation, 
reproducibility was slightly compromised, presumably due to a lower buffering 
capacity.   
 Under the conditions with 30% methanol as the organic modifier, at low pH 
(3.0-3.5) an acceptable retention factor for both H and NH was seen with satisfactory 
baseline resolution and symmetrical peak shape.  A buffer concentration of 20 mM was 
used for further method development as this concentration would less likely precipitate 
with the organic solvents used and would maintain sufficient buffer capacity.   
 Flow rates between 0.8 – 1.2 ml/min were explored, ensuring that the pressure 
requirements for the columns utilized were met (<1800 psi).    For the C8 column used 
(5-μm particle size, 15 x 0.46 cm) the run times and resolution varied, with no intended 
change in selectivity.  The majority of the optimization was performed at controlled 
room temperature (22ºC) with successive increases in column temperature yielding 
shorter run times, sharper peaks, and slightly decreased resolution.   Temperature 
optimization was performed in the later stages of HPLC method development using the 
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biological matrix.  Injection volumes, at the concentration used for optimization, did not 
show peak distortion or irreproducibility between 20 and 80 μl, suggesting that 
sensitivity optimization may be explored between these injection volumes at the later 
stages.   The sample solvent composition was kept similar to that of the mobile phase 
composition.  Deviations of ±15% organic composition for the solvent, relative to the 
mobile phase, resulted in peak distortion and double-peaking.  The final optimized 
conditions, for the neat solution, that were used for system suitability, peak shape 
assessment, and calibration assessment are presented in the table below. 
 
 
Table 3-5: Final Experimental Conditions for RP-HPLC Separation of Ionized H and 
NH in neat solution (mobile phase). 
 
Separation variable    Optimized condition    
 
Column     Agilent® Zorbax Eclipse XDB, C8
       15 x 0.46 cm, 5 μm, endcapped 
Solvents A and B 
     % B     methanol, 30% 
     Buffer (compound, pH, concentration) KH2PO4/H3PO4 buffer (pH=3.2, 25mM) 
 
Flow rate     Isocratic, 0.9 ml/min 
 
Column temperature    22ºC (room temperature) 
 
Injection volume    80 μl     
 
Detection     λexcitation = 300 nm, λ emission = 433 nm 
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 Under these chromatographic conditions, separation of H and NH was optimized 
(figure 3-8).  With this separating system, good resolution, plate numbers and band 
symmetries were found for H and NH and separated rapidly at a mobile phase flow rate 
of 0.9 ml/min. 
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Figure 3-8:  Chromatogram of norharman (406 pg/ml) and harman (452 pg/ml) in a 
neat solution of MeOH: KH PO /H PO2 4 3 4 buffer (pH 3.2) (25:75). Baseline resolved 
retention times are at 5.02 min and 6.51 min for norharman and harman, respectively.    
 
  
 Along with run time, capacity factor and retention time, the peak shape and 
system suitability measurements were assessed to finalize the chromatographic 
conditions.     The system suitability parameters are presented in the table below.  
 
 
 
 
 
 
80 
Table 3-6:  System suitability measurements for the final RP-HPLC Separation 
Conditions for H and NH in neat solution (mobile phase).  Peak shape measurements 
are based on the medium concentration used for both analytes (chromatogram in Figure 
3-8). 
 
Suitability parameter     Norharman     Harman  
 
Resolution, Rs                                       2.99                 
 
Retention time (min)               5.02            6.51 
 
Number of theoretical plates, N             4641          5104  
 
Peak tailing factor, T              1.21          1.05 
 
Peak asymmetry factor, As                1.41          1.10 
 
%RSD (n = 6) of Area:                                       Low                  2.6 (202 pg/ml)       2.3 (260 pg/ml) 
                                            Med                  1.3 (406 pg/ml)                    2.4 (452 pg/ml) 
     High                  0.9 (1.12 ng/ml)                  1.3 (1.25 ng/ml) 
  
 
 The optimized RP-HPLC conditions were consequently used to assess linearity 
of the response via calibration curves.   Linear regression parameters and statistical 
assessment resulted in linearity throughout the concentration range for both H and NH, 
with adequate precision and accuracy for all concentrations.   The regression was 
performed on the relationship between analyte concentration (pg/ml) and peak area 
response with a 1/x2 weighting factor.  The calibration curve results are presented in the 
table below. 
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Table 3-7:  Calibration curve measurements (n=6 injections) for final RP-HPLC 
separation conditions for H and NH in neat solution.    
 
Calibration curve parameter 
 
Norharman 
 
Harman 
 
Slope ± SD 
 
4315 ± 82 
 
5121 ± 128 
Intercept ± SD 23 ± 43 52 ± 67 
% RSD (all concentrations) < 3.2 < 2.7 
% DFN (all concentrations) < 6.7 < 9.2 
R2 (range) 0.9982 (0.9811 – 0.9994) 0.9965 (0.9872 – 0.9991) 
Linear range 20 pg/ml – 2524 pg/ml 26 pg/ml – 2653 pg/ml 
Lowest amount on column, 
LOD (pg)  
1.6 pg  2.1 pg  
 
 The calibration results showed linearity throughout the specified range, deemed 
by the values of R2 > 0.99 for both analytes.  For concentrations tested above the range, 
signal saturation was apparent, suggesting that samples with concentrations above the 
linear range may require dilution.    The slopes for both H and NH yielded reproducible 
results upon replication, with H possessing larger response factor sensitivity.  In other 
words, a given change in concentration of H produced a larger response than that of 
NH.    The accuracy assessment as defined by %DFN (%deviation from nominal), 
showed that a linear regression model was appropriate for calibration purposes and 
interpolation between concentrations may be performed for unknown concentration 
evaluation.    The method exemplified precision with superior relative standard 
deviations (%RSD) in comparison to the limits aforementioned.   
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3.3.2f Discussion    
 The RP-HPLC method for the quantitative analysis of a neat solution of H and 
NH has been optimized for further bioanalytical method development.  The most 
favorable fluorescence detection environment (i.e., pH) and initial RP-HPLC conditions 
used for highly lipophilic compounds were used as a springboard for further 
modifications.  The initial pH of ~3 resulted in the most sensitive signal per 
concentration of analyte for spectrofluorometric results.   The major species of H and 
NH at this pH was in its cationic form, classifying this sample as ionic.   In turn, both 
organic modifier (%B) and pH were optimized, as both are recognized to have a 
profound effect on retention behavior of ionized samples.   
 For the cationic forms of H and NH, the C8 column configuration employed 
confirmed satisfactory baseline resolution and retention, as deemed by the capacity 
factor.  As expected, the less lipophilic NH eluted before H in all chromatographic runs 
and selectivity was maintained.  A range of organic content for the mobile phase was 
determined to be between 15-35%.  Differing strengths of organic solvents (i.e., 
methanol and acetonitrile) can be used for H and NH separation and was considered for 
selectivity and interference chromatographic optimization in the biological matrix.   In 
comparison to previously published methods, improvement in the resolution of H and 
NH was sought, with this range demonstrating adequate and reproducible resolution.  
This range %B was to be further investigated using the biological matrix, in the case of 
interfering endogenous analytes in the chromatography.    In the case of pH adjustment, 
a range between pH 3.0-3.5 provided favorable retention and resolution, giving room 
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for selectivity investigation in the biological matrix.    The concentration of phosphate 
buffer in this pH range provided significant buffering capacity to maintain 
reproducibility without compromising the chromatographic endpoints required.   
 The concentration range used for calibration assessment was in physiological 
range.    Using a neat solution of H and NH, concentrations of up to ~ 2.5 ng/ml (200 pg 
on column) may be detected using the calibration regression; concentrations above may 
require dilution.  A low picogram level can be detected on column, suggesting that this 
method may be sensitive enough to detect reported amounts in human plasma.  A 
formal assessment of sensitivity for the method (lower limit of quantification) was not 
assessed during the current point in the method development and was postponed to the 
validation in the actual biological matrix.    
 Upon assessment of the system suitability requirements, reproducible and 
symmetrical bands for both H and NH were seen under the ideal chromatographic 
parameters.  The chromatographic conditions from these results were used for 
subsequent experimentation in the biological matrix.   Moreover, favorable ranges for 
organic content and pH of the mobile phase were carried forth for further optimization 
in plasma. From the detection and chromatographic investigations, the experimental 
conditions that were to be used in the human plasma matrix are included in the table 
below. 
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Table 3-8:  Experimental conditions, with ranges, to be used for RP-HPLC Separation 
of Ionized H and NH in human plasma matrix. 
 
Separation variable    Optimized condition    
 
Column     Agilent® Zorbax Eclipse XDB, C8
       15 x 0.46 cm, 5 μm, endcapped 
Solvents A and B 
     % B     methanol and/or acetonitrile, 15-35% 
     Buffer (compound, pH, concentration) KH2PO4/H3PO4 buffer (pH=3.0-3.5, 
25mM) 
 
Flow rate     Isocratic, 0.8 – 1.2 ml/min 
 
Column temperature    22 - 40ºC  
 
Injection volume    20-80 μl     
 
Detection for H and NH   λexcitation = 300 nm, λ emission = 433 nm 
 
 
3.3.3 Extraction Optimization and Internal Standard Investigation 
 As an essential part of the bioanalytical method development, the sample 
preparation is intended to provide a reproducible and homogeneous solution that is 
suitable for injection into the HPLC system.  The goal of the sample preparation is to 
produce a sample aliquot that is relatively free of interferences, will not damage the 
HPLC column/system and is compatible with the intended HPLC method.    
Furthermore, the careful method development of the sample extraction method deserves 
scrutiny because the method precision and accuracy are frequently determined by the 
sample pretreatment procedure (van der Wal and Snyder, 1981).    
 Norharman and harman have been analyzed in different matrices including fried 
food, plant extracts, beverages and biological matrices such as urine, blood plasma and 
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organs.     The majority of the extraction techniques have been in part to the evaluation 
of heterocyclic amines (HCA) in food sources.  These methods include liquid-liquid 
extraction with lipophilic solvent at alkaline pH (Airaksinen and Kari, 1981a) or solid-
phase extraction using one ion-exchange column (Herraiz, 2000) or extraction with 
phthalocyanin-based blue cotton, blue rayon or blue chitin (Hayatsu et al., 1991; Bang 
et al., 2002).  Although these methods proved quite successful in the quantification of 
the β-carbolines in food sources, their applicability in human plasma has yet to be 
determined.     
 Since the amounts of norharman and harman in the human plasma matrix are 
low, and plasma is considered a complex matrix, multi-step enrichment and preparation 
techniques are necessary.    A liquid-liquid extraction method involving alkalinization 
and tert-butyl-methyl-ether extraction (Breyer-Pfaff et al., 1996) was developed to 
consolidate norharman and harman from 2-ml of human plasma.  Although the method 
proved sensitive enough to detect physiological concentrations, an internal standard was 
not used and method ruggedness and reproducibility were not reported.  Solid-phase 
extraction (SPE) procedures have also been performed for extraction of H and NH from 
plasma using C18 (Spijkerman et al., 2002) and phenyl (Rommelspacher et al., 1991b) 
SPE sorbent beds, but the methods have inadequacies such as poor sensitivity and the 
lack of an internal standard, respectively.  
 In order to improve upon the inadequacies of reported methods, the following 
extraction investigations were designed to provide a reproducible quantitative recovery 
of both H and NH analytes from human plasma.  The goals for optimization of the 
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extraction was to (1) obtain the highest recovery of each analyte to enhance sensitivity 
and assay precision, (2) to attain a reproducible extraction method, and (3) to minimize 
the sample-pretreatment steps in order to decrease the opportunity for errors.  Moreover, 
the investigation involved an exploration of a suitable internal standard for calibration 
purposes and, in the case of extensive sample preparation, correct for sample losses due 
to the extraction.    
 With respect to the exploration of the extraction process, SPE techniques were 
chosen over the LLE (liquid-liquid extraction) a priori.    SPE was chosen due in part to 
its advantages over LLE methods including a more complete extraction of the 
analyte(s), a more efficient separation of interferences, easier collection of the total 
analyte fraction, and more efficient separation process that LLE methods (Snyder et al., 
1997).    Practically, SPE is effective in removing interferences and “column killers” 
and this extraction technique permits the trace enrichment or concentration of the 
analyte, especially in the case for the low reported concentrations of H and NH.  A 
primary disadvantage of SPE is the variability associated between extraction columns of 
similar column chemistry and configuration (Snyder et al., 1997).   For this reason, 
employment of an internal standard may be necessary to account for differences in the 
efficiency of analyte removal from the sample. 
 Although SPE methods provide fast and efficient pre-analysis sample clean-up 
and concentration, the development requires attention to four related factors:  (1) proper 
physical and chemical characterization of the analyte and the sample is required.  
Factors such as the analytes’ polarity relative to the sample matrix, the presence of 
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ionizable functional groups, solubility and molecular weight determine how strongly the 
analyte is retained by the packing bed; (2) A proper retention strategy needs to be 
explored.   Generally, the analyte is retained on the packing bed while the interferences 
are unretained or washed off the packing bed prior to eluting the analyte; (3) A suitable 
packing type and bed size should be investigated.  Different packing types offer 
different selectivities that should be exploited to maximize the structural differences 
between the analyte and sample interferences.  The goal is to obtain the cleanest extract 
with the highest recovery.  (4)  Suitable conditioning, wash and elution solvents should 
be   explored for maximal and reproducible recoveries.  Attention should be given to the 
solvent strength relative to the packing material.  The final conditioning solvent should 
be relatively weak which will not act as an elution solvent.  Buffers should be used in 
the case of ionizable species.  The wash solvents should remove the weakly retained 
interferences but should not be strong enough to elute the analyte.  Finally, the elution 
solvents should be strong enough to completely elute the analyte in a small volume.  
Post-column concentration may be employed to improve the sensitivity of the method.  
Each of the aforementioned factors should be considered and optimized to result in a 
robust and sensitive SPE method.  
 The physicochemical characteristics of H and NH have to be considered when 
developing a SPE method for human plasma.  As the human plasma matrix is quite 
complex and may possess many interfering substances, the lipophilicity, pKa, and 
chemical structure plays an important role in the isolation of the analytes of interest 
from the matrix.    Successful isolation of the analytes from the biological matrix 
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depends on the relative affinities of the analyte between the biological matrix and the 
adsorbent and relative ease of eluting the compound for subsequent analysis 
(McDowall, 1989).  Both β-carbolines are regarded as hydrophobic molecules that are 
strongly to moderately non-polar.   Moreover, the structure owns to a functional group 
that is basic in nature, the ionizable secondary amine.  The imidazoline nitrogen is 
suspected to play a minor role in the retention characteristics on an SPE column, as the 
pKa is present in an extreme range (pKa > 14).    Due to these characteristics, typical 
SPE phases that may be used for the extraction of H and NH consist of reversed phase 
nonpolar bonded phases that are strong to intermediate in hydrophobicity.  Some 
examples of the typical solid phases that exemplify these characteristics include 
octadecylsilane (C18), octylsiloxane (C8), cyclohexyl and phenyl.  Due to the ionizable 
secondary nitrogen, strong cation exchange columns may be used for the SPE method.  
The physicochemical characteristics of H and NH render retention mechanisms 
comprising of hydrophobic van der Waals forces and π-π interactions.    
 Since several sample preparation steps are required, especially in the case of 
SPE, quantification requires the application of an internal standard.  Deuterated 
norharman or harman would be most suitable internal standards for mass spectrometry 
analysis but are not commercially available.   In biological samples such as plasma or 
tissue where lower levels (pg/ml) are detected, the fluorescent synthetic 1-ethyl-9H-
pyrido[3,4-b]indole or 1-propyl-9H-pyrido[3,4-b]indole have been used successfully as 
internal standards in HPLC analyses with fluorescence detection (Pfau and Skog, 2004).   
The synthesis of these compounds is quite laborious and requires extensive spectral and 
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structural confirmation prior to appropriate use.    Therefore, an appropriate internal 
standard was explored for the use in H and NH quantification in plasma.   
 For HPLC-FD the internal standard is generally a different compound from the 
analyte, but is well resolved in the HPLC separation (Snyder et al., 1997).  The main 
purpose of the internal standard is to compensate for changes in sample size and 
recovery from SPE.   When added prior to sample preparation, a properly chosen 
internal standard can be used to correct for sample losses.  These sample losses may be 
due to variability associated between extraction columns of similar column chemistry 
and configuration.   The internal standard should be chosen, in part, to mimic the 
physicochemical characteristics of the analyte in the pretreatment steps (Snyder et al., 
1997).   Therefore, requirements for the choice of an appropriate internal standard 
include: (1) adequate resolution in the HPLC separation from the other analytes, whilst 
maintaining a similar retention (capacity factor) behavior; (2) should not be in the 
original sample or be a precursor of the endogenous analytes; (3) should mimic the 
analyte in any of the sample pretreatment steps; (4) should be commercially available in 
high purity; and (5) should be stable and unreactive with components of the matrix or 
mobile phase.  These necessities were evaluated in conjunction with the calibration.    
The calibration plot incorporates the ratio of the peak area of the analyte (H or NH) to 
the internal standard peak area plotted vs. the concentration of H or NH.     Calibration 
plots are generally assessed for reproducibility and its capacity to be characterized by a 
simple regression model.   
90 
 The following experiments were performed to appraise an appropriate SPE 
method for the extraction of H and NH from human plasma.  Moreover, the exploration 
of a suitable internal standard for the extraction method was performed.  The 
methodology for assessment of the appropriateness of an SPE method and internal 
standard included the following: 
1. An internal standard that possessed similar physicochemical characteristics to H and 
NH was sought through reported literature.  The physicochemical characteristics 
evaluated included lipophilicity, solubility, and the ability to give an adequate 
fluorescence signal. 
2. Chromatographic resolution of both H and NH along with the internal standard was 
explored by using the aforementioned HPLC parameters (see table 3-8).   The 
criteria for the acceptance of chromatographic parameters included resolution of H 
and NH along with the internal standard, peak shape and favorable capacity factors 
for all compounds. 
3. SPE extraction was initially evaluated for the H and NH analytes in a neat buffered 
solution in order to obtain optimal conditioning, loading, washing and eluting 
conditions for the highest and most reproducible absolute recoveries.  
4. SPE conditions were further evaluated using the internal standard along with both 
analytes to obtain optimal absolute and relative recoveries and reproducibility.  
5. The SPE methodology obtained from neat buffered solution was subsequently used 
for the extraction method from human plasma. Further exploration of additional 
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extraction steps (i.e., protein precipitation) were evaluated in the event that further 
sample clean up was required.  
6. Calibration curves were constructed in neat solution and plasma to evaluate the 
amount of plasma required to quantify a low amount (~5 pg/ml), concentration 
dependency of the extraction recovery, and to assess the concentration range to be 
used for calibration curves. 
 The optimized SPE extraction method was to be carried forth for method 
validation purposes. 
 
3.3.3a Materials and Reagents 
 All chemicals were or analytical grade quality and obtained from commercial 
sources.  Solvents used for the chromatographic optimization measurements were of 
spectroscopic or HPLC grade and used after filtration with a 0.2 μm porosity filter 
(Corning, Corning, NY).    In addition to all reagents used for the aforementioned 
optimized investigations, the extraction experiments also incorporated the following 
materials and reagents. 
1. Yohimbine HCl, 98%  (Sigma-Aldrich Corp., St. Louis, MO) 
2. Potassium phosphate buffer (for buffers at pH 7.0) 
 - monobasic potassium phosphate, KH2PO4 (Sigma-Aldrich Corp, St. Louis, 
 MO) 
 - dibasic potassium phosphate, K2HPO4 (Sigma-Aldrich Corp., St. Louis, MO) 
3. Borate buffer (for buffers pH 8 and 9) 
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 - Sodium tetraborate decahydrate, Na2BB4O7*10 H2O (Sigma-Aldrich Corp., St. 
 Louis, MO) 
 - Boric acid, H3BO4 (Sigma-Aldrich Corp., St. Louis, MO) 
4. Acetonitrile, HPLC grade (VWR, West Chester, PA) 
5. Methanol, HPLC grade (VWR, West Chester, PA) 
6. Perchloric acid, 70% HClO4 , double distilled (GFS Chemicals, Columbus, OH) 
 
3.3.3b Equipment   
1. Solid Phase Extraction (SPE) cartridges - Mixed mode (C18-cation exchange) and 
lipophilic sorbent beds (C2, C8, C18 and phenyl), 100 mg bed mass, 1.5 ml volume 
(Alltech, Deerfield, IL)  
2. Centrifuge – Eppendorf 5804R, Benchtop Temperature Controlled (Westbury, NY) 
3. SPE manifold – 24-port, with stopcocks (Alltech, Deerfield, IL)  
4. Vacuum for SPE manifold (KMF Neuberger Vacuums, Trenton, NJ) 
5. Borosilicate glass test tubes, 15mm x 125mm, 16 ml volume (VWR, West Chester, 
PA) 
6. Polypropylene tubes, 15 ml volume (VWR, West Chester, PA) 
 
3.3.3c Preparation of Solutions and Standards 
1.  Harman and Norharman in methanol – combination standards were made for both 
analytes. A stock solution of 1 µg/µl (1 mg/ml) was made for H and NH.  
Approximately 3 mg for both H and NH was added to a silanized, 4-ml amber vial in 
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which an appropriate volume (~3 ml) was added to dilute to a desired concentration, 
ensuring to account for salt weight and purity.   Serial dilutions of 50 ng/µl and 500 pg/ 
µl were made from the stock solution to create smaller “stock solution” concentrations.  
All concentrations used for the experiments were diluted, with methanol from these 
three stock solutions. 
2.   Yohimbine in methanol - A stock solution of 1 µg/µl (1 mg/ml) was made.  
Approximately 2 mg for both H and NH was added to a silanized, 4-ml amber vial in 
which an appropriate volume (~2 ml) was added to dilute to a desired concentration, 
ensuring to account for salt weight and purity.   Serial dilutions of 100 ng/µl and 1 ng/µl 
were made from the stock solution to create smaller “stock solution” concentrations.  
All concentrations used for the experiments were diluted, with methanol from these 
three stock solutions. 
3.  Protein precipitation solutions – all subsequently kept at 4˚C until use. 
  a)  Acetonitrile:Methanol – approximately a 1:1 ratio of both organic solvents  
  b) 1 M HClO4 –  for 100 ml, 8.54 ml of a 70% HClO4 solution (11.6M) was 
  added to a volumetric flask and qs to 100 ml with Milli-Q® water. 
  c)  1 M HClO4 : Acetonitrile – approximately a 75:25 ratio of acid to organic 
  solvent. 
 
3.3.3d Methods 
 A literature review was conducted in order to find a suitable internal standard 
for H and NH quantification.    Desired characteristics for the internal standard included 
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similar physicochemical properties, structural similarity, and solubility as compared to 
H and NH.    Although an internal standard need not be structurally similar to the 
analytes, the structural attributes of the internal standard was important for the 
fluorescence detection and chromatographic behavior seen with H and NH.  Internal 
standards for use in the extraction of β-carbolines from food sources included sotalol, 
ibogaine, harmaline, and harmine.   With the exception of sotalol, the reported internal 
standards possess a similar planar β-carboline scaffold.    Harmaline and harmine were 
avoided as internal standards as they may be present in human plasma and/or may serve 
as precursors of the H and NH analytes.    The fluorescence qualities of ibogaine is not 
well understood but is suspected to be sufficient in its quantum yield.  However, 
ibogaine could not be purchased for the experimentation due to its classification as a 
Schedule I hallucinogen (Sigma-Aldrich, 1997).     
 Yohimbine (17-hydroxyyohimban-16-carboxylic acid methyl ester) was chosen 
as an initial internal standard as the physicochemical and structural characteristics are 
similar to those of the β-carboline analogues.  Yohimbine has been successfully 
quantified in human plasma via HPLC with fluorescence detection (Owen et al., 1985) 
in sub-nanogram levels.    Most importantly, this compound is not found endogenously 
in humans and is not suspected to be a metabolic precursor of the analytes of interest.    
The strong fluorescent characteristics are similar to those of H and NH, with yohimbine 
possessing a relatively large quantum yield (Gurkan, 1974). The structure and 
physicochemical characteristics of yohimbine are shown in the figure below.  
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            MW* (g/mol)                      390.9 
            pKa                         8.44, 14.39                                 
 Log D                                    2.4                                              
 Solubility*      slightly soluble in H2O (10 mg/ml), sparingly soluble in dilute 
        acids, soluble in ethanol, methanol 
 
Figure 3-9:  Structure and physicochemical characteristics of yohimbine (calculated 
using Advanced Chemistry Development (ACD/Labs) Software V 8.14 for Solaris, © 
1994-2007, ACD/Labs; *(Sigma-Aldrich, 2002) 
 
 Similar to the H and NH compounds, yohimbine has two ionizable nitrogen 
functional groups and a planar, conjugated ring structure.  Both of which can prove 
beneficial for the optimization of chromatographic and SPE experiments.     
 Chromatographic experiments were performed to obtain most favorable 
resolution of the analytes and the proposed internal standard yohimbine (YOH).   
Optimization for H, NH and the YOH separation were made in neat solution, prior to 
SPE exploration.    Initial chromatographic conditions were based on those obtained 
from prior optimization of H and NH separation (see table 3-8).    The percent of 
organic phase was varied from 15-35% methanol or acetonitrile.   If needed, pH of the 
aqueous phase was altered between 3.0-3.5 to optimize the peak shape of all analytes 
and YOH.   Within this pH range, YOH is suspected to be ionized at the pyridine 
nitrogen site of the structure, similar to the other β-carboline analogues.    The influence 
of mobile phase flow rate was investigated to obtain ideal capacity factors and 
96 
resolution.    The fluorescence detection parameters for YOH was taken from reported 
results: λexcitation=  280 nm, λemission = 360 nm (Owen et al., 1985).  Of note, YOH could 
not be detected using the excitation and emission wavelengths needed for H and NH 
detection.   
 In the case of H and NH, a range of expected physiological concentrations were 
tested for quantification and linearity in the presence of the internal standard.    
Calibration curves were constructed within expected physiological ranges (5 pg/ml – 
2.0 ng/ml for both H and NH) to determine linearity and the least quantifiable amount 
on column.  To evaluate the suitability of YOH as an appropriate IS, similar 
concentrations were used for assessment of linearity and to determine an ideal 
concentration needed for the internal standard.   
 Initial exploration of a potential SPE method was performed in water at a 
concentration of 1 ng/ml for both analytes and IS.   Mixed mode (C18-cation exchange) 
and lipophilic sorbent beds (C2, C8, C18 and phenyl), with 100 mg bed mass and 1.5 ml 
volume (Alltech ®) were assessed for retention capacity of H, NH and YOH.   Loading, 
washing, and elution solvents, with pH adjustments were investigated for adequate and 
reproducible recovery.   
 For the lipophilic sorbent beds, loading solvents included unbuffered and 
buffered aqueous solutions at least 2 pH units above the pKa of H and NH.   At pH > 7 
both analytes are expected to be in its neutral state, thereby increasing the retention onto 
the lipophilic sorbent bed.    Buffering solutions included pH 7 phosphate buffer (20 
mM) and pH 8 and 9 H3BO4/Na2BB4O7 buffer (20 mM).   Analyte retention onto the SPE 
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column was assessed by evaluation of breakthrough upon loading.   Ideal conditions 
were regarded as possessing minimal to no analyte breakthrough with maximum 
retention of the analytes.   Washing solvents included water, buffered solutions (same as 
above), and a range of aqueous mixtures with organic solvent (5-30% methanol).   The 
washing solvent with the highest percent organic, with minimal analyte breakthrough, 
was subsequently employed for the plasma analysis for the eluting of potential 
interfering substances.     Elution solvents included 100% organic solutions of methanol 
and/or acetonitrile that was or was not acidified with 0.5% acetic acid.  The pH 
adjustment of the elution solvent was explored to ensure the ionization of the analytes 
to, in turn, release the analytes from the SPE sorbent bed.    Elution volumes ranging 
between 1 and 3-ml were explored with the acceptance criteria being the lowest volume 
of elution solvent that yielded the highest recovery.  If needed, concentration of the 
elution solvent was performed via N2 in order to achieve an adequate signal for HPLC 
analysis.  Upon dry-down, the residue was dissolved in approximately 100 μl of mobile 
phase.    This step required the use of a control to assess for sample loss due to the N2 
(dried down and reconstituted vs. neat solution in reconstitution solvent).   For each 
extraction condition, experiments were performed in triplicate.   The SPE vacuum flow 
was not to exceed 1 ml/min to minimize analyte breakthrough. 
  Absolute recovery (extracted vs. unextracted area under the peak) was evaluated 
for each H and NH at 50 pg/ml, 500 pg/ml, 1.0 ng/ml and 2.0 ng/ml.   Moreover, similar 
concentrations were used to assess absolute recovery for YOH.  Ideal conditions yielded 
maximum and most reproducible recovery for all analytes and internal standard.  In 
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addition, relative recovery (analyte to internal standard peak area ratio for extracted vs. 
unextracted) was assessed to compare the relative retention behavior of H and NH to 
YOH.  The SPE conditions that yielded the most reproducible results were used for 
assessment of H, NH, and YOH extraction recovery from pooled plasma.  Recovery 
experiments were performed in triplicate. 
 The ideal chromatographic parameters and SPE conditions were consequently 
used for evaluation of H and NH extraction from plasma.  Pooled human plasma 
(EDTA anticoagulant, non-smoking, drug-free, pooled from n = 20 males and females) 
was utilized as the matrix for SPE recovery exploration.    Optimization was performed 
using a 1.0 ng/ml concentration of both H and NH with 1 ng of YOH internal standard.  
The concentrations used for H and NH recovery assessment included 10 pg/ml, 50 
pg/ml, 500 pg/ml, 1.0 ng/ml and 2.0 ng/ml.    Moreover, “blank” plasma (unspiked) and 
a “zero” concentration level (spiked with 1 ng YOH internal standard) to evaluate the 
chromatographic interference of the internal standard and assess if an endogenous H 
and NH signal is present, respectively.   No more than 100 μl of standard solution was 
spiked into the plasma, ensuring that > 90% of the total volume was plasma matrix.   
The amount of pooled plasma that was used for the assessment was 1-ml.  In the case 
that the required sensitivity (~5 pg/ml) was not obtained larger volumes were used (up 
to 3-ml).  Larger volumes of plasma were not used due to the clinical sampling volume 
constraint and practicality of using a 100 mg sorbent bed for SPE (volumes greater than 
3-ml may cause decreased capacity of retention for the SPE sorbent bed).           
99 
 In the event that further sample clean-up be required, protein precipitation 
techniques were evaluated as a pretreatment step prior to the optimized SPE method.    
The viscosity and sample size of the plasma was thought to have a functional hindrance 
on the loading of the sample, with the viscous sample not being able to flow through the 
SPE tube at a given flow rate of 1 ml/min.    For 1-ml of pooled plasma, protein 
precipitation solutions included 1-ml cold acetonitrile, 1-ml cold acetonitrile:methanol 
(50:50), 1-ml cold HClO4 and 1-ml cold HClO4:acetonitirile (75:25);  each of which 
have shown to be effective in the extraction of highly lipophilic compounds (Souverain 
et al., 2004).    All solutions were kept in 0 ºC prior to use.  For each experiment, pooled 
plasma spiked with 1.0 ng of each analyte and internal standard was subjected to protein 
precipitation, with a 1:1 mixture of plasma to protein precipitation solution.  The 
mixture was vortexed for 2 minutes and refrigerated between 10 ºC for 10 minutes.  The 
sample was later centrifuged at 2300 rpm for 10 minutes at 4 °C.  The supernatant was 
pH adjusted to pH = 9 with 100 µl of 1 N NaOH and H3BO4/Na2BB4O7 buffer (pH = 9.0, 
20 mM) and subjected to the SPE cartridge.   
 A comparison was made to the plasma sample with and without protein 
precipitation.    The plasma samples evaluated without protein precipitation were treated 
with a buffer dilution (4:1 buffer to plasma) to ensure proper flow rates and minimize 
viscosity effects through the SPE column.   The final SPE and protein precipitation 
extraction method was to be used for subsequent method validation experiments.   
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3.3.3e Results 
 The proposed YOH internal standard was chromatographically resolved from 
the H and NH analytes using the following conditions:   
 
 
Table 3-9:  Experimental conditions for RP-HPLC Separation of Ionized H, NH and the 
internal standard, YOH, in neat solution. 
 
 
Separation variable    Optimized condition    
 
Column     Agilent® Zorbax Eclipse XDB, C8
       15 x 0.46 cm, 5 μm, endcapped 
Solvents A and B 
     % B     35% methanol 
     Buffer (compound, pH, concentration) KH2PO4/H3PO4 buffer (pH=3.2, 25mM) 
 
Flow rate     Isocratic, 0.95 ml/min 
 
Column temperature    40ºC  
 
Injection volume    50 μl     
 
Run Time     11 minutes 
 
Detection for H and NH   λexcitation = 300 nm, λ emission = 433 nm 
           YOH    λexcitation = 280 nm, λ emission = 360 nm  
 
  
 Slight modification of the flow rate and % organic composition from the initial 
RP-HPLC conditions yielded adequate resolution and peak shape of both H and NH (Rs 
>1.9) and the internal standard YOH.      The capacity factor (3 < k < 9) and number of 
theoretical plates (> 4000) for all compounds were in the desired range.  Peak shape 
(including asymmetry and tailing factor) was slightly compromised, but yielded 
sufficient results for quantification purposes.    The HPLC chromatogram for the 
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separation of NH, H and the proposed internal standard, YOH is shown in the figure 
below. 
 
       
Figure 3-10:  Sample chromatogram of spiked NH and H (500 pg/ml each), with YOH 
as internal standard (1 ng/ml) in neat solution.  Retention times for NH, H, and YOH 
were at 4.86, 5.89, and 7.95 minutes, respectively.   
 
 Chromatographic response was linear throughout the concentration range 
through ~2.5 ng/ml for H (R2 > 0.996), NH (R2 > 0.997) and YOH R2 > 0.998).  The 
minimum amount quantified on column (as deemed by the limit of detection) for H, NH 
and YOH was 1.6 pg, 2.1 pg, and 53 pg, respectively.  The optimized RP-HPLC 
conditions were used for the evaluation of a suitable SPE extraction methodology.     
, C Lipophilic sorbent beds including C8 18, and phenyl, yielded high (>80%) and 
reproducible (%COV< 6%) absolute recoveries in buffered water matrix for all analytes 
and internal standard. The phenyl sorbent bed was initially chosen for subsequent 
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plasma analysis to increase the selectivity of the extraction.    All solutions used for SPE 
from a neat matrix required optimization.  The loading conditioning solution required 
buffering to maintain significant retention of all the compounds.  In the case of the 
loading solution, 97±3% of H and NH was retained while 92±4% of YOH was retained 
upon loading of a pH = 9, H3BO4/Na2BB4O7 buffer (pH = 9.0, 20 mM) adjusted solution 
(n=3 extractions).   The systematic decrease in pH of loading and conditioning solvents 
(from pH 8 to 7), decreased the retention of the compounds slightly but caused 
significant amount of variability in the retention capacity (%COV > 9% for all 
compounds).   
 With the specified pH for conditioning, the washing solvents included water and 
the H3BO4/Na2BB4O7 buffer (pH = 9).  The amount of organic solvent for the washing 
step could not exceed 10% methanol without significant analyte breakthrough.    A 
water washing step was employed prior to elution in order to minimize salt transfer into 
the elution solvent step.   The water wash step, although not buffered, did not yield any 
significant analyte breakthrough.  At least 2-ml of elution solvent was required to elute 
H, NH and YOH from the phenyl sorbent bed.   The organic solutions that were capable 
of complete elution included 100% methanol and 100% acetonitrile.   Acidification of 
the elution solvent was not necessary to elute the compounds from the sorbent bed.     
As consequence of the elution volume, a dry-down procedure was required to 
concentrate the analyte mixture prior to introduction to the HPLC.  Concentration of the 
sample via N2 did not lead to significant sample loss.  Silanization of all glassware used 
in the extraction procedure was used as precautionary measures to ensure maximum and 
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recproducible recoveries.  For a neat solution of H, NH and the internal standard YOH, 
the SPE method in depicted in figure 3-11 was employed.  
 
1 ml aliquot of pH = 9 buffered water  
with H/NH and 1 ng of YOH 
SPE Extraction (phenyl, 100 mg sorbent, Alltech®) 
Conditioning 
2 ml MeOH 
1 ml Milli-Q water  
2 ml  H3BO4/Na2B4O7 buffer (pH = 9.0, 20 mM)  
 
Loading 
 1.0 ml sample, adjusted to with  
H3BO4/Na2B4O7 buffer (pH = 9.0, 20 mM)  
 
Washing 
1 ml Milli-Q water 
2 ml H3BO4/Na2B4O7 (pH = 9.0, 20 mM)  
1 ml 10% Methanol and 90% H3BO4/Na2B4O7 buffer, pH = 9 
1 ml Milli-Q water 
 
Eluting 
3.0 ml MeOH 
Sample evaporated to dryness via N2 
Residue dissolved in 100 μl of mobile phase 
Injection volume of 50 μl into HPLC-FD 
 
 
Figure 3-11: Optimized SPE method in a 1-ml neat buffered solution for H, NH, and 
the internal standard YOH.   
  
 The concentration-dependency for the extraction of H, NH, and YOH from a 
neat matrix was evaluated.   Absolute recovery of both analytes and YOH at 
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concentrations of 50, 500, 1000, and 2000 pg/ml was > 94% with %COV < 4.3 % for 
each analyte, across the concentration range evaluated. The relative recovery for both H 
and NH at all concentrations was > 90% with %COV < 2.9 %.       
 
Table 3-10:  Absolute recovery from buffered water of norharman, harman and 
yohimbine following SPE (n=3 for each concentration).  (% mean ± SD). 
 
    50 pg  500 pg  1000 pg 2000 pg
Harman          95.6 ± 2.1 97.1 ± 0.5 96.4 ± 1.9 98.7 ± 5.2 
Norharman          97.6 ± 4.3 98.6 ± 4.1 95.8 ± 1.2 93.4 ± 4.7 
Yohimbine (IS)         94.4 ± 5.2 95.9 ± 1.2 95.2 ± 2.3 94.5 ± 3.6 
 
 The recovery experiments performed in the neat buffered matrix were also 
performed in the pooled plasma matrix.   For plasma experiments, further sample clean 
up was needed for elution through the SPE cartridge.   Protein precipitation was 
employed to ease the loading of the plasma sample and to remove potential additional 
interferences.   Moreover, the use of this additional cleanup step would potential extend 
the lifetime of the HPLC column used for the analysis.   The efficacy of the various 
precipitants in removing the protein from plasma sample and extracting the H and NH is 
shown in table 3-11.   Using 1 ng/ml level of analyte concentration the protein 
precipitation optimization yielded highest and most consistent relative recovery using 1-
ml cold HClO4:acetonitirile (75:25). Moreover, this particular protein precipitation 
treatment yielded statistically similar results to the samples not subjected to protein 
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precipitation (harman: p-value = 0.2701 and norharman: p-value = 0.1685, via unpaired 
Student’s t-test). 
 
 
Table 3-11:  Relative recovery from pooled plasma of norharman and harman (1 ng 
each) using different protein precipitation methods prior to SPE (n=3 for each 
concentration, % mean ± SD). 
 
 None* ACN ACN:MeOH  HClO4 HClO4:ACN*
Harman 85.3 ± 2.1 73.6 ± 14.1 79.1 ± 9.8 80.3 ± 5.9 89.7 ± 3.2 
 
Norharman 
 
83.2 ± 1.9 
 
8.2 ± 11.9 
 
77.2 ± 8.1 
 
5.8 ± 7.9 
 
91.9 ± 2.7 
 
(All solutions were used in a 1:1 ratio of protein precipitation solution to plasma.  ACN: 
acetonitrile; MeOH: methanol, HClO4: perchloric acid) *statistically similar via 
Student’s t-test, p-value > 0.05 
 
 
 The concentration dependency of the extraction procedure was evaluated at five 
different concentrations (see table 3-12).   The “blank” plasma (no spiked H, NH, or 
YOH) yielded a significant chromatographic signal for H and NH but not YOH, 
suggesting that there are no interferences in the pooled plasma for the YOH signal.  The 
“zero” concentration level (spiked with only 1 ng YOH internal standard) resulted in a 
significant signal for H and NH, which is suspected that these are constitutive of the 
pooled plasma.    Chromatograms for the “blank” and “zero” level are present in the 
validation section for this chapter. 
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Table 3-12:  Concentration-dependency of relative recovery of harman and norharman 
from 2-ml of pooled plasma after protein precipitation and SPE (n=3 for each 
concentration, % mean ± SD). 
 
Concentration (pg/ml) Harman Norharman 
10 81.6 ± 2.3 80.9 ± 1.3 
50 85.1 ± 2.5 82.5 ± 1.6 
500 88.2 ± 3.9 91.4 ± 5.3 
1000 89.1 ± 4.2 91.3 ± 3.1 
2000 91.7 ± 6.9 93.6 ± 7.4 
  
 Throughout the concentration range, the relative recovery was > 80% suggesting 
that the method of extraction resulted in a relatively high recovery from pooled plasma.    
A slight concentration dependency on the extraction was observed with larger 
concentrations yielding higher recoveries.  The extraction method throughout the 
concentration range was reproducible with % COV < 6% for both analytes across the 
concentrations.   In is expected that the constitutive contribution of H and NH in pooled 
plasma would increase the relative recovery from samples without endogenous analyte.   
 The amount of plasma needed to attain an adequate lower limit of quantification 
was initially explored.  For the experiments three volumes of “zero” concentration were 
evaluated, 1-ml, 2-ml, and 3-ml of pooled plasma.  The 2-ml plasma volume yielded 
statistically higher signals (peak area) compared to that of the 1-ml volume (p-value > 
0.182 for both analytes, via unpaired Student’s t-test).   In comparison with the 3-ml 
volume, peak areas of H and NH resulted in a less that proportional increase in signal, 
suggesting that these larger volumes affects the retention capacity of the SPE cartridge.  
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Moreover the variability in the extraction increased with the increase to the 3-ml 
volume.   This evaluation of volume suggests that 2-ml of pooled plasma was optimal is 
obtaining an adequate signal from presumably, drug-free, tobacco smoke-free plasma. 
Further evaluation of the accuracy, precision, recovery and endogenous signals of H and 
NH will be presented in the following section on validation of the method. 
 
3.3.3f Discussion  
 Prior to developing the extraction method and choosing an appropriate internal 
standard, proper characterization of the physical and chemical characteristics of H and 
NH was necessary.  Factors such as the β-carbolines’ polarity relative to the matrix, the 
presence of charged functional groups, and solubility, etc. was considered to assess how 
strongly the analyte would be retained by the packing bed.    For the extraction of H and 
NH from human pooled plasma, YOH was successfully used as an internal standard.    
Possessing similar physicochemical characteristics (i.e., logD and pKa), a strong 
fluorophore, and similar retention characteristics on the lipophilic SPE sorbent beds, 
YOH proved to be suitable for H and NH extraction conditions.   The chromatographic 
baseline resolution between H and NH was maintained with the addition of the well 
resolved YOH, maintaining a relatively short chromatographic run time (~11 minutes).    
From the original chromatographic conditions, the addition of YOH required only 
negligible changes in chromatographic parameters.  The signal response for both H and 
NH analytes was not compromised, maintaining peak shape, reproducibility and 
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sensitivity, while yielding a linear response for the YOH internal standard throughout 
the concentration range evaluated. 
 The primary approach used for the extraction involved retaining H and NH on 
the packing bed while interferences were unretained or washed off of the sorbent bed 
prior to elution of the analytes.  Packing beds of different selectivities were exploited to 
explore to maximize structural differences between the analytes and the sample 
interferences.  The phenyl sorbent bed was chosen, in part, due to the high and 
reproducible recoveries seen in the neat buffered matrix.   Moreover, the retention 
chemistry of the phenyl ring of the sorbent is hypothesized to interact with the phenyl 
rings associated with the H and NH analytes and the proposed internal standard, 
improving selectivity of the extraction method.     In essence, the selectivity of the 
phenyl sorbent bed was expected to provide a unique, non-polar retention mechanism 
via π-π and hydrophobic interactions with the phenyl rings of the analytes and internal 
standard.    This phase has been successfully utilized in the extraction of other aromatic 
hydrophobic compounds from biological fluids. 
 In addition to the SPE column configuration, thorough experimentation of 
suitable conditioning, wash and elution solvent was performed.  For each step, attention 
was given to the solvent strength and pH relative to the packing material.   A pH = 9 
buffered conditioning step (H3BO4/Na2BB4O7 buffer: pH = 9.0, 20 mM) minimized the 
variability associated with the absolute and relative recovery of H and NH to YOH.    
The pKa’s of all compounds tested for the extraction dictated the need for a buffered 
conditioning and loading step in order to control the ionization of the potentially 
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charged compounds.  The wash solvents were used effectively and removed weakly 
retained interferences, but were not strong enough to elute the analytes and internal 
standard.  A 10% methanol buffered solution proved successful in the removal of 
interferences while maintaining a high and reproducible recovery.   The methanol 
elution solvent was strong enough to completely elute the analytes in a relatively small 
volume.  Using the optimized extraction procedure provided high and reproducible 
absolute recoveries from the neat matrix, prompting its use in the plasma matrix. 
   A 1-ml plasma sample was insufficient to obtain a significant endogenous peak 
of both H and NH from pooled plasma (healthy, not drug-dependent subjects).   
Therefore, a 2-ml plasma sample was necessary to detect a significant chromatographic 
response.  Extraction of plasma samples greater than 2-ml resulted in the functional 
issues of irreproducible SPE solvent flow and pressure fluctuations of the vacuum 
manifold.     Dilution of the sample, albeit a solution, required relatively large volumes 
to be passed through the SPE cartridge, increasing the chances of analyte breakthrough 
and prolonging the time for analysis.    The effects of the sample volume on the SPE 
extraction required an additional protein precipitation step to the SPE procedure in order 
to provide a cleaner extract and to minimize SPE time.  A 1-ml cold HClO4:acetonitirile 
(75:25) treatment provided a clean extract and reproducible recovery for subsequent 
HPLC analysis.  The 1 M HClO4 solution alone provided a superiorly clean extract but 
the addition of acetonitrile provided additional extraction efficiency.  As all compounds 
of interest are highly lipophilic, the addition of a strong solvent like acetonitrile, would 
increase the extraction yield more so than the use of the aqueous HClO4 solution.   
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 Upon investigation of the concentration dependency of the extraction of H and 
NH from 2-ml of plasma, recoveries varied only slightly but were all above 80%.  The 
endogenous contribution, in addition to the spiked H and NH, are expected to cause an 
increased absolute and relative recovery from sample not containing constitutive H and 
NH.  Therefore, the relative recoveries obtained in the concentration dependency 
investigation are thought to be a product of endogenous and spiked H and NH.   On a 
side note, the artifactual formation of the β-carbolines upon subjecting the biological 
matrix to an acidic environment may cause circulating precursors to condense with 
aldehydes (Tsuchiya et al., 1999).    The evaluation of artifactual formation of H and 
NH from the extraction process will be assessed in the next section.    For the most part, 
the recoveries obtained from the final extraction procedure are relatively high (>80%), 
and more importantly reproducible.   
 Extraction from the pooled plasma matrix resulted in no interfering substances 
for the internal standard, as deemed by a lack of a substantial signal, at the expected 
YOH retention time, from the blank sample (no H, NH or YOH spiked).   Moreover, the 
addition of YOH to pooled plasma did not affect the signal for either H or NH, 
suggesting that YOH is not a precursor of the analytes of interest. 
 In summary, a combination protein precipitation-SPE extraction procedure was 
developed for the analysis of H and NH in 2-ml of human pooled plasma.  An internal 
standard, YOH, was successfully employed for the extraction process.  The optimized 
procedure was subsequently used for the validation of the complete method.  The final 
extraction method is summarized in the figure below. 
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Conditioning 
2 ml MeOH 
1 ml Milli-Q water  
2 ml  H3BO4/Na2B4O7 buffer (pH = 9.0, 20 mM)  
 
Loading 
 2.0 ml sample, adjusted to with  
H3BO4/Na2B4O7 buffer (pH = 9.0, 20 mM) and 1N NaOH  
 
Washing 
1 ml Milli-Q water 
2 ml H3BO4/Na2B4O7 (pH = 9.0, 20 mM)  
1 ml 10% Methanol and 90% H3BO4/Na2B4O7 buffer, pH = 9 
1 ml Milli-Q water 
 
Eluting 
3.0 ml MeOH 
Sample evaporated to dryness via N2 
2 ml plasma  
Addition of internal standard, YOH 
SPE Extraction (phenyl, 100 mg sorbent, Alltech®) 
Residue dissolved in 100 μl of mobile phase 
Injection volume of 50 μl into HPLC-FD 
Protein precipitation with 1 ml cold 1M HClO4:ACN 
Centrifuged at 2300 rpm for 10 minutes at 4 °C, 
Supernatant pH adjusted to pH = 9 
Figure 3-12: Optimized protein-precipitation/SPE method using 2-ml human plasma 
and YOH for H and NH quantification.   
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3.3.4 Validation of Assay Method 
 The general issue of analytical method validation has been discussed and 
documented in great detail (Karnes et al., 1991; FDA, 2001; Bansal and DeStefano, 
2007; Viswanathan et al., 2007), with many official groups establishing guidelines and 
recommendations.  However, these guidelines are generally not specific or only apply to 
certain applications.  Preferred approaches for each phase of an assay validation 
includes the assessment of selectivity, sensitivity, accuracy, precision, reproducibility 
and precision (FDA, 2001).  Other parameters of interests include those of extraction 
efficiency, calibration range, matrix effects, a dilution integrity, and response function 
(e.g., nonlinear or linear)(Bansal and DeStefano, 2007).    As for any bioanalytical 
method, the extent to which an assay should be validated depends on the intended 
application of the method and, in turn, different validation parameters require different 
levels of scrutiny.   Along with testing the acceptability of a method, the validation 
process challenges the bioanalytical method and determines allowed variability for the 
conditions needed to run the method.   
 Special consideration is required for the validation of assays quantifying 
constitutive components of a biological matrix.   In the case for putative biomarkers 
such as H and NH, appropriate clinical and assay controls should be incorporated to 
produce unbiased clinical results.  As most biomarkers are endogenous compounds with 
quantifiable baseline levels in the biological matrix of interest, the nature of biomarkers 
posts a challenge to find analyte-free biological matrix to prepare calibrator standards.  
As calibrators used for drug compound analysis, the biomarker assays require the 
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similar parameters (e.g., accuracy and precision) for validation of the assay method.   
One primary difference between biomarker assays and that of drug compounds is the 
preparation of calibrators not in the intended sample matrix, but in a “surrogate matrix”.  
As a consequence of this divergence, validation is required to demonstrate that the 
analytical concentration-responses relationships are similar in the sample matrix and the 
surrogate matrix.    
 Of the reported methods used for the quantification of H and NH in biological 
matrices, the majority of the validation was performed in a neat buffered matrix, 
without the formal assessment of a matrix effect.  The buffered solutions utilized for 
calibration curves are most likely not representative of calibrations used in biological 
matrix.   It has been recommended that validation be performed and calibration 
curves/control samples be prepared in a matrix same as those being analyzed (Findlay 
and Das, 1998; Shah et al., 2000).   As the background signal of constitutive H and NH 
poses an issue with calibration curve construction, a strategy limiting or completely 
eliminating the background needs to be investigated.  There is no limitation to what can 
be an appropriate substitute matrix for standard preparation.  Removal of the 
endogenous analyte or alterations of the biological matrix have proven successful form 
quantification purposes, but this results in a matrix that it is no longer representative of 
the test sample matrix.   Therefore, if modification of the matrix is necessary, behavior 
(i.e., slope) of the calibration curves between the unadulterated and the altered matrix 
needs to be statistically similar to deem matrix surrogacy.   A “matrix effect” should not 
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be present upon testing the calibration between the two matrices.  Only when surrogacy 
is proven, quantification using the modified matrix may be performed.     
 Considering the issues of endogenous H and NH background and the lack of a 
true blank matrix, the following strategy was employed for the H and NH assay 
bioanalytical validation in human plasma: 
 
1. A pooled plasma matrix was used for the initial exploration of validation, with the 
parameters such as precision, linear range, and selectivity being assessed.    In this 
investigation the goal was to determine, in an unadulterated matrix, the precision of 
the bioanalytical assay throughout a given concentration range.  Accuracy was 
expected to be confounded by the constitutive concentrations of H and NH and was 
not scrutinized during the pooled plasma analysis.  Moreover, an exploration of a 
suitable concentration of internal standard was evaluated at this step.   Short-term 
and long-term stability studies were conducted in the unadulterated pooled plasma. 
2. Exploration of a suitable surrogate matrix included dilution of pooled plasma, to 
decrease the signal for the endogenous H and NH background signal.   The pooled 
plasma matrix was modified until devoid of a significant H and NH 
chromatographic signal (<20% of LLOQ), while minimizing the difference of 
composition in the true matrix.  Therefore, the goal was to obtain a minimal dilution 
factor, attempting to maintain a comparable matrix to the unadulterated plasma 
matrix.    Subsequently, H and NH were spiked into the modified matrix to assess 
the validation parameters aforementioned.  Full calibration curves (n = 6) and 
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quality control samples were used to evaluate the linear range, accuracy and 
precision.  In addition, an AULOQ (Above Upper Limit of Quantification) 
dilutional control was evaluated for precision and accuracy. Of importance, the 
Lower Limit of Quantification (LLOQ) was determined during this step using n = 6 
replicates.   Sensitivity of the method was enhanced by increasing the sample 
volume, if needed.  Recovery assessment was evaluated using this matrix to assess 
the relative recovery and, more importantly, the precision.    
3. Upon calibration curve evaluation of both pooled plasma and modified plasma 
matrix, n = 6 individual, unmodified plasma sources were subsequently spiked with 
H and NH standards.   Owing to the different constitutive concentrations of H and 
NH in the individual plasma sources, it was expected that the intercepts for each 
calibration regression would differ.  Therefore, precision was the primary 
assessment in this portion of the investigation. 
4. To appraise surrogacy of the modified plasma matrix, parallelism studies were 
performed.  The slopes of all calibration curves from pooled plasma matrix, 
modified matrix and the n = 5 different sources were to be statistically similar 
(parallel) in order to deem the modified matrix and appropriate “surrogate” matrix.   
If statistically different, the method was considered to have a significant matrix 
effect and issues of selectivity.   In the case that selectivity was of concern, 
chromatographic or extraction re-optimization experiments were conducted to rid 
the interference. 
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5. For all successive experiments, including ultimate sample analysis, the calibration 
curves and quality control samples were to be constructed using the “surrogate” 
plasma matrix.   
 To account for matrix effects associated with quantification, studies for the 
small molecule validation in a surrogate matrix requires the implementation of 
“parallelism” studies.  In essence, the surrogate matrix should behave similarly to the 
sample matrix for intended use with regard to calibration.  Parallelism (of 
concentration–response curves) is defined as the concentration– response curves of the 
test (surrogate) and standard (unmodified) being identical in shape and differ only in a 
constant horizontal difference (Singer et al., 2006).   If the two curves are shown to be 
sufficiently similar (equivalent) in shape by its linearity and slope, and tested 
statistically for similarity, “surrogacy” of the modified matrix is verified.   The 
parallelism studies were based on reported strategies for large-molecule validation 
(Miller et al., 2001).  The design of the method validation procedures were based on 
previously published reports (Karnes et al., 1991; FDA, 2001; Lee et al., 2006)  
 
3.3.4a Materials and Reagents 
 All chemicals were or analytical grade quality and obtained from commercial 
sources.  All solvents used for the H and NH validation analysis were of spectroscopic 
or HPLC grade and used after filtration with a 0.2 μm porosity filter (Corning, Corning, 
NY).    The validation required the following materials and reagents, in addition to 
those aforementioned: 
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1. Perchloric acid, 70% HClO4 , double distilled (GFS Chemicals, Columbus, OH) 
2. Sodium Hydroxide, 10 N (VWR, Westchester, PA) 
3. Ascorbic Acid, reagent grade crystalline, C6H8O6, (Fluka, Buchs, Switzerland) 
4. Semicarbazide HCl, purum >99% (Aldrich, St.Louis, MO) 
5. Pooled human plasma, n = 20 donors – Healthy, fasting, drug-free, non-smoker, 
collected in EDTA (Biochemed Services, Winchester, VA) 
6. Individual human plasma – six different donors, healthy, drug-free, non-smokers or 
smokers, collected in EDTA (from clinical study)  
 
3.3.4b Equipment   
 The same equipment used for extraction and optimization procedures were used 
for subsequent validation.  
 
3.3.4c Preparation of Solutions and Standards 
1. Harman and Norharman in methanol – combination standards were made for 
both analytes.  A stock solution of 1 µg/µl (1 mg/ml) was made for H and NH.  Serial 
dilutions of 50 ng/µl and 500 pg/µl were made from the stock solution to create smaller 
“stock solution” concentrations.  All concentrations used for the experiments were 
diluted, with methanol from these three stock solutions.  In order to minimize error of 
volumetric transfer of the H and NH standard solution to the plasma matrices, stock 
calibrators were made to ensure that an appropriate mass of each concentration level 
was transferred with 10 µl of volume.  All standards were made fresh and checked via 
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HPLC-FD prior to each and any experiment to confirm concentrations did not deviate 
from batch to batch.    
 Approximately 3 mg of H and NH were weighed and subsequently placed in a 4 
ml silanized amber vial.   The appropriate volume of methanol was used as the solvent 
to ensure a 1 mg/ml (µg/µl) concentration of solution was made (e.g., 3.2 mg in 3.2 ml 
of methanol), accounting for salt and impurity of the powder form.  The primary 
standard concentrations were 1 µg/µl, 50 ng/µl, and 500 pg/µl. 
 
Table 3-12:  Preparation of Primary H and NH standards at 1 µg/µl, 50 ng/µl, and 500 
pg/µl levels. 
 
 Final STD conc        amount of STD    methanol  
 1 µg/µl  H and NH  ~3 mg    ~ 3 ml     
 50 ng/µl H/NH  100 µl of H and NH (1 µg/µl)    1.8 ml 
 500 pg/µl H/NH  30 µl of H/NH mix (50 ng/µl)      2.97 ml 
 
From the primary stock solutions, 1-ml volumes of calibrators and quality control 
standards were created to ensure that the mass required for each level was transferred 
into plasma matrix via a 10 µl volume.  The preparation of all the concentration levels is 
presented in the table below. 
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Table 3-13:  Preparation of calibrator and quality control standards.    Standards were 
prepared at concentrations to ensure that a 10 µl volume was transferred into the matrix 
of interest.  
  
STD  Final STD conc amount of Primary STD   methanol
2.5 ng  250 pg/µl   5 µl (50 ng/µl)    995 µl 
1.0 ng  100 pg/µl   200 µl (500 pg/µl)   800 µl 
800 pg  80.0 pg/µl   160 µl (500 pg/µl)   840 µl 
625 pg  62.5 pg/µl   125 µl (500 pg/µl)   775 µl 
500 pg  50.0 pg/µl  100 µl (500 pg/µl)   900 µl 
400 pg  40.0 pg/µl  80 µl (500 pg/µl)   920 µl 
250 pg  25.0 pg/µl  50 µl (500 pg/µl)   950 µl 
100 pg  10.0 pg/µl  20 µl (500 pg/µl)   980 µl 
50 pg  5.0 pg/µl  10 µl (500 pg/µl)   990 µl 
25 pg  2.5 pg/µl  5 µl (500 pg/µl)    995 µl 
12.5 pg  1.25 pg/µl  2.5 µl (500 pg/µl)   997.5 µl 
6.25 pg (2ml) 0.625 pg/µl  2.5 µl (500 pg/µl)   1997.5 µl 
3.12 pg  0.321 pg/µl  1.0 ml (0.625 pg/µl)   1000.0 µl 
 
  
 All standards were checked chromatographically, with triplicate injection, to 
ensure stability of stocks and reproducibility of construction.    Solution stability, of all 
compounds was assessed at room temperature and storage temperature (-20˚C).  H and 
NH solutions were stable for > 24 hours at room temp and > 1 month in storage 
temperature.  
2.  Yohimbine in methanol - A stock solution of 1 µg/µl (1 mg/ml) was made for YOH.  
Approximately 2 mg for both H and NH was added to a silanized, 4-ml amber vial in 
which an appropriate volume (~2 ml) was added to dilute to a desired concentration, 
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ensuring to account for salt weight and purity.   Serial dilutions of 100 ng/µl and 1 ng/µl 
were made from the stock solution to create smaller “stock solution” concentrations.  
All concentrations used for the experiments were diluted, with methanol from these 
three stock solutions.  YOH solution was stable for > 24 hours at room temp and > 1 
month in storage temperature (-20˚C).  
3.  Protein precipitation/antioxidant solution – A 1 M HClO4 : acetonitrile solution 
(75:25) was made by making a 1 M HClO4 solution and adding appropriate volume of 
acetonitrile to make the appropriate ratio.    For the protein precipitation solution, an 
antioxidant (ascorbic acid) and aldehyde trapping agent (semicarbazide) was added. Per 
750 ml of HClO4 in the protein precipitation solution, 112.5 mg of ascorbic acid and 45 
mg of semicarbazide was added. The final solution was subsequently kept at 4˚C until 
use. 
4.  Mobile phase (aqueous) – For 4 L of buffer a 90% K2HPO4/H3PO4: 10% methanol 
solution was made.  Methanol was added to the aqueous phase to hinder bacterial 
growth in the buffer.  Monobasic K2HPO4 (11.02 g) was added to 3.6 L of Milli-Q® 
water along with 621 µl of H3PO4 as the acidic component to make a pH=3.2, 25 mM 
solution. The pH was recorded to ensure the required buffering before and after adding 
400 ml of methanol.   
5.  Extraction buffer – A 1.0 L solution of H3BO4/Na2BB4O7 buffer (pH = 9, 10 mM) was 
made for the pH adjustment, conditioning and was solvent.  Approximately 0.316 g of 
H3BO4 and 1.854 g of Na2B4B O7*10 H2O was added to 1.0 L of Milli-Q® water and 
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subsequently measured for pH.  A 500 ml wash solution of 75% H3BO4/Na2BB4O7 buffer 
25% methanol was made from this solution.  
  
3.3.4d Methods 
 Validation of the bioanalytical assay was performed using optimized ideal 
extraction conditions (see figure 3-12).  The HPLC-FD parameters were modified 
slightly because of selectivity issues approached in the later validation stages of the 
assay.  Therefore, all subsequent experiments and results were obtained with parameters 
denoted in table 3-14.  
 
Table 3-14:  Experimental conditions used for validation of the RP-HPLC bioanalytical 
assay for H and NH in a human plasma matrix. 
 
Separation variable    Optimized condition_______________                                   
 
Column w/guard column   Agilent® Zorbax Eclipse XDB, C8
       15 x 0.46 cm, 5 μm, endcapped 
Solvents A,B, and C 
      %A      80% KH2PO4/H3PO4 (pH=3.2, 25mM) 
      %B     15% acetonitrile 
      %C     5% methanol   
 
Flow rate     Isocratic, 0.9 ml/min 
 
Column temperature    40ºC  
 
Sample temperature    4ºC 
 
Injection volume    75 μl     
 
Detection for H and NH   λexcitation = 300 nm, λ emission = 433 nm 
      for YOH    λexcitation = 280 nm, λ emission = 360 nm 
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 Another major distinction from the previous experimentation incorporated the 
use of an antioxidant/aldehyde trapping agent.  Several investigators noted a major 
concern in the quantitative analysis of β-carboline alkaloids is the suppression of 
artifactual formation during sample preparation (Allen and Holmstedt, 1980; Bosin and 
Faull, 1988; Tsuchiya et al., 1999).   The successful use of semicarbazide as an 
aldehyde trapping reagent and ascorbic acid as an antioxidant in decreasing artifactual 
formation has been exemplified (Rommelspacher et al., 1984; Adell and Myers, 1994; 
Fekkes et al., 2004).   Therefore, a solution of semicarbazide (4.5 mmol), ascorbic acid 
(0.5 nmol), and EDTA (0.05 nmol) per 1.0 ml of 1M HC1O4 was implemented in the 
extraction of H and NH from human plasma to circumvent any issues pertaining to 
artifactual formation.   
 Before formal matrix experiments, stock solution stability for H, NH and YOH, 
post preparative (extracted samples/autosampler tray) and benchtop stability 
experiments were performed.   Stock solution and benchtop stability for both analytes 
and internal standard at two different concentrations was assessed for 6 hours at room 
temperature.   
 
3.3.4d-1 Pooled plasma experiments 
 Using pooled plasma (from presumably healthy, fasting, drug-free, non-
smokers, collected in EDTA) initial partial validation experiments were explored to 
evaluate the linear concentration range for H and NH, a concentration of the internal 
standard, YOH, needed to produce a representative response for calibration purposes, 
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precision of the method and stability.    Parameters such as accuracy and LLOQ were 
not scrutinized during this initial exploration due to the probable significant 
confounding effects of endogenous H and NH in the pooled plasma.     
 The linearity of the developed method was evaluated by preparing n=2 standard 
curves for the two analytes in duplicate (2 x 1 day) with varying (n = 5) concentrations 
of YOH.  The concentrations of both H and NH used for a nine-point standard curve 
were 3.2, 6.3, 12.5, 25, 50, 100, 250, 500, 1000, and 2500 pg/ml.   YOH internal 
standard amounts evaluated included: 100 pg, 300 pg, 500 pg, 750 pg and 1000 pg, for 
each calibration curve. Moreover, along with at least 9 non-zero standards, a blank 
sample (matrix processed without internal standard) and a zero sample (matrix 
processed with internal standard) were processed.  A 10 µl volume of standard 
calibrator solutions were used at each concentration level to ensure that the volume of 
the stock solution added was <10% of the total matrix volume.  Initial experiments were 
performed using 1-ml of human pooled plasma.  In the case that adequate sensitivity 
was not obtained, 2-ml of pooled plasma was used.  Plots of peak area ratio (H or NH / 
YOH) against analyte concentration were constructed.  Plots of the residual against 
concentration assessed the behavior of the response variance across the calibration 
range.  If the residuals for the linear regression analysis were heteroschedastic in nature, 
an appropriate weighting factor was investigated (1/x and 1/x2).       
 Initially, the linear range was approximately based on an observable 
chromatographic response (peak) for both H and NH between the concentration ranges, 
until formally tested.  In the case that higher concentrations distorted the peak signal, 
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the upper limit was deemed to be the highest standard that did not distort the peak 
shape, in order to have a reliable estimate of the peak area response.  In the case that the 
upper limit was lower than that reported in physiological levels, an AULOQ (above 
upper limit of quantification) dilutional control was used in subsequent calibration 
curves. The calibration function (e.g., linear or weighted-linear) was established through 
observation of reverse calculated standard concentrations of which were reverse 
predicted from the curve.   The appropriateness of the concentration of YOH was based 
on the peak height of the YOH being approximately at the mean of H and NH response 
of the concentration range tested.   Moreover, the analyte to internal standard ratio at the 
upper and lower limits were not to exceed 10 or be less than 0.1, respectively, in order 
to minimize error associated at the extremes of the linear calibration curve.       
  The optimized internal standard and linear range were subsequently tested in the 
pooled plasma with n = 6 replicates (2 calibration curves x 3 days) to assess precision of 
the method.  Moreover, quality control samples were created at the following levels: 
• Low QC is ≤ 3 X LLOQ 
 
• Medium QC approximately the geometric mean between low and high 
QC. 
 
• High QC between 75% to 90% of highest calibrator. 
 
• AULQC (above upper limit quality control 2.5 x highest calibrator and 
diluted. 
  
 The LQC, MQC, and HQC concentrations were used to assess relative recovery 
from the pooled plasma.   The comparison of an extracted to unextracted analyte to 
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internal standard ratio, at each concentration, was used to calculate the relative 
recovery.  Experiments were performed in triplicate.  
 It was expected that a systematic bias (positive y-intercept) would be present in 
the calibration curve because of the presence of endogenous H and NH. Therefore, 
accuracy and precision calculations were performed on the analyte to internal standard 
ratio, across the concentration range.  For accuracy assessment, the predicted area ratio 
was based on the linear regression parameters, where the predicted area ratio is: 
 
 Predicted area ratio = (slope of calibration curve x conc.) + y-intercept  
 
Accuracy and precision, for each analyte to internal standard ratio, were calculated as 
follows: 
Accuracy (%DFN – deviation from nominal)   
 %DFN = {observed ratio – predicted ratio} / predicted ratio x 100% 
Precision (%COV – coefficient of variation) 
 %COV = {standard deviation of the observed ratio / average ratio} x 100% 
  
 Within-run and between-run precision and practical LLOQ was assessed in the 
later stages of validation.   The basis for accepting the precision was that >75% of all  
standards must be within ±15 % COV, with the exception of the LLOQ where a ±20 % 
COV, would be permitted.  
 For long-term stability, standard solutions using a high, low, and zero (unspiked) 
control concentrations in biological matrix were portioned and stored under the 
conditions of study sample storage (-80˚C).  Measurements were taken in triplicate over 
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a six-month period on four separate occasions. For each sample, the ratio of the analyte 
to internal standard was recorded and concentration back-calculated and compared 
between measurements and across occasions for statistical deviations (accuracy and 
precision within ±15 % nominal value).    Freeze-thaw stability was assessed over three 
cycles, in which the initial freeze was 24 hours and subsequent cycles was held in -80˚C 
for 12 hours.   A low and high concentration control (n=3) was used to assess deviations 
from expected (evaluation of precision).    
 Of primary importance, the linear regression parameters for the calibration 
curves, including slope and y-intercept, for the pooled plasma validation were assessed 
upon evaluating the estimates and corresponding 95% confidence interval (CI) along 
with the precision of the slope and y-intercepts (% COV).  In the case that a significant 
peak was observed in the zero standard (with only IS spiked), the back calculated 
concentration from the regression slope with a fixed intercept of zero (corrected 
baseline) was compared to the positive y-intercept value obtained from the calibration 
regression (non-corrected).  This was to determine if the calibration curve was able to 
reliably quantify the endogenous H and NH.   
 
3.3.4d-2 Pooled plasma results 
 Initial exploration of a calibration range and an appropriate concentration of the 
internal standard were performed in pooled plasma.  Using 1-ml of plasma, a linear 
concentration range between 12.5 pg/ml and 1.0 ng/ml was seen for both H and NH.  
The calibration levels detected less than 12.5 pg/ml, although detectable, did not show 
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adequate reproducibility in measurement (%COV> 17% for both H and NH).  At the 
concentration of 2.5 ng/ml, chromatographic peak distortion was seen for both analytes 
(saturation of signal).  Sensitivity for the calibration was subsequently improved using 
2-ml of plasma.   A mass of 300 pg of YOH yielded an analyte to internal standard ratio 
at the upper (1.0 ng/ml) and lower limit (12.5 pg/ml) of approximately < 11.5 and > 
0.04, respectively for both H and NH.  These ratios loosely met the criteria for 
minimizing error associated with the extremes of the linear calibration curve.     Larger 
concentrations (>300 pg/ml) of the YOH internal standard yielded results that were not 
representative of the linear calibration range for both H and NH.    According to the 
“blank” sample (no IS) measurements, there were no significant peaks associated with 
the retention time of the YOH, exemplifying selectivity of the YOH chromatography.  
Significant peaks at the representative H and NH retention times were present (data not 
shown).    Using the optimal concentration range of H and NH (6.3, 25, 50, 100, 250, 
500, 1000 pg per 2 ml plasma) and 300 pg of internal standard, n = 6 calibration curves 
were constructed in pooled plasma with quality control samples of  12.5 pg (LQC), 400 
pg (MQC) and 750 pg (HQC),  and 2.5 ng (AULQC, dilutional control).  Area ratios of 
the calibration points and quality control samples with precision estimates (%COV) are 
presented in the following tables for NH (Table 3-15) and H (Table 3-16).   Moreover, 
the individual linear regression parameters for each calibration curve for both NH and H 
are presented with a goodness of fit (R2) metric for linearity.    An average calibration 
curve is presented for both NH (Figure 3-13) and H (Figure 3-14).  Of note, the 
calibration curve for both H and NH was constructed upon calculation of an average 
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response (across n=6 calibration levels).  A linear regression, utilizing a 1/x2 weighting 
factor, was performed on the average response for each concentration level.    The 
calibration levels all showed acceptable precision for NH and H with %COV less than 
13.5% and 11.3%, respectively.  The precision of the quality control samples ranged 
from 5.3% to 12.11% for NH while the H quality control precision resulted in a %COV 
ranged 3.5% to 9.9%.    The dilutional control (2.5 ng/2ml) precision was acceptable for 
both analytes. 
 
Table 3-15:  Peak area ratio for norharman in pooled plasma (n=6), with precision 
assessment (%COV) and calibration curve parameters (1/x2 weighting). 
 
pg NH calib #1 calib #2 calib #3 calib #4 calib #5 calib #6 average sd %COV
6.25 0.148 0.142 0.144 0.140 0.141 0.136 0.142 0.004 2.93
25 0.254 0.268 0.270 0.273 0.256 0.244 0.261 0.011 4.38
50 0.381 0.398 0.382 0.398 0.342 0.410 0.385 0.024 6.16
100 0.793 0.752 0.722 0.761 0.639 0.711 0.730 0.053 7.28
250 1.923 1.653 1.782 1.423 1.673 1.513 1.661 0.180 10.83
500 3.669 3.069 2.826 3.023 3.262 2.862 3.118 0.312 10.00
1000 5.946 7.446 6.562 5.562 5.110 6.610 6.206 0.838 13.50
12.5 (LQC) 0.177 0.196 0.186 0.176 0.177 0.169 0.180 0.010 5.28
400 (MQC) 2.421 2.525 2.112 2.852 2.110 2.228 2.375 0.287 12.11
800 (HQC) 5.532 4.913 5.022 4.571 4.639 4.433 4.852 0.399 8.22
2500 (AUL QC) 4.402 3.902 3.424 3.553 3.616 3.323 3.703 0.395 10.67
zero 0.078 0.071 0.059 0.082 0.071 0.065 0.071 0.008 11.76
slope 0.0068 0.0072 0.0065 0.0065 0.0068 0.0064 0.0067 0.0003
y-int 0.0670 0.0713 0.0660 0.0780 0.0810 0.0691 0.0721 0.0061
R2 0.9874 0.9910 0.9933 0.9982 0.9832 0.9971 0.9917 0.0057  
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Figure 3-13:  Average calibration curve (n=6) for Norharman in pooled plasma.   
Linear regression performed on the average of the response across concentrations.   
Each point represents the average response ± SD.   
 
 
 
 
 
 
Table 3-16:  Peak area ratio for harman in pooled plasma (n=6), with precision 
assessment (%COV) and calibration curve parameters (1/x2 weighting). 
 
pg H calib #1 calib #2 calib #3 calib #4 calib #5 calib #6 average sd %COV
6.25 0.173 0.165 0.152 0.171 0.156 0.168 0.164 0.008 5.16
25 0.363 0.373 0.331 0.387 0.346 0.323 0.354 0.025 7.09
50 0.636 0.587 0.590 0.587 0.527 0.600 0.588 0.035 5.96
100 0.976 1.093 1.193 1.217 1.088 1.046 1.102 0.090 8.20
250 2.364 2.873 2.339 2.609 2.440 2.668 2.549 0.206 8.09
500 4.390 5.573 5.573 5.193 5.185 5.003 5.153 0.438 8.51
1000 9.620 11.371 10.939 12.098 9.628 9.092 10.458 1.184 11.32
12.5 (LQC) 0.228 0.236 0.223 0.245 0.226 0.230 0.231 0.008 3.45
400 (MQC) 3.539 3.833 3.863 4.032 4.154 4.377 3.966 0.290 7.30
800 (HQC) 7.688 8.532 8.213 9.328 7.102 7.541 8.067 0.797 9.88
2500 (AUL QC) 6.491 7.424 7.153 6.373 6.093 6.543 6.680 0.504 7.55
zero 0.065 0.061 0.059 0.078 0.071 0.065 0.067 0.007 10.60
slope 0.0094 0.0113 0.0109 0.0118 0.0096 0.0091 0.0104 0.0011
y-int 0.0580 0.0524 0.0642 0.0688 0.0721 0.0830 0.0664 0.0108
R2 0.9963 0.9877 0.9980 0.9938 0.9897 0.9974 0.9938 0.0043  
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Figure 3-14:  Average calibration curve (n=6) for Harman in pooled plasma.   Linear 
regression performed on the average of the response across concentrations.  Each point 
represents the average response ± SD.   
 
 
 The “zero” level, consisting of 2-ml plasma with only internal standard, yielded 
a significant response for both H and NH, suggestive of the significant constitutive 
nature of these analytes in the matrix.  The peak area ratios for both analytes were 
reproducible, yielding %COV of 11.8% and 12.2% and for NH and H, respectively.     
With respect to accuracy of the measurements within the calibration range, back-
calculated concentrations were compared to the linear-regression, corrected for the 
baseline.  Throughout the concentration range, %DFN were less than 13.6% and 14.8% 
(absolute value) for NH and H, respectively.  
 Regarding the linear regression of the calibration curves, a weighting factor of 
1/x2 was required to rid the unequal variance associated with the residuals (data not 
shown).  Therefore, a weighted linear regression was performed on each individual 
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calibration curve for both analytes.    Linearity of the calibration curves, as assessed by 
the coefficient of determination (R2), was acceptable for both analytes with NH 
possessing R2 ranging between 0.983 - 0.998 and H having a range between 0.987 - 
0.998.   For both analytes, the 95% CI for each individual calibration slopes included 
the estimate of the other individual calibration slopes, signifying similarity between the 
slope calibration parameter of each curve.   Of major note, each calibration curve 
yielded a significant y-intercept for both analytes, indicating a significant background.  
The y-intercepts were significantly different from zero with NH having an intercept 
(mean ± SD) of 0.072 ± 0.006 (p-value > 0.34) and H having an intercept of 0.066 ± 
0.011 (p-value > 0.17).   Moreover, the y-intercepts obtained from the linear regressions 
for both analytes were reproducible.   
 In order to assess the precision and accuracy of the endogenous measured 
amount of H and NH in pooled plasma, a comparison of the “blank” sample was made 
to the y-intercept of the regression of its respective calibration construction.  In 
addition, a concentration of the endogenous measurement of NH and H was calculated 
from the respective calibration curve, corrected for the significant y-intercept.  
Accuracy (%DFN) was calculated by evaluation of the 100% x (observed concentration 
– predicted concentration) / predicted concentration.   In this investigation, the observed 
concentration for the “zero sample” was obtained from the respective calibration curve, 
correcting for the y-intercept (equaling zero).    The predicted concentration was 
obtained from evaluation of the y-intercept of the calibration curve and back-calculating 
the concentration using a baseline-corrected calibration curve.   A comparison was 
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made to assess if a difference in the values was seen and if the calibration curve was 
able to accurately quantify the endogenous H and NH within pooled plasma.    The 
results from each calibration curve for each analyte is presented below.  
 
Table 3-17:  Accuracy and precision assessment for “zero” calibration level for 
norharman.   
 
corrected corrected
calibration slope y-intercept conc zero conc %DFN
1 0.0068 0.067 9.9 0.078 11.5 16.4
2 0.0072 0.071 9.9 0.071 9.9 -0.4
3 0.0065 0.066 10.2 0.059 9.1 -10.6
4 0.0065 0.078 12.0 0.082 12.6 5.1
5 0.0068 0.081 11.9 0.071 10.4 -12.3
6 0.0064 0.069 10.8 0.065 10.2 -5.9
avg 10.8 10.6
stdev 1.0 1.3
%COV 9.1 11.9
predicted observed
                
 
Table 3-18:  Accuracy and precision assessment for “zero” calibration level for harman.   
corrected corrected
calibration slope y-intercept conc zero conc %DFN
1 0.0094 0.058 6.2 0.065 6.9 12.1
2 0.0113 0.052 4.6 0.061 5.4 16.4
3 0.0109 0.064 5.9 0.059 5.4 -8.1
4 0.0118 0.069 5.8 0.078 6.6 13.4
5 0.0096 0.072 7.5 0.071 7.4 -1.5
6 0.0091 0.083 9.1 0.065 7.1 -21.7
avg 6.5 6.5
stdev 1.6 0.9
%COV 24.0 13.4
predicted observed
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 This evaluation was to deem the calibration curve as useful for the quantification 
of H and NH in pooled plasma.  According to the corrected calibration curves, the 
accuracy for the measurement was in a range of -12.3 and 16.4% for NH and 12.1 and     
-21.7% for H.    The precision for the NH and H measurement was 11.9 and 13.4%, 
respectively.   Upon statistical comparison (unpaired t-test, two-tailed assuming unequal 
variance), the concentration calculated from the y-intercept and the observed response 
ratio (from the “zero” calibration sample), was similar.  No statistically significant 
difference was detected (p-values < 0.05) for both NH and H.   According to the 
analysis, and using the baseline corrected calibration curves, the pooled plasma 
contained 10.6 pg of NH and 6.5 pg of H per 2-ml, which is within reported 
physiological range.   
 Long-term stability, in pooled plasma was evaluated at three different levels of 
High (500 pg/2ml), Low (25 pg/2ml) and zero (unspiked H and NH) over a six month 
period.  Of note, the theoretical concentrations for the High and Low controls are those 
of spiked and constitutive, additive. The concentrations were measured, using baseline 
corrected calibration curves, at 15 days, 1, 3 and 6 months after standard pooled plasma 
preparation.   At each time-point the analysis was performed in triplicate.     Over a six-
month period, there was a negligible variation in concentration for both H and NH, with 
most of the variability seen at the zero concentration level (unspiked H and NH; see 
table 3-19).  
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Table 3-19:  Long-term stability assessment for “zero”, Low and High level of Harman 
and Norharman in 2 ml pooled plasma over a 6-month period.  Each value presented as 
mean of n=3 back calculated concentrations (pg/2ml)  
 
Norharman zero control low control high control
day 0 12.5 37.3 520.1
day 15 14.1 32.1 515.8
month 1 13.2 33.8 518.3
month 3 10.7 34.1 531.4
month 6 9.1 33.1 522.6
concentration (pg/2ml) 10.6 35.6 510.6
mean 11.9 34.1 521.6
stdev 2.0 2.0 6.0
%COV 16.9 5.7 1.1
%DFN 12.5 -4.3 2.2
Harman zero control low control high control
day 0 7.2 31.2 518.1
day 15 5.2 35.4 522.1
month 1 6.4 32.1 537.5
month 3 7.7 32.5 518.4
month 6 7.1 35.6 527.9
concentration (pg/2ml) 6.5 31.5 506.5
mean 6.7 33.4 524.8
stdev 1.0 2.0 8.1
%COV 14.4 6.0 1.5
%DFN 3.4 5.9 3.6   
 
 Freeze-thaw stability assessment did not yield any significant changes in H or 
NH at all concentration levels evaluated through three-cycles, with %DFN and %COV 
not exceeding 6.7% for both analytes at all concentration levels. 
 The relative recovery, across the quality control concentrations, did not show 
much variation within and across concentrations (see table 3-20).   Of note, the analyte 
to internal standard ratio obtained from the extraction procedure includes constitutive H 
and NH, contributing to the relative recovery.  Therefore, the recoveries obtained from 
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the analysis are expected to be larger than if the endogenous analyte was not present in 
the matrix.  
 
Table 3-20:  Relative recovery from 2 ml pooled plasma of norharman and harman 
(n=3 for each concentration).  (% mean ± SD). 
    
    12.5 pg  400 pg   800 pg  
Harman          87.2 ± 4.1  90.9 ± 1.4  91.6 ± 2.3 
Norharman          85.2 ± 3.9  89.2 ± 3.5  90.3 ± 2.8 
  
 The information obtained from the pooled plasma analysis was used to design a 
more formal validation using a modified matrix for assessing surrogacy.   Using 2-ml of 
matrix, the calibration range between 6.3 and 1000 pg of both H and NH with 300 pg of 
YOH internal standard was used for validation purposes.  Quality control samples used 
for subsequent tests included 12.5 pg (LQC), 400 pg (MQC) and 750 pg (HQC), and 
2500 pg (AULQC, dilutional control).    The results of minimal deviation for long-term 
and freeze-thaw stability tests proved the chemical robustness of analyzing H and NH in 
the plasma matrix.    
 
3.3.4d-3 Surrogate matrix experiments 
 Similar experiments to the aforementioned were performed using a modified 
pooled plasma matrix, with an emphasis on both accuracy and precision assessment.  
The modification employed the dilution, with pH = 9 buffer, of plasma until 
chromatogram for H and NH was devoid of a significant peak area response (unable to 
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integrate under the peak).   Moreover, the goal was to minimize the dilution factor in 
order to maintain unmodified plasma composition as close possible.   Dilution factors 
(buffer to plasma) such as 0.5:1, 1:1, 2:1, 4:1, 5:1 and 10:1 were evaluated to decrease 
the signal.   Experiments in triplicate were evaluated for each dilution factor under two 
conditions:  plasma spiked with 300 pg internal standard only and “blank” plasma.   
Devoid of peak areas for both H and NH were assessed.  
 Upon appropriate dilution of the modified matrix, full calibration curves (n = 6) 
and quality control samples were used to evaluate the linear range, accuracy and 
precision.  The concentrations evaluated in 2-ml of modified matrix included a seven-
point standard curve including 6.3, 25, 50, 100, 250, 500, 1000 pg.  Quality controls 
(QC) for the low, medium and high were 12.5, 400, and 750 pg, respectively.   In 
addition, an AUL (Above Upper Limit) dilutional control of and 2500 pg was evaluated 
for precision and accuracy.  Of importance, the Lower Limit of Quantification (LLOQ) 
was determined during this step using n = 6 replicates, separate from the calibrators.   
At this point, recovery assessment was evaluated using this matrix to assess the relative 
recovery and, more importantly, the precision or the recovery.  The room temperature 
stability measurements, as mentioned before, was also performed in this in modified, 
pH = 9 buffer matrix.      
A more formal evaluation for precision and accuracy was conducted by 
evaluation of n = 6 each of the LLOQ, low, medium, high, and AUL control sample 
concentrations in one day for within-run assessment.  Between run-precision and 
accuracy was assessed in triplicate over three days for the same controls.   The accuracy 
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(%DFN) and the precision (%COV) between and within-runs were found acceptable at 
a level of within ±15%.   All quality control samples, including those that failed with no 
assignable cause, were used for the final calculation.   
 Using the modified matrix, extraction efficiency (recovery) was assessed at 
three quality control levels in triplicate of 12.5 pg, 400 pg and 750 pg (LQC, MQC, and 
HQC).   The normalized extraction efficiency was evaluated by reviewing the H or NH / 
YOH ratio from an extracted sample to the peak area response ratio obtained from the 
unextracted sample.    In addition to the relative recovery, the precision of the extraction 
method was evaluated at this step.   
 As the case for the calibration curves obtained for the pooled plasma, the linear 
regression parameters for the calibration curves, including slope and y-intercept, for the 
modified plasma validation were assessed.   The estimates and corresponding 95% 
confidence interval along with the precision of the slope and y-intercepts (% COV) 
were evaluated.  For approval of the matrix modification via dilution factor, the mean of 
the y-intercepts should not be statistically different from zero (as deemed by a one-sided 
unpaired Student’s t-test).  The individual confidence intervals of the y-intercept 
estimates should include zero for each individual calibration curve.   
 The slope of the linear regressions within all calibration curves should not be 
statistically different from one another (as deemed by a 95% CI).  Moreover, the mean 
of all calibration slopes between the pooled plasma and the modified plasma matrix 
were evaluated for “parallelism” (i.e., the average slopes obtained between each matrix 
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should be statistically similar).  Lack of similarity was evaluated by a two-sided 
unpaired Student’s t-test.   
 
3.3.4d-4  Surrogate matrix results 
 A modified matrix, using pH = 9 buffer used for dilution, was constructed from 
pooled plasma until chromatogram for H and NH was devoid of a significant peak area 
response.   The minimum dilution factor required to rid significant chromatographic 
signal was the 4:1 dilution (buffer: plasma).  Dilutions less than this resulted in 
significant chromatographic peaks for both H and NH.    From previous experiments in 
pooled plasma, it was expected that at least a 3:1 fold dilution would be required to 
significantly decrease the detectable signal.    Although the analysis of larger dilution 
factors (5:1 and 10:1) resulted in peaks that were not able to be integrated, the 4:1 
dilution was used for validation purposes to keep the matrix as similar to the original 
sample as possible.    Full calibration curves (n=6) were constructed using 2-ml of 
modified matrix along with corresponding quality control samples.  For NH, throughout 
the concentration range the precision (%COV) was less than 12.1% and the accuracy 
(%DFN, absolute value) was less than 14.9% (see table 3-21).   In addition, the analysis 
of H yielded acceptable results with a precision < 9.7% and an accuracy of < 15.3% 
(table 3-22).  Of note, the analysis met the criteria in which >75% of all standards must 
be within ±15 % COV, with the exception of the LLOQ where a ±20 % COV. 
 Further evaluation at the LLOQ level (6.3 pg/2ml) yielded a %COV of 14.8% 
and %DFN of 11.5%, with n = 6 replicates different from the calibration points.  The 
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additional quality control samples, including the dilutional control, yielded a suitable 
accuracy and precision.  For inter-run precision and accuracy (3 replicates for 3 days), 
%COV was no greater than 11.4% and no more than an absolute variation in 
concentration of 14.6% across the quality control concentrations (data not shown).   
 The linear regression parameters for each calibration curve were compared to 
assess consistency of slope and for lack of a y-intercept.  Using a 1/x2 weighting factor 
for each calibration curve, the parameters presented (tables 3-23 and 3-24) showed 
consistency between calibration curves.  The slope parameters were statistically 
different from zero, while the intercept did not show a statistical difference from zero 
(p-values > 0.3 for both analytes).   The zero intercept highlights the ability for the 
dilution factor to be appropriate for the H and NH analysis.    For both analytes, the 
coefficient of determination (R2) was acceptable for each calibration curve, supporting 
the use of a linear regression for the calibration.  
 Of note, “blank” and “zero” samples did not result in a significant peak for 
either H or NH at the respective retention time (see figure 3-15).   The diluted plasma 
matrix did not yield a significant YOH peak in the “blank” sample.   Throughout all 
calibration runs, the YOH peak was consistent and showed minimal variability of the 
absolute peak area (%COV < 5.2%).  The extraction recovery was assessed at three 
quality control levels in triplicate of 12.5 pg, 400 pg and 750 pg (LQC, MQC, and 
HQC).   The normalized extraction efficiency is shown in table 3-25.    The recoveries 
obtained from this analysis were constant but showed a slightly less recovery from that 
of unmodified pooled plasma.   
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Table 3-23:  Standard curve parameters for n = 6 norharman calibration curves in 
modified plasma.  Each parameter presented as an estimate with standard error (SE).   
 
Calibration slope SE y-intercept SE R2
1 0.0064 0.0008 0.0091 0.0035 0.9858
2 0.0067 0.0004 (-)0.0081 0.0037 0.9817
3 0.0059 0.0007 (-)0.0067 0.0018 0.9908
4 0.0062 0.0003 0.0044 0.0023 0.9912
5 0.0055 0.0007 (-)0.0049 0.0025 0.9855
6 0.0058 0.0004 0.0029 0.0049 0.9890
average 0.0061 0.0055 0.9873
stdev 0.0004 0.0032 0.0037  
 
 
Table 3-24: Standard curve parameters for n = 6 harman calibration curves in modified 
plasma.  Each parameter presented as an estimate with standard error (SE).   
 
Calibration slope SE y-intercept SE R2
1 0.0097 0.0004 0.0051 0.0044 0.9802
2 0.0103 0.0005 0.0037 0.0031 0.9977
3 0.0098 0.0011 (-)0.0039 0.0022 0.9834
4 0.0105 0.0009 0.0040 0.0028 0.9822
5 0.0092 0.0005 (-)0.0031 0.0021 0.9873
6 0.0097 0.0012 0.0013 0.0027 0.9888
average 0.0099 0.0035 0.9866
stdev 0.0005 0.0016 0.0063  
 
Table 3-25:  Relative recovery from 2 ml modified diluted plasma of norharman and 
harman (n=3 for each concentration).  (% mean ± SD). 
 
     
    12.5 pg  400 pg   800 pg  
Harman          82.8 ± 3.5  86.5 ± 2.8  89.2 ± 5.2 
Norharman          79.4 ± 2.1  82.7 ± 4.2  86.5 ± 3.7 
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 In comparison to the unmodified, pooled plasma matrix surrogacy for the diluted 
matrix was established.   From the linear regression parameters (i.e., slope) obtained 
with calibration curves constructed of both sets of matrices, a statistical similarity was 
seen.  Table 3-26 presents the comparison of the pooled plasma (PP) linear regression 
parameters to those found in the modified plasma (MP) matrix for both analytes.  An 
unpaired, two-tailed Student’s t-test was performed on the slope and y-intercept 
parameters, assuming unequal variances.   
 The y-intercept showed a statistically significant difference between matrices.  
While the modified, diluted plasma was not significantly different from zero, the pooled 
plasma matrix possessed a significant y-intercept, reflecting the constitutive H and NH 
concentrations in the plasma.  Moreover, the lack of a significant y-intercept in the 
modified plasma denotes successful dilution of the matrix.   The statistical comparison 
of the y-intercept illustrates a successful dilution of the matrix. 
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Table 3-26:  Linear regression comparison between pooled plasma (PP) and modified 
plasma (MP), n = 6 each, for NH (top) and H (bottom).  Statistical significance was 
defined at the α = 0.05 level.  
 
calibration PP MP PP MP
1 0.0068 0.0064 0.0670 0.0091
2 0.0072 0.0067 0.0713 (-)0.0081
3 0.0065 0.0059 0.0660 (-)0.0067
4 0.0065 0.0062 0.0780 0.0044
5 0.0068 0.0055 0.0810 (-)0.0049
6 0.0064 0.0058 0.0691 0.0029
avg 0.0067 0.0061 0.0721 0.0055
stdev 0.0003 0.0004 0.0061 0.0032
p-value 0.9399 <0.01
Regression Parameter
Slope Y-intercept
   
 
calibration PP MP PP MP
1 0.0094 0.0097 0.0580 0.0051
2 0.0113 0.0103 0.0524 0.0037
3 0.0109 0.0098 0.0642 (-)0.0039
4 0.0118 0.0105 0.0688 0.0040
5 0.0096 0.0092 0.0721 (-)0.0031
6 0.0091 0.0097 0.0830 0.0013
avg 0.0104 0.0099 0.0664 0.0035
stdev 0.0011 0.0005 0.0108 0.0016
p-value 0.3337 <0.01
Regression Parameter
Slope Y-intercept
  
 
 
   
 Of primary importance is the statistical similarity in the slopes for both H and 
NH in both matrices. The comparison proves similarity and supports the 
interchangeability of the matrix for calibration purposes.   In essence, for a given 
change in concentration of H or NH analyte, a similar change in response will be seen, 
regardless of using a modified or pooled plasma matrix.  Moreover, “parallelism” 
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between the matrices was proven between the modified and the pooled plasma matrix. 
Further assessment of selectivity was warranted for this method, evaluating additional 
plasma sources for potential interferences.  A similar approach was used to assess 
“parallelism” in patient plasma samples.    
 
3.3.4d-5   Patient plasma experiments 
 In order further evaluate selectivity and parallelism, individual plasma from 
separate donors was used as a matrix.   Selectivity should be assessed to show that the 
anticipated analytes are measured and that their quantification is not affected by the 
presence of biological matrix, known metabolites, degradation products, or co-
administered drugs (Viswanathan et al., 2007).   In assay wherein the intrinsic 
selectivity is low (e.g., HPLC with detection other than MS), it is essential to confirm 
using blank matrices from at least n=6 independent sources, that the matrix will not 
impede the assay significantly.  The White Paper from the 3rd Bioanalytical Workshop 
has proposed determination of matrix factors from 6 independent sources of matrix as a 
way of assessing the matrix effect (AAPS, 2006).    
 In the case for drug molecules, the “blank” matrix should not produce any 
significant background at the retention time of the analytes.  For chromatographic 
assays, the peak response in the blank matrix at the retention time for the analytes 
should be no more than 20% of the response for the LLOQ of the assay.  Both 
statements would be violated in the assessment of selectivity of H and NH 
quantification, because of the endogenous nature of the analytes in plasma. Nonetheless, 
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selectivity of the bioanalytical assay may still be assessed by spiking known 
concentrations of analyte into the matrix of interest, as performed as a standard addition 
experiment.    Standard addition methods are particularly useful for analyzing complex 
samples in which the likelihood of matrix effects is substantial (Skoog et al., 1998).    In 
this approach, different weights of the analyte(s) are added to the sample matrix, which 
initially contains an unknown concentration of analyte.    Extrapolation of a plot of 
response found for the standard-addition calibration concentrations to zero 
concentration defines the original concentration of the unspiked sample.   One 
disadvantage of this calibration method is the fact that at least three to five aliquots need 
to be prepared because and increasing amount of calibrant must be added to these 
different aliquots.    In general, this method may require a significant volume of plasma 
that may not be available for the intended method.    Moreover, an important aspect of 
standard addition is that the response prior to spiking additional analyte should be high 
enough to provide a reasonable S/N ratio (>10), otherwise, the result will have poor 
precision (Snyder et al., 1997).   
 The major criteria in establishing “surrogacy” of the proxy matrix, is that the 
response factor, or slope of the calibration curves obtained in the substitute matrix, 
should be statistically similar.  Upon approval, matrix differences between the surrogate 
and unmodified, sample matrix, may presumably be accounted for.  The parallelism 
between the calibration curves of both matrices suggests that quantification via a 
common calibration curve would be similar between the surrogate and actual sample 
matrix.    In essence, parallelism studies need to be performed where the response of the 
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assay to a range of calibration standard concentrations made up in the surrogate matrix 
is compared to that of a series of dilutions of patient samples. This method of deeming 
“surrogacy” of a proxy matrix for quantification has been successfully employed  
(DeSilva et al., 2003; Smolec et al., 2005).   In order to evaluate the use of the HPLC-
FD method along with the modified matrix, a total of six sources of unmodified plasma 
were used in the subsequent experiments.  
 Using individual plasma (n=5, presumably healthy, drugs of abuse-free, smokers 
and non-smokers, collected in EDTA) and pooled plasma were used to satisfy the 
conditions for testing selectivity.  Using the finalized extraction method, spiked 
concentrations of H and NH was evaluated in 2-ml of human patient plasma.  As the 
availability of significant volumes of individual human plasma was limited, full 
calibration curves could not be constructed in the patient plasma.   For the individual 
plasma experiments a total of five concentrations was used for the standard addition 
calibration curve construction including 12.5, 100, 400, 625, and 800 pg of H and NH 
and 300 pg of YOH in 2-ml of plasma.  Moreover, a “zero” concentration (unspiked H 
or NH with 300 pg of YOH) was evaluated to assess the endogenous H and NH 
concentrations.   Individual plasma calibration curves were constructed in singlicate.  
The concentrations assessed in these experiments are representative of those used in 
previous calibration curves.    
 In order to assess potential interferences with YOH retention time, absolute peak 
area was compared to that of the pooled plasma chromatogram, where there was no 
observable interference.  A significant observable interference was defined as a %COV 
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>10% of absolute peak area at the YOH retention time for all individual plasma 
chromatograms.  In addition to the patient plasma calibration curves, a pooled plasma 
matrix calibration curve was constructed (n=1), using the full range of calibration 
concentrations. 
 In order to appraise the identity of the constitutive H and NH, spectral 
confirmation studies were performed.  The emission spectra of authentic H and NH 
were scanned at a fixed excitation wavelength of 300 nm for both authentic (spiked) and 
constitutive (unspiked) patient samples at the respective retention times    Comparison 
was made between the emission spectra scans of the samples to assess the spectra shape 
and emission wavelength maximum.   
 A five-point, linear calibration curve was constructed for each individual plasma 
donor using a 1/x2 weighing, identical to the weighted regressions performed as the 
other experiments.   The linear regression parameters for the calibration curves, 
including slope and y-intercept, for the individual plasma were assessed.  The y-
intercept for each individual calibration curve presumably reflected the constitutive 
contribution of H and NH and compared to that of the “zero” concentration level, as 
calculated from the surrogate matrix calibration curve.  The 95% confidence interval for 
the y-intercept (peak area ratio) should include the peak area ratio of that seen of the 
“zero” sample for both H and NH.   This method was to ensure the accuracy of using 
the surrogate matrix calibration curve to calculate a concentration in unmodified, real 
sample. 
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 Of primary importance was the evaluation of the slope parameter for each 
individual plasma calibration curve.  The estimate and its corresponding 95% CI was 
calculated and compared across donors.   The estimates for the slope parameter should 
be statistically similar upon evaluation of the 95% CI.  Across patient calibration 
curves, concentrations were back-calculated using (1) the regression obtained from the 
patient calibration curve, with baseline correction and (2) the full calibration curve 
using the modified “surrogate” matrix.  At each level, the concentrations were 
compared between matrices to appraise difference between the two quantification 
methods.  It was defined that, if the percent difference was greater than 20%, surrogacy 
of the matrix was not obtained and a significant issue of selectivity was present. 
Individual NH and H concentrations were calculated and compared for each patient 
sample using the standard addition method and the surrogate matrix calibration.  
 Moreover, the slopes ± standard deviation between the surrogate matrix plasma 
(n=6), individual patient plasma (n=5), and pooled plasma (n=6) calibrations were 
compared via one-way analysis of variance (ANOVA) to ensure a matrix effect between 
the matrices was not present.   Prior to statistical contrast, the residuals were evaluated 
for equal variance and tested accordingly if that assumption did not hold true.   If 
significant deviations and variability in the slopes was present in the analysis, the 
chromatographic parameters and/or extraction method was further optimized eliminate 
the interfering substances. 
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3.3.4d-6   Patient plasma results  
 Using the finalized extraction method, spiked concentrations of H and NH was 
evaluated in 2-ml of human patient plasma from n=5, presumably healthy, drugs of 
abuse-free, smokers and non-smokers.  Representative chromatograms for LLOQ in 
modified matrix, patient plasma, and “zero” modified matrix are presented in figure 3-
15 below.   The respective retention times for NH, H and the internals standard, YOH 
are 3.82, 4.43, and 8.09 minutes, respectively.  The LLOQ of 6.3 pg/2ml of modified 
plasma (Figure 3-15a) shows distinct bands at the respective retention times of H and 
NH while figure 3-15c exemplifies the “zero” sample level (dilution of H and NH) in 
the presence of the internal standard, YOH.  Unmodified patient plasma (2 ml) sample 
was quantified with the surrogate matrix calibration curve and resulted in 42.5 pg/2 ml 
of NH and 25 pg/ 2ml of H, both of which fall within reported physiological ranges of 
plasma β-carboline (Figure 3-15b). 
 The goal of patient plasma experiments was to assess selectivity of the assay 
methodology.   Of note, the accessibility of significant volumes of individual human 
plasma was limited, as consequence, full calibration curves could not be constructed in 
the patient plasma.  The corresponding calibration curve parameters are presented 
below. 
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Table 3-27:  Linear regression parameters obtained from patient plasma (PP #1-5) and 
one modified plasma (MP) calibration curve for NH (top) and H (bottom).  95% CI 
denotes the upper and lower bounds in brackets for both slope and y-intercept.  
 
Norharman
plasma slope 95% CI y-int 95% CI R2
MP 0.0064 [0.0058, 0.0074] 0.01 [-0.06, 0.04] 0.9985
PP#1 0.0065 [0.0054, 0.0078] 1.40 [1.12, 1.73] 0.9882
PP#2 0.0071 [0.0051, 0.0080] 1.05 [0.91, 1.16] 0.9748
PP#3 0.0071 [0.0066, 0.0074] 0.32 [0.22, 0.41] 0.9955
PP#4 0.0073 [0.0063, 0.0081] 0.10 [0.03, 0.16] 0.9833
PP#5 0.0059 [0.0040, 0.0075] 2.00 [1.45, 2.33] 0.9722
avg 0.0067 0.81 0.9854
stdev 0.0005 0.80 0.0107  
Harman
plasma slope 95% CI y-int 95% CI R2
MP 0.0099 [0.0094, 0.0105] 0.00 [-0.03, 0.05] 0.9974
PP#1 0.0107 [0.0101, 0.0114] 0.37 [0.28, 0.45] 0.9872
PP#2 0.0098 [0.0092, 0.0103] 1.47 [1.43, 1.52] 0.9987
PP#3 0.0091 [0.0079, 0.0111] 0.25 [0.11, 0.41] 0.9637
PP#4 0.0089 [0.0082, 0.0096] 0.08 [0.05, 0.14] 0.9911
PP#5 0.0109 [0.0093, 0.0115] 2.68 [2.55, 2.74] 0.9884
avg 0.0099 1.01 0.9878
stdev 0.0008 1.06 0.0127  
  
 The coefficients of determinations for NH and H, in the patient plasma, were 
greater than 0.96 for both, suggesting the linear calibration function is acceptable for 
this matrix (using 1/x2 weighting).   The y-intercepts obtained for all calibration curves, 
with the exception of the modified plasma, were all statistically different from zero, as 
deemed by the 95% CI.    Moreover, the intercepts between the plasma sources resulted 
in significant deviations, suggesting the variable nature of the constitutive NH and H 
between the five patients (COV%, NH: 98.4% and H: 130%).   
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 The slope parameters from the calibration curves were all statistically similar 
between the patient plasma sources and in comparison to the modified matrix.   Because 
of the limited number of concentration points on each calibration curve (5-point) for the 
patient plasma, the 95% CI range was relatively large as compared to the modified 
plasma matrix (i.e., a full calibration curve).  Of note, according to the aforementioned 
criteria, no significant interference was seen at the YOH, internal standard retention 
time.  For all individual plasma chromatograms and pooled plasma chromatograms the 
%COV in absolute peak area for the internal standard was 7.2%. 
 Results of spectral confirmation studies compare the authentic to that of 
constitutive H and NH.  According to the shape and maximum wavelength of emission 
spectra for both analytes, the patient plasma peaks seen at the respective retention times 
of H and NH (i.e., 3.82 and 4.43 minutes) are similar to those of authentic, spiked H and 
NH (see figure 3-16).    
 
 
 
 
 
 
 
H NH 
Figure 3-16:  Spectral confirmation of NH and H comparing the emission spectra of 50 
pg of authentic (spiked) NH and H (top spectra) to endogenous NH and H (bottom 
spectra). 
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 To further evaluate the “surrogacy” of using the modified matrix, a comparison 
of the utility between the patient plasma and the modified plasma calibrations was 
appraised.  This analysis compares the back calculated concentrations obtained from the 
modified matrix calibration curve to that of the back-calculated concentrations of the 
standard addition calibration of the patient plasma (see tables 3-28 and 3-29).  Of 
importance is the calculation of the constitutive concentrations of H and NH within the 
patient plasma sources.  Upon comparison of both calibration methods, a significant 
percent difference (denoted as %diff on tables) is present between both methods of 
quantification for both analytes.  The standard addition method of calibration possesses 
greater inaccuracy as compared to the surrogate matrix calibration.  This discrepancy 
maybe caused by the difference in the number of calibration points used in each method 
(n=5 for standard addition vs. n = 8 for the surrogate matrix calibration).    This 
limitation of using the standard addition method for calibration purposes is due to the 
lack of significant volumes of patient plasma.  In order to run an accurate standard 
addition calibration for this developed assay, at least 16-ml of patient plasma would be 
required.   
 The concentrations obtained from the surrogate matrix calibration curves 
yielded endogenous levels that were within reported physiological ranges.  For NH, the 
concentration range within the individual patient samples ranged 12.6 - 309 pg per 2 ml 
plasma.  For H the concentration range within the five patient samples ranged from 6.2 - 
292 pg per 2 ml plasma. 
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 Surrogacy of the modified matrix was further evaluated by statistical 
comparison of calibration curves from pooled plasma and patient plasma.  One-way 
ANOVA was performed on the slopes of the calibration curves between three different 
plasma matrices, modified (surrogate), pooled, and patient plasma.    The summary 
table of all calibration slopes is presented in the table 3-30 below. The three groups of 
plasma matrices, compared using the unequal variance F-test, was not significantly 
different for both NH and H.  For NH the means were found to be statistically similar, 
F(1, 15) = 1.3, p-value = 0.067, while the same conclusion was drawn for the H 
calibration parameter F(1, 15) = 0.96, p-value = 0.341.    The results are presented as F-
test calculation (degrees of freedom for groups, residuals) and p-value.   All statistical 
comparisons were performed on S-PLUS 8.0 for Windows.   
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Table 3-28: Concentration calculations (pg/2ml) between standard addition calibration 
and surrogate matrix (SM) calibration curve for Norharman (measurements, n=1).   
 
patient #1 pg NH calc conc %DFN SM conc %DFN % Diff
12.5 222.2 10.0 208.5 -1.2 -6.1
100 332.5 14.9 336.8 12.8 1.3
400 598.9 1.6 597.1 -0.2 -0.3
625 777.5 -4.5 838.8 1.9 7.9
800 1036.0 4.7 1011.4 1.3 -2.4
zero 189.4 ** 198.5 ** 4.8
patient #2 pg NH calc conc %DFN SM conc %DFN % Diff
12.5 178.9 11.0 176.4 5.4 -1.4
100 274.3 10.3 271.9 6.6 -0.9
400 545.8 -0.5 508.6 -8.3 -6.8
625 683.8 -11.6 741.1 -5.0 8.4
800 1067.5 12.5 1003.6 5.1 -6.0
zero 148.7 ** 155.0 ** 4.2
patient #3 pg NH calc conc %DFN SM conc %DFN % Diff
12.5 61.0 15.6 55.5 0.9 -9.1
100 146.9 4.7 136.7 -4.0 -6.9
400 417.7 -5.1 461.2 4.2 10.4
625 641.0 -3.6 676.9 1.4 5.6
800 889.3 5.8 872.2 3.5 -1.9
zero 40.3 ** 42.5 ** 5.4
patient #4 pg NH calc conc %DFN SM conc %DFN % Diff
12.5 31.3 24.2 23.3 -7.3 -25.6
100 91.9 -18.5 103.6 -8.0 12.7
400 397.0 -3.8 433.9 5.2 9.3
625 665.0 4.3 711.6 11.6 7.0
800 895.4 10.2 885.6 9.0 -1.1
zero 12.7 ** 12.6 ** -0.8
patient #5 pg NH calc conc %DFN SM conc %DFN % Diff
12.5 392.0 4.6 327.1 1.8 -16.6
100 492.7 6.6 426.2 4.2 -13.5
400 709.5 -6.9 665.7 -6.1 -6.2
625 1033.8 4.7 957.6 2.5 -7.4
800 1043.9 -10.2 1053.2 -5.0 0.9
zero 362.3 ** 309.0 ** -14.7
standard addition surrogate mat calib
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Table 3-29: Concentration calculations (pg/2ml) between standard addition calibration 
and surrogate matrix calibration curve for Harman (measurements, n=1).   
 
patient #1 pg H calc conc %DFN SM conc %DFN % Diff
12.5 38.0 -3.0 43.1 1.7 13.3
100 119.8 -5.5 131.4 1.2 9.8
400 478.2 12.1 439.3 2.2 -8.1
625 712.6 9.3 670.1 2.3 -6.0
800 787.7 -4.7 863.4 4.0 9.6
zero 26.7 ** 29.8 ** 11.8
patient #2 pg H calc conc %DFN SM conc %DFN % Diff
12.5 168.6 8.1 166.2 7.3 -1.4
100 275.1 13.0 233.7 -3.6 -15.0
400 573.9 5.6 545.7 0.6 -4.9
625 791.5 3.0 780.2 1.7 -1.4
800 941.0 -0.3 919.5 -2.4 -2.3
zero 143.5 ** 142.4 ** -0.7
patient #3 pg H calc conc %DFN SM conc %DFN % Diff
12.5 29.8 -20.9 38.3 2.2 28.8
100 102.4 -18.2 111.0 -11.2 8.4
400 525.1 23.5 477.2 12.3 -9.1
625 791.9 21.8 757.3 16.5 -4.4
800 843.8 2.3 787.0 -4.6 -6.7
zero 25.1 ** 25.0 ** -0.6
patient #4 pg H calc conc %DFN SM conc %DFN % Diff
12.5 21.2 16.0 18.8 0.6 -11.3
100 102.7 -17.9 130.1 4.1 26.6
400 449.5 5.7 388.9 -8.5 -13.5
625 667.4 2.7 644.4 -0.9 -3.4
800 855.6 3.7 757.5 -8.2 -11.5
zero 5.8 ** 6.2 ** 7.0
patient #5 pg H calc conc %DFN SM conc %DFN % Diff
12.5 294.6 6.1 310.4 1.9 5.4
100 338.4 -7.3 376.6 -4.0 11.3
400 573.4 -13.8 624.5 -9.8 8.9
625 953.8 7.1 997.2 8.7 4.6
800 1018.9 -4.3 1078.7 -1.2 5.9
zero 265.3 ** 292.2 ** 10.2
standard addition surrogate mat calib
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Table 3-30: Statistical comparison of calibration regression slope parameter between 
pooled, patient and surrogate matrix for NH and H.  One-way ANOVA performed 
between matrices with significance at the α = 0.05 level. 
 
Norharman
calibration Pooled Patient Surrogate
1 0.0068 0.0065 0.0064
2 0.0072 0.0071 0.0067
3 0.0065 0.0071 0.0059
4 0.0065 0.0073 0.0062
5 0.0068 0.0059 0.0055
6 0.0064 0.006
avg 0.0067 0.0068 0.0062
stdev 0.0003 0.0006 0.0004
p-value 0.067
Slope of Regression
4
       
   
Harman
calibration Pooled Patient Surrogate
1 0.0094 0.0107 0.0097
2 0.0113 0.0098 0.0103
3 0.0109 0.0091 0.0098
4 0.0118 0.0089 0.0105
5 0.0096 0.0109 0.0092
6 0.0091 0.009
avg 0.0104 0.0099 0.0099
stdev 0.0011 0.0009 0.0005
p-value 0.341
Slope of Regression
7
 
 
 From these results, the appropriateness of using the modified plasma matrix as a 
surrogate matrix was demonstrated.    Parallelism between the calibration curves in 
different matrices suggests the interchangeable nature of using either matrix for 
validation purposes.    Limitations of using patient plasma pertain to insufficient 
volumes available for constructing an accurate calibration curve.  Moreover, an accurate 
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and precise assessment of an LLOQ for the standard addition method is dependent on 
the constitutive concentration of the analyte in the plasma.  The utilization of pooled 
plasma, solely, does not address the selectivity assessment as required for any 
bioanalytical method development.     Therefore, the surrogate matrix will be 
incorporated for the clinical sample analysis.   
 
3.3.4e Validation Conclusions  
 In summary, the acceptance criteria for validation were met according to 
predetermined specifications. In the surrogate and unmodified matrices, 
chromatographic response was linear throughout the concentration range of 6.3 pg/2 ml 
(LLOQ) and 1 ng/2 ml (ULOQ).    For both analytes, accuracy throughout the 
calibration range was acceptable with %DFN ranging from -7.6 to 14.9%.   Surrogacy 
of the modified matrix was confirmed via statistical comparison of calibration curve 
slopes with those of unmodified matrix (pooled and patient plasma).   For both types of 
calibration matrices, the slope precision (%COV) for H and NH were < 6.5% for both 
analytes with both analytes possessing R2 precision of <3.7%.   
  Accuracy and precision estimates for the assay were in acceptable ranges for the 
calibration points, the LLOQ and quality control samples with %COV and %DFN 
meeting analytical validation criteria.  Selectivity of the method was evaluated with 6 
donor lots (5 individual plasma and 1 pooled plasma) and no interference was apparent 
with the analyte or YOH detection.   Across all quality control samples, recovery was 
relatively high (>80.2%) and reproducible for both H and NH.    
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 Long-term plasma stability experiments for 6 months at -80ºC resulted in 
negligible deviations over time for both analytes.  Additional stability experiments, 
including stock solution, bench-top, and post-preparative resulted in negligible 
deviations throughout the respective tested time-spans.   Under the optimized SPE 
experimental conditions and chromatography, endogenous H and NH were detected in 
plasma at concentrations comparable to reported literature values.    
 
3.4  β-carboline assay conclusions  
 A robust, sensitive, selective and reproducible assay has been developed for the 
quantification of the endogenous β-carbolines, H and NH, in 2 ml of human plasma. 
This optimized assay technique involves a simple protein precipitation with SPE 
extraction along with 300 pg of the internal standard, YOH.   
 In comparison to reported methodologies for the quantification of H and NH in 
human plasma, this procedure has overcome the limitations aforementioned.  The 
optimized chromatography has preserved the baseline resolution of the H and NH 
analytes (Rs > 1.5) throughout the concentration range, improving the reliability of 
quantification.   In addition, an appropriate internal standard, YOH, was chosen in part 
to the similar physicochemical characteristics of H and NH.  The internal standard 
possesses comparable HPLC retention attributes, stability in plasma, and extraction 
recovery efficiency.  For these reasons, YOH proved to be a valuable candidate for H 
and NH extraction from human plasma.  
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 Successful quantitation without a true blank matrix requires the use of surrogate 
matrices, especially in the case where the analytes of interests are in low concentrations.  
This method justified the use of a surrogate matrix for validation and practical purposes.  
The standard addition method, although useful, resulted in less accurate results 
compared to the surrogate matrix calibration method.    This is presumably due to the 
lack of significant patient plasma volume to run a full and accurate calibration curve.    
 The current developed method has maintained resolution between analytes, 
utilizes a novel internal standard to assess sample loss from extraction and has been 
fully validated using and appropriate surrogate matrix, unlike currently reported assays 
for H and NH quantification in plasma. Moreover, this new method has maintained 
adequate sensitivity for physiological studies. The chromatographic separation 
conditions along with the optimized extraction technique and surrogate matrix 
calibration will be used to support clinical studies for the quantification if the β-
carbolines, H and NH, in human plasma. 
 
  
 
 
 
 
CHAPTER 4  
BIOANALYTICAL ASSAY OPTIMIZATION AND VALIDATION FOR R/S-
SALSOLINOL AND DOPAMINE IN HUMAN PLASMA 
 
 
4.1  Introduction – Selection of Analytical method 
 
 Salsolinol (1-methyl-1,2,3,4-tetrahydro-6,7-dihydroxy-isoquinoline, SAL) is a 
dopamine-derived tetrahydroisoquinoline (TIQ) alkaloid that has been purported to play 
a role in the neurochemical mechanisms underlying addiction.  However, results found 
in previous human studies on SAL plasma and urine concentrations and its enantiomeric 
ratio between healthy and alcoholic populations show conflicting results and show large 
variability.   A sensitive and reliable method to determine the enantiomeric composition 
of endogenous SAL is required to test a possible correlation between alcoholism and 
R/S-SAL exposure.  Moreover, as SAL is a dopamine derived TIQ alkaloid, it would be 
useful to determine the physiological concentrations of dopamine (DA) to assess SAL 
synthesis characteristics in human populations.  Assessment of the DA precursor along 
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with the SAL product may provide valuable information on the characterization of SAL 
biosynthesis.   
 Both enantiomers of SAL are found in urine, cerebrospinal fluid (CSF), blood, 
and brain of humans.  As physiological concentrations of SAL are reported to be in the 
low nanogram to low picogram / ml plasma range, and the available samples from 
humans are complex matrices, multi-step enhancement and preparation techniques are 
necessary for ultimate detection and quantification.   
 Few reports of bioanalytical assays for total SAL in biofluids and foods have 
been published including GC-MS (Musshoff et al., 1997), HPLC-ECD (Riggin and 
Kissinger, 1977; Dufay et al., 1991) and HPLC-FD (Pagel et al., 2000) methodologies.  
Recently, LC/MS methods using electrospray ionization (ESI) tandem mass 
spectrometry (MS) (Song et al., 2006) or atmospheric pressure photoionization MS 
(Starkey et al., 2006) have been used for SAL analysis without enantiomeric separation.   
 The enantiomeric discrimination of SAL became of importance when in-vitro 
and in-vivo pharmacological differences between R-SAL and S-SAL were identified.   
SAL enantiomers were first analyzed by GC and nitrogen-phosphorus detection after 
derivatization with N-trifluoroacetyl-L-proyl chloride (Strolin-Benedetti et al., 1989).  
Regular analyses of SAL enantiomers from biological matrices using this methodology 
have been complex and irreproducible.  A GC/MS method was developed by a two-step 
derivatization process to SAL diastereomers with N-methyl-N-trimethyl-silyl-
trifluoroacetamide (MSTFA) and (R)-(-)-2-phenylbutyryl chloride as a chiral 
derivatizing agent (Haber et al., 1995b; Musshoff et al., 2000).  Although baseline 
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separation of SAL enantiomers was established, this method utilized water sensitive 
derivatization procedures that required evaporation of aqueous solvent to absolute 
dryness, frequently promoting oxidative degradation of SAL.  Moreover, the resulting 
chiral derivatives were unstable, hindering a consistent quantifiable analysis for both R- 
and S-SAL. 
 Use of chiral HPLC employing β-cyclodextrin stationary phases or as mobile 
phase additives has been used to provide enantiomeric separation of SAL 
(Rommelspacher et al., 1995; Stammel et al., 1995; Deng et al., 1997).   In addition, 
determination of SAL enantiomers by HPLC-ECD has been conducted as 
diastereoisomeric derivatives, via reaction with (S)-1-(1-naphthyl) ethyl isothiocyanate 
as a chiral derivatizing reagent (Pianezzola et al., 1989).  Yet, poor resolution, 
specificity, and sensitivity as well as lack of positive identification were severe 
limitations in the reported HPLC/ECD methods.  The reported methodologies for 
quantification of R- and S-SAL in a biological matrix have been sensitive but several 
shortcomings exist for the published techniques.  A list of published records of R-SAL 
and S-SAL analysis in a biological matrix is presented in the table below.     
 Further critique of the reported bioanalytical assays is warranted as inadequacies 
in the chromatography, extraction, and validation of the SAL assay methods are present.  
Adequate chromatographic baseline resolution between the SAL enantiomers has not 
been accomplished with majority of the assays presented, even after sophisticated 
techniques used for the separation.  In regard to quantification, several deficiencies are
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present in reported methods.  Firstly, internal standards have not been used in the 
reported assays.  Significant sample pretreatment and preparation steps utilized in these 
methods necessitate the use of an internal standard. 
 Aside from the methodological issues pertaining to R/S-SAL assays, appropriate 
bioanalytical validation metrics (i.e., accuracy and precision) have either not been 
presented or assessed.   Most importantly, the calibration matrix that has been used for 
quantitation in published assays has been via external calibration in buffer or mobile 
phase (see discussion in Chapter 3).  This practice of calibration completely disregards 
sample extraction efficiency or matrix effects that may occur during the analysis or 
detection.    
 In summary, the reported bioanalytical methodologies for quantification of the 
SAL enantiomers in human plasma are not adequate for clinical study.   In this 
investigation, a new robust analytical technique to determine SAL enantiomers and their 
precursor DA simultaneously based on chemical derivatization and chiral HPLC/ESI-
tandem mass spectrometry was developed, optimized and validated (Lee et al., 2007). 
Presented throughout this chapter is the investigation on the optimization and validation 
of the already developed assay.  The current method developed for R-SAL, S-SAL and 
DA quantification addresses the limitations associated with reported assay literature, 
maintaining the sensitivity required for use in human pharmacology studies. 
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4.2 Physicochemical Characteristics of R/S-SAL and DA 
 Tetrahydroisoquinolines, such as SAL (1-methyl-6,7-hydroxy-1,2,3,4-
tetrahydroisoquinoline), are a class of partially aromatic compounds that are formed via 
the condensation of catecholamines (e.g., dopamine) with aldehydes.  Recall the 
structure and pertinent physiochemical characteristics of salsolinol (SAL, figure 1-1). 
 Like many other TIQ’s, SAL has an asymmetric center at the C-1 position of the 
heterocycle, thus leading to two stereo-isomeric forms (+)-(R)-SAL and (-)-(S)-SAL.  
SAL is an isoquinoline analog consisting of a catechol ring and a secondary amine that 
is able to be protonated at physiological pH (primarily ionized).  Under acidic pH the 
secondary nitrogen possesses the propensity to form a quarternary ammonium species.  
The catechol moiety of SAL is speculated to have a pKa of ~ 9.4 in which, at 
physiological pH, is primarily unionized.  The solubility and lipophilicity of S-SAL has 
not been well characterized.  The logD has not been experimentally determined.  
Therefore, as SAL is primarily ionized at physiological pH and is moderately 
hydrophilic.  
 The precursor dopamine (4-(2-aminoethyl)benzene-1,2-diol, DA), is one of the 
primary catecholamine neurotransmitters in the brain. It is derived from tyrosine and is 
the precursor to norepinephrine and epinephrine.  Dopamine is a major transmitter in 
the extrapyramidal system of the brain, and important in regulating movement, in which 
a family of receptors mediate its action.  The structure and pertinent physicochemical 
characteristics are shown in the figure below. 
 
167 
 
NH2OH
OH                              
 
 
Mol Weight (g/mol)  153.2 g/mol 
pKa     9.8 (primary amine)  
log D    -2.34 
solubility   Very soluble (1000 g/L water) 
 
Figure 4-1:  Structure and physicochemical characteristics of dopamine (calculated 
from Advanced Chemistry Development, ACD/Labs, Software V 8.19 for Solaris © 
1994-2008). 
 
DA is an biogenic amine consisting of a catechol ring and a primary amine that is able 
to be protonated at physiological pH (primarily ionized).  Like SAL, the catechol 
moiety of DA is speculated to have a pKa of ~ 9.0 in which, at physiological pH, is 
primarily unionized.  DA is very soluble in water and the logD suggests that it is very 
hydrophilic in nature.   
 
4.3  Enantiomeric Determination of R/S-SAL and DA via HPLC-ESI MS/MS  
 A method for the simultaneous determination of the enantiomeric concentrations 
of R- and S-SAL, along with the precursor, DA, was developed in the Laboratory of 
Molecular Signaling, National Institute of Alcohol Abuse and Alcoholism, National 
Institutes of Health (Lee et al., 2007).  Along with a synopsis of the reported method, 
below summarizes the optimization of derivatization steps along with final validation of 
the assay in human plasma.  The method was subsequently used to the support the 
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quantification of R/S-SAL and DA in two clinical studies involving alcohol dependent 
and tobacco smoking population.   
 
4.3.1    Materials and Reagents 
 All chemicals were or analytical grade quality and obtained from commercial 
sources.  Solvents used for experiments and measurements were of spectroscopic or 
HPLC grade and used without further purification.   
 
1. (±)-Salsolinol hydrochloride (racemic, SAL-HCl, Sigma-Aldrich Corp., St. Louis, 
MO) 
2. Dopamine hydrochloride (DA-HCl, Sigma-Aldrich Corp., St. Louis, MO) 
3. N,N-diisopropylethylamine (DIPEA, Sigma-Aldrich Corp., St. Louis, MO) 
4. Pentafluorobenzyl bromide (PFBBr, Pierce Chemical Company, Rockford, IL) 
5. Deuterium-labeled (S)-SAL-d4-HBr (1’-methyl-d4) and (R)-SAL-d4-HBr (1’-
methyl-d4) prepared by Cambridge Isotope Laboratories (Andover, MA) 
6. Deuterium-labeled 1,1,2,2-d4-DA-HCl (Cambridge Isotope Laboratories, Andover, 
MA) 
7. Perchloric acid, 70% HClO4 , double distilled (GFS Chemicals, Columbus, OH) 
8. Ethylene glycol bis-2-aminoethyl ether-tetraacetic acid, (EGTA, Sigma-Aldrich 
Corp., St. Louis, MO) 
9. Semicarbazide hydrochloride (Fluka Chemie., Buchs, Switzerland) 
10. Sodium metabisulfite (Sigma-Aldrich Corp., St. Louis, MO) 
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11. Monobasic sodium phosphate, NaH2PO4 • H20 (Sigma-Aldrich Corp, St. Louis, 
MO) 
12. Dibasic sodium phosphate, Na2HPO4 • 7 H20 (Sigma-Aldrich Corp., St. Louis, MO) 
13. 10 M NaOH (VWR, Westchester, PA) 
14. Hydrochloric Acid, ACS Reagent grade, 37% (Sigma-Aldrich Corp., St. Louis, MO) 
15. Methanol, HPLC Grade (Burdick and Jackson, Morristown, NJ) 
16. Hexane (Burdick and Jackson, Morristown, NJ) 
17. Acetonitrile (Burdick and Jackson, Morristown, NJ) 
18. Isopronanol, HPLC grade (Burdick and Jackson, Morristown, NJ) 
19. Milli-Q water (Millipore, Bedford, MA) 
20. Human plasma samples for validation - collected from healthy volunteers at the 
National Institutes of Health Apheresis Clinic and were either analyzed immediately 
or stored at -80 °C until the time of analysis.  
21. Pooled plasma for validation, n = 20 males and females, drug free, nonsmokers 
(BioChemed Services, Winchester, VA). 
 
4.3.2    Equipment   
1. Solid Phase Extraction Manifold, 20-port with stopcocks – (Alltech, Deerfield, IL) 
2. Solid phase extraction cartridges, Bond Elute phenyl boronic acid (PBA) – 100 mg, 
1.0 ml (Varian Inc., Palo Alto, CA) 
3. 10-μl, 100-μl, and 1000-μl Eppendorf variable volume pipette and corresponding 
pipette tips.  
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4. Instrumentation: 
a. Mass spectrometer: TSQ Quantum mass spectrometer with Electrospray 
Ionization source (Thermo-Finnigan, San Jose, CA) 
b. HPLC:  Agilent 1100 HPLC System (Agilent, San Jose, CA) 
c. Column: Chiralpak AD-H column, 2.1 mm x 150 mm, 5 µm, (Chiral 
Technologies, Inc., West Chester, PA) 
d. Guard Column: Chiralpak AD-H column, 2.1 mm x 10 mm, 5 µm, (Chiral 
Technologies, Inc., West Chester, PA) 
e. Data acquisition:  Excalibur 2.0 Software (Thermo-Finnigan, San Jose, CA) 
 
4.3.3 Preparation of Solutions and Standards 
 As neither of the (S)-SAL and (R)-SAL enantiomers are available separately, 
standard solutions of SAL were prepared by dissolving the racemic mixture of (R/S)-
SAL-HCl in methanol.  Standard stock solutions of (R/S)-SAL-HCl as well as DA-HCl 
were prepared in methanol at a concentration of 1 mg/ml in amber, silanized vials.  The 
deuterated internal standard stock solutions were additionally made in methanol at a 
concentration of 100 ng/ml for (S)-SAL-d4-HBr and (R)-SAL-d4-HBr and 1 mg/ml for 
d4-DA-HCl.  Of note, the individual enantiomers of R-SAL-d4 and S-SAL-d4 were 
synthesized and purchased.  Stock standard solutions were stored in darkness at -20 °C 
until further use. The working internal standard solutions were prepared by further 
dilution of the stock solutions to 500 pg/ml of each SAL-d4 enantiomer and 500 pg/ml 
of DA-d4.  Further dilutions used for calibration and validation are presented below in 
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the SAL validation section.  The solutions used for the assay methodology and 
validation are presented below.   
 
1.  Sodium phosphate buffer (pH 8.2, 0.2 M) for derivatization procedure  
 In 500 ml of Milli-Q® water 26.81 g of Na2HPO4 • 7 H20 and 1.38 g of 
 NaH2PO4 • H20 to a 500 ml volumetric flask.  The maximum buffering capacity 
 ~ 33% at this pH level and buffer concentration. 
2.  Sodium phosphate buffer (pH 8.5, 0.5 M) for solid-phase extraction  
 In 500 ml of Milli-Q® water 67.04 g of Na2HPO4 • 7 H20 and 1.725 g of 
 NaH2PO4 • H20 to a 500 ml volumetric flask.  The maximum buffering capacity 
 ~ 18.2% at this pH level and buffer concentration. 
3.  Protein precipitation/Antioxidant solution (1M perchloric acid with 0.01% EGTA,       
 0.02% semicarbazide HCL, 0.02% sodium metabisulfite)  
 Approximately 400 ml of 1M perchloric acid was made by adding 34.18 ml of 
 70% HClO4 to 365 ml Milli-Q® water.  To this solution 80 mg EGTA, 80 mg of 
 sodium metabisulfite and 400 mg of semicarbazide HCl was added and 
 subsequently stirred.   
4.  6N NaOH and 2N NaOH for pH adjustment of sample for solid phase extraction and 
 derivatization procedure.   
 A 10 N NaOH solution was diluted accordingly to obtain the required normality. 
5.  10% Pentafluorobenzyl bromide (PFBBr) in acetonitrile for derivatization 
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 Approximately 500 µl of PFBBr was added to 4.5 ml of acetonitrile in an amber 
 vial and vortexed.   
6.  10%  N,N-diisopropylethylamine (DIPEA) in acetonitrile for derivatization 
  Approximately 500 µl of DIPEA was added to 4.5 ml of acetonitrile in an amber 
 vial and vortexed. 
7.  0.1 M Hydrochloric acid: Methanol (HCl:MeOH, 1:1 ratio) for elution solvent  
   2.06 ml of 37% HCl was added to 248 ml of Milli-Q® water and mixed.  250 ml 
 of methanol was added and mixed accordingly.   
8.  1% acetic acid for post-column addition 
 5 ml of glacial acetic acid was added to 495 ml of Milli-Q® water. 
 
4.3.4 Method Summary for the Analysis of R/S-SAL and DA in human plasma 
4.3.4a Sample Preparation 
 Pooled plasma and human plasma samples that were collected from healthy 
volunteers were stored at -80 °C until the time of analysis.  Aliquots of 1.0 ml plasma 
were spiked with 1 ng each of (S)-SAL-d4 and (R)-SAL-d4 and 5 ng of DA-d4 as 
internal standards.    Extraction of SAL from human plasma was carried out as 
described by Haber et al. with a slight modification (Haber et al., 1995b).  Samples 
were acidified with 1.0 ml of a 1 M HClO4 antioxidant solution containing 0.01% 
EGTA, 0.02% semicarbazide hydrochloride, and 0.02% sodium metabisulfite.   This 
solution was used primarily for protein precipitation.  The additives utilized in the 
HClO4 solution were used as a precautionary measure to inhibit artifactual formation of 
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SAL during the sample work up.  EGTA is a chelating agent that acts as a preservative 
and antioxidant while sodium metabisulfite serves as a strong antioxidant.  The 
semicarbazide component acts as an “aldehyde trapping” agent to prevent artifactual 
formation of SAL.   
 The plasma solution was subsequently centrifuged at 2000g for 15 min at 4 °C 
to remove precipitated proteins.  In order to hydrolyze any conjugated SAL and DA, the 
supernatant was collected and heated for 60 min at 80 °C.  More than 90-98% of SAL 
and DA were present as the conjugated form in plasma based on their levels determined 
with or without acid hydrolysis (data not shown).   This assessment is consistent with 
the reported literature.  The protein free, hydrolyzed sample was cooled and the pH of 
the sample was adjusted to 8.5 using ~ 100 µl of a 6 N NaOH solution and buffered 
with 0.5 ml of 0.5 N potassium phosphate buffer (pH 8.5).  A further, more fine, 
adjustment of pH was performed with a less concentrated 2N NaOH, if needed.   
 
4.3.4b Solid Phase Extraction by Phenyl Boronic Acid (PBA) 
 After pH adjustment, the SAL and DA in plasma were isolated by PBA solid-
phase extraction.    PBA has been successfully used to isolate SAL and DA from 
biological matrices (see table 4-1).   PBA is a distinctive sorbent comprising of a 
phenylboronic acid covalently linked to a silica gel surface.  The boronate group has a 
high specificity for cis-diol containing compounds like catechols, nucleic acids, low 
molecular weight proteins and carbohydrates.  PBA utilizes a covalent retention 
mechanism that involves an interaction of 10-100 times greater energy than other 
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extraction mechanisms (Varian, 2005).  PBA has proven to be especially effective in the 
isolation of catecholamines from biological fluids.  Retention is usually strongest when 
the analytes' functional groups are co-planar, as in the case of SAL and DA. 
 The PBA solid-phase cartridge was rinsed twice with 2 ml each of methanol and 
water to remove any contaminants and subsequently conditioned with 2 ml of potassium 
phosphate buffer (0.5 M, pH 8.5).  The pH 8.5 buffered sample was loaded on the PBA 
cartridge and washed twice with 1 ml each of water and methanol.  Two 750 ml aliquots 
of the 0.1 M HCl/MeOH (1:1) elution solvent mixture was used to elute SAL and DA 
from the cartridges.  The acidic component of the elution solvent was employed to 
break the covalent bonds between the PBA solid phase and the cis-diol groups from the 
SAL and DA.  The elution solvent containing the analytes of interest was directly 
subjected to derivatization without drying and reconstituting in organic solvents.  
 
4.3.4c SAL and DA derivatization via direct PFBBr alkylation 
 Derivatization of SAL and DA from the SPE column directly in the eluting 
solvent minimized the sample loss and oxidation.  After elution, the sample was 
adjusted to a pH of 8.2 using 5-10 µl of 2 N NaOH and 100 µL of 0.2 N potassium 
phosphate buffer (pH 8.2).   PFBBr was used as the primary reagent for the 
derivatization of both SAL and DA.  DIPEA was used to prevent the formation of 
quaternary ammonium species from “over-alkylation” of SAL, of which would not be 
the product of interest for analysis.   Optimization of this derivatization step was pH, 
temperature, and reagent concentration dependent.   Further discussion on the 
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procedures used to optimize this step is presented in the succeeding section.   As result, 
approximately 100 µL of 10% PFBBr and 20 µL of 10% DIPEA in acetonitrile were 
added.  The derivatization was performed at 68 °C for 2.5 h with intermittent vortexing, 
to ensure completeness of the reaction.    A schematic summarizing the reaction of R- 
and S-SAL to their respective tri-PFB derivatives is shown below. 
 
 HO
HO
NH
H CH3
HO
HO
NH
 
 
 
 
 
    
 
Figure 4-2:  Chemical structures and derivatization reaction summary of (R)- and (S)-
SAL to their respective PFB derivatives. 
 
 Resultant SAL-PFB and DA-PFB derivatives were extracted into a 500 µL 
hexane phase followed by simple water-hexane partitioning to remove water soluble 
salt components from the reaction mixture.  A 200 µl aliquot of the hexane layer 
containing the derivatives was removed and evaporated to dryness, reconstituted in 
methanol, and subjected to chiral phase HPLC/ESI-MS/MS analysis.  A schematic of 
the entire sample preparation is presented in the figure below.   
H CH3
PFB O
N PFB
O
H CH3
PFB
O
O
N
H CH3
PFB
PFB
PFB
(S)-SAL
(R)-SAL
PFBBr/DIPEA
pH=8.2, 68°C, 2hrs
tri-PFB-(S)-SAL
tri-PFB-(R)-SAL
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Figure 4-3:  Flow chart of sample preparation for the analysis of R/S-SAL and DA 
from human plasma. 
 
 
 
4.3.4d  Chromatographic and Mass Spectrometric Conditions 
 After extraction and derivatization, of the analytes of interest were analyzed via 
HPLC-MS/MS analysis, with an electrospray ionization source (ESI). Simultaneous 
chromatographic separation of both derivatized SAL enantiomers and DA, was attained 
using a Chiralpak AD-H column (2.1 mm x 150 mm, 5 µm).  This type of column 
utilizes a cellulose chiral stationary phase, specifically tris(3,5-
dimethylphenylcarbamate)-amylose, to attain separation of enantiomers. The 
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phenylcarbamate derivative of the optically active amylose polysaccharide exhibits a 
high chiral recognition capability (Yashima et al., 1995). These types of columns 
involve a combination of attractive interactions and inclusion complexes to produce 
separation.     Each unit of the amylose phases displays a propeller-type shape and are 
believed to form helical polymeric structures which combine polar, π-π interactions 
with inclusion complexation (Ghanem and Naim, 2006).  These phases are generally 
used in the normal phase mode due to the water solubility of cellulose-type stationary 
phases.  For chromatographic separation, an isocratic mobile phase consisting of 
isopropyl alcohol and methanol (IPA/MeOH, 3:2) at a flow rate of 0.12 ml/min was 
delivered by the HPLC system.   
 Detection after chromatographic separation of the derivatized analytes was 
conducted via MS/MS analysis with an ESI source in the positive ion mode.  The heated 
capillary temperature was set at 350 °C, sheath gas (nitrogen) flow rate at 35 units, 
auxiliary gas at 5 units, and spray voltage at 3.5 kV.  For quantitation, the mass 
spectrometer was operated in the multiple reaction monitoring (MRM) mode.   
Collision-induced dissociation (CID) was performed using argon as the collision gas at 
1.5 mtorr with relative collision energy set at 35 V for SAL and 28 V for DA.   Signal 
intensity was significantly improved via post-column addition of 1% acetic acid in 
water (~50 µL/ min) and was employed prior to the detection by MS. 
 ESI mass spectra of tri-PFB derivatives of SAL and d4-SAL contained [M+H]+ 
ion as the base peaks at m/z 720 and m/z 724, respectively.  Chromatograms of MRM 
transitions m/z 720→181, 210, 358 for (R/S)-SAL and m/z 724→181, 210, 362 for d4-
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(S)-SAL were used upon initial analysis.  For SAL enantiomers the MRM 
corresponding to the ring cleavage, m/z 720→210 (SAL) and m/z 724→210 (d4-SAL), 
was selected to ensure the selectivity of detection.  The quantitation of DA was 
performed by MRM using the transitions of m/z 874 → 497 (DA) and m/z 878 → 501 
(d4-DA).   The ESI-MS/MS product ion mass spectra of [M+H]+ produced from tri-PFB 
derivatives of SAL and  d4-SAL with the tetra-PFB derivatives for DA and d4-DA are 
shown in the figures below.   
 The chromatograms of derivatized (R/S)-SAL and d4-(S)-SAL show resolution, 
Rs > 2.2 between SAL enantiomers and that the (S)-form (retention time: 8.2 min) 
eluted prior to the (R)-form (retention time: 12.6 min).  DA possessed a retention time 
of 7.9 minutes.  Of importance, the inter-conversion, from R to S or vice versa, between 
two enantiomers did not occur throughout the analysis.  The SRM chromatograms of 
(R/S)-SAL further indicated that each isomer was detected with approximately 1:1 
relative peak area ratio.  The deuterium labeled SAL and DA internal standards were 
stable during the analysis and there was no evidence of deuterium/hydrogen exchange.  
Separate MS and MS/MS analyses was performed to test lack of this phenomenon in an 
aqueous environment over a wide pH range (data not shown).  
 Even though monitoring all three transitions in the MRM mode for SAL yielded 
a higher relative intensity, the sensitivity of the assay was not improved due to a 
compromise in specificity when plasma samples were analyzed.  Consequently, the 
SRM to the ring cleavage, m/z 720→210 (SAL) and m/z 724→210 (d4-SAL), was 
selected to ensure the selectivity of detection.  Post-column infusion of 1% acetic acid 
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in water (~50 μL/min) to the main column flow considerably improved the sensitivity 
(by > 10-fold) by enhancing ionization efficiency while circumventing the adverse 
effects of and acidic and aqueous environment that may affect the chiral column 
stability.  
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4.3.4e Method Summary Discussion  
 Only a few analytical assays for the measurement of total (unconjugated and 
conjugated) R- and S-SAL in biological samples have been developed, including HPLC 
with electrochemical detection and GC/MS.  Quantitation of the enantiomeric 
composition in biological samples can be difficult due to inadequate baseline separation 
of enantiomers, irreproducibility, and lack of internal standard use for extraction 
techniques.  Therefore, the development of analytical techniques for the enantiomeric 
determination of SAL is indispensable due to its enantioselective occurrence and 
physiological activities underlying alcoholism.   
 The selectivity of this method in determining SAL and DA from plasma is 
superior to those already reported.  Utilization of PBA SPE was able to discriminately 
remove catechol moieties from plasma, namely the SAL enantiomers and DA.   Use of 
this method of extraction of SAL from plasma has been exemplified in the literature.  
Novel deuterium-labeled R-SAL and S-SAL along with DA allowed for the adequate 
compensation of analyte loss throughout the assay method.   A stable isotopically 
labeled analogue is believed to be the most appropriate internal standard in a 
quantitative bioanalytical LC/MS/MS assay.  It is assumed that a this type of internal 
standard compensates for variability in chemical derivatization, sample extraction and 
LC/MS/MS analysis due to its nearly identical chemical and physical properties to the 
unlabeled analyte.  The derivatization of SAL and DA to its corresponding PFBBr 
analogues, along with the innovative chiral stationary phase, allowed for sufficient 
resolution of both SAL enantiomers, in addition to simultaneous separation of DA.     
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Moreover, racemization of the analytes was not observed, permitting reliable 
interpretation of pharmacological studies discerning specific roles for each SAL 
enantiomer.   
 Selectivity of the assay was reinforced by the detection via ESI-MS/MS.   
Choosing the appropriate MRM transitions improved the selectivity, whilst maintaining 
the sensitivity required for ultimate plasma analysis.  The product ion spectra of 
[M+H]+ acquired from the SAL derivatives possessed the major peaks at m/z 181, 210 
and 358 for SAL and at m/z 181, 210 and 362 for d4-SAL, respectively.  The most 
prevalent product ion appeared at m/z 181 corresponding to the PFB fragment ion.  The 
product ions at m/z 358 and 362 were derived from the loss of two PFB groups from the 
corresponding [M+H]+ ions of SAL and d4-SAL derivatives, respectively. The product 
ion at m/z 210 and 210 derived from the ring cleavage with one PFB group on the 
amine group, was common for SAL and d4-SAL, respectively.   Therefore, the reaction 
monitoring transition of m/z 720→210 for SAL and m/z 724→210 for d4-SAL was used 
to ensure the selectivity of detection. 
Detection of DA in plasma was also achievable with use of the assay method 
and LC-MS/MS system.  The MS/MS analysis revealed the presence of four derivatives 
of DA corresponding to three tri-PFB-DA isomers (m/z 694) and a fully derivatized 
tetra-PFB-DA derivative (m/z 874).   Experiments exemplified the tetra-PFB-DA is the 
major derivative under the conditions employed (data not shown), which was ultimately 
chosen as the derivative of interest for quantitative analysis of DA.  The mass spectrum 
obtained by CID of tetra-PFB-DA produced major product ions at m/z 181, 316 and 
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497.   The ultimate quantitation of DA was performed by MRM using the transitions of 
m/z 874 → 497 (DA) and m/z 878 → 501 (d4-DA).   
This novel method was developed at NIH-NIAAA Laboratory of Molecular 
Signaling.    Prior to validation of the method, optimization of the PFBBr derivatization 
was carried further to ensure high reaction yield and, more importantly, consistent and 
reproducible derivatization products for the primary analyte(s) of interest, R- and S-
SAL.  Subsequently, validation of the assay methodology was performed to ensure 
accurate and precise results for the support of two clinical studies.    
 
4.3.5 PFBBr Derivatization Optimization for R/S-SAL and DA  
 The efficient separation of the SAL enantiomers required the use of a PFBBr 
derivatization procedure after SPE from plasma.    Derivatization involves a chemical 
reaction between an analyte and a reagent to change the chemical and physical 
properties of the analyte of interest.  In turn, the method improves detectability and 
chromatographic separation, thereby enhancing the assay method sensitivity (Snyder et 
al., 1997).    In the case of SAL, the key to the chiral analysis is the ability to react an 
optically active target with PFBBr, in order to achieve adequate resolution between the 
enantiomers.    The derivatization of SAL enables the chiral recognition by the novel 
chiral column used for this analysis.     The ability of the derivatized analyte and the 
chiral stationary phase to form transient-diastereomeric complexes utilizing hydrogen 
bonding, dipole stacking, inclusion complexing and π-π interactions governs the 
enantioseparation.  Therefore, the derivatization step involved in the R- and S-SAL 
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analysis is of great importance.   Of note, successfully resolved enantioseparation of 
SAL without derivatization has not been reported.   
 The first step for derivatization for chiral method development is to examine the 
chemical structure of the analyte and identify information such as solubility in different 
solvents, hydrogen and π-bonding capability, pKa, functional groups and inclusion-
complexing capability.    All characteristics, of which, determine the ability for the 
chiral stationary phase to resolve the sample enantiomers.  The ultimate arrangement of 
the substituent groups, relative to the achiral center plays an important role in the 
enantiomer separation (Snyder et al., 1997).    Recall the structure of SAL.  This analyte 
is primarily water soluble with three important functional groups, two being the 
hydroxyls of the cis-diol catechols moiety of the molecule.  The chiral center at the C-1 
position is directly adjacent to the secondary amine present in the molecule.    In most 
cases, the closer a functional group is to the chiral center, the more likely is chiral 
recognition.  Therefore, derivatization of the secondary nitrogen is of greater 
importance than that of the hydroxyl groups of SAL.   
 The use of PFBBr was used for its ease and successful use for derivatization of 
amines and hydroxyl functional groups that are present in SAL.  PFBBr converts 
carboxylic acids, mercaptans, phenols, and sulfonamides to halogenated derivatives that 
are easily detected by electron capture.  Electron capturing esters are popular for gas 
chromatographic analyses of short chain fatty acids.  Specifically, PFBBr has been 
effectively used as a derivatizing agent for GC analysis of polyfunctional thiols 
(Montanari et al., 2006).  In addition, this reagent was used for the preparation of 
187 
pentafluorobenzyl esters of organic acids for determination by capillary (Cataldi et al., 
1999) and GC (Husek et al., 2008).    PFBBr is used in extractive alkylation 
(simultaneous extraction and derivatization), in conjunction with tetrabutylammonium 
hydrogen sulfate as the counterion an ion-pairing reagent (Sigma-Aldrich, 1999).  
Pentafluorobenzylation by alkylation gives derivatives of phenols, carboxylic acids, and 
sulfonamides to create esters, ethers, alkyl amines and alkyl amides.  The specific 
alkylation reaction reduces molecular polarity by replacing active hydrogens with an 
alkyl group.  The principal reaction employed for preparation of these derivatives is 
nucleophilic displacement (Knapp, 1979). 
 PFBBr is generally used to convert organic acids into esters.  Of note, the 
primary functional moiety of interest in the secondary nitrogen of SAL because its 
proximity to the chiral center.  As the acidity of the active hydrogen decreases, the 
strength of the alkylating reagent must be increased.   The harsher the reaction 
conditions or reagents, the more limited the selectivity and applicability of this method.  
For these reasons, optimization of the derivatization reaction was pertinent.   Some 
advantages of PFBBr derivatization include 1) reaction conditions can vary from 
strongly acidic to strongly basic, 2) some reactions can be done in aqueous solutions, 
and more importantly , 3) the alkylation derivatives are generally stable (Sigma-
Aldrich, 1999).  The disadvantages include sometimes severe reaction conditions and 
toxicity of PFBBr (this reagent is a strong lachrymator).   Nevertheless, PFBBr is an 
effective reagent for alkylation of amines and acidic hydroxyls, as those part of the SAL 
structure.   
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 The following experiments were designed to optimize the derivatization of SAL 
with PFBBr.  As the primary goal of the optimization, the derivatization of the 
secondary nitrogen of SAL was imperative for chiral recognition.    
 
4.3.5a Methods  
 Prior to optimization of the PFBBr-SAL reaction, preliminary information about 
the reaction was obtained from the literature.    The environment of the reaction was to 
take place in the elution solvent from the PBA extraction (0.1 M HCl:MeOH = 1:1), 
which is highly acidic and primarily aqueous in nature.    SAL is known to possess two 
types of functional groups that may be derivatized.  The hydroxyl groups of the catechol 
moiety are primarily unionized while the secondary nitrogen is in its ionized form in 
this acidic milieu.   This characteristic suggests that pH dependency of the reaction is 
important for a high and reproducible reaction yield.  The physicochemical 
characteristics of both PFBBr and SAL differ greatly where PFBBr is highly lipophilic 
as opposed to the analyte.   A consideration on use of a dispersion agent in order to 
ensure the interaction and subsequent reaction of PFBBr and SAL was necessary 
because of the differing characteristics.   The structure of PFBBr is shown below. 
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Figure 4-7:  Chemical structure of pentafluorobenzyl bromide (PFBBr). 
 
 As PFBBr has been used extensively for the derivatization for GC detection, 
molar ratios of reagent to the functional groups have been thoroughly explored.   An 
approximate molar ratio of 1 to 0.3 (reagent to phenols) is necessary for derivatization 
of the catechol portion of SAL (Sigma-Aldrich, 1999), while the secondary amine 
requires a molar ratio of 1.1 to 1 (reagent to secondary amine) for alkylation to occur 
(Moore et al., 2005).     
 Of importance is the alkylation of the secondary amine with the PFBBr alkyl 
halide to form a tertiary amine.   From a methodological view, direct alkylation to the 
tertiary amine is straight-forward but has been somewhat limited.  Direct N-alkylation 
of secondary amines often results in the formation of the quaternary ammonium salts 
and a mixture of the desired tertiary amine and the starting secondary amine (Moore et 
al., 2005).   In turn, derivatization yields of the desired products have been low and 
irreproducible.    The use of a Huenig base, N,N-Diisopropylethylamine (DIPEA), has 
been proven to hamper the formation of quaternary ammonium salts to yield desired 
tertiary amines from alkylation of secondary amines (Moore et al., 2005).  This 
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compound is a good base but a poor nucleophile, which makes it a useful organic 
reagent.  The recommended molar ratio of secondary amine to DIPEA to alkyl halide is 
(1 to 1.5 to 1:1) in acetonitrile at room temperature.  
 With prior information about the PFBBr reaction with the functional groups of 
SAL, experiments were designed to evaluate several factors to construct a reproducible 
and high reaction yield.    In a univariate manner the following factors were explored to 
improve the reaction equilibrium of the alkylation in elution solvent (1M HCl: MeOH), 
in priority order: 
1. molar ratio of total SAL to PFBBr (1:3) 
2. molar ratio of SAL:PFBBr with respect to the Huenig base, DIPEA, (1 : 3 : 1.5)  
3.   use of a dispersion agent:  (i.e., acetonitrile, chloroform, hexane, benzene) 
4. pH dependency, buffer type and concentration 
5. time dependency (15 min, 1, 2, 3, 6, 8, 12, and 24 hours) 
6. temperature dependency (RT, 40, 50, 60, 70, 80, 100°C) 
 
 For formal evaluation, relatively high concentrations of total SAL and d4-R/S-
SAL were prepared in 1.5 ml of elution solvent (total of 2 ng for total internal standard 
and 4 ng of total analyte).  Throughout the experiments it was assumed that smaller 
concentration would yield similar results.    All experiments were performed in 
triplicate to assess precision of the reaction conditions.  The formation of the desired tri-
PFB-SAL product was identified by GC/NCI-MS.  Reversed phase HPLC/ESI-MS was 
further used to confirm results.    Of note, total SAL and total d4-SAL was used for the 
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interpretation of results.  The individual SAL enantiomers were not evaluated for 
reaction yield.    
 Prior to optimization, initial reaction conditions included those that have been 
reported (Knapp, 1979; Moore et al., 2005).  Initial reaction conditions in the elution 
solvent included excess of reagent to SAL ratio (1:100), at pH 7.0, for 2 hours at 68ºC.  
For PFBBr: SAL reaction ratio in elution solvent, molar ratios of 1:1, 1:3, 1:10 and 
1:1000 were varied from initial conditions.    Conditions for reaction include without 
and with varying concentrations of the DIPEA Huenig base.   As the physicochemical 
characteristics of the SAL and PFBBr differ greatly, dispersion agents such as 
acetonitrile, chloroform, hexane, and benzene were evaluated for improvement of 
reaction yields.    In the elution solvent, pH ranging studies were performed by 
adjusting pH at the following values: 7.0, 7.5, 8.0, 8.2, 8.5, 9.1, 9.5, and 10.0.    1N 
NaOH was used to adjust to the desired pH and varying concentrations of phosphate 
and borate buffer were used to maintain pH.  Reaction time and temperature 
dependency experiments were performed for 15 min, 1, 2, 2.5, 3, 6, 12 hours and room 
temperature, 40, 68, 80, 100°C, respectively.   In priority order the factors were varied 
and optimal results were carried through for evaluation of the next factor.   
 Throughout each experiment the SAL was subsequently extracted with 500 µl of 
hexane, washed with 2 ml water to remove salts and unwanted polar products.  A 200 µl 
aliquot was dried down and reconstituted in 20 µl of methanol and subjected to HPLC-
MS/MS analysis.  Further confirmation was performed by GC/NCI-MS and PCI-MS.     
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4.3.5b Results 
 Excess reagent was used for the reaction of PFBBr and SAL to result in a >90% 
reaction yield.  Approximately 100 µl of 10% PFBBr in acetonitrile reagent was used 
for reproducible reaction equilibrium.  The molar ratio of PFBBr to SAL for this 
reaction was approximately 1000:1.   DIPEA was necessary to produce a precise 
derivatization yield in which a 20 µl of 10% DIPEA in acetonitrile reagent was used to 
prevent formation of the quaternary ammonium species.  As both reagents were 
dissolved in acteonitrile, additional use of a dispersion agent was not needed for the 
reaction.  Consistent yields were observed with or without the use of additional 
acetonitrile, chloroform, hexane, or benzene.   
 Upon evaluation, the pH dependency of the reaction yield ad reproducibility 
proved important.    The result of the pH dependency study is shown in the figure 
below. The final pH utilized for the reaction was 8.2 using 100 µl of 0.2M 
K2HPO4/KH2PO4 buffer.  Apparently, at this pH both phenol and amine groups of SAL 
were deprotonated for efficient alkylation, and yet degradation of SAL and PFBBr was 
minimal.    For the reaction to occur, the pH of the environment needed to be between 
pH 7 and 9.5.    Relatively large and precise reaction yields were observed at between 
pH 8.0-8.2.   The reaction time and temperature dependency experiments yielded 
consistent results at a time of 2.5 hours at 68°C.    The results of the pH ranging 
experiment are shown in the figure below. 
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Figure 4-8:  pH dependency of the PFBBr – SAL derivatization reaction in 1.5 ml 1M 
HCl:MeOH (1:1).  Presented as pH vs. total SAL area (mean ± SD).  Reaction 
conditions:  100 µl of 10% PFBBr and 20 µl of 10% DIPEA in acetonitrile, for 2 hours 
at 68°C.   
 
 Under the optimized conditions, the extracted ion chromatograms from 
GC/NCI-MS analysis indicated that the desired tri-PFB-SAL was the predominant 
product while the mono- and di-derivatized forms were the minor components. The 
positive ion spectrum obtained by GC/PCI-MS contained [M+H]+ at m/z 720.  Reversed 
phase HPLC/ESI-MS and HPLC/ESI-MS/MS analyses confirmed the results obtained 
by GC/MS analyses (data not shown). The reaction products were stable for > 8 hours at 
room temperature and > 48 hours in -20°C.    The final desired SAL derivative is shown 
in the figure below. 
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Figure 4-9:  Structure of the desired S-SAL-PFB3 (MW = 719) reaction product under 
optimized derivatization conditions. 
 
 
4.3.5c Discussion 
 Derivatization conditions vary widely, depending upon the specific compounds 
being derivatized.  If derivatization is not complete under the recommended procedures, 
the addition of a catalyst, use of another solvent, pH control, higher reaction 
temperature, longer reaction time, and/or higher reagent concentration should be 
evaluated. Experiments confirmed that, in presence of excess PFBBr reagent, both 
DIPEA and pH dependency were important for formation of the desired SAL product.    
The use of DIPEA for the formation of tertiary amines via alkylation has been 
exemplified in other reports.   The distinctive role of DIPEA in preventing the 
quaternization is not well understood.  It can be implicitly understood that this non-
nucleophilic strong base forms a salt with the released hydrogen halide permitting the 
reaction to proceed under kinetically restricted conditions.   In this case, the reaction of 
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the secondary amine with the starting alkyl halide may be faster than the reaction of the 
tertiary amine product with the starting alkyl halide.  Of note, higher concentrations 
employed of DIPEA resulted in a decrease of reaction yield.  This is presumed to be a 
result of an increase in unfavorable side reaction products of PFBBr with DIPEA.  
Moreover, DIPEA is a strong base that may cause the lack of an appropriate pH 
buffering in the elution solvent.  
 The influence of pH has a profound effect on the derivatization reaction.   As the 
desired product involved the simultaneous deprotonation of the both the catechol and 
secondary amine, pH effects were expected.    At lower pH, SAL functional groups are 
primarily protonated hindering the preferred alkylation.  At higher pH (> pH 9) the 
reaction yield was minimal to none for the desired product.    In a basic milieu, both 
SAL (Haber et al., 1996) and PFBBr (Gyllenhaal, 1978) are reported to be unstable 
which would explain the lack of the preferred reaction product.   The pH ranging study 
suggests that a tight regulation of the pH (between 8.0 – 8.2) is necessary for the 
reproducible and high (>90%) reaction yields.  The buffer concentration used in the 
reaction was strong enough to maintain and adequate buffering capacity (~30% of 
maximum).  As a phosphate buffer was utilized for the reaction, it was imperative that a 
wash step be employed to the hexane extract to prevent instrumental exposure to 
phosphate salts. Additional inclusion of a dispersing agent or phase transfer catalysts 
was not necessary for the reaction equilibrium.     
These experimental conditions were also chosen for the simultaneous 
derivatization of DA.  The HPLC/ESI-MS/MS analysis revealed presence of four 
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derivatives of DA corresponding to three tri-PFB-DA isomers (m/z 694) and a fully 
derivatized tetra-PFB-DA derivative (m/z 874).  Since the tetra-PFB-DA is the major 
derivative under the optimized SAL derivatization conditions, we chose this form for 
quantitative analysis of DA.  The mass spectrum obtained by CID of tetra-PFB-DA 
produced major product ions at m/z 181, 316 and 497. The characteristic fragment ion 
at m/z 497 resulted from the loss of NH-(PFB)2 from [M+H]+ ions as depicted in figure 
4-5.  
 
4.3.5d Conclusion  
 In a primarily aqueous environment both SAL and DA were able to be 
derivatized by PFBBr to its tri-PFB and tetra-PFB products, respectively.    Structural 
confirmation of the products was evaluated via separate analytical methods to ensure 
the reaction yield.  The optimal conditions used for subsequent analytes in plasma 
included a favorable molar ratio of analyte to PFBBr to DIPEA.    With an unyielding 
control of pH, the desired products were derivatized with high and reproducible yield.    
The summarized method, along with the optimized derivatization reaction was 
subsequently used for the validation of R/S-SAL and DA quantification in human 
plasma. 
 
4.3.6 Validation of the Assay Method in Human Plasma  
 Discussion of analytical method validation has been discussed in the prior 
chapter for the β-carboline HPLC-FD assay in human plasma.  The approaches for 
197 
validation of the R/S/-SAL assay presented henceforth includes the assessment of 
selectivity, sensitivity, accuracy, precision, reproducibility and precision.  Other 
parameters of interests that will be investigated include those of extraction efficiency, 
calibration range, matrix effects, a dilution integrity, and response function.     
 Similar special considerations are required for the validation of the R/S-SAL 
assay as the β-carbolines for quantification of constitutive SAL components in a 
biological matrix.   R/S-SAL are endogenous compounds with quantifiable baseline 
levels in the biological matrix of interest, therefore the nature of biomarkers posts a 
challenge to find analyte-free biological matrix to prepare calibrator standards.    For 
this reason, the “surrogate matrix” approach for calibration was also used for the R/S-
SAL quantification. 
 Along with formal validation of the R/S-SAL method, this section will 
investigate the similarity of the analytical concentration-responses relationships 
between the unadulterated sample matrix and the surrogate matrix.   All reported 
methodologies used for the quantification of R/S-SAL and DA in biological matrices 
utilized a neat buffered matrix for validation purposes, without the formal assessment of 
a matrix effect.   As the hindrance of constitutive SAL and DA poses an issue with 
calibration curve construction, a strategy limiting or completely eliminating the 
background was investigated.   
 Moreover, if alteration of the plasma matrix is necessary, the response behavior 
(i.e., slope) of the calibration curves between the unadulterated and the altered matrix 
needs to be statistically indistinguishable to judge matrix surrogacy.   “Matrix effect” 
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should not be present upon testing the calibration between the two matrices.  Only until 
surrogacy is proven, quantification using the modified matrix may be performed.     
 Considering the issues of endogenous R/S-SAL and DA background and the 
lack of a true blank matrix, the same strategy to that of the β-carbolines was employed 
for this assay for bioanalytical validation in human plasma.    The strategy for the 
bioanalytical validation of the R/S-SAL and DA assay is as follows: 
 
1. Preliminary exploration of the assay was evaluated in a pooled plasma matrix, with 
the parameters such as precision, calibration range, and selectivity being assessed.    
Moreover, the type of calibration function (i.e., linear or nonlinear) used was 
assessed at this point.  The primary objective was to determine, in an unadulterated 
matrix, the precision of the bioanalytical assay throughout a given concentration 
range.  Accuracy was expected to be confounded by the constitutive concentrations 
of SAL and was not scrutinized during the pooled plasma analysis.  Short-term and 
long-term stability studies were conducted in the unadulterated pooled plasma. 
2. Exploration of a suitable surrogate matrix included destruction of constitutive SAL 
and DA in pooled plasma, to create a “blank” matrix.   The pooled plasma matrix 
was modified until devoid of a significant SAL and DA chromatographic signal, 
while minimizing the difference of composition in the true matrix.  Subsequently, 
SAL and DA were spiked into the modified matrix to assess the validation 
parameters aforementioned.  Full calibration curves (n = 6) and quality control 
samples were used to evaluate the linear range, accuracy and precision.  Of 
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importance, the Lower Limit of Quantification (LLOQ) was determined during this 
step using n = 6 non-calibration point replicates.  Recovery assessment was 
evaluated using this matrix to assess the relative recovery and, more importantly, the 
precision.    
3. Upon calibration curve evaluation of both pooled plasma and modified plasma 
matrix, n = 5 individual, unmodified plasma sources were subsequently spiked with 
a range of SAL and DA standards.   Owing to the different constitutive 
concentrations of SAL and DA in the individual plasma sources, it was expected 
that the intercepts for each calibration regression would differ.  Therefore, precision 
was the primary assessment in this portion of the investigation. 
4. To appraise surrogacy of the modified plasma matrix, parallelism studies were 
performed.  The slopes of all calibration curves from pooled plasma matrix, 
modified matrix and the n = 5 different sources were to be statistically similar 
(parallel) in order to deem the modified matrix and appropriate “surrogate” matrix.   
If statistically different, the method was considered to have a significant matrix 
effect and issues of selectivity.   In the case that selectivity was of concern, MS 
detection or chromatographic re-optimization experiments were conducted to rid the 
interference. 
5. For all successive experiments, including ultimate sample analysis, the calibration 
curves and quality control samples were to be constructed using the “surrogate” 
plasma matrix.   
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Comprehensive discussion for the use and validation of a “surrogate matrix” is 
summarized in the previous chapter.   
 
4.3.6a Materials and Reagents 
 All chemicals were or analytical grade quality and obtained from commercial 
sources.  All solvents used for the R/S-SAL and DA validation analysis were of 
spectroscopic or HPLC grade.  The validation required the materials and reagents listed 
in section 4.3.1 of this chapter. 
 
4.3.6b  Equipment  
 The analytical equipment used for validation of the assay is presented in section 
4.3.2 of this chapter.    
 
4.3.6c Preparation of Solutions and Standards 
 (S)-SAL and (R)-SAL enantiomers are not separately available, standard 
solutions of SAL were prepared by dissolving the racemic mixture of (R/S)-SAL-HCl in 
methanol.  Standard stock solutions of (R/S)-SAL-HCl as well as DA-HCl were 
prepared in methanol at a concentration of 1 mg/ml (1µg/µl) in amber, silanized vials.  
Further dilutions were created to obtain lower concentrations, if needed.  The deuterated 
internal standard stock solutions were additionally made in methanol at a concentration 
of 100 ng/ml for (S)-SAL-d4-HBr and (R)-SAL-d4-HBr and 1 mg/ml for d4-DA-HCl.  
Of Stock standard solutions were stored in darkness at -20 °C until further use.  The 
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working internal standard solutions were prepared by further dilution of the stock 
solutions to 500 pg/ml of each SAL-d4 enantiomer and 500 pg/ml of DA-d4.  From the 
primary stock solutions, 1-ml volumes of calibrators and quality control standards were 
created to ensure that the mass required for each level was transferred into the matrix 
via 10 µl.   
 
 
Table 4-2:  Preparation of SAL calibrator and quality control standards.  Standards 
were prepared at concentrations to ensure that a 10 µl volume was transferred into the 
matrix of interest.  SAL concentrations reported are individual enantiomers. 
  
STD  Final STD conc amount of STD    methanol
4000 pg 400.0 pg/µl  800 µl (500 pg/µl)   200 µl 
2000 pg 200.0 pg/µl  400 µl (500 pg/µl)   600 µl 
1200 pg 120.0 pg/µl  240 µl (500 pg/µl)   760 µl 
1000 pg 100.0 pg/µl  200 µl (500 pg/µl)   800 µl 
750 pg  75.0 pg/µl  150 µl (500 pg/µl)   850 µl 
500 pg  50.0 pg/µl  100 µl (500 pg/µl)   900 µl 
200 pg  20.0 pg/µl  40 µl (500 pg/µl)   980 µl 
160 pg  16.0 pg/µl  32 µl (500 pg/µl)   968 µl 
100 pg  10.0 pg/µl  20 µl (500 pg/µl)   980 µl 
50 pg  5.0 pg/µl  10 µl (500 pg/µl)   990 µl 
20 pg  2.0 pg/µl  4 µl (500 pg/µl)    996 µl 
10 pg  1.0 pg/µl  2 µl (500 pg/µl)    998 µl 
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Table 4-3:  Preparation of DA calibrator and quality control standards.  Standards were 
prepared at concentrations to ensure that a 10 µl volume was transferred into the matrix 
of interest.   
 
STD  Final STD conc amount of STD            methanol 
20000 pg 2000.0 pg/µl  20 µl (10 ng/µl)    980 µl 
10000 pg 1000.0 pg/µl  1000 µl (1 ng/µl)   0 µl 
8000 pg 800.0 pg/µl  800 µl (1 ng/µl)    200 µl 
5000 pg 500.0 pg/µl  500 µl (1 ng/µl)    500 µl 
4000 pg 400.0 pg/µl  400 µl (1 ng/µl)    600 µl 
2000 pg 200.0 pg/µl  200 µl (1 ng/µl)    800 µl 
1000 pg 100.0 pg/µl  100 µl (1 ng/µl)    900 µl 
600 pg  60.0 pg/µl  60 µl (1 ng/µl)    940 µl 
500 pg  50.0 pg/µl  50 µl (1 ng/µl)    950 µl 
200 pg  20.0 pg/µl  20 µl (1 ng/µl)    980 µl 
100 pg  10.0 pg/µl  10 µl (1 ng/µl)    990 µl 
 
 All other solution prepared for the analysis is presented in section 4.3.3 of this 
chapter. 
 
4.3.6d Methods 
 Validation of the bioanalytical assay was performed using optimized ideal 
extraction and derivatization conditions.  The HPLC-ESI-MS/MS parameters are 
denoted in method summary previously reported in this chapter and by Lee and 
colleagues (Lee et al., 2007).  A table summarizing the parameters is presented in the 
table below. 
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Table 4-4:  Experimental conditions used for validation of the HPLC-ESI MS/MS 
bioanalytical assay for R/S-SAL and DA in a human plasma matrix. 
 
Variable     Condition                                   
 
HPLC System      Agilent 1100 system (autosampler/pump) 
 
Column w/guard column   Chiralpak AD-H (2.1x 150 mm, 5 μm) 
       protected with a guard column 
 
Solvents A and B (normal phase) 
      %A      50% isopropyl alcohol 
      %B     50% methanol 
      
Flow rate     Isocratic, 150 µl/min 
 
Column, sample temperature   room temperature, 5ºC 
 
Injection volume    10 μl     
 
Run time     20 minutes 
 
Post column addition     1% CH3COOH in H2O, ~50 μl/min   
____________________________________________________________ 
MS/MS System    Thermo-Finnegan TSQ Ultra 
Ionization      ESI – positive ion mode 
Capillary temperature    150°C 
Sheath, Auxiliary gas    N2 flow rate, 35 units, 5 units  
Spray voltage     3.5 kV 
Collision-induced dissociation (CID)  Argon @ 1.5 mTorr in the second (rf 
      only) quadrupole 
 
Relative collision energy    35 eV  
 
Detection (Selective Reaction Monitoring) R/S-SAL   m/z  720→210  
      d4-R/S-SAL  m/z  724→210 
      DA   m/z  874→497  
      d4-DA    m/z  878→501 
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 Another major distinction from the previous reports incorporated the use of an 
antioxidant/aldehyde trapping agent.  Several investigators noted a major concern in the 
quantitative analysis of TIQ alkaloids is the suppression of artifactual formation during 
sample preparation.   The successful use of semicarbazide as an aldehyde trapping 
reagent and ascorbic acid as an antioxidant in decreasing artifactual formation has been 
exemplified (Rommelspacher et al., 1984; Adell and Myers, 1994; Fekkes et al., 2004).   
Therefore, the protein precipitation/antioxidant solution describes in section 4.3.3 was 
implemented in the extraction of R/S-SAL from human plasma to circumvent any issues 
pertaining to artifactual formation. 
 Stock solution stability for R/S-SAL and DA, deuterated and non-deuterated 
were performed and did not vary at -20°C for 6 months.   Stock solution and benchtop 
stability for both analytes and internal standard at two different concentrations was 
assessed for 6 hours at room temperature and no variation was seen.   The plasma 
samples used for validation were subjected to three freeze and thaw cycles during which 
no appreciable degradation of R/S-SAL or DA was observed (<2%, data not shown). 
 
4.3.6d-1   Pooled plasma experiments 
 Using pooled plasma (presumably healthy, fasting drug free, non smokers, 
collected in EDTA) initial partial validation experiments were explored to evaluate the 
linear concentration range for R/S-SAL along with precision and stability of the 
method.    Of note, evaluation of DA in pooled plasma was not performed.  Further 
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calibration assessment of DA was involved in subsequent testing with surrogate and 
individual plasma matrices. 
 The linearity of the developed method was evaluated by preparing n=3 standard 
curves for the R/S-SAL analytes in duplicate (2 x 1 day) with 1 ng of d4-R/S-SAL.  The 
concentrations of R/S-SAL used for a seven-point standard curve were 20, 50, 100, 500, 
1000, and 2000 and 4000 pg/ml for each enantiomer.   Moreover, along with at least 8 
non-zero standards, a blank sample (matrix processed without internal standard) and a 
zero sample (matrix processed with internal standard) were processed.  A 10 µl volume 
of standard calibrator solutions were used at each concentration level to ensure that the 
volume of the stock solution added was <10% of the total matrix volume.  Experiments 
were performed using 1-ml of human pooled plasma.  Plots of peak area ratio (R-
SAL/d4-R-SAL and S-SAL/d4-S-SAL) against analyte concentration were constructed.  
Plots of the residual against concentration assessed the behavior of the response 
variance across the calibration range.  If the residuals for the linear regression analysis 
were heteroschedastic in nature, an appropriate weighting factor was investigated (1/x 
and 1/x2).       
 The calibration function (e.g., linear or weighted-linear) was established through 
observation of reverse calculated standard concentrations of which were reverse 
predicted from the curve.   The appropriateness of the concentration of internal standard 
for R/S-SAL was based on the peak height of the internal standard being approximately 
at the mean of analyte response of the concentration range tested.   Moreover, the 
analyte to internal standard ratio at the upper and lower limits were not to exceed 10 or 
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be less than 0.1, respectively, in order to minimize error associated at the extremes of 
the linear calibration curve.       
  The linear range was subsequently tested in the pooled plasma with n = 3 
replicates (1 calibration curves x 3 days) to assess precision of the method.  Moreover, 
quality control samples for SAL were created at the following levels: Low QC: 125 
pg/ml, Medium QC 1: 600 pg/ml, Medium QC 2: 1200 pg/ml and High QC: 2500 pg/ml 
for each SAL enantiomer.     The QC concentrations were used to assess relative 
recovery from the pooled plasma.   The comparison of an extracted to unextracted 
analyte to internal standard ratio, at each concentration, was used to calculate the 
relative recovery.  Experiments were performed in triplicate.  
 It was suspected that a systematic bias (positive y-intercept) would be present in 
the calibration curve because of the endogenous R/S-SAL.  Therefore, accuracy and 
precision calculations were performed on the analyte to internal standard ratio, across 
the concentration range.   Accuracy and precision assessment and acceptance criteria for 
the calibration range along with the QC samples were calculated as seen in the previous 
chapter.   
 For long-term stability, standard solutions using a high, low, and zero (unspiked) 
control concentrations in biological matrix were portioned and stored under the 
conditions of study sample storage (-80˚C).   Measurements were taken in triplicate 
over a six-month period on three separate occasions.  For each sample, the ratio of the 
analyte to internal standard was recorded and concentration back-calculated and 
compared between measurements and across occasions for statistical deviations 
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(accuracy and precision within ±15 % nominal value).  Freeze-thaw stability was 
assessed over three cycles, in which the initial freeze was 24 hours and subsequent 
cycles was held in -80˚C for 12 hours.   
 Of primary importance, the linear regression parameters for the calibration 
curves, including slope and y-intercept, for the pooled plasma validation were assessed 
upon evaluating the estimates and corresponding 95% confidence interval (CI) along 
with the precision of the slope and y-intercepts (% COV) for R/S-SAL.   
 
4.3.6d-2  Pooled plasma results 
 Using 1-ml of plasma, a linear concentration range between 10.0 pg/ml and 4.0 
ng/ml was seen for both R-SAL and S-SAL and between 100 pg/ml and 20 ng/ml for 
DA.  According to the “blank” sample (no IS) measurements, there were no significant 
peaks associated with the retention time and SRM of the SAL-d4 and DA-d4, 
exemplifying a lack of interference with the internal standard.  Significant peaks at the 
representative R-SAL, S-SAL and DA retention times were present (data not shown).    
Using the calibration concentration range of R/S-SAL with 1 ng d4-R/S-SAL, (each 
enantiomer)  n = 3 calibration curves were constructed in pooled plasma with quality 
control samples.  Area ratios of the calibration points and quality control samples with 
precision estimates (%COV) are presented in the following tables for S-SAL (table 4-5) 
and R-SAL (table 4-6).   
 The individual linear regression parameters for each calibration curve for both 
R/S-SAL and DA are presented with a goodness of fit (R2) metric for linearity.    An 
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average calibration curve is presented for both S-SAL (figure 4-10) and R-SAL (figure 
4-11).  Of note, the calibration curve for both SAL was constructed upon calculation of 
an average response (across n=3 calibration levels).   
 
Table 4-5:  Peak area ratio for S-SAL in pooled plasma (n=3), with precision 
assessment (%COV) and calibration curve parameters (1/x2 weighting). 
 
           
pg S-SAL calib #1 calib #2 calib #3 average sd %COV
20 0.583 0.572 0.616 0.590 0.023 3.88
50 0.771 0.788 0.792 0.784 0.011 1.42
100 1.172 1.155 1.303 1.210 0.081 6.69
500 1.732 1.653 1.782 1.722 0.065 3.78
1000 2.447 3.069 2.826 2.781 0.313 11.27
2000 4.810 4.530 4.784 4.708 0.155 3.29
4000 8.920 8.489 8.122 8.511 0.399 4.69
125 (LQC) 1.023 1.044 1.230 1.099 0.114 10.37
600 (MQC1) 1.827 1.745 1.801 1.791 0.042 2.33
1200 (MQC2) 2.625 2.598 2.929 2.837 0.184 6.47
2500 (HQC) 5.233 5.001 5.627 5.287 0.316 5.99
zero 0.433 0.455 0.412 0.433 0.022 4.96
slope 2.5300 2.6060 2.5982 2.5781 0.0418
y-int 0.5127 0.4256 0.4872 0.4251 0.0448
R2 0.9928 0.9990 0.9891 0.9936 0.0050  
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Figure 4-10:  Average calibration curve (n=3) for S-SAL in pooled plasma.   Linear 
regression performed on the average of the response across concentrations.   Each point 
represents the average response ± SD.   
 
 
 
Table 4-6:  Peak area ratio for R-SAL in pooled plasma (n=3), with precision 
assessment (%COV) and calibration curve parameters (1/x2 weighting). 
 
      
pg R-SAL calib #1 calib #2 calib #3 average sd %COV
20 0.896 0.853 0.802 0.850 0.047 5.54
50 1.094 1.172 1.266 1.177 0.086 7.32
100 1.523 1.255 1.272 1.350 0.150 11.11
500 2.171 2.526 2.727 2.475 0.281 11.37
1000 3.083 3.192 3.626 3.300 0.287 8.71
2000 4.945 4.992 4.819 4.919 0.089 1.82
4000 9.798 9.517 10.244 9.853 0.367 3.72
125 (LQC) 1.583 1.526 1.552 1.554 0.029 1.84
600 (MQC1) 2.292 2.335 2.371 2.333 0.040 1.70
1200 (MQC2) 3.227 3.524 3.223 3.325 0.173 5.19
2500 (HQC) 5.934 6.102 6.533 6.190 0.309 4.99
zero 0.671 0.626 0.653 0.650 0.023 3.51
slope 2.1120 2.2810 2.0182 2.1371 0.1332
y-int 0.6270 0.6521 0.6132 0.6308 0.0197
R2 0.9988 0.9892 0.9817 0.9899 0.0086  
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Figure 4-11:  Average calibration curve (n=3) for R-SAL in pooled plasma.   Linear 
regression performed on the average of the response across concentrations.  Each point 
represents the average response ± SD.   
 
  
 A linear regression, utilizing a 1/x2 weighting factor, was performed on the 
average response for each concentration level.    The calibration levels all showed 
acceptable precision for S-SAL and R-SAL with %COV less than 11.3% and 11.4%, 
respectively.   The precision of the quality control samples ranged from 2.3% to 10.4% 
for S-SAL while the R-SAL quality control precision resulted in a %COV ranged 1.7% 
to 5.2%.     
 The “zero” level, consisting of 1-ml plasma with only internal standard, yielded 
a significant instrumental response for both SAL enantiomers, suggestive of the 
noteworthy constitutive nature of these analytes in the matrix.   
 Regarding the linear regression of the calibration curves, a weighting factor of 
1/x2 was required correct for the unequal variance associated with the residuals (data 
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not shown).  In turn, a weighted linear regression was performed on each individual 
calibration curve for both analytes.    Linearity of the calibration curves, as assessed by 
the coefficient of determination (R2), was acceptable for both analytes with S-SAL 
possessing R2 ranging between 0.989 – 0.999 and R-SAL having a range between 0.982 
- 0.998.   For both analytes, the 95% CI for each individual calibration slopes included 
the estimate of the other individual calibration slopes, signifying similarity between the 
slope calibration parameter of each curve.   Of major note, each calibration curve 
yielded a significant y-intercept for both analytes, indicating a significant background 
signal.  The y-intercepts were significantly different from zero with S-SAL having an 
intercept (mean ± SD) of 0.425 ± 0.045 (p-value = 0.042) and R-SAL having an 
intercept of 0.631 ± 0.019 (p-value = 0.034).   Moreover, the y-intercepts obtained from 
the linear regressions for both analytes were reproducible.   
 Of note the intercepts obtained from the weighted linear regression were not 
significantly different from that obtained from the “blank” sample for both S-SAL and 
R-SAL (p-value for both enantiomers > 0.14).  According to the analysis, and using the 
baseline corrected calibration curves, the pooled plasma contained 259 pg of S-SAL and 
430 pg of R-SAL per 1-ml plasma, which is within reported physiological range.   
 Long-term stability, in pooled plasma was evaluated at three different levels of 
High (2500 pg/1ml), Low (600 pg/1ml) and zero (unspiked R and S-SAL) over a six 
month period.  Of note, the theoretical concentrations for the High and Low controls are 
those of spiked and constitutive, additive. The concentrations were measured, using 
baseline corrected calibration curves, at 15 days, 1 and 6 months after standard pooled 
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plasma preparation.   At each time-point the analysis was performed in triplicate.     
Over a six-month period, there was a negligible variation in concentration for both SAL 
enantiomers (<2%). Freeze-thaw stability assessment did not yield any significant 
changes in R-SAL or S-SAL at all concentration levels evaluated through three-cycles, 
with %DFN and %COV not exceeding 4% for both analytes at all concentration levels. 
 The relative recovery, across the quality control concentrations, did not show 
much variation within concentrations (see table below).   A slight increase of the 
recovery for both enantiomers was observed at the highest concentration level.   Of 
note, the analyte to internal standard ratio obtained from the extraction procedure 
includes constitutive R- and S-SAL, contributing to the relative recovery.  Therefore, 
the recoveries obtained from the analysis are expected to be larger than if the 
endogenous analyte was not present in the matrix.  
 
Table 4-7:  Relative recovery from 1 ml pooled plasma of R-SAL and S-SAL (n=3 for 
each concentration).  (% mean ± SD). 
 
 
    50  pg   200 pg   1000 pg
S-SAL           82.2 ± 2.6  84.1 ± 5.7  94.6 ± 2.4 
R-SAL           83.1 ± 2.7  82.2 ± 4.6  90.8 ± 4.2 
 
 The information obtained from the pooled plasma analysis was used to design a 
more formal validation using a modified matrix for assessing surrogacy.   Using 1-ml of 
matrix, the calibration range between 10 and 4000 pg of both R-SAL and S-SAL with 
1.0 ng of deuterated internal standard for each enantiomer was used for validation 
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purposes.  Quality control samples used for subsequent tests included 125 pg (LQC), 
600 pg (MQC1) and 1200 pg (MQC2), and 2500 pg (HQC).    The results of minimal 
deviation for long-term and freeze-thaw stability tests proved the chemical robustness 
of analyzing R- and S-SAL in the plasma matrix.    
 
4.3.6d-3   Surrogate matrix experiments  
 Similar experiments aforementioned were performed using a modified pooled 
plasma matrix, with an emphasis on both accuracy and precision assessment.  The 
matrix modification employed the destruction of constitutive R/S-SAL and DA in the 
pooled plasma via alkalization of the plasma to pH~10 and kept under refrigeration for 
24 hours.  Upon destruction of the constitutive SAL and DA from pooled plasma, the 
pH was readjusted to a physiological pH and the assay was performed per protocol.    
 The linearity of the developed method was evaluated by preparing n = 6 
standard curves for the R/S-SAL and DA analytes in duplicate (2 x 3 days) with 1 ng of 
d4-R/S-SAL and 5 ng d4-DA internal standard.   Similar concentrations of R/S-SAL 
were used for the standard curve constructed in the pooled plasma.   In addition DA 
concentrations used for the calibration curve included 100, 200, 500, 1000, 2500, 5000, 
and 10000 pg/ml.  Moreover, along with at least 7 non-zero standards, a blank sample 
(matrix processed without internal standard) and a zero sample (matrix processed with 
internal standard) were processed to assess for effectiveness of SAL and DA 
destruction.   Experiments were performed using 1-ml of modified human plasma.  
Plots of peak area ratio (R-SAL/d4-R-SAL, S-SAL/d4-S-SAL and  DA/d4-DA) against 
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analyte concentration were constructed.   Calibration data were analyzed similarly to 
that of the pooled plasma experiments (i.e., upon evaluation of the residuals of the 
linear fit).         
 The calibration function (e.g., linear or weighted-linear) was established through 
observation of reverse calculated standard concentrations of which were reverse 
predicted from the curve.    The linear range was subsequently compared to that 
obtained in pooled plasma.   Quality control samples for SAL were created at the same 
levels previously mentioned.  For DA the following QC levels were tested: Low QC: 
600 pg/ml, Medium QC 1: 2000 pg/ml, Medium QC 2: 4000 pg/ml and High QC: 8000 
pg/ml.  The QC concentrations were used to assess relative recovery from the modified 
plasma.   The comparison of an extracted to unextracted analyte to internal standard 
ratio, at each concentration, was used to calculate the relative recovery.  Experiments 
were performed in triplicate.  
 Accuracy and precision calculations were performed on the back-calculated 
concentrations from the regression, across the concentration range for both R/S-SAL 
and DA.     Unlike the pooled plasma experiments, a formal assessment of the Lower 
Limit of Quantification (LLOQ) was determined during this step using n = 6 replicates 
of 20 pg/ml in modified matrix, separate from the calibrators.   The linear regression 
parameters for the calibration curves, including slope and y-intercept, for the modified 
plasma validation were assessed upon evaluating the estimates and corresponding 95% 
confidence interval (CI) along with the precision of the slope and y-intercepts (% COV) 
for R/S-SAL and DA.  Recovery assessment was evaluated using this matrix to assess 
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the relative recovery and the precision or the recovery.  The room temperature stability 
measurements, as mentioned before, was also performed in this in modified matrix.      
A more formal evaluation for precision and accuracy was conducted by 
evaluation of n = 6 each of the LLOQ, LQC, MQC1, MQC2, and HQC sample 
concentrations in one day for within-run assessment.  Between run-precision and 
accuracy was assessed in triplicate over three days for the same controls.   The accuracy 
(%DFN) and the precision (%COV) between and within-runs were found acceptable at 
a level of within ±15% for each.   All quality control samples, including those that 
failed with no assignable cause, were used for the final calculation.    
 As the case for the calibration curves obtained for the pooled plasma, the linear 
regression parameters for the calibration curves, including slope and y-intercept, for the 
modified plasma validation were assessed and compared to that obtained in the pooled 
plasma experiments.  For approval of the matrix modification via constitutive analyte 
destruction, the mean of the y-intercepts should not be statistically different from zero 
(as deemed by a one-sided unpaired Student’s t-test).  The individual confidence 
intervals of the y-intercept estimates should include zero for each individual calibration 
curve.   
 The slope of the linear regressions within all calibration curves should not be 
statistically different from one another (as deemed by a 95% CI).  Moreover, the mean 
of all calibration slopes between the pooled plasma and the modified plasma matrix 
were evaluated for “parallelism” (i.e., the average slopes obtained between each matrix 
should 
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be statistically similar).  Lack of similarity was evaluated by a two-sided unpaired 
Student’s t-test.   
 
4.3.6d-4   Surrogate matrix results  
 The modified matrix was constructed from destruction of endogenous R/S-SAL 
and DA from pooled plasma.  Criteria to evaluate the removal of the analytes included 
devoid of an analytical response at the respective retention times of R/S-SAL and DA.   
Using this destruction technique, both R and S-SAL along with DA were successfully 
removed.  The blank plasma spiked with d4-SAL and d4-DA showed no MRM peaks 
corresponding to endogenous SAL and DA (See figure below). 
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Figure 4-12: SRM chromatogram of SAL and DA prepared with 1 ml modified plasma.  
(spiked with 1 ng each of d -(S)- and d -(R)-SAL and 5 ng d4 4 4-DA. No endogenous SAL 
or DA was detected.  
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 Full calibration curves (n=6 for R/S-SAL, n=5 for DA) were constructed using 
1-ml of modified matrix along with corresponding quality control samples.   For S-
SAL, throughout the concentration range the imprecision (%COV) was less than 14.4% 
and the inaccuracy (%DFN, absolute value) was less than 7.9% (see table 4-8).   In 
addition, the analysis of R-SAL yielded acceptable results with a imprecision < 14.4% 
and an inaccuracy of < 9.6% (table 4-9).   DA yielded acceptable results with an 
imprecision < 10.3% and an inaccuracy of < 12.4% (table 4-10).  Of note, the analysis 
met the criteria in which >75% of all standards must be within ±15 % COV, with the 
exception of the LLOQ where a ±20 % COV is acceptable. 
 In separate experiments, further evaluation at the SAL LLOQ level (20 pg/1ml) 
yielded an imprecision %COV of < 11.7% and %DFN of < 6.5%, with n = 6 replicates 
of both R- and S-SAL.  For DA %COV of < 6.8% and %DFN of < 5.2%.  All quality 
control samples for all analytes yielded a suitable accuracy and precision.  For inter-run 
precision and accuracy (3 replicates for 3 days), %COV was no greater than 12.7% and 
no more than an absolute variation in concentration of 14.1% across the quality control 
concentrations for all analytes (data not shown).  The LLOQ of 20 pg/ml for R/S-SAL 
and 100 pg/ml for DA in the modified plasma is shown in the figure below.   
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Figure 4-13: SRM chromatogram of SAL and DA prepared with 1 ml modified plasma 
at the LLOQ level (spiked 20 pg R and S-SAL with 1 ng each of d4-(S)- and d4-(R)-SAL 
and 100 pg of DA with 5 ng d -DA).  4
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 The linear regression parameters for each calibration curve were compared to 
assess consistency of slope and for lack of a y-intercept.  Using a 1/x2 weighting factor 
for each calibration curve, the parameters presented showed consistency between 
calibration curves.    The slope parameters for S/R-SAL and DA were statistically 
different from zero, while the intercept did not show a statistical departure from zero (p-
values > 0.23 for all analytes).   The zero intercept signifies the effective destruction of 
the constitutive SAL and DA.  For all analytes, the coefficient of determination (R2) 
was acceptable for each calibration curve, supporting the use of a linear regression for 
the calibration (see tables 4-11, 4-12 and 4-13 below).  
 The extraction efficiency (recovery) was assessed at three quality control levels 
in triplicate.  The recoveries obtained from this analysis were constant across 
concentrations of all analytes with recoveries > 82% with less than 6% variation for all 
analytes. 
 In comparison to the unmodified, pooled plasma matrix surrogacy for the 
modified matrix was established.   From the linear regression parameters (i.e., slope) 
obtained with calibration curves constructed of both sets of matrices, a statistical 
similarity was seen.  An unpaired, two-tailed Student’s t-test was performed on the 
slope and y-intercept parameters, assuming unequal variances, for all analytes between 
pooled plasma and modified plasma matrices.   For S-SAL, R-SAL and DA the p-values 
were 0.35, 0.51, and 0.22 respectively.  Statistical significance was defined at the α = 
0.05 level.    
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Table 4-11:  Standard curve parameters for n = 6 S-SAL calibration curves in modified 
plasma.  Each parameter presented as an estimate with standard error (SE).   
 
Calibration slope SE y-intercept SE R2
1 2.5820 0.0922 (-)0.0124 0.0275 0.9892
2 2.6129 0.0721 (-)0.0833 0.0359 0.9917
3 2.4672 0.0733 0.0127 0.0223 0.9748
4 2.4422 0.0261 0.0245 0.0425 0.9933
5 2.5342 0.0526 (-)0.0101 0.0266 0.9898
6 2.3272 0.0882 0.0229 0.0355 0.9913
average 2.4943 0.0200 0.9884
stdev 0.1046 0.0064 0.0068  
 
 
Table 4-12: Standard curve parameters for n = 6 R-SAL calibration curves in modified 
plasma.  Each parameter presented as an estimate with standard error (SE).   
 
Calibration slope SE y-intercept SE R2
1 2.1452 0.0883 (-)0.0251 0.0139 0.9934
2 2.2316 0.0728 0.0247 0.0227 0.9897
3 2.0928 0.0557 (-)0.0133 0.0182 0.9912
4 2.1330 0.0623 0.0154 0.0266 0.9855
5 2.2516 0.0611 (-)0.0088 0.0019 0.9914
6 2.2199 0.0572 0.0122 0.0214 0.9937
average 2.1790 0.0174 0.9908
stdev 0.0639 0.0065 0.0030  
 
Table 4-13: Standard curve parameters for n = 5 DA calibration curves in modified 
plasma.  Each parameter presented as an estimate with standard error (SE).   
 
Calibration slope SE y-intercept SE R2
1 0.9962 0.0251 0.0133 0.0237 0.9823
2 0.9881 0.0099 (-)0.0092 0.0241 0.9899
3 0.9928 0.0172 (-)0.0221 0.0035 0.9846
4 0.9821 0.0133 0.0258 0.0102 0.9915
5 0.9954 0.0352 (-)0.0288 0.0196 0.9977
average 0.9909 0.0196 0.9892
stdev 0.0059 0.0088 0.0061  
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 The y-intercept showed a statistically significant difference between matrices.  
While the modified plasma was not significantly different from zero, the pooled plasma 
matrix possessed a significant y-intercept, reflecting the constitutive R/S-SAL and DA 
concentrations in the plasma.  Moreover, the lack of a statistically significant y-intercept 
in the modified plasma denotes successful removal of the constitutive background 
signal.    
 Of primary importance is the statistical similarity in the slopes for all analytes in 
both matrices.    The comparison supports the interchangeability of the matrix for 
calibration purposes.   Moreover, “parallelism” between the matrices was demonstrated 
between the modified and pooled plasma matrix.  Further assessment of selectivity was 
warranted for this method, evaluating additional plasma sources for potential 
interferences.  A similar approach was used to assess “parallelism” in patient plasma 
samples.    
 
4.3.6d-5   Patient plasma experiments  
 In order further evaluate selectivity and parallelism, individual plasma from 
separate donors was used as a matrix.   Further selectivity should be assessed to show 
that the anticipated analytes are measured and that their quantification is not affected by 
the presence of any interferences in the biological matrix (see discussion in chapter 3).  
Although the intrinsic selectivity of this assay is high (compared to other types of 
analytical methods, e.g., HPLC-FD), further confirmation using matrices from at least n 
= 5 independent sources was evaluated for matrix effects.   
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 Nonetheless, selectivity of the bioanalytical assay will be assessed by spiking 
known concentrations of analyte into the matrix of interest, as performed as a standard 
addition experiment.    In this approach, different masses of R-SAL, S-SAL and DA are 
spiked to the sample matrix, which initially contains an unknown concentration of 
analyte.    Extrapolation of a plot of response found for the standard-addition calibration 
concentrations to zero concentration defines the original concentration of the unspiked 
sample.     
 The primary criteria in establishing “surrogacy” of the modified matrix, is that 
the response factor, or slope of the calibration curves obtained in the substitute matrix, 
should be statistically similar to that of unmodified matrix and “parallelism” between 
the calibration curves of both matrices be present.   In order to evaluate the use of the 
HPLC-ESI-MS/MS method along with the modified matrix, a total of five sources of 
unmodified plasma were used in the subsequent experiments.  
 Individual patient plasma samples (n=5, presumably healthy, drugs of abuse-
free, smokers and non-smokers, collected in EDTA) were used to test the conditions for 
selectivity.  Using the finalized extraction method, spiked concentrations of R- and S-
SAL along with DA was evaluated in 1-ml of human patient plasma.  As the availability 
of significant volumes of individual human plasma was limited, full calibration curves 
could not be constructed in the patient plasma.   For the individual plasma experiments 
a total of four concentrations were used for the standard addition calibration curve 
construction including 20, 160, 600, and 1250 pg of both R- and S-SAL using 1 ng of 
the deuterated R/S-SAL internal standard in 1-ml of plasma.  In these experiments DA 
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selectivity was assessed with 200, 600, 2000, and 4000 pg of DA using 5 ng of the DA 
internal standard.  Moreover, a “zero” concentration (unspiked SAL and DA with 
internal standard) was evaluated to assess the endogenous R/S-SAL and DA 
concentrations.   Individual plasma calibration curves were constructed in singlicate.  
The concentrations assessed in these experiments are representative of those used in 
previous calibration curves.     
 A four-point, linear calibration curve was constructed with each individual 
donation of plasma using a 1/x2 weighing, identical to the weighted regressions 
performed as the other experiments.   The linear regression parameters for the 
calibration curves, including slope and y-intercept, for the individual plasma were 
assessed.  The y-intercept for each individual calibration curve was presumably the 
amount of constitutive contribution of R/S-SAL and DA and compared to that of the 
“zero” concentration level, as calculated from the surrogate matrix calibration curve.  
The 95% confidence interval for the y-intercept (peak area ratio) should include the 
peak area ratio of that seen of the “zero” sample for all analytes.   This method was to 
ensure the accuracy of using the surrogate matrix calibration curve to calculate a 
concentration in unmodified, real sample. 
 Of primary importance was the evaluation of the slope parameter for each 
individual plasma calibration curve.  The estimate and its corresponding 95% CI was 
calculated and compared across donors.   The estimates for the slope parameter should 
be statistically similar upon evaluation of the 95% CI.  Individual R/S-SAL 
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concentrations were calculated and compared for each patient sample using the 
surrogate matrix calibration.  
 Moreover, the slopes ± standard deviation between the surrogate matrix plasma 
(n=6), individual patient plasma (n=5), and pooled plasma (n=3) calibrations were 
compared via one-way analysis of variance (ANOVA) to ensure a matrix effect between 
the matrices was not present.   Prior to statistical comparison, the residuals were 
evaluated for equal variance and tested accordingly if that assumption did not hold true.   
If significant deviations and variability in the slopes was present in the analysis, the 
HPLC-MS/MS parameters and/or extraction method was further optimized eliminate 
the interfering substances. 
 
4.3.6d-6   Patient plasma results  
 Using the finalized extraction method, spiked concentrations of R/S-SAL and 
DA were evaluated in 1-ml of human patient plasma from n=5, presumably healthy, 
drugs of abuse-free, smokers and non-smokers.  Representative chromatograms for an 
individual patient plasma are present in figure 4-18 below.   The calculated 
concentrations were obtained from the linear regression from a calibration curve in 
modified plasma. The respective retention times for S-SAL, R-SAL and DA are 7.92, 
12.3, and 7.42 minutes, respectively.   
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Figure 4-14: Representative SRM chromatograms of endogenous SAL and DA found 
in 1.0 ml human plasma spiked with 1 ng each of d -(S)- and d4 4-(R)-SAL and 5 ng of 
d4-DA as internal standards. The concentrations of (S)-SAL, (R)-SAL and DA were 
determined to be 146 pg/ml, 194 pg/ml and 3.13 ng/ml, respectively. 
 
  
 The goal of patient plasma experiments was to assess selectivity of the assay 
methodology.   Of note, the accessibility of significant volumes of individual human 
plasma was limited, as consequence, full calibration curves could not be constructed in 
the patient plasma.   The corresponding calibration curve parameters are presented 
below. 
 
 
 
229 
Table 4-14:  Linear regression parameters obtained from patient plasma (PP #1-5) 
calibration curve for S-SAL, R-SAL and DA.  95% CI denotes the upper and lower 
bounds in brackets for both slope and y-intercept.  
 
S-SAL
plasma slope 95% CI y-int 95% CI R2
PP#1 2.553 [2.231, 2.774] 0.56 [0.44, 0.67] 0.9734
PP#2 2.511 [2.229, 2.825] 1.32 [1.15, 1.56] 0.9883
PP#3 2.736 [2.483, 2.955] 1.72 [1.63, 1.84] 0.9921
PP#4 2.637 [2.232, 3.036] 0.64 [0.56, 0.72] 0.9853
PP#5 2.441 [2.136, 2.750] 2.23 [2.10, 2.37] 0.9798
avg 2.576 1.29 0.9838
stdev 0.114 0.71 0.0073  
 
R-SAL
plasma slope 95% CI y-int 95% CI R2
PP#1 2.167 [1.940, 2.305] 0.49 [0.35, 0.54] 0.9811
PP#2 2.189 [1.998, 2.283] 1.65 [1.43, 1.81] 0.9859
PP#3 2.059 [1.824, 2.187] 1.93 [1.78, 2.17] 0.9955
PP#4 2.114 [2.056, 2.170] 0.91 [0.75, 1.09] 0.9993
PP#5 2.154 [2.155, 2.387] 2.77 [2.40, 2.97] 0.9784
avg 2.137 1.55 0.9880
stdev 0.051 0.89 0.0091   
 
DA
plasma slope 95% CI y-int 95% CI R2
PP#1 0.986 [0.954, 1.092] 2.31 [2.16, 2.54] 0.982
PP#2 0.991 [0.975, 1.105] 3.81 [3.33, 4.07] 0.9777
PP#3 0.994 [0.970, 1.068] 0.63 [0.44, 0.82] 0.9833
PP#4 0.979 [0.958, 1.070] 1.02 [0.83, 1.24] 0.9875
PP#5 0.984 [0.953, 1.035] 1.42 [1.29, 1.56] 0.9899
avg 0.987 1.84 0.9841
stdev 0.006 1.27 0.0048             
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 The coefficients of determinations for S-SAL, R-SAL and DA in the patient 
plasma were greater than 0.97, suggesting the linear calibration function is acceptable 
for this matrix (using 1/x2 weighting).   From evaluation of the 95% CI, the y-intercepts 
obtained for all calibration curves, were all statistically different from zero.  Moreover, 
the intercepts between the plasma sources resulted in significant deviations, suggesting 
the variable nature of the constitutive S/R-SAL and DA between the five patients.   
 Slope parameters from the calibration curves were all statistically similar 
between the patient plasma sources and in comparison to the modified matrix.   Because 
of the limited number of concentration points on each calibration curve (4-point) for the 
patient plasma, the 95% CI range was relatively large as compared to the modified 
plasma matrix (i.e., a full calibration curve).      
    
 The concentrations obtained from the surrogate matrix calibration curves 
yielded endogenous levels that were within reported physiological ranges.  For S-SAL, 
the concentration range within the individual patient samples ranged from 32 - 224 
pg/ml plasma.  For R-SAL the concentration range within the five patient samples 
ranged from 38 - 304 pg/ml plasma.  As for DA, the concentrations ranged from 1.06 – 
2.05 ng/ml plasma.   
 Surrogacy of the modified matrix was further evaluated by statistical 
comparison of calibration curves from pooled plasma and patient plasma.  One-way 
ANOVA was performed on the slopes of the calibration curves between three different 
plasma matrices, modified (surrogate), pooled, and patient plasma.    The summary 
table of all calibration slopes is presented in the table below. The three groups of plasma 
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matrices, compared using the unequal variance F-test, were not significantly different 
for all analytes.  For S-SAL the means were found to be statistically similar, F(2, 13) = 
1.14, p-value = 0.355; while the same conclusion was drawn for the R-SAL calibration 
parameter F(2, 13) = 0.506, p-value = 0.615 and DA was F(2,10) = 0.523, p-value = 
0.608.    The results are presented as F-test calculation (degrees of freedom for groups, 
total) and p-value.   All statistical comparisons were performed on S-PLUS 8.0 for 
Windows.   
 From these results, the appropriateness of using the modified plasma matrix as a 
surrogate matrix was demonstrated.    Parallelism between the calibration curves in 
different matrices suggests the interchangeable nature of using either matrix for 
validation purposes.    The surrogate matrix will be incorporated for the clinical sample 
analysis.   
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4.3.6e Validation conclusion  
 In summary the acceptance criteria for validation were met according to 
predetermined specifications.  In the surrogate and unmodified matrices, 
chromatographic response was linear throughout the concentration range of 20 pg/1 ml 
(LLOQ) and 4000 pg/1 ml (ULOQ) for S- and R-SAL, while for DA the range was 
between 100-10000 pg/ml.   Accuracy and precision estimates for the assay were in 
acceptable ranges for the calibration points, the LLOQ and quality control samples with 
%COV and %DFN meeting analytical validation criteria.  Selectivity of the method was 
evaluated with 5 donor lots and no interference was apparent with the analyte or internal 
standard.   Across all quality control samples, recovery was relatively high (>80.2%) 
and reproducible for both H and NH. 
   Of importance, surrogacy of the matrix was demonstrated by the statistically 
indistinguishable slopes between modified and unadulterated matrix.   “Parallelism” of 
the slopes confirms the interchangeability of calibration matrices.     
 Long-term plasma stability experiments for 6 months at -80ºC resulted in 
negligible deviations over time for both analytes.  Additional stability experiments, 
including stock solution, bench-top, and post-preparative resulted in negligible 
deviations throughout the respective tested time-spans.   Under the optimized SPE, 
derivatization and HPLC-MS/MS conditions endogenous R/S-SAL and DA in plasma at 
concentrations comparable to reported literature values.    
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4.4 HPLC-MS/MS Assay Conclusion  
 A robust, sensitive, selective and reproducible assay has been developed for the 
quantification of the endogenous tetrahydroisoquinolines S and R-SAL along with their 
precursor DA, in 1 ml of human plasma.  A direct single-step pentafluorobenzyl (PFB) 
derivatization scheme in an aqueous media, without extractive alkylation using phase 
transfer catalysts, was devised for the enantioseparation of SAL with simultaneous 
detection of DA.  This procedure permitted high derivatization yields with minimal 
sample degradation and low chemical background. As stable PFB derivatives, SAL 
enantiomers were baseline separated on a chiral phase HPLC column. Coupling with 
ESI-MS/MS analysis in the SRM mode allowed the detection of SAL enantiomers and 
DA with increased specificity and sensitivity. In the presence of deuterium-labeled 
internal standards, this approach allowed accurate and reliable quantitative analysis of 
enantiomeric (R/S)-SAL and DA in human plasma. 
 In comparison to reported methodologies for the quantification of R and S-SAL  
in human plasma, this procedure has surmounted the limitations aforementioned.  The 
optimized chromatography has preserved the baseline resolution of the both 
enantiomers (Rs > 2.1) throughout the concentration range, improving the reliability of 
quantification.   Quantification with the isotopically labeled internal standards of R and 
S-SAL with DA yielded suitable assay performance results for the quantitative 
bioanalytical HPLC-MS/MS assay. 
 
  
 
 
 
 
CHAPTER 5  
CLINICAL STUDY #1 – EFFECTS OF GENDER AND SMOKING ON 
BASELINE TIQ’S AND β-CARBOLINES 
 
 
5.1   Specific Aims 
 The primary objective of this investigation was to evaluate the effects of 
smoking and gender on the baseline levels of TIQ and β-carboline concentrations in the 
blood of non-, light- and heavy-smokers.   In this study, the baseline measurement in 
smoking subjects is considered to be concentration measurements 30 minutes after 
cigarette smoke inhalation.   In particular, aims of this study included: 
1)  To determine information on the baseline concentrations of plasma TIQ’s and β-
carbolines in the blood of non-, light-, and heavy-smokers and assess if differences exist 
between these groups.  
2)  To evaluate if gender has an effect on baseline concentrations of the plasma TIQ’s 
and β-carbolines. 
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3)  To classify subjects according to smoking history and nicotine dependence with the 
Fagerström Test for Nicotine Dependence (FTND) into nonsmokers, light smokers, and 
heavy smokers. 
4)  To assess a possible association between the concentration of plasma TIQ’s and β-
carbolines with the smoking history and dependence of the volunteers. 
5)  Statistical assessment of inter- and intra-individual variability in the plasma TIQ’s 
and β-carbolines along with smoking history/nicotine dependence scores. 
 
5.2   Study Design  
 In order to address the objectives aforementioned, the study was designed as an 
observational, two-period outpatient clinical study in which each study period was 
separated by at least one week.  To determine the effects of smoking and gender on TIQ 
and β-carboline plasma concentrations, the study integrated a classification scheme to 
stratify the volunteers into nonsmoking (NS), light-smoking (LS) and heavy-smoking 
(HS) groups and with respect to gender, respectively.     
 Forty-one (41) healthy male and female volunteers, aged 21-35, were recruited, 
including 19 nonsmokers, 11 light-smokers, and 11 heavy-smokers.  Although this was 
a pilot study, the sample size for the study was determined a priori, via a two-way 
ANOVA power analysis (with gender and smoking status as factors). The number of 
subjects in each smoking status group required to show a difference of 50% in TIQ and 
β-carboline baseline concentrations between smoking groups with an α value of 0.05 
and a power of 1 – β = 0.8, was ten (10), assuming a coefficient of variation (CV%) of 
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50%.  To evaluate the effects of smoking, the Fagerström Test for Nicotine Dependence 
(FTND) was administered to determine their dependence on smoking in order to 
classify the potential subjects into three groups: nonsmokers, light-smokers, and heavy-
smokers (Fagerström and Schneider, 1989).   In this study, smokers were required to 
smoke one complete cigarette prior to sampling of the biological specimen.   As a 
separate analysis, a comparison of these results will be made to an additional eighteen 
(18) subjects from a separate study, balanced for smoking status and gender, that 
abstained from smoking for at least 15 hours prior to biological sampling (Leu, 2002). 
 
5.3   Experimental methods 
5.3.1 Subjects 
 Forty-three (43) male and female volunteers were screened for the study (11 NS 
females, 9 NS males, 7 LS females, 5 LS males, 6 HS females and 5 HS males).    A 
total of forty-one (41) healthy volunteers successfully completed the study (10 NS 
females, 9 NS males, 6 LS females, 5 LS males, 6 HS females and 5 HS males).   
Subjects were required to be between the ages of 21-35 and be healthy.   The 
recruitment of volunteers who participated in the study involved VCU-IRB approved 
advertisements that were placed around the Richmond, VA metro area.  Potential 
volunteers called on their own accord, and information regarding the logistics of the 
study was given over the telephone.    Upon their permission, a confidential health 
survey was administered to determine initial study qualification.  Information such as 
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gender, ethnicity, height and weight, present disease states, concurrent medications or 
dietary supplements, drugs of abuse and alcohol usage, smoking history and the 
Fagerström Test for Nicotine Dependence (FTND) was gathered from each subject 
participant.  In order to participate, the potential subject could not possesses any 
significant health disease state, not be currently taking any prescribed medications, nor 
be using any other drugs of abuse other than nicotine from cigarette smoking.    Alcohol 
intake was informally assessed during the telephone interview. 
 
5.3.2 Procedures 
5.3.2a  Smoking Classification 
 According to the number of cigarettes smoked per day and the FTND score, 
each patient was classified into a smoking status classification including nonsmoker 
(NS), light-smoker (LS), and heavy-smoker (HS).  The FTND is a standard instrument 
to assess the intensity of this physical addiction (Fagerström and Schneider, 1989). This 
test is designed to help physicians document the indications for prescribing medication 
for nicotine withdrawal.   The survey is measured on a scale of 0-10 with the higher the 
FTND score, the more intense the patient's physical dependence on nicotine.   
 Specifically, the requirements listed in table 5-1 were necessary for subjects to 
be classified in each group.  In the situation that the smoking history and FTND scores 
put the subject into two different categories (specifically for LS and HS), preference 
was given to the smoking history (number of cigarettes per day) over the FTND score. 
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Table 5-1:  Smoking status classification criteria. 
Subject Group Inclusion/Exclusion Criteria 
Nonsmoker (NS) 1. No current tobacco product use 
 2. Not a smoker for the past 5 years 
 3. If previously a smoker, did not smoke more than once a 
year continuously and < 10 cigarettes/year 
 4. FTND score = 0 
 
Light-smoker (LS) 
 
1. Current smoker of cigarettes (No other tobacco products) 
 2. Smokes at least 10 cigarettes/day 
 3. Smoked for at least 1 year continuously 
 4. FTND score 1-7 
 
Heavy-smoker (HS) 
 
1. Current smoker of cigarettes (No other tobacco products) 
 2. At least more than 20 cigarettes/day 
 3. Smoked for at least 1 year continuously 
 4. FTND score > 7 
 
 
5.3.2b  Admission to the Clinical Research Unit 
 Upon qualification of the telephone screening, each patient was categorized into 
a smoking status classification and visits to the clinical center were scheduled.   Prior to 
participation, the subject was required to abstain from prescription/over-the-
counter/herbal medications or caffeinated products for 72-hours prior to each visit (with 
exception of oral contraceptives prescription for females) and no alcoholic beverages 
12-hours prior to each visit.  The subject was given a chance to decline participation in 
the study or, if necessary, to seek his/her personal physician's advice as to whether to 
discontinue any medications he/she may be on.   
 The study involved two visits in which the volunteer presented to the Virginia 
Commonwealth University Health Systems General Clinical Research Center (VCUHS-
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GCRC).   Before participation in the study procedures, each subject signed a VCU-IRB 
approved Informed Consent Form (Appendix E) attesting that the study procedures 
were explained to them and that their participation in the study was voluntary.   
 Both clinical visits took place between 8 – 10 AM with sampling of biological 
specimens and additional observations were performed before 10 AM (see figure 5-1 
for study flow chart).  During the first screening visit, each volunteer completed forms 
including:  Comprehensive Medical History, Subject Entry Probe, Smoking History, 
Annual Alcohol Intake (AAI, Appendix C), and a TIQ/BC Food and Beverage 
Inventory (Appendix D).   The food and beverage inventory, including caffeinated 
beverages, were logged by self-report prior to sampling to explore the influences of 
dietary factors on TIQ and β-carboline levels at baseline.  All female subjects were 
requested to give information pertaining to the date of their last menses.  Of important 
note, subjects who were light- and heavy-smokers were asked to smoke one (1) 
complete cigarette within 30 minutes prior to biological sampling, for standardization 
purposes.  
 Additionally, during each visit, the subject was tested for abstention of alcohol 
via an alcohol breathalyzer and breath carbon monoxide test for assessment of exposure 
to cigarette smoke.  A 60-ml blood sample for estimation of TIQ and β-carboline 
plasma concentrations was drawn during each visit.  The volunteer also provided a urine 
sample for drugs of abuse screen.   
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Figure 5-1:  Activity Flow for Clinical Study #1 
  
 Screening/Visit #1               Visit #2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Activity Activity 
Outpatient Admission to GCRC Outpatient Admission to GCRC 
Subject Entry Probe Informed Consent Form 
Breathalyzer Test Subject Entry Probe 
Breath Carbon Monoxide Test Weight and Height Recording 
SMOKE* Medical History and Smoking History 
Vital Signs Zuckerman Sensation Seeking Scale 
Blood Sample Temperament and Character Inventory 
Vital Signs Annual Alcohol Intake 
Urine Sample Breathalyzer Test 
EXIT  Breath Carbon Monoxide Test 
SMOKE* 
Vital Signs 
Blood Sample 
Vital Signs 
Urine Sample 
EXIT 
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 Official enrollment and subject number assignment was allocated after the 
screening visit upon meeting particular inclusion/exclusion criteria.  The criteria for 
enrollment were as follows: 
1)   Demographics:  Participating subjects were required to be between the ages of 
21-35 years of age and be a healthy male or female.  Female subjects could not be 
pregnant during the clinical study and were to be using acceptable methods of 
contraception (abstinence, barrier methods, or oral contraceptives).  However, females 
that were not using oral contraceptives must have had regular menstrual cycles of 28-32 
days on average and must not have dysmenorrhea.  Subjects were required to be within 
± 15% ideal body weight according to their height.   
2) Medical history:  During the initial screening visit, a six-page medical 
evaluation form, in which the patient self-reported questions regarding personal medical 
history, family medical history, personal habits, current medications, social history, and 
current symptoms, was administered.  The subject had to have no history of clinically 
significant renal, hepatic, cardiovascular, gastrointestinal, pulmonary, neurological, and 
psychiatric diseases upon evaluation of the medical history questionnaire.  Moreover, 
subjects had to have no history of alcohol or illicit drug abuse.   Classification of the 
health status was based solely on the medical history form.  A physical exam was not 
performed on these subjects prior to participation. 
3) Laboratory results:  The primary laboratory tests performed on each subject 
were urine drugs of abuse test, urine human chorionic gonadotropin to test for 
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pregnancy of female subjects and a spot urine creatinine.    All pregnancy tests and 
urine drug screens had to be negative for further participation in the study.  
4) Vital Signs:  Sitting systolic and diastolic blood pressure (after five minutes of 
sitting), heart rate and oral temperature had to be within normal limits. 
5) Medications:  Subjects who qualified for the study were not allowed to take any 
prescription or over-the-counter medications.   Females that were currently taking oral 
contraceptives were permitted to participate in the study.     
 Upon successful screening, the volunteer was subsequently scheduled for a 
second visit to the clinical unit.  The same abstentions applied, as what was followed for 
the first screening visit.   During the second visit, only the breath tests, blood and urine 
sample were repeated.  A pregnancy test was given to female subjects and repeated if 
the time elapsed between the two visits exceeded one week.    
  
5.3.2c  Blood/urine sampling and safety measurements 
 During participation in the protocol, a total of one (1) blood sample was drawn 
during each study period.  The total amount of blood from each session was 60-ml and a 
total of 120-ml over the entire duration of the study.  During the two outpatient periods, 
the subjects’ vital signs was recorded before and after sampling and was monitored for 
appearance of any adverse events by the VCU-GCRC nursing staff.  A medical monitor 
was available to monitor for signs of adverse events associated with blood drawing such 
as mental confusion, dizziness, and weakness.  If necessary, adverse events were 
followed up until resolution. 
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Of note, subjects who were light- (LS) and heavy-smokers (HS) were asked to 
smoke one (1) complete cigarette within 30 minutes prior to biological sampling.  The 
exact time before sampling was noted as well as the type of cigarette smoked.  A 60-ml 
blood sample was collected from the non-dominant forearm in a reclined, seated 
position during the study.   Blood was collected into four 10-ml purple top vacutainer 
tubes containing K2-ethylenediaminetetraacetic acid (K2-EDTA) and was immediately 
centrifuged for 10 minutes at 4 °C at 3000 rpm to obtain plasma (Sorvall RC 3C Plus 
Centrifuge, Kendro Laboratory Products, Newton, CT).  Approximately 6-ml of plasma 
was placed into a Sarstedt Tube (Newton, NC) along with a 2-ml solution containing 
60% HClO4, ascorbic acid, semicarbazide HCl in aqua distillata for consequent SAL 
quantification analysis.   The anti-oxidant/aldehyde-trapping reagent solution was added 
to ensure the prevention of in-vitro artifactual formation of SAL.   An aliquot of 
approximately 10-ml of plasma was placed in a Sarstedt Tube for future β-carboline 
analysis.  Both sets of plasma samples were stored at -80°C until analysis. 
 
5.3.2d  Breath sampling 
 As part of protocol, subjects were required to abstain from alcohol for 12-hours 
prior to participation in each visit.   Moreover, smokers were required to smoke one 
complete cigarette prior to blood sampling.  Therefore, breath alcohol (BrAC) and 
breath carbon monoxide (CO) tests were performed to ensure that the subject was 
abstinent from alcohol (BrAC of 0.0 mg / 210ml), and to measure tobacco smoke 
exposure, respectively.   
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5.3.2e Diet and alcohol intake 
 As diet and alcohol intake are speculated to contribute to circulating TIQ’s and 
β-carbolines, a dietary survey and alcohol consumption scale were given to each 
subject.  These “pen and paper” style scales were administered to further characterize 
the subjects according to dietary intake of TIQ’s and β-carbolines.    Subjects were 
asked to abstain from caffeinated beverages and alcoholic beverages for 72-hours and 
12-hours, respectively, prior to each clinical visit.   
 The food survey incorporated a list of foods that are known to have a 
considerable composition of TIQ’s and β-carbolines.  Of major note, this survey is not a 
validated instrument.  The subject was required to mark the type of TIQ and/or β-
carbolines containing food they eat along with the frequency of intake. The TIQ/BC 
food inventory may be seen in Appendix D.   From the information provided, a 
calculation of weekly dietary intake of TIQ and/or β-carbolines in nanograms was 
reported. 
 Alcohol consumption was assessed for each subject participant via the Annual 
Alcohol Inventory (AAI, (Khavari and Farber, 1978).  This survey assesses the 
frequency and type (e.g., beer, wine and spirits) of alcohol consumed in a twelve 
question format.    Based on the responses, annual absolute alcohol intake can be 
estimated via a mathematical calculation.  This process is thought to capture both 
regular and binge drinking consumption but does not diagnose alcoholism.  The survey 
takes approximately 1-2 minutes to complete and was performed once per protocol at 
screening.  
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5.3.2f Discharge from VCU-GCRC 
 For each visit, subjects were discharged from the VCU-GCRC after 
approximately 2 hours of start of protocol procedures.  The volunteers were followed up 
the following day to assess for any discomfort from the protocol procedures, primarily 
the needle stick site.   The Flow Sheet that summarizes all procedures performed per 
protocol can be seen in Figure 5-1.  
 
5.3.3 Blood Sample Analysis 
 The samples containing TIQ’s and β-carbolines were kept at -80°C until 
analysis.   β-carboline analysis was conducted by the investigator using resources and 
equipment from the PK/PD Research Laboratory, Department of Pharmaceutics, 
Virginia Commonwealth University, Richmond, VA.     The β-carbolines, harman and 
norharman were analyzed via a validated HPLC-FD method (see chapter 3).  In brief, 2-
ml of patient plasma sample was subjected to protein precipitation with subsequent 
solid phase extraction (SPE).  Quantification for both analytes was conducted using 
yohimbine as an internal standard and detected via HPLC-FD.  
 TIQ samples were analyzed and assayed by the investigator using resources and 
equipment with generous permission granted from the Laboratory of Molecular 
Signaling, National Institute on Alcohol Abuse and Alcoholism-NIH, Rockville, MD.   
The assay procedure incorporated the use of 1-ml of patient plasma sample in addition 
to the equivalent volume of 1-ml antioxidant solution (total volume of 2-ml).    Phenyl 
boronic acid SPE followed by PFBBr derivatization was used to isolate R-SAL, S-SAL 
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and DA.  The final sample was chromatographically resolved via a chiral column and 
subjected to ESI-MS/MS detection.   Deuterated internal standards of each analyte were 
incorporated into the samples for adequate quantification (see Chapter 4 for further 
details). 
 
5.3.4 Statistical Analysis 
5.3.4a Descriptive statistics 
 Descriptive statistics, including mean, standard deviation, and coefficient of 
variation were calculated for each endpoint.    In addition, intra-individual variability 
(e.g., COV%) was calculated for all measured endpoints, i.e., TIQ and β-carboline 
concentrations, for each volunteer.   
 In the case that assumptions of normal distribution and equal variance was not 
met, raw data were log-transformed to comply with the parametric assumptions of equal 
variance across groups and normal distribution of the residuals.   Appropriate summary 
statistics, using the log-transformed data, such as, median, COV%, percentiles and 
ranges were computed.  
 
5.3.4b Inferential statistics 
 Inter-individual variability (i.e., COV% and range) was calculated for the above 
endpoints as well as all the rating scale scores for each of the three groups and across all 
groups.  The effects of smoking status and gender were evaluated via two-way 
ANCOVA, incorporating comparison of the factors smoking history and gender.  The 
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effect of sampling occasion (visit) was additionally explored.   Specifically, TIQ and β-
carboline individual concentrations were evaluated using the following model: 
 
   Yijk = μ + δi + πj + (δπ)ij + mγk + εijk
   i = NS, LS, HS 
   j = M, F 
   k = baseline covariate 
 
where Yijk was the response (concentration of TIQ or β-carboline) of the ith smoking 
status and jth gender relative to their kth covariate.  μ is the overall mean, δi is the effect 
of the ith smoking status, πj  is the effect of gender, (δπ)ij  is the interaction between the 
effect of the ith smoking status and the jth gender, γk is the effect of the kth baseline 
covariate possessing a m slope and, εijk is the random error associated with the Yijk 
response.  The error term is assumed to be independent and randomly distributed with a 
mean of 0 and variance σ2 respective to their effects and independent from each other.   
 Further exploratory analysis was performed.  Both TIQ and β-carboline 
individual concentrations were correlated with the measures of cigarette exposure (# 
cigarettes smoked/day) and dependence (FTND) using Pearson’s product-moment 
correlation to evaluate whether these variables are better descriptors for TIQ and β-
carboline exposure than the pre-specified smoking status.  
 Moreover, both TIQ and β-carboline mean concentrations were correlated with 
the measures dietary intake (TIQ/BC Food Inventory) and alcohol consumption (AAI) 
using Pearson’s product-moment correlation and linear regression to evaluate if these 
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are significant covariates that need to be implemented into the full model.  Associations 
are to be considered significant with a p-value of <0.05 and a coefficient of 
determination (R2) > 0.2.   Multiple covariate analysis was performed similar to as 
defined for exposure if there was more than one significant covariate. 
 All endpoints were tested and compared across all groups in S-PLUS 8.0 
(Insightful Corporation, Seattle, WA).  The full statistical model was implemented 
incorporating covariates, if required.    The residuals were tested for normality using 
Quantile-Quantile (Q-Q) plots and further tested using the Shapiro-Wilk test, where α 
was set to 0.05 such that any p-values > 0.05 indicated that the data was normally 
distributed.  If the data were not normally distributed, the data were log-transformed 
and the full model was repeated.    If the interaction or the baseline covariate was found 
not to contribute significantly to the full model, the interaction and/or the baseline were 
removed and a simpler model was used.  The level of significance was set a-priori at 
0.05.  Any statistically significant differences found via ANCOVA were further 
investigated via Scheffé test to isolate factor differences.  All ANCOVAS performed 
are included in Appendix L. 
 
5.4 Results 
5.4.1 Clinical Results 
 
5.4.1a Subject Demographics 
 
 A total of forty-three subjects qualified for the study after successfully passing 
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the initial telephone screening.   Forty-one subjects completed both observational 
periods according to protocol procedures.   Two subjects were disqualified from the 
study due to a positive urine drug screen.   Into each smoking status group, 19 NS, 11 
LS and, 11 HS were recruited and completed protocol, with twenty-two females and 
nineteen males comprising the gender distribution within the entire population.   The 
distribution of gender and smoking status for subjects who completed the protocol is as 
follows: 10 NS females, 9 NS males, 6 LS females, 5 LS males, 6 HS females and 5 HS 
males.  Final subject demographics are included in Table 5-2.  The patient summary is 
included in Appendix G.    The subjects were of a mean age of 25.1 years old, ranging 
from 21-32 years.  Females weighed an average of 64.1 kg (range 48.7 – 86.2), while 
males weighed an average of 80.1 kg (range 66.5 – 107.4).  No differences in weight 
and age were found between smoking groups.  Twenty-four Caucasians, fifteen Asians, 
one Hispanic and one African-American completed the study. 
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Table 5-2:  Clinical Study #1 Subject Demographics 
Nonsmokers
mean CO 
Subject # Race Gender Age Weight FTND # Cig/day pack years     ppm 
1 White F 21 68 0 0 0 2
2 Black F 22 52.7 0 0 0 3
3 White F 31 86.2 0 0 0 2.2
4 Asian F 26 52.2 0 0 0 1
5 White F 26 73.3 0 0 0 2.1
6 Asian F 30 65.3 0 0 0 2
7 White F 25 65.1 0 0 0 1.8
8 Asian F 26 52.6 0 0 0 2
9 Asian F 28 51.8 0 0 0 2.1
10 Asian F 25 56.8 0 0 0 2.2
11 Hispanic M 26 70.2 0 0 0 1.6
12 White M 22 88.1 0 0 0 2
13 White M 25 71.3 0 0 0 1.8
14 Asian M 24 71.3 0 0 0 3.2
15 Asian M 26 67.5 0 0 0 2.2
16 White M 22 103.6 0 0 0 2.1
17 Asian M 26 90.8 0 0 0 2
18 Asian M 30 83.7 0 0 0 1.7
19 Asian M 23 72.5 0 0 0 2.1
Total Mean 25.5 70.7 0.0 0.0 0.0 2.1
Total SD 2.8 14.6 0.0 0.0 0.0 0.5
Mean Female 26.0 62.4 0.0 0.0 0.0 2.0
SD 3.1 11.4 0.0 0.0 0.0 0.5
Mean Male 24.9 79.9 0.0 0.0 0.0 2.1
SD 2.5 12.3 0.0 0.0 0.0 0.5  
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Table 5-2:  Subject Demographics (continued) 
Light-smokers
mean CO 
Subject # Race Gender Age Weight FTND # Cig/day pack years     ppm 
21 White F 23 49.5 4 16 2.6 8.0
22 White F 22 60.9 0 5 1.8 12.2
23 White F 21 86.0 2 10 1.7 14.1
24 White F 21 58.7 1 10 3.2 13.2
25 White F 31 54.1 1 5 1.5 14.5
26 White F 22 70.2 1 4 1.4 11.7
31 Asian M 24 67.7 6 10 2.2 16.5
32 White M 32 78.5 3 17 2.1 14.1
33 Asian M 26 81 0 5 2.4 9.5
34 Asian M 24 81.1 2 6 1.4 12.2
35 Asian M 21 66.5 1 7 1.7 13.4
Total Mean 24.3 68.6 1.9 8.6 2.0 12.7
Total SD 3.9 12.0 1.8 4.5 0.6 2.4
Mean Female 23.3 63.2 1.5 8.3 2.0 12.3
SD 3.8 13.1 1.4 4.6 0.7 2.4
Mean Male 25.4 75.0 2.4 9.0 2.0 13.1
SD 4.1 7.3 2.3 4.8 0.4 2.6  
 
Heavy-smokers
mean CO 
Subject # Race Gender Age Weight FTND # Cig/day pack years     ppm 
41 White F 21 51.2 4 20 9.5 18.4
42 White F 23 59.0 5 20 11.2 19.5
43 White F 21 48.7 6 30 13.2 11.7
44 White F 24 79.7 7 25 11.5 17.5
45 White F 28 83.6 7 30 7.4 23.7
46 White F 31 83.6 4 30 11.2 11.9
51 White M 23 107.4 7 15 5.8 13.7
52 White M 24 78.8 8 15 12.2 19.5
53 White M 25 79.8 6 17 10.2 16.8
54 Asian M 25 79.7 7 20 7.5 20.4
55 White M 31 82.6 6 20 10.5 22.7
Total Mean 25.1 75.8 6.1 22.0 10.0 17.8
Total SD 3.5 16.9 1.3 5.8 2.3 4.0
Mean Female 24.7 67.6 5.5 25.8 10.7 17.1
SD 4.0 16.5 1.4 4.9 2.0 4.6
Mean Male 25.6 85.7 6.8 17.4 9.2 18.6
SD 3.1 12.2 0.8 2.5 2.6 3.5  
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 Of note, no statistically significant difference was observed with respect to 
weight and age between smoking groups.   With regard to smoking status and frequency 
of cigarette smoking, figures 5-2, 5-3 and 5-4 show FTND scores, mean cigarette 
consumption per day and breath carbon monoxide (CO), respectively.  Both 
nonsmoking (NS) males and females scored a mean of 0 (± 0 SD) on the FTND and self 
reported mean number of cigarettes smoked per day, as expected.  LS females scored a 
mean FTND of 1.5 (± 1.4 SD) while LS males scored a slightly higher value of 2.4 (± 
2.3 SD).    HS females scored a 5.5 (± 1.4 SD) compared to HS males who scored on 
average a 6.6 (± 0.9 SD).  Of note, the FTND difference between the genders was not 
significantly different (two-tailed unpaired t-test, p-values were greater than 0.088 for 
both LS and HS status).    With respect to the number of cigarettes smoked per day, LS 
females and LS males had similar results with averages of both groups being 8.3 (± 4.6 
SD) and 9.0 (± 4.8 SD) cigarettes smoked per day for females and males, respectively.   
HS subjects smoked on average a two-fold more number of cigarettes per day than the 
LS counterparts.    In this group, female smokers possessed a higher average than that of 
males with an average of 25.8 (± 4.9 SD) for females and 17.4 (± 2.5 SD) for males.   
As expected, smokers had both higher FTND and number of cigarettes smoked per day 
than that of nonsmokers.    
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Figure 5-2:  Mean (± SD) Fagerström Test for Nicotine Dependence (FTND) Score vs. 
Smoking Status (F: female, M: male) 
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Figure 5-3:  Mean (± SD) Cigarettes smoked per day vs. Smoking Status (F: female, M: 
male) 
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Figure 5-4:  Mean (± SD) Expired Carbon Monoxide vs. Smoking Status (F: female, 
M: male) 
   
 With respect to breath carbon monoxide (CO), negligible differences were 
observed between genders within smoking groups.    NS males and females possessed a 
mean CO level of 2.0 (± 0.5 SD) and 2.1 ppm (± 0.5 SD), respectively.    This positive 
value of expired CO in the NS group is presumed to stem from incidental environmental 
exposure.    Conversely, LS and HS possessed significantly higher levels of expired CO, 
seemingly due to recent cigarette smoking (within 30 minutes) by the smoking subjects.  
The mean CO measured in LS males and females was 13.1 (± 2.6 SD) and 12.3 (± 0.5 
SD) while CO measurement in HS males and females resulted in 18.6 (± 3.5 SD) and 
17.1 (± 4.6 SD), respectively.  
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5.4.1b Alcohol Intake and Food Inventory 
 In addition to the demographic and TIQ and β-carboline plasma measurements, 
information including alcohol intake and weekly exposure to dietary total SAL, harman 
and norharman was recorded via the Annual Alcohol Intake (Khavari and Farber, 1978) 
and TIQ/BC Food Inventory (Appendix C and D).     As dietary intake of ethanol and/or 
TIQ and β-carboline containing foods may affect the overall exposure, these 
assessments may provide clues into the variability associated with the plasma 
measurement of SAL, harman and norharman.    If alcohol intake and/or dietary 
exposure were found to significantly correlate with SAL or β-carboline exposure, AAI 
or Food Intake was considered a significant covariate and implemented into the 
statistical model. 
 With regard to ethanol intake, the AAI was administered to each subject on a 
single occasion.  The total amount of alcohol consumed, in terms of milligrams of pure 
ethanol, was calculated upon evaluation of the usual and maximum frequencies along 
with usual and maximum volumes of three different types of alcoholic beverages 
including, wine, beer and spirits.    From the assessment a total quantity of alcohol was 
calculated in milliliters with subsequent calculation of the absolute yearly ethanol 
content, accounting for the different percentage of ethanol in each type of beverage.   Of 
primary note, this is a self-report measure of overall estimate of total ethanol 
consumption.  It is not a diagnostic tool for alcoholism disease status nor is it sensitive 
to detect change in drinking patterns.  The descriptive results of the AAI may be viewed 
in the table below in milligrams of annual absolute ethanol consumed. 
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  In regard to dietary exposure of the analytes, the food survey incorporated 
measurements of type of food, average frequency and average portion size of each 
known food source to have significant quantities of SAL or β-carboline.   A numerical 
value for each food type was calculated for each subject accounting for frequency and 
portion size.   The ordinal value was subsequently multiplied by the absolute amount of 
SAL or β-carboline present in that food source.     Absolute amounts within those food 
sources that have known, measureable quantities of SAL and/or β-carboline were 
calculated using reported literature values (Hirst et al., 1985; Collins et al., 1990; Pfau 
and Skog, 2004).  SAL, harman and norharman amounts are reported as weekly intake 
of analyte in nanograms.   The descriptive results of the TIQ/BC Food Inventory may be 
viewed table 5-3 below in average nanograms of weekly total SAL, norharman and 
harman consumed. 
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Table 5-3:  Descriptive statistics of alcohol intake and dietary consumption 
 
GRAND
Mean 3055
%COV 99
Median 1266
Mean 1301
%COV 151
Median 702
Mean 2114
%COV 125
Median 970
Mean 1296
%COV 65
Median 1218
Mean 1369
%COV 48
Median 1203
Mean 1335
%COV 56
Median 1218
Mean 2051
%COV 58
Median 1826
Mean 2027
%COV 48
Median 1805
Mean 2038
%COV 53
Median 1826
Mean 2568
%COV 91
Median 1562
Mean 2176
%COV 100
Median 1559
Mean 2358
%COV 95
Median 1562
A
A
I  
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) Male
1219 3219
717 4744
6196
127 71 52
6516
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 Estimated annual ethanol exposure (AAI) resulted in substantial differences 
between genders within smoking groups.   Results here are reported as median and 
range.  NS males and females possessed a median annual ethanol exposure of 717 
mg/year (range: 0 – 4614 mg/year) and 506 mg/year (26.5 – 2758 mg/year), 
respectively.    Conversely, LS and HS possessed significantly higher AAI scores.  The 
median mg of ethanol estimated in LS males and females was 4744 mg/year (184 – 
4764 mg/year) and 804 mg/year (57.9 – 3214 mg/year) while in HS males and females 
resulted in 6516 mg/year (969 – 10264 mg/year) and 910 mg/year (129 – 9120 
mg/year), respectively.   Nonsmokers possessed a median mg of annual ethanol 
consumed of 668 mg/day (range 0 – 4614 mg/day) while the estimated LS and HS 
annual ethanol intake was 1004 mg/day (58 – 5399 mg/day) and 1159 (128 – 10624 
mg/day).    Figure 5-5 represents the distribution of the mg of ethanol intake, per 
smoking status and gender. 
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Figure 5-5:  Estimated annual absolute alcohol intake in mg ethanol / year  
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 A systematic trend was observed between smoking groups and gender for the 
total amount of ethanol consumed per annum.  On average, females had a lower 
estimated ethanol intake compared to males as a whole and across smoking groups.   
Interestingly smoking status showed a significant trend with a resultant increase in 
estimated ethanol consumption with increasing level of smoking status.  This result was 
expected as smokers are known to consume twice as much alcohol as do non-smokers 
(DiFranza and Guerrera, 1990).   Formal evaluation of AAI as a significant covariate 
will be explored further as alcohol intake may affect the exposure of plasma SAL and β-
carbolines.  
 Dietary TIQ and β-carboline exposure measured via the TIQ/BC food inventory 
yielded estimates that were statistically similar across smoking groups.  For weekly 
dietary harman intake, NS males and females possessed an estimated median weekly 
dietary harman exposure of 1168 ng/week while in LS and HS, estimated median 
dietary exposure was 1393 ng/week and 1334 ng/week, respectively.    For weekly 
dietary norharman intake, estimated median weekly dietary exposure for NS was 1752 
ng/week while in LS and HS, estimated median dietary exposure was 2089 ng/week and 
1998 ng/week.   Within all smoking status groups, a large range of dietary intake of 
harman and norharman was observed. 
 In the case of weekly dietary SAL exposure, the individual enantiomeric 
composition of the food sources was not available.  Therefore, dietary total SAL was 
estimated.  It has been purported that, in food sources, the enantiomeric ratio is 1:1, as 
previously discussed.   For weekly dietary SAL intake, estimated median weekly dietary 
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exposure for NS was 1663 ng/week (range: 243 – 9182 ng/week) while in LS and HS, 
estimated median dietary exposure was 1555 ng/week (range: 109 – 8729 ng/week) and 
1421 ng/week (range: 109 – 4322 ng/week).     
 The average dietary intake between smoking status and gender groups for 
harman, norharman, and SAL are shown in the figures 5-6, 5-7, and 5-8, respectively. 
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 Figure 5-6:  Estimated dietary harman intake in ng / week (mean ± SD) 
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 Figure 5-7:  Estimated dietary norharman intake in ng / week (mean ± SD) 
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 Figure 5-8:  Estimated dietary total salsolinol (SAL) intake in ng / week (mean 
 ± SD) 
 
 
 
 With the exception of dietary SAL, no statistically significant difference was 
observed between the smoking status groups.  The LS group possessed, on average, a 
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higher estimated consumption of dietary SAL than NS and HS groups but the variability 
associated with this estimate is large (%COV of 107%). 
 
5.4.1c  Adverse Events 
 Due to the minimally invasive nature of this study, the investigation progressed 
without major complications.   Out of all subject completions, only one subject 
complained of bruising at the injection site but was subsequently resolved within 12 
hours upon follow up telephone call.    During the first visit, three subjects possessed 
asymptomatic systolic hypotension after blood draw.  For the second visit, four different 
individuals had similar signs.   At the end of each visit, all subjects, including those 
with mild hypotension, were alert and able to ambulate independently and return to 
daily routines.  
 
 
5.4.2 Primary Analysis for β-carbolines – Effects of smoking and gender 
5.4.2a β-carbolines – Within Subject Variability 
 Prior to formal statistical comparison of H and NH between smoking and gender 
factors, within-subject variability of both β-carbolines for each subject was evaluated.  
This analysis was performed to assess the baseline stability of H and NH over two 
observational time points with the second observation being collected within one week 
of the first clinical visit.   The intra-subject variability (%COV and inter-quartile ranges) 
for NH and H may be seen in the tables 5-4 and 5-5 below.   
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Table 5-4:  Within Subject Variability for Plasma Norharman (pg/ml)  
Sample # GEN NH avg stdev %COV median 25% IQR 75% IQR
Nonsmokers
1 F 9 11 123 9 5 13
2 F 5 1 31 5 4 5
3 F 19 3 15 19 18 20
4 F 7 0 4 7 7 7
5 F 28 3 10 28 27 29
6 F 5 0 5 5 5 5
7 F 45 28 62 45 35 55
8 F 21 3 14 21 20 22
9 F 2 0.1 10 2 2 2
10 F 25 11 43 25 21 28
11 M 23 7 31 23 21 26
12 M 7 2 24 7 7 8
13 M 60 36 60 60 47 72
14 M 24 20 83 24 17 31
15 M 51 33 64 51 39 62
16 M 15 1 10 15 14 15
17 M 62 10 17 62 58 65
18 M 4 1 25 4 4 4
19 M 30 28 92 30 20 40
Light Smokers
21 F 89 4 5 89 87 90
22 F 39 23 58 39 31 47
23 F 36 5 15 36 34 38
24 F 17 7 41 17 15 20
25 F 45 12 26 45 41 50
26 F 84 30 36 84 73 94
31 M 333 85 26 333 303 364
32 M 81 5 6 81 79 83
33 M 40 8 21 40 37 43
34 M 140 17 12 140 134 146
35 M 43 1 2 43 42 43
Heavy Smokers
41 F 236 124 52 236 193 280
42 F 289 117 40 289 247 330
43 F 109 15 14 109 104 114
44 F 161 181 112 161 97 225
45 F 284 177 62 284 221 347
46 F 238 109 46 238 199 277
51 M 67 53 78 67 49 86
52 M 33 12 35 33 29 37
53 M 119 116 98 119 78 160
54 M 181 3 2 181 180 182
55 M 145 150 104 145 92 198  
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Table 5-5:  Within Subject Variability for Plasma Harman (pg/ml)  
Sample # GEN H avg stdev %COV median 25% IQR 75% IQR
Nonsmokers
1 F 12 13 115 12 7 16
2 F 2 4 165 5 4 6
3 F 26 4 16 29 28 31
4 F 7 1 8 8 8 8
5 F 19 3 17 21 20 22
6 F 4 0 8 4 4 4
7 F 74 29 39 54 43 64
8 F 13 13 101 22 18 27
9 F 2 0 14 2 2 2
10 F 13 5 41 9 7 11
11 M 12 16 138 23 17 28
12 M 10 2 19 8 8 9
13 M 16 3 18 14 13 15
14 M 7 13 176 16 12 21
15 M 88 7 8 93 90 95
16 M 23 1 5 22 21 22
17 M 96 17 18 84 78 90
18 M 5 0 7 6 5 6
19 M 4 3 72 5 5 6
Light Smokers
21 F 129 5 4 125 124 127
22 F 76 33 43 53 42 65
23 F 55 11 19 62 58 66
24 F 5 47 1026 38 21 55
25 F 4 62 1668 47 26 69
26 F 139 23 17 155 147 163
31 M 36 2 5 37 37 38
32 M 102 57 56 62 42 82
33 M 68 70 103 118 93 142
34 M 144 31 22 121 110 132
35 M 68 5 8 64 62 66
Heavy Smokers
41 F 422 41 10 393 379 408
42 F 12 5 40 15 13 16
43 F 386 181 47 258 194 322
44 F 63 106 168 138 100 175
45 F 55 63 115 99 77 121
46 F 49 110 224 127 88 166
51 M 36 4 12 39 38 41
52 M 11 13 121 20 15 24
53 M 356 217 61 202 126 279
54 M 46 65 142 91 68 114
55 M 4 30 760 26 15 36  
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 For NH and H concentrations, it can be noted that the variability between 
sampling occasions ranged from a %COV 1.8 to 123 % for NH and %COV 3.6 to 
1668% for H,  suggesting that baseline concentrations of these β-carboline analytes are 
not always stable or reproducible between occasions.   Inter-quartile ranges for the 
between occasion variability is the more appropriate assessment for variability between 
two observations but, for simplicity sake, %COV were computed and compared.  For 
non-smokers %COV ranged from 3.7 – 123% for NH and 7.4 – 165% for H.   
Presumably, these persons have not been recently exogenously exposed to H and NH, 
inferring that factors, other than smoking status or gender may contribute to the 
variability in baseline between occasions.  For the LS population, %COV 2.1 – 58% for 
NH and %COV 3.6 – 1668% for H were observed, while the HS population possessed 
%COV 1.8 – 112% for NH and %COV 9.7 – 760% for H.   The large variability 
between occasions observed within the smoking status populations may be due to the 
different times of sampling with respect to cigarette smoking.  Although each subject 
was sampled within 30 minutes of smoking, the sampling times varied considerably 
within this time frame for each subject.  As it has been noted by two researchers, plasma 
half-lives of 51 minutes (Breyer-Pfaff et al., 1996) and 25-30 minutes (Rommelspacher 
et al., 2002) for harman and norharman, respectively, have been estimated from human 
studies.    Because of short plasma half-lives, and the time it takes for the subject to 
smoke a complete cigarette and arrive to the clinic for a blood draw is variable, it was 
difficult to consistently sample at a reproducible time.   Of note, both genders possessed 
the similar amount of within-subject variability with males possessing a %COV 1.8 – 
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103.7% for NH and %COV 4.7 to 760% for H were observed while in the female 
counterparts, a  %COV 2.1 – 123.0% for NH and %COV 7.2 to 1668.1% for H were 
observed.   Only two subjects in the LS female group possessed very large within 
subject variability (%COV >1000%) for H concentrations.    This is seemingly due to 
the large sampling time differences with respect to smoking a cigarette, between 
occasions.    
 As large within-subject variability was observed with majority of the subjects, 
individual subject concentrations were used, as opposed to average subject 
concentrations for providing descriptive statistics of the overall measure of central 
tendency and variability.    This was to ensure that the intra-subject variability was not 
masked during descriptive and inferential statistical analysis.    
 Tables 5-6 and 5-7 exemplify the descriptive statistics for the concentrations 
observed for each smoking status and gender.    Measures of central tendency, such as 
mean and median, along with the variability including %COV and range are presented 
for each factor.  Of note, the distribution for the number of subjects is unbalanced with 
respect to smoking status and gender within each group.  The distribution of gender and 
smoking status for subjects who completed the protocol is as follows: 10 NS females, 9 
NS males, 6 LS females, 5 LS males, 6 HS females and 5 HS males.    It is important to 
note that each smoking status: gender group contains at least 5 subjects.   
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Table 5-6: Descriptive statistics for Norharman concentrations (pg/ml) divided into 
smoking status and gender. 
 
NORHARMAN
Mean 81
Stdev 107
%COV 132
Median 32
MIN 2
MAX 410
Mean 77
Stdev 87
%COV 113
Median 42
MIN 3
MAX 394
Mean 79
Stdev 98
%COV 123
Median 38
MIN 2
MAX 410
   
 F
em
al
e
   
   
M
al
e
Non-smoker
16
65
2
17
93
Light-smoker Heavy-smoker GRAND
15
85
3
23
84
26
31
52
30
57
47
93
81
34
12
105
127
394
220
119
55
183
33
410
109
86119
79
73
25
251
89
105
   
 G
R
A
N
D
85
2
17
95
22
23
54
12
394
169
117
69
160
25
410
86
 
 
Table 5-7: Descriptive statistics for Harman concentrations (pg/ml) divided into 
smoking status and gender. 
 
HARMAN
Mean 76
Stdev 103
%COV 136
Median 32
MIN 2
MAX 422
Mean 55
Stdev 66
%COV 119
Median 36
MIN 4
MAX 356
Mean 66
Stdev 88
%COV 132
Median 34
MIN 2
MAX 422
Non-smoker Light-smoker Heavy-smoker GRAND
   
 F
em
al
e
16 80 172
17 53 148
107 66 86
10 74 137
2 4 12
74 172 422
   
   
M
al
e
30 80 76
33 47 105
111 59 139
14 68 44
4 22 4
98 167 356
   
 G
R
A
N
D
23 80 128
27 49 136
117 61 107
12 71 52
2 4 4
98 172 422  
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 The overall average, across all patients for NH and H were 79.2 (123.4%) and 
66.4 pg/ml (132.4%) suggesting that the plasma β-carboline concentrations are quite 
variable between all patients.    The significant differences between the median and 
mean NH and H concentrations suggest that the data follow non-normal distribution.    
Upon comparison of the median concentrations and ranges, females were observed to 
have a median NH concentration of 32 pg/ml while median H concentrations were 31.8 
pg/ml.  Their male counterparts had a similar median NH concentration of 41.8 pg/ml 
and median H concentrations were 36.3 pg/ml.   With respect to smoking status, median 
concentrations along with ranges are presented in the preceding table. 
 Median H concentrations of female NS, LS and HS were 10.4, 73.8 and 136.5 
pg/ml, respectively while median NH concentrations were 16.8, 44.6 and 183.3 pg/ml.  
Males within NS, LS and HS groups had median H concentrations of 13.5, 70.5, and 
51.9 pg/ml and median NH concentrations of 17.2, 54.4, and 159.6 pg/ml, respectively. 
 
5.4.2b β-carbolines - Primary Factors of Smoking and Gender Analysis 
 
 The distribution of the data within each smoking group for both H and NH 
followed a non-normal distribution upon evaluation of quantile-quantile (Q-Q) plots.  
The large discrepancy between the median and mean concentrations within each group 
also exemplifies the non-normality of the distributions.  Further evaluation of normality 
of the data via the Shapiro-Wilk test resulted in p-values all less than 0.03 for both 
analytes across all groups, suggesting that the data were indeed non-normally 
distributed.  Moreover, unequal variance was present with the data upon visual 
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inspection of the residuals.    For these reasons, log-transformed data were used for the 
primary analysis.  
 Separate evaluation of the effects of smoking status and gender were performed 
on both log H and log NH concentrations.  Correlation analysis between the analytes 
suggested that the association between the two analytes was moderate (r = 0.65, see 
figure 5-9 below), therefore both analytes are treated separately for statistical analysis.    
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Figure 5-9:  Correlation between log H and log NH.  Correlation coefficient for the 
association is r = 0.652. 
 
 Two-way ANOVA was performed on the log transformed H and NH evaluating 
the factors of smoking status and gender.  Evaluation of the effects of sampling visit 
was performed and was further explored upon significance of the effect.   Box-plots 
showing the median and distribution, including outliers for the effects of gender and 
smoking status are presented below for both H (figure 5-10) and NH (figure 5-11).   The 
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horizontal line in the interior of the box is located at the median log β-carboline, while 
the “x” denotes the mean concentration.    The height of the box is equal to the 
interquartile distance or IQD, which is the difference between the third and first 
quartiles of the data.   The whiskers include 99.3% of all data while the outliers are 
presented as horizontal lines outside of the whiskers.    
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 Two-way ANOVA was performed to evaluate the effects of gender and smoking 
on log H concentrations.    Statistical data are presented as F test for two-way ANOVA 
(df for factors, df for residuals = F-statistic, p-value).    
 A significant effect of smoking status (SS) was observed with respect to log H 
concentrations with F (2, 75) = 16.7, p-value = 1.0 x 10-6.   The effect of gender (GEN) 
was not significant with the test statistic resulting in F (1, 75) = 0.09, p-value = 0.756.    
No interaction between the SS and GEN factors was observed (F (2, 75) = 3.02, p-value 
= 0.074).  An effect of sampling visit was not observed (p-value = 0.08). The coefficient 
of determination (R2) for the entire model was 0.312 (p-value = 7.4 x 10-6).  Thus, the 
factors of SS and GEN account for approximately 31.2% of the variability associated 
with the log H concentration measurements.   
 In order to determine where the difference within smoking status resides, a post-
hoc multiple comparison test was performed.  The Scheffé method for multiple 
comparisons found that the primary differences were observed between the HS and NS 
groups as well as the LS and NS groups.   Via this comparison, a significant difference 
was not observed between the HS and LS smoking status groups.     
 The full two-way ANOVA output for Log H can be seen in figure 5-12 below 
along with the residual plot of the model fit (figure 5-13).   Upon visual evaluation, the 
residuals show an even spread of the distribution of data suggesting the lack of unequal 
variance.  The results of the multiple comparisons are presented below the ANOVA 
table where a significant difference between groups is denoted by asterisks.  
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 *** Analysis of Variance Model *** 
 
Short Output: 
Call: 
   aov(formula = log.H ~ SS + GEN + visit + SS:GEN, data =  
 SAL.BC..Final.Bioanalysis.Data.VCU.Smoking.031808, na.action =  
 na.exclude) 
 
 
          Df Sum of Sq  Mean Sq  F Value     Pr(F)  
       SS  2   7.40497 3.702483 16.69658 0.0000010 
      GEN  1   0.02159 0.021590  0.09736 0.7558877 
    visit  1   0.71119 0.711188  3.20715 0.0773521 
   SS:GEN  2   1.34362 0.671812  3.02958 0.0742898 
Residuals 75  16.63132 0.221751                  
 
Multiple R-Squared: 0.3116  
F-statistic: 8.715 on 4 and 77 degrees of freedom, the p-value is 7.41e-006 
 
 
95 % simultaneous confidence intervals for specified  
linear combinations, by the Scheffé method  
 
critical point: 2.86  
response variable: log.H  
rank used for Scheffé method: 3  
 
intervals excluding 0 are flagged by '****'  
 
      Estimate Std.Error Lower Bound Upper Bound       
HS-LS   -0.032     0.143      -0.440       0.376      
HS-NS    0.571     0.127       0.209       0.933 **** 
LS-NS    0.603     0.127       0.241       0.965 **** 
 
 
 
Figure 5-12:  Two-way ANOVA output, with multiple comparisons, for the effects of 
SS and GEN on Log H plasma concentrations. 
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Figure 5-13:  Residual plot for two-way ANOVA fit for Log H. 
   
Fitted : SS + GEN + visit + SS:GEN
Residuals
1.2 1.4 1.6 1.8 2.0 2.2
-1.0
-0.5
0.0
0.5
1.0
13 
4718
 
 With respect to Log NH concentrations, a significant effect of smoking status 
(SS) was observed with F (2, 75) = 41.67, p-value = 0.3 x 10-7.   The effect of gender 
(GEN) was not significant with the test statistic resulting in F (1, 75) = 2.11, p-value = 
0.150.    No interaction between the SS and GEN factors was observed (F (2, 75) = 2.7, 
p-value = 0.065).   An effect of sampling visit was not observed (p-value = 0.74). The 
coefficient of determination (R2) for the entire model was 0.498 (p-value = 6.2 x 10-11).   
Thus, the factors of SS and GEN account for approximately 49.8% of the variability 
associated with the log NH concentration measurements.   
 The Scheffé method for multiple comparisons found that the primary differences 
were observed between the HS and NS groups as well as the LS and NS groups.   Via 
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this comparison, a significant difference was not observed between the HS and LS 
smoking status groups, as in the same case for H.  
 The full two-way ANOVA output for Log NH may be seen in the figure 5-14 
below along with the residual plot of the model fit (figure 5-15).   Upon visual 
evaluation, the residuals show an even spread of the distribution of data suggesting the 
lack of unequal variance. 
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*** Analysis of Variance Model *** 
 
Short Output: 
Call: 
aov(formula = log.NH ~ SS + GEN + visit + SS:GEN, data =  
 SAL.BC..Final.Bioanalysis.Data.VCU.Smoking.031808, na.action =  
 na.exclude) 
 
Residual standard error: 0.4090246  
Estimated effects may be unbalanced 
 
          Df Sum of Sq  Mean Sq  F Value     Pr(F)  
       SS  2  13.94415 6.972076 41.67382 0.0000000 
      GEN  1   0.35342 0.353417  2.11246 0.1502757 
    visit  1   0.01848 0.018483  0.11048 0.7405308 
   SS:GEN  2   1.90789 0.953946  5.70197 0.0649521 
Residuals 75  12.54758 0.167301                 
 
 
Multiple R-Squared: 0.4976  
F-statistic: 19.06 on 4 and 77 degrees of freedom, the p-value is 6.246e-011  
 
 
 
95 % simultaneous confidence intervals for specified  
linear combinations, by the Scheffé method  
 
critical point: 2.86  
response variable: log.NH  
rank used for Scheffé method: 3  
 
intervals excluding 0 are flagged by '****'  
 
      Estimate Std.Error Lower Bound Upper Bound       
HS-LS    0.276     0.124     -0.0778       0.631      
HS-NS    0.924     0.110      0.6100       1.240 **** 
LS-NS    0.648     0.110      0.3330       0.962 **** 
 
 
 
Figure 5-14:  Two-way ANOVA output, with multiple comparisons, for the effects of 
SS and GEN on Log NH plasma concentrations. 
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           Figure 5-15:  Residual plot for two-way ANOVA fit for Log NH. 
 
 A significant effect of smoking status was observed for both log H and log NH 
plasma concentrations.   A statistically significant effect of gender was not observed in 
the exposure and an interaction between the factors was not observed for either analyte.  
According to the two-way ANOVA, the following rank was observed with plasma H 
concentrations (geometric means) across smoking groups and gender.  NS F < NS M < 
HS M < LS M < LS F < HS F.   The post-hoc multiple comparisons via Scheffé test 
showed that the major difference that was observed with the smoking groups were the 
HS – NS group and the LS – NS groups.  According to this analysis, no significant 
difference was observed between the two smoking groups of LS and HS.     On average, 
the LS group had a slightly larger mean than that of the HS groups for log H.     
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 ANOVA results assigned the following rank with respect to observed plasma 
NH concentrations across smoking groups and gender.  NS F < NS M < LS F < HS M < 
LS M < HS F.   The post-hoc multiple comparisons via Scheffé test showed that the 
major difference that was observed with the smoking groups were the HS – NS group 
and the LS – NS groups.  A statistically significant difference was not observed 
between the two smoking groups of LS and HS.     On average, across smoking groups, 
the HS group > LS group > NS group for log NH.  See figures below.       
 For both NS and LS smoking status groups, males possessed higher 
concentrations than females.  The female HS group yielded higher average 
concentrations than that of their male counterparts for both H and NH.    The fact that 
HS females smoked more cigarettes per day on average compared to males may provide 
an explanation for this divergence in plasma concentrations.     
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 Figure 5-16:  Log H as function of smoking status and gender (mean ± SD). 
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 Figure 5-17:  Log H as function of smoking status (mean ± SD).  Statistically 
 significant results observed between NS-LS and NS-HS groups. 
  
 
 
282 
 
 
0
0.5
1
1.5
2
2.5
3
NS LS HS
smoking status
lo
g 
no
rh
ar
m
an
 
males
females
 
 Figure 5-18:  Log NH as function of smoking status and gender (mean ± SD). 
 
 
0
0.5
1
1.5
2
2.5
NS LS HS
smoking status
lo
g 
no
rh
ar
m
an
 
  
 Figure 5-19:  Log NH as function of smoking status (mean ± SD).   
 Statistically significant results observed between NS-LS and NS-HS groups. 
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5.4.2c β-carbolines – Exploratory Analyses 
 As observed from the primary analysis, a statistically significant effect of 
smoking status was observed on both log H and log NH plasma concentrations.  In 
order to further explain the variability of H and NH exposure associated with smoking 
status, the criteria of FTND and number of cigarettes smoked per day were analyzed as 
continuous dependent variables to explain the individual subjects’ H and NH exposures.   
FTND and the number of cigarettes smoked per day were replaced by the SS category 
for the ANOVA analysis.      The individual concentrations for each subject were used 
to assess the relationship between FTND and number of cigarettes and the analyte 
concentrations in order to represent the intra-subject variability for the log H and log 
NH in the analysis.     
 The tables below summarize the regression analysis for log H and log NH using 
different explanatory variables for the dependent variable.  For reference, results of the 
primary analysis using smoking status and gender for the model fit are supplied.  As 
FTND and the number of cigarettes smoked per day are measures of nicotine 
dependence that were not expected to change between sampling periods, intra-subject 
average log H and log NH concentrations were also explored for an association.   
 Although the model fits were statistically significant on the individual log H 
concentrations, use of the FTND and number of cigarettes/day did not improve 
coefficient of determinations from the initial model.   Of note, all model fits were  
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Table 5-8:  Explanatory variable model comparison for Log H.  
Log Harman     
Model Description R2 p-value 
Slope (for continuous 
dependent variable) 
and notes 
SS + GEN 
(pre-specified 
primary factors) 
Original 2-way 
ANOVA with SS and 
GEN as factors 
 
0.3116 < 0.0001 No interaction 
FTND + GEN 
 
Linear regression 
with continuous 
FTND as dependent 
variable 
 
0.2558 < 0.0001 0.1516, sig interaction 
observed between FTND 
and GEN 
#cig/day+ GEN Linear regression 
with continuous 
#cig/day as 
dependent variable 
 
0.2757 < 0.0001 0.0342, no interaction, no 
effect of gender 
 
Avg log H 
    
FTND + GEN Linear regression on 
avg log H with 
continuous FTND as 
dependent variable 
 
0.2123 0.003 0.0866, sig interaction 
observed between FTND 
and GEN 
#cig/day + GEN Linear regression on 
avg log H with 
continuous #cig/day 
as dependent variable 
 
0.3306 < 0.0005 0.0303, no interaction 
No effect of gender. 
 
 
 
 
 
 
 
 
 
 
 
285 
statistically significant (all p-values < 0.003).  Upon evaluation of the average log H 
concentrations, an improvement was observed when the number of cigarettes smoked 
per day was implemented into the model in place of smoking status.   Average 
concentrations were expected to show a better model fit compared to the individual 
concentrations as the average masks the intra-subject variability associated with the 
observations.  According to this model, gender or the gender:cigarettes/day interaction 
was not significant.  Figure 5-20 below shows the final model regression for log H as a 
function of # of cigarettes smoked per day.       
 Smoking status was able to explain more of the variability associated with log H 
concentrations (31.6%) than the FTND (25.8%) and #cigarettes/day (27.5%) covariates.   
0 5 10 15 20 25 30
.cig.day
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Figure 5-20:  Linear regression of #of cigarettes smoked per day vs. average log H.  
Dotted lines represent 95% confidence bounds (R2 = 0.3306, log H = 0.0303 #cig/day + 
1.1). 
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According to this model, 33.6% of the variability associated with average log H plasma 
concentration can be explained by the number of cigarettes smoked per day.  For every 
single cigarette smoked on average results in an increase in average log H concentration 
of 0.03. 
 With respect to the individual log NH, all model fits were statistically significant 
with use of the FTND and number of cigarettes/day (all p-values < 0.0001).   The model 
fit is shown in the following table.  In this case, the use of the # of cigarettes smoked 
per day was a slightly better predictor of individual log NH concentrations than 
smoking status possessing a R2 of > 0.50.  In other words, the # of cigarettes smoked 
per day was able to explain 50.2% of the variability associated with the log NH 
concentrations as opposed to the smoking status, which explained 49.7%.  A plot 
showing the regression between the individual log NH concentrations as a function of 
the number of cigarettes smoked per day is shown below the table.   
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Table 5-9:  Explanatory variable model comparison for Log NH.  
Log norharman     
Model Description R2 p-value 
Slope (for continuous 
dependent variable) 
and notes 
SS + GEN 
(pre-specified 
primary factors) 
Original 2-way 
ANOVA with SS 
and GEN as factors 
 
0.4976 < 0.0001 No interaction 
FTND + GEN 
 
Linear regression 
with continuous 
FTND as dependent 
variable 
 
0.4417 < 0.0001 0.2006, sig interaction 
observed between FTND 
and GEN 
#cig/day + GEN Linear regression 
with continuous 
#cig/day as 
dependent variable 
 
0.5016 < 0.0001 0.0443, no interaction 
 
Avg log NH 
    
FTND + GEN Linear regression on 
avg log NH with 
continuous FTND as 
dependent variable 
 
0.5505 < 0.0001 0.0866, sig interaction 
observed between FTND 
and GEN 
#cig/day + GEN Linear regression on 
avg log NH with 
continuous #cig/day 
as dependent 
variable 
 
0.5639 < 0.0001 0.0449, no interaction 
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Figure 5-21:  Linear regression of #of cigarettes smoked per day vs. individual log NH.  
Dotted lines represent 95% confidence bounds (R2 = 0.5016, log NH = 0.0443 #cig/day 
+ 1.2). 
 
In this model, gender or the gender:cigarettes/day interaction was not significant and 
was not implemented into the model.   Approximately 50.2% of the variability 
associated with individual log NH plasma concentration can be explained by the 
average number of cigarettes smoked per day.  Every 1 cigarette smoked on average 
results in an increase in average log NH concentration of 0.044.  
 Upon comparison of all models for log NH, smoking status was able to and 
FTND were able to explain 49.7% and 44.2% of the variability associated with 
individual log NH concentrations, while the # of cigarettes smoked per day design 
variable was able to explain a slightly higher percentage of 50.2%. 
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 Further evaluation of fitting the model to average log NH concentrations as a 
function of number of cigarettes smoked per day resulted in a superior fit (p-value < 
0.0001, R2 = 0.5639).   Approximately 56.4% of the variability associated with average 
log NH concentrations could be explained by the average number of cigarettes smoked 
per day.  This improvement of fit was expected as the factor of intra-subject variability 
is stabilized upon averaging, decreasing the variability associated with the linear 
regression fit. 
 According to the exploratory analyses, for both log H and log NH, the number 
of cigarettes smoked per day would be a better predictor of β-carboline exposure as 
opposed to smoking status.  Further studies implementing the number of cigarette 
smoked per day as a design factor would be needed for further evaluation the 
association with log H and log NH.    Smoking status, the FTND measurement and the 
average number of cigarettes smoked per day were better predictors for log NH 
measurement than log H.    This may be due to the fact that norharman concentrations in 
dry weight of tobacco are two-fold higher than that of harman (Pfau and Skog, 2004).  
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5.4.2d β-carbolines – Covariate Analysis 
 Information including alcohol intake and weekly exposure to dietary total H and 
NH was recorded to evaluate for their effects on circulating levels of H and NH.     As 
dietary intake of ethanol and/or β-carboline containing foods may affect the overall 
exposure, this covariate assessments may provide information into the variability 
associated with the plasma measurement log H and/or NH.    If alcohol intake and/or 
dietary exposure were found to significantly correlate with SAL or β-carboline 
exposure, AAI or Food Intake was considered a significant covariate and implemented 
into the statistical model. 
 Linear regressions were performed on log H and log NH as a function of mg of 
annual absolute ethanol (AAI) or average weekly dietary H or NH (Food Inventory) 
intake.   If the regression was significant (p-value < 0.05) with a coefficient of 
determination of > 0.2, the variable of interest was considered a significant covariate, in 
which it was implemented into the model.  Of note the covariate analysis was 
incorporated into the model fit for the original factors smoking status and gender.     
Evaluation of the significance of the covariate was additionally assessed upon 
implementation into the final ANCOVA model.  The p-value was evaluated for 
significance of the covariate.  If considered significant, the fit of the entire model was 
evaluated for goodness of fit, with use of the covariate.      
 A table summarizing the covariate regression analysis for AAI and dietary 
intake is shown below.   
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Table 5-10:  Covariate analysis results for log H and log NH 
 
variable Log harman Log norharman 
R2 0.0091 R2 0.1514 
p-value 0.3741 p-value 0.0003 
AAI 
(mg 
ethanol/annum) significance NS significance YES 
R2 0.0281 R2 0.0215 
p-value 0.1330 p-value 0.1302 
Weekly 
Dietary intake 
(ng/H or ng/NH) significance NS significance NS 
 
 
 The covariate analysis revealed that a poor association was observed between 
weekly dietary intake of H and NH to circulating concentrations, which was 
unexpected.  Several reasons, including the use of a non-validated measure of dietary H 
and NH intake, may explain this discrepancy.    As H and NH are present in various 
sources of foods in relatively large amounts, it was expected that influence of dietary 
consumption of H and NH would contribute to the circulating plasma concentrations.    
Formal assessment of pharmacokinetics has not been performed on the influence of 
circulating H and NH on acute exposure to a food source rich in β-carbolines.  The 
results of this covariate analysis suggest that the weekly average intake of H and NH do 
not influence circulating levels.     Implementation of the dietary H and NH intake was 
subsequently incorporated into the ANCOVA model and was found to be not significant 
for either analyte (H:  p-value = 0.19, NH: p-value = 0.18). 
 Annual absolute alcohol did not have a significant effect on circulating H 
concentrations.   The association between this alcohol intake measurement to log H was 
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inferior (R2 = 0.0091) to that of the food inventory (R2 = 0.0281).   Upon incorporation 
of AAI into the ANCOVA statistical model for log H, significance of mg of ethanol per 
annum was not considered a significant covariate (p-value = 0.21).   In the case of 
circulating NH, a statistically significant (p-value < 0.001) effect of AAI was apparent 
with the mg of ethanol consumed per annum explaining 15.1% of the variability 
associated with log NH concentrations.  Upon incorporation of AAI into the ANCOVA 
statistical model for log NH, significance of mg of ethanol per annum was not 
considered a significant covariate (p-value = 0.38).  
 Use of the AAI or Food Intake as a covariate was not significant and was not 
implemented into the full model.   Of note, AAI may be a confounding variable that 
shows a strong relationship with smoking status (see table 5-3).  ANOVA analysis 
found a significant relation between AAI and smoking status (p-value < 0.01), 
suggesting that the smoking status factor and AAI are considered to be collinear.  
Therefore the AAI should not be considered a covariate because of its correlation with 
smoking status. 
 
5.4.3   Primary Analysis for TIQ’s and DA – Effects of Smoking and Gender 
5.4.3a R/S-SAL and DA – Within Subject Variability 
 Before appropriate statistical comparison of R-SAL, S-SAL and DA for the 
smoking and gender factors, within subject variability of both TIQ’s and DA for each 
individual was evaluated.  This analysis was performed to evaluate the baseline 
concentration of R-SAL, S-SAL and DA over two observational time points.  The intra-
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subject variability (%COV and inter-quartile ranges) for R-SAL, S-SAL and the DA 
precursor may be seen in the tables 5-11, 5-12 and 5-13 below.   
 For R-SAL and S-SAL concentrations, it can be noted that the variability 
between sampling occasions ranged from a %COV 0.0 to 1745% for S-SAL and %COV 
0.0 to 4473% for R-SAL, suggesting that baseline concentrations of the TIQ analytes 
vary considerably between occasions.  The within-subject variability associated with the 
DA measurements was more consistent, as compared to the SAL analytes, with intra-
subject %COV ranging from 3.8 – 159%.   
 For non-smokers %COV ranged from 0.0 – 1272% for S-SAL, 12.2 – 1352% 
for R-SAL and 2.5 – 159% for DA.   Presumably, these persons have not been 
exogenously exposed to SAL enantiomers recently, inferring that other factors, other 
than smoking status or gender may contribute to the varying baseline between 
occasions.    Of note, DA concentrations showed less intra-subject variability between 
occasions than that of the TIQ’s.   Results are suggestive that DA concentrations are 
less variable compared to the SAL enantiomers between sampling occasions.  
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Table 5-11:  Within Subject Variability for Plasma S-SAL (pg/ml) 
Sample # GEN S-SAL avg stdev %COV median 25% IQR 75% IQR
Nonsmokers
1 F 66 22 33 66 58 73
2 F 860 593 69 441 231 650
3 F 183 43 24 153 137 168
4 F 25 1 3 25 24 25
5 F 160 47 29 193 177 210
6 F 13 14 109 23 18 28
7 F 16 0 0 16 16 16
8 F 23 19 83 37 30 43
9 F 98 264 269 285 191 378
10 F 17 216 1273 170 94 247
11 M 359 240 67 190 105 274
12 M 75 36 48 50 37 62
13 M 56 8 14 51 48 53
14 M 54 8 16 48 45 51
15 M 57 13 24 48 43 52
16 M 42 17 40 30 24 36
17 M 91 43 47 61 45 76
18 M 67 182 272 196 132 261
19 M 50 14 28 60 55 65
Light Smokers
21 F 18 14 79 28 23 33
22 F 306 194 64 169 100 237
23 F 25 16 65 37 31 42
24 F 47 14 30 37 32 42
25 F 36 51 141 72 54 90
26 F 808 281 35 609 510 709
31 M 448 209 47 300 226 374
32 M 236 98 42 306 271 340
33 M 134 49 36 100 82 117
34 M 1188 684 58 705 463 946
35 M 230 991 431 931 581 1282
Heavy Smokers
41 F 66 16 24 77 72 83
42 F 1238 238 19 1070 986 1154
43 F 49 18 36 62 55 68
44 F 866 3690 426 3475 2171 4780
45 F 602 190 31 468 401 535
46 F 761 325 43 531 416 646
51 M 43 47 110 77 60 93
52 M 25 1 3 26 25 26
53 M 1210 752 62 679 413 944
54 M 2438 113 5 2518 2478 2558
55 M 90 1571 1746 1201 646 1757  
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Table 5-12:  Within Subject Variability for Plasma R-SAL (pg/ml) 
Sample # GEN R-SAL avg stdev %COV median 25% IQR 75% IQR
Nonsmokers
1 F 68 42 62 68 53 83
2 F 1210 837 69 619 323 914
3 F 222 48 22 188 171 205
4 F 21 5 24 18 16 19
5 F 286 75 26 339 313 366
6 F 17 22 129 33 25 40
7 F 13 6 49 9 6 11
8 F 32 20 62 46 39 53
9 F 100 384 384 372 236 507
10 F 24 325 1352 254 139 368
11 M 507 344 68 264 142 385
12 M 86 47 54 53 37 70
13 M 45 18 39 33 26 39
14 M 60 10 16 53 50 57
15 M 64 8 12 70 67 72
16 M 46 23 49 30 22 38
17 M 93 31 33 71 60 82
18 M 105 105 100 179 142 216
19 M 35 8 24 29 26 32
Light Smokers
21 F 12 16 136 24 18 29
22 F 386 247 64 211 124 299
23 F 25 17 68 37 31 43
24 F 24 5 21 28 26 29
25 F 23 1029 4473 751 387 1114
26 F 1094 386 35 821 685 958
31 M 772 419 54 476 328 624
32 M 285 226 79 445 365 525
33 M 186 90 48 123 91 154
34 M 1304 716 55 798 544 1051
35 M 266 73 27 318 292 343
Heavy Smokers
41 F 87 10 11 94 91 98
42 F 2864 1213 42 2006 1577 2435
43 F 50 15 30 61 55 66
44 F 1102 4675 424 4408 2755 6061
45 F 671 176 26 547 484 609
46 F 771 471 61 438 272 605
51 M 42 0 0 42 42 42
52 M 25 7 28 30 28 33
53 M 1450 865 60 838 532 1144
54 M 4308 186 4 4177 4111 4242
55 M 87 2337 2686 1740 913 2566  
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Table 5-13:  Within Subject Variability for Plasma DA (ng/ml) 
Sample # GEN DA avg stdev %COV median 25% IQR 75% IQR
Nonsmokers
1 F 10.3 6.4 62.1 10.3 8.0 12.5
2 F 9.4 3.6 37.8 6.9 5.6 8.2
3 F 13.7 1.2 8.6 12.8 12.4 13.3
4 F 5.7 0.5 8.3 6.1 5.9 6.2
5 F 6.6 5.4 82.5 10.4 8.5 12.3
6 F 2.3 0.6 25.9 1.9 1.7 2.1
7 F 4.6 0.8 17.3 5.1 4.8 5.4
8 F 3.2 0.7 21.9 2.7 2.4 2.9
9 F 3.7 1.2 31.2 2.9 2.5 3.3
10 F 5.1 0.4 8.5 4.8 4.6 4.9
11 M 9.1 2.3 25.5 7.5 6.6 8.3
12 M 13.7 1.1 8.1 14.5 14.1 14.9
13 M 6.3 0.8 12.9 6.9 6.6 7.2
14 M 8.7 2.1 24.7 7.2 6.4 7.9
15 M 8.4 0.2 2.5 8.5 8.4 8.6
16 M 6.0 1.0 17.4 5.2 4.9 5.6
17 M 3.6 3.5 98.0 6.1 4.8 7.3
18 M 5.1 8.1 158.6 10.8 8.0 13.7
19 M 4.0 5.0 124.9 7.5 5.8 9.3
Light Smokers
21 F 11.3 14.7 130.3 21.7 16.5 26.9
22 F 12.9 0.6 4.8 12.4 12.2 12.6
23 F 8.6 1.7 20.2 9.8 9.2 10.4
24 F 4.0 0.9 22.4 4.6 4.3 4.9
25 F 6.8 0.5 7.3 6.5 6.3 6.6
26 F 14.2 4.7 32.7 10.9 9.3 12.6
31 M 9.8 1.5 15.4 8.8 8.2 9.3
32 M 22.7 4.5 19.9 19.5 17.9 21.1
33 M 11.7 9.5 81.0 18.4 15.1 21.8
34 M 9.9 6.8 68.6 5.1 2.7 7.5
35 M 7.0 1.7 23.9 5.9 5.3 6.4
Heavy Smokers
41 F 10.2 5.2 51.3 13.9 12.1 15.8
42 F 22.4 10.8 48.4 30.1 26.2 33.9
43 F 17.8 0.7 3.8 18.2 18.0 18.5
44 F 30.7 2.1 6.7 32.2 31.4 32.9
45 F 27.8 9.8 35.3 20.9 17.4 24.4
46 F 9.8 4.2 42.5 12.7 11.3 14.2
51 M 17.6 2.1 12.0 16.1 15.3 16.8
52 M 9.1 1.4 15.1 8.1 7.6 8.6
53 M 7.4 0.6 8.3 6.9 6.7 7.1
54 M 14.3 6.8 47.7 9.5 7.1 11.9
55 M 9.3 3.7 39.6 11.9 10.6 13.2  
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For the LS population, %COV 30.1 – 430% for S-SAL, 20.6 – 4473% for R-SAL and 
4.8 – 130.3% for DA were observed, while the HS population possessed a  %COV 
range of 2.8 – 1745% for S-SAL, 0.0 – 2686% for R-SAL, and 3.8 – 48% for DA.  The 
large variability between occasions observed within the smoking status populations are 
speculated to be due to the different times of sampling with respect to cigarette 
smoking.     
 Of important note, SAL enantiomers and DA are not found in tobacco.  The 
exposure of SAL is hypothesized to occur from the endogenous biosynthesis of SAL 
from the acetaldehyde from cigarette smoke and endogenous circulating DA.  In-vivo 
condensation reaction rates have not been characterized, but may contribute to the wide 
intra-subject variability observed within the smoking groups. Although each subject 
was sampled within 30 minutes of smoking, the sampling times varied considerably 
within this time frame for each subject.  It is important to comment that DA 
concentrations within HS individuals were more stable than LS and NS. 
 Both genders possessed the similar amount of within subject variability with 
males possessing a %COV 2.8 – 1745% for S-SAL, 0.0 – 2686% for R-SAL and 2.5 – 
158% for DA were observed, while in the female counterparts, a  %COV 0.0 – 1272% 
for S-SAL, 11.4 – 4473% for R-SAL and 3.8 – 130% for DA were observed.   As large 
within-subject variability was observed with majority of the subjects, individual subject 
concentrations were used, as opposed to average subject concentrations for providing 
descriptive statistics of the overall measure of central tendency and variability.    This 
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was to ensure that the intra-subject variability was not masked during descriptive and 
inferential statistical analysis. 
 Tables 5-14, 5-15 and 5-16 show the descriptive statistics for the concentrations 
S-SAL, R-SAL and DA observed for each smoking status and gender.  Measures of 
central tendency, such as mean and median, along with the variability including %COV 
and range is presented for each factor.  Of note the distribution for the number of 
subjects are unbalanced with respect to smoking status and gender within each group.  
The distribution of gender and smoking status for subjects who completed the protocol 
is the same to that of the β-carbolines.   
 
 
Table 5-14: Descriptive statistics for S-SAL concentrations (pg/ml) divided into 
smoking status and gender. 
 
S-SAL
Mean 365
Stdev 935
%COV 256
Median 78
MIN 13
MAX 6084
Mean 399
Stdev 705
%COV 177
Median 83
MIN 18
MAX 2598
Mean 381
Stdev 831
%COV 218
Median 78
MIN 13
MAX 6084
Non-smoker Light-smoker Heavy-smoker GRAND
   
 F
em
al
e
141 159 947
208 240 1665
148 152 176
50 43 468
13 18 49
860 808 6084
   
   
M
al
e
81 468 900
97 519 1128
119 111 125
52 233 129
18 65 25
359 1632 2598
   
 G
R
A
N
D
113 299 926
166 413 1414
147 138 153
50 143 318
13 18 25
860 1632 6084  
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Table 5-15: Descriptive statistics for R-SAL concentrations (pg/ml) divided into 
smoking status and gender. 
 
R-SAL
Mean 517
Stdev 1239
%COV 240
Median 93
MIN 4
MAX 7714
Mean 514
Stdev 1066
%COV 207
Median 87
MIN 14
MAX 4308
Mean 515
Stdev 1155
%COV 224
Median 87
MIN 4
MAX 7714
Non-smoker Light-smoker Heavy-smoker GRAND
   
 F
em
al
e
194 312 1259
299 493 2184
154 158 174
54 36 547
4 12 50
1210 1478 7714
   
   
M
al
e
87 432 1365
118 371 1824
136 86 134
48 288 157
14 59 25
507 1304 4308
   
 G
R
A
N
D
143 366 1307
235 436 1982
164 119 152
49 226 324
4 12 25
1210 1478 7714  
 
Table 5-16: Descriptive statistics for DA concentrations (ng/ml) divided into smoking 
status and gender. 
 
DA
Mean 11.7
Stdev 9.1
%COV 77.6
Median 9.6
MIN 1.5
MAX 37.7
Mean 9.7
Stdev 5.3
%COV 54.7
Median 8.6
MIN 0.3
MAX 25.2
Mean 10.8
Stdev 7.6
%COV 70.4
Median 8.7
MIN 0.3
MAX 37.7
Non-smoker Light-smoker Heavy-smoker GRAND
   
 F
em
al
e
6.4 11.0 21.3
4.2 7.4 9.2
65.8 67.3 43.1
5.4 9.8 18.2
1.5 4.0 9.8
14.8 32.1 37.7
   
   
M
al
e
8.2 11.5 10.5
3.8 7.8 4.4
46.0 67.6 41.7
7.9 9.9 9.2
3.6 0.3 4.7
16.6 25.2 17.6
   
 G
R
A
N
D
7.3 11.2 16.4
4.1 7.4 9.1
56.0 65.9 55.5
5.9 9.9 14.6
1.5 0.3 4.7
16.6 32.1 37.7  
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 The overall average (mean and %COV), across all patients for S-SAL, R-SAL 
and DA were 380.8 (218.3%), 515.4 pg/ml (224.1%) and 10.8 ng/ml (70.4%) 
suggesting that the plasma SAL and DA concentrations are quite variable between all 
patients. The significant differences between the median and mean R/S-SAL and DA 
concentrations suggest that the data follow non-normal distribution.    Upon comparison 
of the median concentrations, females were observed to have a median S-SAL 
concentration of 77.5 pg/ml, while the median R-SAL concentration was 92.5 pg/ml.  
Their male counterparts had similar median S-SAL concentration of 82.5 pg/ml and a 
median R-SAL concentration of 86.5 pg/ml.   Median DA concentrations were similar 
between genders with similar ranges. 
 With respect to smoking status, the NS median S-SAL concentration was 50.0 
pg/ml while the median R-SAL concentration was 48.5 pg/ml.  LS possessed a higher 
median S-SAL concentration of 143 pg/ml while the median R-SAL concentration was 
226.0 pg/ml.  The HS group resulted in a median S-SAL concentration of 317.5 pg/ml 
while the median R-SAL concentration was 324.0 pg/ml.  Median DA concentrations of 
female NS, LS and HS were 5.4, 9.8 and 18.2 ng/ml, respectively while males within 
NS, LS and HS groups had median DA concentrations of 7.9, 9.9, and 9.2 ng/ml. 
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5.4.3b  TIQ’s and DA – Primary factors of Smoking and Gender Analysis 
 
 The distribution of the data within each smoking group for R-SAL, S-SAL and 
DA followed a non-normal distribution upon assessment of quantile-quantile (Q-Q) 
plots.   Divergence among the median and mean concentrations within each group also 
exemplified the non-normality of the distribution, with the Shapiro-Wilk test resulting 
in p-values all less than 0.048 for R/S-SAL and DA analytes across all groups, 
suggesting that the data was non-normally distributed.  Moreover, unequal variance was 
present with the data upon visual inspection of the residuals.    For these reasons, log-
transformed data were used for the primary analysis.  
 Separate evaluation of the effects of smoking status and gender were performed 
on both log S-SAL and log R-SAL concentrations.  Correlation analysis between the 
analytes suggest that the association between the two analytes is very strong (r = 0.954).  
Nevertheless, separate statistical analysis for the two analytes was conducted.   
Moreover, associations between DA and the SAL enantiomers was relatively weak with 
log DA vs. log S-SAL possessing a correlation coefficient of 0.410 and log DA vs. log 
R-SAL was 0.374.   A matrix evaluating the correlation may be seen in figure 5-22 
below. 
 
  Two-way ANOVA was performed on the log transformed R-SAL, S-SAL and 
DA, evaluating the factors of smoking status and gender.  Box-plots exemplifying the 
median and distribution, including outliers for the effects of gender and smoking status 
are presented below for all analytes.  Observation of the box-plots suggest that there is 
no significant difference between gender group while a trend is observed between 
smoking groups, with HS > LS > NS across all analytes. 
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Figure 5-22:  Correlation between log R-SAL vs. log S-SAL (r = 0.954), log DA vs. S-
SAL (r = 0.410) and log DA vs. R-SAL (r =0.374).   
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 Two-way ANOVA was performed to evaluate the effects of gender and smoking 
on log S-SAL concentrations.   A significant effect of smoking status (SS) was observed 
with respect to log S-SAL concentrations with F (2, 75) = 15.5, p-value = 1.2 x 10-6.   
The effect of gender (GEN) was not significant with the test statistic resulting in F (1, 
75) = 0.57, p-value = 0.45.    No interaction between the SS and GEN factors was 
observed (F (2, 75) = 2.99, p-value = 0.054).  Therefore, linear contrasts were 
unnecessary. An effect of sampling visit was not observed (p-value = 0.89).   The 
coefficient of determination (R2) for the entire model was 0.192 (p-value = 0.008).  The 
factors of SS and GEN account for approximately 19.2% of the variability associated 
with the log S-SAL concentration.   
 The Scheffé method for multiple comparisons found that the primary differences 
were observed between the HS and NS groups as well as the LS and NS groups.   Via 
this comparison, a significant difference in S-SAL was not observed between the HS 
and LS smoking status groups.    The full two-way ANOVA output for Log S-SAL may 
be seen in the figure below along with the residual plot of the model fit.   Upon visual 
evaluation, the residuals show an even spread of the distribution of data suggesting the 
lack of unequal variance. 
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*** Analysis of Variance Model *** 
 
Short Output: 
Call: 
   aov(formula = log.S.SAL ~ SS + GEN + SS:GEN, data =  
 SAL.BC..Final.Bioanalysis.Data.VCU.Smoking.032608, na.action =  
 na.exclude) 
 
 
Response: LOG S-SAL 
 
           Df Sum of Sq  Mean Sq  F Value     Pr(F)  
       SS   2   7.89131 3.945656 15.52240 0.0000012 
      GEN   1   0.14529 0.145293  0.57159 0.4512744 
    visit   1   0.00779 0.007790 0.017859 0.8940485 
   SS:GEN   2   1.52140 0.760699  2.99263 0.0543319 
 Residuals 75  32.71512 0.436202      
 
 
Multiple R-Squared: 0.1921  
F-statistic: 3.402 on 5 and 76 degrees of freedom, the p-value is 0.007939  
 
 
95 % simultaneous confidence intervals for specified  
linear combinations, by the Scheffé method  
 
critical point: 2.8393  
response variable: log.S.SAL  
rank used for Scheffé method: 3  
 
intervals excluding 0 are flagged by '****'  
 
      Estimate Std.Error Lower Bound Upper Bound       
HS-LS    0.267     0.128     -0.0969       0.632      
HS-NS    0.623     0.116      0.2930       0.952 **** 
LS-NS    0.355     0.116      0.0252       0.685 **** 
 
 
 
Figure 5-26:  Two-way ANOVA output, with multiple comparisons, for the effects of 
SS and GEN on Log S-SAL plasma concentrations. 
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  Figure 5-27:  Residual plot for two-way ANOVA fit for Log S-SAL. 
 
 
 
 
 
 
 
 
 
 
309 
 With respect to R-SAL, two-way ANOVA was performed to evaluate the effects 
of gender and smoking.   A significant effect of smoking status was observed with 
respect to log R-SAL concentrations with F (2, 75) = 13.9, p-value = 0.4 x 10-6.   The 
effect of gender (GEN) was not significant with the test statistic resulting in F (1, 75) = 
0.052, p-value = 0.819.    No interaction between the SS and GEN factors was observed 
(F (2, 75) = 2.05, p-value = 0.113).  The coefficient of determination (R2) for the entire 
model was 0.271 (p-value = 1.8 x 10-5).  The factors of SS and GEN account for 
approximately 27.1% of the variability associated with the R-SAL concentration 
measurements.   
 The Scheffé method for multiple comparisons found that the primary differences 
were observed between the HS and NS groups as well as the LS and NS groups.   Via 
this comparison, a significant difference in R-SAL was not observed between the HS 
and LS smoking status groups.     
 The full two-way ANOVA output for log R-SAL may be seen in the figure 
below along with the residual plot of the model fit.   Upon visual evaluation, the 
residuals show an even spread of the distribution of data suggesting the lack of unequal 
variance. 
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*** Analysis of Variance Model *** 
 
Short Output: 
Call: 
   aov(formula = log.R.SAL ~ SS + GEN + visit + SS:GEN, data =  
 SAL.BC..Final.Bioanalysis.Data.VCU.Smoking.032908, na.action =  
 na.exclude) 
 
 
 
Response: LOG R-SAL 
 
         Df Sum of Sq  Mean Sq  F Value     Pr(F)  
       SS   2   9.62605 4.813024 13.97085 0.0000040 
      GEN   1   0.01798 0.017981  0.05219 0.8197207 
    visit   1   0.00047 0.000468 0.000777 0.9778414 
   SS:GEN   2   1.41383 0.706913  2.05197 0.1334615 
Residuals  75  37.20651 0.344505                    
 
 
 
Multiple R-Squared: 0.2571  
F-statistic: 9.156 on 3 and 75 degrees of freedom, the p-value is 0.00001845  
 
 
95 % simultaneous confidence intervals for specified  
linear combinations, by the Scheffé method  
 
critical point: 2.8401  
response variable: log.R.SAL  
rank used for Scheffé method: 3  
 
intervals excluding 0 are flagged by '****'  
 
      Estimate Std.Error Lower Bound Upper Bound       
HS-LS    0.233     0.147     -0.1840       0.650      
HS-NS    0.676     0.133      0.2990       1.050 **** 
LS-NS    0.443     0.133      0.0656       0.821 **** 
 
 
 
Figure 5-28:  Two-way ANOVA output, with multiple comparisons, for the effects of 
SS and GEN on Log R-SAL plasma concentrations. 
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  Figure 5-29:  Residual plot for two-way ANOVA fit for Log R-SAL. 
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 For DA, a significant effect of smoking status was observed with F (2, 75) = 
5.89, p-value = 0.004.    The effect of gender (GEN) was not significant with the test 
statistic resulting in F (1, 75) = 0.199, p-value = 0.656.   A significant interaction 
between the SS and GEN factors was observed (F (2, 75) = 7.21, p-value = 0.021).  
Further linear contrasts with respect to the interaction were performed as the 
interpretability of the main effects were confounded by the interaction.  Upon linear 
contrasts, it was observed that a significant effect for smoking status was observed 
between the NS females and HS females.  For the most part, a significant effect of 
smoking status was not seen in the male groups.  The coefficient of determination (R2) 
for the entire model was 0.265 (p-value = 2.2 x 10-4).  The factors of SS and GEN, 
including the interaction, account for approximately 26.5% of the variability associated 
with the log DA concentration measurements.  The Scheffé method for multiple 
comparisons across smoking status found that the primary differences were observed 
between the HS and NS groups.    
 The full two-way ANOVA output for log DA may be seen in the figure below 
along with the residual plot of the model fit.   Upon visual evaluation, the residuals 
show an even spread of the distribution of data suggesting the lack of unequal variance. 
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*** Analysis of Variance Model *** 
 
Short Output: 
Call: 
   aov(formula = log.DA ~ SS + GEN + visit + SS:GEN, data =  
 SAL.BC..Final.Bioanalysis.Data.VCU.Smoking.032908, na.action =  
 na.exclude) 
 
 
          Df Sum of Sq   Mean Sq  F Value     Pr(F)  
       SS  2  1.165686 0.5828430 5.897008 0.0041824 
      GEN  1  0.019696 0.0196963 0.199280 0.6565887 
    visit  1  0.000109 0.0001090 0.001103 0.9735986 
   SS:GEN  2  1.426734 0.7133668 7.217604 0.0213590 
Residuals 75  7.412780 0.0988371                    
 
                   
R-Squared:  0.2656  
F-statistic: 5.277 on 2 and 75 degrees of freedom, the p-value is 0.0002244 
 
95 % simultaneous confidence intervals for specified  
linear combinations, by the Scheffé method  
 
critical point: 2.86  
response variable: log.DA  
rank used for Scheffé method: 3  
 
intervals excluding 0 are flagged by '****'  
 
      Estimate Std.Error Lower Bound Upper Bound       
HS-LS   0.1980    0.0952     -0.0742       0.470      
HS-NS   0.2650    0.0845      0.0238       0.507 **** 
LS-NS   0.0674    0.0845     -0.1740       0.309      
 
 
 
 
Figure 5-30:  Two-way ANOVA output, with multiple comparisons, for the effects of 
SS and GEN on Log DA plasma concentrations.  
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 Figure 5-31:  Residual plot for two-way ANOVA fit for Log DA. 
 
 A significant effect of smoking status was observed for log S-SAL, log R-SAL 
and log DA plasma concentrations.   A statistically significant effect of gender was not 
observed in the exposure of log S- or R-SAL and an interaction between the factors was 
not observed for either analyte.   A gender:smoking status interaction was observed with 
the log DA concentrations.  
 According to the two-way ANOVA, the following ranking was observed with 
plasma S-SAL concentrations (geometric means) across smoking groups and gender.  
NS F < NS M < LS F < LS M < HS M < HS F.   The post-hoc multiple comparisons via 
Scheffé test showed that the major difference that was observed with the smoking 
groups were the HS – NS group and the LS – NS groups with no significant difference 
being observed between the two smoking groups of LS and HS.  
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Figure 5-32:  Log S-SAL as function of smoking status and gender (mean ± SD). 
 
1
1.5
2
2.5
3
3.5
NS LS HS
smoking status
lo
g 
S-
SA
L
     
Figure 5-33:  Log S-SAL as function of smoking status (mean ± SD).  Statistically 
significant results observed between NS-LS and NS-HS groups. 
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Both HS and LS groups possessed larger means than NS.  On average, the HS group 
had a larger mean than that of the LS groups for log S-SAL, but the difference was not 
statistically significant. 
 ANOVA results assigned the following rank with respect to observed plasma R-
SAL concentrations across smoking groups and gender:  NS M < NS F < LS F < LS M 
< HS F < HS M.   The post-hoc multiple comparisons via Scheffé test showed that the 
major difference that was observed with the smoking groups were the HS – NS group 
and the LS – NS groups.  A statistically significant difference was not observed 
between the two smoking groups of LS and HS.     On average, across smoking groups, 
the HS group > LS group > NS group for log R-SAL.  See figures below.  
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          Figure 5-34:  Log R-SAL as function of smoking status and gender (mean ± SD). 
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 Figure 5-35:  Log R-SAL as function of smoking status (mean ± SD).   
 Statistically significant results observed between NS-LS and NS-HS groups. 
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 ANOVA results assigned the following rank with respect to observed plasma 
log DA concentrations across smoking groups and gender:   NS F < NS M < LS M < 
HS M < LS M < HS F.   The post-hoc multiple comparisons via Scheffé test showed 
that the major difference that was observed with the smoking groups were the HS – NS 
group.  A statistically significant difference was not observed between the NS and LS or 
the two smoking groups of LS and HS.     On average, across smoking groups, the HS 
group > LS group > NS group for log DA.  See figures below.       
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 Figure 5-36:  Log DA as function of smoking status and gender (mean ± SD). 
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 Figure 5-37:  Log DA as function of smoking status (mean ± SD).  Statistically 
 significant results observed between NS-HS. 
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 With respect to R and S-SAL, LS and HS smoking status groups were 
significantly different from NS..  Within the LS and HS groups, males possessed 
slightly higher R-SAL and S-SAL concentrations than females (not significant), but the 
incongruity was reversed in the case of the NS groups, with females resulting in larger 
SAL concentrations.    Interestingly, a trend was observed with log DA, in which the 
trend in observed means between the smoking status groups was NS < LS < HS.  DA 
concentrations were not statistically different from one another between genders.   
 For both SAL enantiomers an increase of log TIQ concentration was observed 
with the level of smoking status.    This is presumed to be due to an acute effect of 
inhalation of aldehydes from the cigarette smoke.   SAL enantiomers are not present in 
dry cigarette tobacco, but may form from pyrrolysis of tobacco and inhaled upon 
smoking.  Acetaldehyde is a known component of cigarette tobacco that may be inhaled 
upon cigarette smoke exposure, thereby non-enzymatically condensing with 
endogenous circulating DA to form the SAL enantiomers.   Of note, R and S-SAL 
enantiomers were present in similar concentrations within the plasma of nonsmokers 
and smokers.    Therefore, mechanistic differences between the SAL enantiomers 
cannot be interpreted from the design of this clinical study 
 Of interesting note, a trend was observed with plasma DA concentrations in 
which smokers on average, possessed higher concentrations than nonsmokers.    DA is 
not known to be present in tobacco or tobacco smoke.    The trend observed in DA 
concentrations may be a physiological difference between smokers and non-smokers, 
due to different peripheral and central MAO activity between nonsmokers and smokers.   
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It is known that smoking a cigarette increases DA within the nucleus accumbens in the 
CNS, but the peripheral concentrations after acute cigarette smoke exposure have been 
less thoroughly evaluated.    An investigation evaluated the combined impact of 
smoking and stress on catecholaminergic and cardiovascular reactivity in disease-free 
adult smokers (Robinson and Cinciripini, 2006).   The authors propose that ad-lib 
smoking increases catecholamine and cardiovascular response to stress in smokers.    
All of these reasons may explain the trend of plasma DA observed within this study.  
 
5.4.3c  TIQ’s and DA – Exploratory Analysis 
 A statistically significant effect of smoking status was observed on log R-SAL, 
log S-SAL and log DA plasma concentrations.   To further elucidate the variability 
associated with R/S-SAL and DA exposure, the criteria of FTND and number of 
cigarettes smoked per day were analyzed as continuous dependent variables to explain 
the individual subjects’ exposures.   As in the case of the β-carbolines, FTND and the 
number of cigarettes smoked per day were replaced by the SS category for the ANOVA 
analysis for SAL enantiomers and DA.    The individual concentrations for each subject 
were used to assess the association between FTND and number of cigarettes and the 
analyte concentrations in order to represent the intra-subject variability for the log R-
SAL, log S-SAL, and log DA in the analysis.     
 The tables below summarize the regression analysis for all three analytes using 
different explanatory variables for the dependent variable.  For reference, results of the 
primary analysis using smoking status and gender for the model fit are supplied.  As 
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FTND and the number of cigarettes smoked per day are measures of nicotine 
dependence that were not expected to change between sampling periods, intra-subject 
average log R-SAL, S-SAL and DA concentrations were also explored for an 
association.   
 All model fits were statistically significant on the individual log S-SAL 
concentrations incorporating the use of the FTND and number of cigarettes/day.     The 
use of FTND and number of cigarettes smoked per day in place of smoking status 
resulted in statistically significant fits but yielded an inferior coefficient of 
determinations from the initial model.    In essence, the smoking status + gender factors 
was able to explain more to the variability associated with log S-SAL concentrations 
(19.2%) than its FTND (15.2%) and #cigarettes/day (11.4%) design variables.   
 Upon evaluation of the average log S-SAL concentrations, an improvement was 
observed when the number of cigarettes smoked per day was implemented into the 
model in place of smoking status.  According to this model, gender or the 
gender:cigarettes/day interaction was not significant.   
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Table 5-17:  Explanatory variable model comparison for Log S-SAL.  
Log S-SAL     
Model Description R2 p-value 
Slope (for continuous 
dependent variable) 
and notes 
SS + GEN 
(primary pre-
specified factors) 
Original 2-way 
ANOVA with SS and 
GEN as factors 
 
0.1921 < 0.0001 No interaction 
FTND + GEN 
 
Linear regression 
with continuous 
FTND as dependent 
variable 
 
0.1521 0.004 0.123, sig interaction 
observed between FTND 
and GEN 
#cig/day + GEN Linear regression 
with continuous 
#cig/day as 
dependent variable 
 
0.1143 0.0113 0.024, no interaction, yes 
effect of gender 
 
Avg log S-SAL 
    
FTND + GEN Linear regression on 
avg log S-SAL with 
continuous FTND as 
dependent variable 
 
0.1995 0.0257 0.1149, no sig interaction 
observed between FTND 
and GEN 
No effect of GEN 
#cig/day + GEN Linear regression on 
avg log S-SAL with 
continuous #cig/day 
as dependent variable 
 
0.2544 < 0.01 0.0211, no interaction 
No effect of gender. 
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 With respect to the individual log R-SAL, FTND model fits were not 
statistically significant (all p-values > 0.05).   The results of the model fits are shown in 
the following table.   In this case, the use of the # of cigarettes smoked per day was a 
more inferior predictor of individual log R-SAL concentrations than smoking status 
possessing a R2 of > 0.061.  In other words, the # of cigarettes smoked per day was only 
able to explain 6.1% of the variability associated with the log R-SAL concentrations as 
opposed to the smoking status, which explained 25.7%.  Replacement of the smoking 
status factor with FTND did show statistically significant results (p-value= 0.01, R2 = 
0.101), suggesting that FTND is a poorer predictor of log R-SAL than the other 
smoking design variables.    
 Upon assessment of the average log R-SAL concentrations, a statistically 
significant effect of number of cigarettes smoked per day was observed.   However, the 
variability that could be accounted for by this model was approximately 21%, which is 
inferior to the original smoking status model.      
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Table 5-18:  Explanatory variable model comparison for Log R-SAL.  
Log R-SAL     
Model Description R2 p-value 
Slope (for continuous 
dependent variable) 
and notes 
SS + GEN 
(primary pre-
specified factors) 
Original 2-way 
ANOVA with SS 
and GEN as factors 
 
0.2571 < 0.0001 No interaction 
FTND + GEN 
 
Linear regression 
with continuous 
FTND as dependent 
variable 
 
0.1016 0.013 0.122, sig interaction 
observed between FTND 
and GEN 
#cig/day + GEN Linear regression 
with continuous 
#cig/day as 
dependent variable 
 
0.0661 0.045 0.0215, no interaction 
 
Avg log R-SAL 
    
FTND + GEN Linear regression on 
avg log R-SAL with 
continuous FTND as 
dependent variable 
 
NS NS NS, sig interaction 
observed between FTND 
and GEN 
#cig/day + GEN Linear regression on 
avg log R-SAL with 
continuous #cig/day 
as dependent 
variable 
 
0.2191 < 0.026 0.0186, no interaction 
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 For individual log DA, all model fits were statistically significant with use of the 
FTND and number of cigarettes/day (all p-values < 0.002).   Information obtained from 
the model fits are shown in the following table.  In this case, the use of FTND was a 
slightly better predictor of individual log DA concentrations than smoking status 
possessing a R2 of > 0.288.  In other words, FTND was able to explain 28.8% of the 
variability associated with the log DA concentrations as opposed to the smoking status, 
which explained 26.1%.  Incorporating the number of cigarettes/day into the model 
resulted in an inferior fit compared to that of the smoking status group.     Results of the 
model fits with respect to log DA should be interpreted with caution as significant 
interactions between the gender and FTND factors exist.  
 Upon assessment of the average log DA concentrations, a statistically 
significant effect of number of cigarettes smoked per day and FTND was observed upon 
incorporation into the model.   Replacement of both FTND and number of cigarette per 
day design variables into the model resulted in fits that were able to explain 50.2% and 
41.9% of the variability associated with log DA concentrations.     Of note, in the case 
of FTND, a significant interaction was observed with GEN, hindering interpretability of 
the results. 
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Table 5-19:  Explanatory variable model comparison for Log DA.  
Log DA     
Model Description R2 p-value 
Slope (for continuous 
dependent variable) 
and notes 
SS + GEN 
(primary pre-
specified factors) 
Original 2-way 
ANOVA with SS 
and GEN as factors 
 
0.2606 < 0.0003 Interaction between GEN 
and SS 
FTND + GEN 
 
Linear regression 
with continuous 
FTND as dependent 
variable 
 
0.2888 < 0.0001 0.105, sig interaction 
observed between FTND 
and GEN 
#cig/day + GEN Linear regression 
with continuous 
#cig/day as 
dependent variable 
 
0.2311 < 0.002 0.0205, effect of GEN 
and interaction present 
 
Avg log DA 
    
FTND + GEN Linear regression on 
avg log DA with 
continuous FTND as 
dependent variable 
 
0.5016 < 0.0001 0.1745, sig interaction 
observed between FTND 
and GEN 
#cig/day + GEN Linear regression on 
avg log DA with 
continuous #cig/day 
as dependent 
variable 
 
0.4197 < 0.0002 0.0205, no interaction, no 
effect of gender 
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 According to the exploratory analysis, for both individual log R-SAL and S-
SAL, smoking status resulted in a superior model fit than that of the FTND and number 
of cigarettes smoked per day design variables.    This is suggestive that variability 
associated with the log R- or S-SAL cannot be explained by the design factors 
themselves, but with the overall combination of both, which were used for stratification 
into the smoking status groups.   Although a significant effect of smoking status was 
observed on log DA, similar results were observed upon replacement of the smoking 
status factor with the FTND and number of cigarettes smoked per day design variables.  
A significant interaction of gender was observed with all smoking design factors, 
hindering the statistical inference of the final model results.  
 
5.4.3d TIQ’s and DA – Covariate Analysis 
 As the case for the β-carbolines, information including alcohol intake and 
weekly exposure to dietary total SAL was recorded to evaluate for their effects on 
circulating levels of R-SAL, S-SAL and DA.     As dietary intake of ethanol and/or SAL 
containing foods may affect the overall exposure, this covariate assessments may 
provide information into the variability associated with the plasma measurement log R-
SAL and/or S-SAL.    If alcohol intake and/or dietary exposure were found to 
significantly correlate with SAL exposure, AAI or Food Intake was considered a 
significant covariate and implemented into the statistical model. 
 Linear regressions were performed on log R-SAL, log S-SAL as a function of 
mg of annual absolute ethanol (AAI) or average weekly dietary total SAL (Food 
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Inventory) intake.   Similar criteria aforementioned for the β-carboline covariate 
analysis were used for the SAL and DA analysis.     Evaluation of the significance of 
the covariate was additionally assessed upon implementation into a final ANCOVA 
model.  The p-value was evaluated for significance of the covariate.  If considered 
significant, the fit of the entire model was evaluated for goodness of fit, with use of the 
covariate.   Dietary DA intake was not captured from the study, therefore was not 
computed as a covariate of log DA concentrations.     
 A table summarizing the covariate regression analysis for AAI and dietary 
intake is shown below.   
 
 
Table 5-20:  Covariate analysis results for log R-SAL, log S-SAL and log DA 
 AAI Weekly 
(mg ethanol/ Dietary intake variable annum) (ng SAL) 
NS:   not significant 
N/A: dietary intake of DA was not available   
  
R2 0.0743 R2 0.001 
p-value 0.076 p-value 0.996 Log R-SAL 
significance NS significance NS 
R2 0.0655 R2 0.004 
p-value 0.203 p-value 0.882 Log S-SAL 
significance NS significance NS 
R2 0.0211 R2 N/A 
p-value 0.1925 p-value N/A Log DA 
significance NS significance N/A 
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 The covariate analysis revealed that a poor association was observed between 
weekly dietary intake of total SAL to circulating concentrations.  As SAL enantiomers 
are present in various sources of foods in substantial amounts, it was expected that 
influence of dietary consumption of SAL would contribute to the circulating plasma 
concentrations.    Formal assessment of pharmacokinetics has not been performed on 
the influence of circulating SAL on acute exposure to a food source rich in these 
compounds.  The results of this covariate analysis suggest that the weekly average 
intake of total SAL do not influence circulating levels of R-SAL or S-SAL.     
Implementation of the dietary SAL intake was subsequently incorporated into the 
ANCOVA model and was found to be not significant for either analyte (R-SAL:  p-
value = 0.99, S-SAL: p-value = 0.87). 
 Annual absolute alcohol intake did not have a significant effect on circulating R-
SAL, S-SAL or DA concentrations.  Upon incorporation of AAI into the ANCOVA 
statistical model for log R-SAL, mg of ethanol per annum was not considered a 
significant covariate (p-value = 0.06).   In the case of circulating S-SAL, the AAI 
yielded an insignificant effect as a covariate (p-value = 0.164).  Upon incorporation of 
AAI into the ANCOVA statistical model for log DA, significance of mg of ethanol per 
annum was not considered a significant covariate (p-value = 0.77).   Use of the AAI or 
Food Intake as a covariate was not significant and was not implemented into the full 
statistical model.   ANOVA analysis found a significant relation between AAI and 
smoking status (p-value < 0.01), suggesting that the smoking status factor and AAI are 
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considered to be collinear variables.  Of note, AAI may be a confounding variable that 
shows a strong relationship with smoking status.   
 
5.5 TIQ and β-carbolines – Acute Cigarette Exposure vs. Smoking Abstinence 
 All information presented thus far summarizes TIQ and β-carboline exposure 
information obtained from non-smokers, in addition to light-smokers and heavy 
smokers within thirty-minutes of smoking one complete cigarette.  In essence, the 
presented information compares nonsmokers, who were not exposed to inhaled and 
environmental tobacco smoke to that of light-smokers and heavy smokers who just 
smoked a cigarette.     The significant relationship of smoking status and TIQ and/or β-
carboline exposure observed may be resultant of acute inhalation of tobacco smoke.  To 
further clarify this relationship, a comparison was made to subjects who had abstained 
from smoking for 15 hours prior to plasma sampling of the analytes of interest.   
 In brief, the study design incorporated 18 healthy volunteers (6 NS, 6 LS, and 6 
HS, in which there were 3 males and 3 females in each group).  This study was 
designed to evaluate the effects of intranasal nicotine on neuroendocrine, cognitive and 
behavioral function in healthy, young, nonsmokers and smokers (Leu, 2002).     
Subjects were randomized into one of two sequences based on smoking status such that 
they received intranasal nicotine or placebo.    Prior to treatment administrations during 
each of two visits, subjects provided plasma samples for the analysis of baseline TIQ’s 
and β-carboline exposure.   The volunteers were required to abstain from smoking for 
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15-hours prior to sampling, which was conducted pre-prandially during the inpatient 
visit.    
 Subjects were young and healthy, using the same inclusion/exclusion criteria, 
and more importantly, utilized the same smoking status classification as the study 
aforementioned.    Plasma samples for the evaluation of TIQ’s and β-carboline exposure 
were obtained on two-different visits.    Similar procedures were used for the sampling, 
processing and ultimate analysis of the plasma.  Demographic results of this study may 
be seen in the table 5-21 below.   This study is referred to as abstained smokers (ABST 
SM).  As a comparison was made to the primary investigation, a demographic summary 
of the study is also provided below.  This study is referred to as the recently smoked 
(REC SM) keeping in mind that the NS group did not smoke a cigarette prior to 
biological sampling.   Demographic variables such as age, FTND and number of 
cigarettes smoked per day are reported as mean ± SD. 
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Table 5-21:  Demographic Results of ABST SM study (mean ± SD) 
Smoking 
Status 
Demographic 
variable 
Males Females Overall 
N 3 3 6 
Age 28.0 (2.6) 25.7 (1.5) 26.8 (2.3) 
 
Table 5-22:  Demographic Results of REC SM study (mean ± SD) 
FTND 0 (0) 0 (0) 0 (0) NS 
# Cig/day 0 (0) 0 (0) 0 (0) 
N 3 3 6 
Age 24.3 (4.9) 23.3 (4.9) 23.8 (3.3) 
FTND 2.7 (1.5) 2.0 (1.0) 2.3 (1.0) LS 
# Cig/day 10.8 (3.8) 10.0 (6.1) 14.0 (3.6) 
N 3 3 6 
Age 26.7 (5.7) 24.0 (2.6) 25.3 (4.2) 
FTND 6.0 (2.6) 6.3 (2.5) 6.2 (2.3) HS 
# Cig/day 20.8 (1.4) 22.3 (4.5) 21.2 (4.8) 
Demographic 
variable 
Smoking Status Males Females Overall 
N 9 10 19 
Age 24.9 (2.5) 26.0 (3.1) 25.5 (2.8) 
FTND 0 (0) 0 (0) 0 (0) NS 
# Cig/day 0 (0) 0 (0) 0 (0) 
N 5 6 11 
Age 25.4 (4.1) 23.3 (3.8) 24.3 (3.9) 
FTND 2.4 (2.3) 1.5 (1.4) 1.9 (1.8) LS 
# Cig/day 9.0 (4.8) 8.3 (4.6) 8.6 (4.5) 
N 5 6 11 
Age 25.6 (3.1) 24.7 (4.0) 25.1 (3.5) 
FTND 6.8 (0.8) 5.5 (1.4) 6.1 (1.3) HS 
# Cig/day 17.4 (2.5) 25.8 (4.9) 22.0 (5.8) 
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 With the exception of the number of subjects within each smoking status and 
gender group, the demographics between studies are similar with respect to age, FTND 
and the number of cigarettes smoked per day.   
 As performed in the REC SM study, statistical analysis via two-way ANOVA 
was conducted on the individual concentrations of the β-carbolines, H and NH along 
with the TIQ’s and DA.   Log transformed values were compared evaluating the two 
primary factors of gender and smoking status.   
 Prior to formal analysis, within subject variability was assessed across the two 
sampling periods.  Of note, the variability between occasions for smokers was much 
less in the ABST SM study compared to that of the REC SM study.    For nonsmokers, 
the within-subject variability was similar between studies.  Below is a chart of the 
ranges of within subject variability obtained from both studies reported in ranges of 
COV% across all subjects per study for each analyte.   
 
Table 5-23:   Ranges of Within-Subject Variability of Smokers between both studies
  
Analyte ABST SM REC SM 
Harman 3 – 63 %COV 4 – 760% COV 
Norharman 8 – 54% COV 2 – 112% COV 
S-SAL 2 – 93% COV 3 – 1745% COV 
R-SAL 8 – 82% COV 0 – 2686% COV 
DA 0.5 – 28% COV 3.8 – 130% COV 
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 The large range of the within-subject variability associated with the REC SM 
study suggests that the recent smoking of a cigarette, along with the lack of an 
inconsistent sampling schedule after smoking between sampling occasions, contributes 
to the overall variability associated with the analyte.  The %COV observed in the ABST 
SM study is suggestive of a more stable baseline measurement and less inter-occasion 
variability.   
 Table 5-24 exemplifies the comparison of the two-way ANOVA fits, accounting 
for smoking status and gender between the study in which smokers abstained from 
smoking for 15 hours (ABST SM) and recently smoked smokers (REC SM).    Multiple 
comparison tests were performed on both studies for each log transformed analyte 
concentration and the significant group differences are reported.  Coefficients of 
determination are reported to evaluate the fit of the model between studies.  To further 
support the observations of the model fits, median and ranges are reported in table 5-25 
for both studies, accounting only for smoking status.    An unpaired t-test was 
performed between studies (abstaining vs. smoking) on the average log transformed 
concentrations within each smoking status group. Note, the assumption equal 
variance was violated upon comparison of the smoking status groups between studies.
 As in the case for the primary REC SM study, in which measurements were 
taken within 30 minutes of smoking, a smoking status effect was observed with respect 
to log S-SAL, log R-SAL, and log NH in the ABST SM study (table 5-24).    A 
significant effect of smoking status was not observed for log H and log DA.  A gender 
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effect or a gender – smoking status interaction was not observed with any of the 
analytes.      
 Contrary to the REC SM study, the only observed difference between smoking 
statuses resided between the NS-HS groups for R-SAL and S-SAL.  No observed 
difference was apparent between the HS-LS and, as in the opposite case of the REC SM 
study, the LS-NS groups.    For median R-SAL and S-SAL, a trend was observed in 
which HS > LS > NS.    In the ANOVA model fit smoking status was able to account 
for approximately 33.7% of the variability associated with log S-SAL concentrations 
and 36.0% of the variability of log R-SAL concentrations.   While in the REC SM 
study, only 18.3% and 25.5% of the variability was accounted for by smoking status for 
S-SAL and R-SAL respectively.  This suggests that there exists an inherent constitutive 
difference in R-SAL and S-SAL concentrations between NS and HS, regardless of 
recent smoking.  Upon consuming a cigarette, the difference in concentrations became 
more pronounced with LS-NS groups.  In essence, R-SAL and S-SAL concentrations 
are intrinsically different between smoking status groups and additional smoking makes 
this discrepancy more pronounced.   The incongruity in results between studies suggest 
that the exogenous contribution of these analytes from recent smoking provides 
additional exposure of R-SAL and S-SAL to the LS and HS groups, resulting in an 
overall observed difference between the smoking and nonsmoking groups.  
 With respect to log NH concentrations in the ABST SM study, the observed 
difference between smoking statuses resided both between the NS-HS and NS-LS 
groups.  No observed difference was apparent between the HS-LS as already seen in the 
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REC SM study.    For median NH a trend was observed in which HS > LS > NS.   With 
the ANOVA model fit, smoking status in abstinent smokers was able to account for 
approximately 44.0% of the variability associated with log NH concentrations while 
after smoking 49.7% of the variability associated with log NH concentrations could be 
explained.   This suggests that there exists an inherent constitutive difference in NH 
concentrations between NS-HS and NS-LS groups, regardless of recent smoking.  Upon 
consuming a cigarette, the difference in concentrations became more pronounced 
between both sets of groups, especially the NS-HS difference.  In essence, NH 
concentrations are fundamentally dissimilar between smoking status groups and 
additional smoking makes this discrepancy more pronounced.   As in the case of SAL 
enantiomers, the disparity in observations between studies suggest that the exogenous 
contribution of these analytes from recent smoking provides additional exposure of NH 
to the LS and HS groups, resulting in an overall observed difference between the 
smoking and nonsmoking groups.    This is expected, as NH is present in significant 
concentrations within tobacco.   
 It is of interest that H concentrations did not show a similar trend in the ABST 
SM study and the effect of smoking status was not observed.   This suggests that 
harman differences between smoking status groups is due to the recent exposure of H 
after smoking, as seen in the REC SM study.    For DA, it is apparent that a difference 
in median concentrations between smokers and nonsmokers is present.  Recent smoking 
results in a greater and statistically different difference between HS-NS and LS-NS 
groups.   
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Table 5-24:  Comparison of Two-way ANOVA model fits between ABST SM and 
REC SM study for all analytes.   
 
Analyte Model Factor 
ABST SM Study 
 
REC SM Study 
log S-SAL 
SS 
GEN 
SS:GEN 
R2
difference 
sig (p-value = 0.017) 
NS  
NS 
0.3371 
HS-NS 
sig (p-value < 0.0001) 
NS  
NS 
0.1829 
HS-NS, LS-NS 
log R-SAL 
SS 
GEN 
SS:GEN 
R2
difference 
sig (p-value = 0.008) 
NS  
NS 
0.3602 
HS-NS 
sig (p-value < 0.0001) 
NS  
NS 
0.2556 
HS-NS, LS-NS 
log Harman 
SS 
GEN 
SS:GEN 
R2
difference 
NS 
NS  
NS 
0.2254 
No difference 
sig (p-value < 0.0001) 
NS  
NS 
0.2844 
HS-NS, LS-NS 
log Norharman 
SS 
GEN 
SS:GEN 
R2
difference 
sig (p-value = 0.001) 
NS  
NS 
0.4440 
HS-NS, LS-NS 
sig (p-value < 0.0001) 
NS  
NS 
0.4969 
HS-NS, LS-NS 
log DA 
SS 
GEN 
SS:GEN 
R2
difference 
NS 
NS  
NS 
0.2421 
No difference 
sig (p-value < 0.0002) 
NS  
sig (p-value < 0.05) 
0.2606 
HS-NS, LS-NS 
 
SS:   Smoking status factor 
GEN:   Gender factor 
SS:GEN:   Smoking status : gender interaction 
Sig:  Significant 
Difference:  Observed difference via Scheffé multiple comparison  
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Table 5-25:  Comparison of median (range) between ABST SM and REC SM study for 
all analytes. 
 
Analyte 
Smoking 
status 
ABST SM Study 
median (range) 
NS, LS, HS = 6, 
6, 6 
REC SM Study 
median (range) 
NS, LS, HS = 19, 
11, 11 
significance 
unpaired t-
test* 
(p-value) 
NS 77 (51 – 437) 50 (13 – 860) NS  
LS 175 (40 – 250) 143 (18  – 1632) NS S-SAL 
HS 228 (81  – 693 ) 317 (25  – 6084) < 0.05 
NS 45  (5 – 609) 48 (4  – 1210) NS 
LS 277  (149 – 705) 226  (12  – 1478) NS R-SAL 
HS 547(76 – 1002 ) 324  (2  – 7714) < 0.05 
NS 19 (3  – 56) 12 (1 – 98) NS 
LS 31 (12  – 54) 71 (4 – 172) NS Harman 
HS 29  (5  – 110) 52 (4  – 422) NS 
NS 12 (2 – 65) 17  (2  – 850) NS 
LS 49 (20 – 104 ) 54  (12  – 396) < 0.05 Norharman 
HS 59 (5  – 133) 159 (25 – 410) < 0.05 
NS 2.3 (1.0 – 9.5) 5.9 (1.5 – 17) NS 
LS 5.5 (3.6 – 7.5) 9.9 (0.3 – 32) < 0.05 DA 
HS 5.1 (3.4 – 8.2) 14.6 (4.7 – 37.7) < 0.05 
* unpaired t-test performed on log-analyte concentration between two studies, 
assumption of unequal variance.   
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 The measurements observed in the ABST SM study were presumably due to 
constitutive concentrations with no influence of acute exogenous exposure of cigarette 
smoke.    Having abstained from smoking for 15 hours prior to sampling under fasting 
conditions, the significant effect of smoking status may also be due to accumulation of 
S-SAL, R-SAL and NH in which the analytes reside in the physiological system well 
after exposure to exogenous sources.  In addition, the analytes that were significant with 
respect to smoking status may be an inherent discrepancy between smokers and 
nonsmokers that may be related to the dependence of tobacco smoking itself.    Of 
importance, this study is not designed to test causality between these analytes to 
smoking dependence, but results obtained from the ABST SM study are suggestive of 
inherent differences in endogenous physiological concentrations of S-SAL, R-SAL and 
NH.   
 
5.6 Summary of Clinical Study #1 
 This investigation was designed to test the effects of smoking status and gender 
on plasma concentrations of TIQ’s and β-carbolines in a healthy population.   The study 
utilized a nicotine dependence scale and the number of cigarettes smoked per day in 
order to stratify the subjects into smoking status groups.    Besides the alleged nicotine 
dependence difference, all subjects were relatively homogeneous with respect to 
demographics.   
Overall the variability observed between subjects was pronounced across all 
groups for all analytes tested.     The effect of smoking status was significant within this 
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study with the primary difference being between nonsmokers and smokers.    Although 
a trend was observed, a statistically significant difference was not noticed between the 
two LS and HS smoking groups.    It is important to report that the smoking groups 
were sampled within thirty minutes of smoking an entire cigarette.  Therefore, the 
exposures of the TIQ’s and β-carbolines between smokers and nonsmokers may be 
resultant of the acute inhalation of β-carbolines from tobacco smoke or spontaneous 
condensation of the acetaldehyde and dopamine, as in the case of the SAL enantiomers.     
Moreover, the endogenous formation of the β-carbolines via condensation of 
acetaldehyde with 5-HT or tryptamine may also contribute to the overall exposure of H 
and NH from cigarette smoke.    As β-carbolines are present in significant 
concentrations in tobacco, the rationale of inhalation of these analytes causing the 
“baseline” difference between nonsmoking and smoking groups is a plausible 
mechanistic reason.  On the other hand, the SAL enantiomers and dopamine are not 
known to be constituents of tobacco smoke.   It is presumed that the acute exposure of 
acetaldehyde from the tobacco smoke is responsible for the divergence of SAL 
concentrations between nonsmokers and smokers.     
Dopamine differences between smoking status groups were also observed.  This 
effect may be due to a few reasons.    Acute smoking may induce a stress response 
thereby releasing dopamine from the medulla of the adrenal glands.  The phasic 
responses of dopamine neurons are observed when a reward is presented, such as in 
smoking.  A more indirect reason for the increase in peripheral dopamine 
concentrations observed pertained to the TIQ’s and β-carbolines.  As these analytes are 
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elevated upon acute cigarette exposure, their pharmacological actions upon inhibiting 
the enzymes responsible for degrading dopamine may cause the peripheral elevation of 
dopamine.   In order to characterize this relationship, further studies are necessary for 
evaluating the enzymes responsible for the metabolism of dopamine and the inhibitory 
relationship with TIQ and β-carboline concentrations. 
For all analytes, a large inter-occasion variability was observed between 
observational periods.  Thorough characterization of the analyte pharmacokinetics is 
imperative in order to evaluate this variability.  The within subject variability was 
relatively small for the nonsmokers as compared to smokers.  The sampling schedule, 
with respect to inhalation of tobacco smoke, required more rigid control to minimize 
variability associated with the separate sampling occasion.  This variability may 
contribute to the overall between group variability observed within the smoking 
subjects.   
An attempt was made to characterize true baseline differences between smoking 
status groups with evaluation of a population of smokers who abstained from smoking 
for 15 hours.    A significant baseline difference was observed for the SAL enantiomers 
and norharman within this study with the primary difference being between the heavy 
and nonsmokers.    This is presumed to be a function of a true constitutive difference 
between smokers and nonsmokers or an additive accumulation of SAL enantiomer and 
norharman concentrations within the body.  Of note, a formal conclusion with respect to 
this study cannot be deduced without full understanding of the pharmacokinetics.  
When compared to the study involving smoker’s recent exposure to tobacco smoke, the 
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difference between nonsmokers and smokers was more pronounced.   This suggests 
that, in addition to a supposed baseline difference, inhalation of tobacco smoke provides 
additional exposure to circulating TIQ and β-carbolines contributing to the incongruity 
of concentrations between smoking status groups.   A major critique of this analysis is 
that the two separate populations were compared to assess the baseline differences, one 
study abstaining from smoking and one study not.  Ideally, a study consisting of 
observations in the same population, sampling before and after smoking, with an 
adequate sampling schedule would be needed to further support the notion of “true” 
smoking status differences.     
In addition, the primary study was not balanced with respect to gender and 
smoking status.   This insufficiency confounds the results and variability associated 
between smoking status groups.  Of note, a gender difference was not observed but the 
true difference may have been masked due to the unbalanced design for this factor.      
Additional information was gathered from the volunteers that may have an 
effect on circulating TIQ and β-carboline concentrations.  A non-validated food 
inventory was designed to evaluate average weekly intake of TIQ and β-carboline 
amounts.   This assessment was used to review chronic dietary intake of the analytes 
and its speculated effects on circulating levels.    Nevertheless, a significant difference 
was not observed between smoking groups with respect to dietary intake while smoking 
status had an effect on circulating TIQ and β-carbolines.  A more robust manner to 
evaluate the effects is to have adequate dietary control throughout the observational 
period to sufficiently account for dietary intake. The exposure of circulating TIQ and β-
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carbolines with respect to acute dietary intake of TIQ and β-carbolines needs to be 
further evaluated in order to properly assess its influence.   
 A well-known variable associated with TIQ and β-carboline exposure is alcohol 
intake.  The AAI was used to evaluate the intake of absolute ethanol from alcoholic 
beverages over a year.    It is important to account that a strong relationship between 
AAI and smoking status was present.  In essence, the characteristics of smoking 
dependence, as deemed by the smoking status classification and the AAI showed a 
strong relation.   Persons who had a higher degree of smoking dependence also imbibed 
more alcohol per annum.    Using AAI as a sole predictor, alcohol consumption was 
only able to explain less than 10% of the variability associated with TIQ and β-
carboline exposure.    Further multiple regression techniques would be necessary to 
evaluate the relative contribution of AAI and smoking status on TIQ and β-carboline 
exposure in order to make an assessment.   Nevertheless, smoking status as a sole 
predictor was able to explain more of the variability associated with the analyte 
concentrations compared to that of AAI.   
 It was found that, in a healthy population, a noteworthy trend was observed 
between smoking status and TIQ and β-carboline exposure.   This trend is hypothesized 
to be a product of a combination of true endogenous differences between smoking 
status groups and exposure via the inhalation of the analytes themselves and/or 
inhalation of precursors required for endogenous synthesis, acetaldehyde.  The 
concentrations of TIQ and β-carboline exposure are assumed to be reflective of central 
dopaminergic activity.    The baseline level difference in the study involving smoking 
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abstinence suggests that smokers have higher concentrations.  Smokers may require 
maintenance of these higher concentrations in order to experience feelings of pleasure, 
simultaneously circumventing negative symptoms of nicotine withdrawal.   Behavioral 
studies do indicate that nicotine is an addictive drug that reinforces self-administration 
and the effects of nicotine on tests of reinforcement and behavioral sensitization are 
primarily mediated through the mesolimbic dopamine system.   TIQ and β-carboline 
exposure within this “reward pathway” may play a synergistic role, along with the 
pharmacological actions of nicotine, in the reinforcing aspects of tobacco smoking.  
 TIQ and β-carboline exposure has been purported to be influenced by acute 
ethanol intake and chronic alcoholism (See tables 1-1 and 1-2).    Significant variability 
within these studies have been reported, hampering the ability for these compounds to 
be an adequate marker for alcohol abuse.  As the association of smoking and alcohol 
abuse is strong, it is suspected that the variability in TIQ and β-carboline exposure 
observed may be explained by tobacco smoking.    As smoking status had a significant 
effect on TIQ and β-carboline exposure in a healthy population, it is expected that this 
effect would be observed in an alcoholic population.  The next chapter attempts to 
investigate the effects of smoking status in an alcoholic population undergoing inpatient 
detoxification. 
 
  
 
 
 
 
CHAPTER 6  
CLINICAL STUDY #2 – TEMPORAL EFFECTS OF GENDER AND SMOKING 
ON R/S-SALSOLINOL DURING ALCOHOL DETOXIFICATION  
 
 
6.1   Specific Aims 
 The key objective of this study was to evaluate the influence of time on R/S-
SAL and DA concentrations in the plasma of alcohol-dependent patients undergoing 
alcohol-detoxification.  This observational study was conducted as part of an ongoing 
NIH-IRB approved investigational protocol conducted at the National Institutes of 
Health – National Institute on Alcohol Abuse and Alcoholism (Herion, 2004), referred 
to here onward as the NIAAA-Natural History Protocol (NIAAA-NHP).  Moreover, a 
formal comparison of R/S-SAL plasma concentrations between alcohol-dependent 
patients and the healthy population from Clinical Study #1 was conducted. 
 Thirty-six alcohol-dependent patients (18 M, 18 F) were stratified into non-, 
light-, and heavy smoker (NS, LS, and HS) subgroups to determine the influence of 
smoking on R/S-SAL and DA concentrations.  In principle, observed differences of 
R/S-SAL levels could be interpreted as either a consequence of alcohol and/or tobacco 
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use (exogenous) or as a primitive condition of the brain that leads people to drink and 
smoke (endogenous).   Specific aims of this study included: 
1) Determine whether there are time-related changes in plasma TIQ’s (R- and S- SAL) 
and DA in a cohort of alcohol-dependent subjects during early abstinence. 
2) Assess if variations of R/S-SAL and DA exist between NS, LS and HS subgroups 
within the alcohol-dependent population; specifically, a comparison of the average 
concentrations and concentrations at predetermined time points during 
detoxification that may exist with R/S-SAL and DA levels between these subgroups. 
3) Evaluate the Clinical Institute Withdrawal Assessment-Alcohol Revised (CIWA-
AR) scores of the volunteers throughout the detoxification period and assess if 
differences are present between subgroups; appraise if an association exists with 
levels of R/S-SAL and DA with CIWA-AR scores. 
4) Characterize severity of alcohol dependence of the volunteers via the Timeline 
Follow Back assessment and determine in an association exists with the exposure of 
alcohol and R/S-SAL concentrations. 
5) Determine if a gender effect exists in R/S-SAL and DA concentrations and CIWA-
AR scores within this special population.  
6) Provide statistical measurement of inter- and intra-individual variability in the levels 
of R/S-SAL and DA concentrations along with CIWA-AR scores, which would 
permit formal sample size calculations in future studies. 
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7) Compare all pertinent endpoints and measurements between the abstaining, alcohol-
dependent cohort and results from the study involving a healthy, non alcohol-
dependent, healthy population of NS, LS, and HS (Clinical Study #1). 
 
 The design of the study allows characterization of plasma levels of R/S-SAL in 
order to evaluate these compounds as potential biomarkers alcohol dependence.  It was 
additionally designed to evaluate the effects of smoking and gender on the observed 
R/S-SAL concentrations to allow comparison with clinical study #1.  In essence, this 
study attempts to assess whether potential confounding factors, such as smoking status 
and gender, influence the temporal pattern of R/S-SAL concentrations in an alcoholic 
population.   
 A comparison between the alcohol dependent population and a healthy 
population will be made to assess influence of the effect of alcohol dependence on the 
R/S-SAL concentrations.    The stratification of smoking status groups within both 
populations will permit formal assessment of the relative contribution of smoking or 
chronic alcoholism on R/S-SAL plasma concentrations.   
 
6.2   Study Design  
 This clinical study was designed as an observational, longitudinal study in a 
cohort of alcohol-dependent patients that may or may not be dependent on cigarette 
smoking.   The alcohol-dependent cohort participated in an inpatient detoxification 
program for duration of 4-weeks in which observations, such as plasma R/S-SAL and 
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DA concentrations, were assessed.  The protocol involved the typical clinical course of 
events in people with alcohol dependence and abuse over a brief, intensive time period.  
During this time, the standard-of-care, as deemed by the clinical staff at NIH-NIAAA, 
was employed to all patients enrolled in the study.  Informed consent was obtained 
before the start of the study after explaining the purpose, risks and benefits of the study 
to the prospective study subjects.   
 To determine the effects of smoking and gender on R/S-SAL and DA plasma 
concentrations, the study integrated a classification scheme to stratify the volunteers 
into nonsmoking (NS), light-smoking (LS) and heavy-smoking (HS) groups and with 
respect to gender, respectively.    The stratification incorporated the same criteria 
incorporated in the healthy population from clinical study #1 (see table 5-1).  
 This investigation was not prospective in design, rather subjects were chosen 
from a database of 115 subjects that possessed already incurred samples and 
information with regards to health status, concurrent medications, demographics and 
smoking dependence information (FTND and number of cigarettes smoked per day).   
Thirty-six (36) alcohol-dependent male and female volunteers were chosen, including 
12 NS, 12 LS, and 12 HS.   The number of subjects in each group required to show a 
difference of 50% in SAL concentrations between smoking groups with an α risk of 
0.05 and a power of 1 – β = 0.8, was twelve (12), assuming a coefficient of variation 
(CV%) of 75%.  To evaluate the effects of smoking, the FTND was administered to 
determine their dependence on smoking in order to classify the potential subjects into 
the three groups of NS, LS, and HS.    To evaluate the effects of gender, an even 
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distribution was chosen within each group.  The factorial design of this study was to be 
similar to the clinical study #1 design for comparison. 
 
6.3   Experimental methods 
6.3.1 Subject Selection 
 From a database consisting of 115 alcohol dependent patients that were recruited 
into the NIAAA-NHP protocol between December 2006 – December 2007, patients 
were chosen based on a few primary criteria.    The NIAAA-NHP database consisted of 
information about each alcohol-dependent volunteer including:  admission date, subject 
demographics (e.g., age, weight, height, gender, ethnicity, etc.), medications that were 
given as part of protocol and for other concurrent disease states, other drugs of 
dependence, and most importantly, smoking habit assessment.  Each patient had been 
administered the FTND and a smoking history evaluation form during their stay in 
order to assess the severity of nicotine dependence.    Moreover, information with 
respect to the sampling schedule that was conducted on each subject during the first tree 
weeks of inpatient detoxification was supplied.   
 The primary criteria that were used to choose subjects for the analysis included 
the following, in order of priority. 
1)  As the time-course of R/S-SAL and DA was of primary interest, subjects that 
obtained at least five-sampling time points throughout detoxification were included.  
Specifically, subjects that were sampled on day 1 (admission), day 2, day 3, day 8 and 
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day 15 were included in the analysis.    The sampling schedule was restricted to only 
five-samples throughout the detoxification period.    Moreover, the schedule involved 
observations that were hypothesized to characterize the effects of recent alcohol-
detoxification on plasma R/S-SAL and DA concentrations.  
2)   Of the patients who possessed a complete time-course, subjects that met the criteria 
for inclusion into the smoking status groups were included in the analysis.    
Approximately 12 subjects for each smoking status group were required to evaluate the 
effects of smoking.  Within each smoking status group, patients were selected to ensure 
that gender was evenly distributed.  Therefore, the analysis required 6 HS males, 6 HS 
females, 6 LS males, 6 LS females, 6 NS males, and 6 LS females.   
3)   The subjects that were involved in the analysis were required to be relatively 
healthy and free of significant disease.   As the physiological effects of alcohol 
detoxification are severe to life-threatening, benzodiazepines and/or acamprosate 
(Campral®) was used in subjects that required them for withdrawal symptoms.    The 
use of these drugs did not preclude the subject from participation in the analysis.  
Further information, with respect to the protocol employed, is included in the section 
below. 
 
6.3.2 NIH-NIAAA Natural History Protocol  
 As part of the NIAAA-NHP, participants were recruited through local media and 
professional avenues in the Washington, DC Metro area.  They were evaluated by a 
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nurse and physician, among others, who determined the need for hospitalization, 
detoxification and to address other issues.  For those participants who needed medically 
supervised detoxification, a standard program of monitoring and treatment with 
benzodiazepines and other medications was instituted. 
 The alcohol-dependent cohort participated in an inpatient detoxification program 
for duration of 4-weeks.  Therefore, it consisted of a series of periods involving a pre-
visit gathering of subject information, physical and psychiatric evaluation at NIH-
NIAAA clinical research center, inpatient alcohol withdrawal and psychosocial 
management, and baseline observation.  The procedures involved scheduled verbal and 
observational procedures typically used in detoxification, and minimally invasive 
procedures (e.g., phlebotomy and urine collection), vital signs evaluation, 
electrocardiogram, chest-X-ray to provide a comprehensive medical and psychiatric 
evaluation.  
 Volunteers who passed the initial telephone screening were invited to the NIH-
NIAAA CRC for an outpatient visit including medical history (particularly personal or 
family history of psychiatric disorders and/or drug dependence), smoking history, 
physical and neurological exam, ECG, vital signs, blood chemistry, and complete blood 
count in order to ensure the health status of the subject prior to participation.  This 
excluded the participation of subjects with significant concurrent disease.  
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6.3.2a Inclusion / Exclusion Criteria 
 In order to be enrolled in the study, subjects had to meet the following criteria 
for inclusion: 1)  age of 21 years or older; 2) ability to give informed consent; 3) 
seeking help for alcohol drinking related problems; and 4) diagnosis of alcohol 
dependence by the Structures Clinical Interview for Diagnostics and Statistics Manual 
IV (DSM-IV, SCID-I) criteria.   
 Exclusion criteria for participation in the NIAAA-NHP included: 1) unstable or 
emergent medical or psychiatric conditions; 2) serious neuro-psychiatric conditions 
which impair judgment or cognitive function to an extent that precludes them from 
providing informed consent (incompetent individuals); 3) individuals with major 
depression, bipolar disorders, serious medical disorders, and those receiving 
psychotropic medications (with the exception of benzodiazepines used for withdrawal 
treatment); 4) people presenting with complicated medical problems such as, 
hypertensive emergency, serious GI bleeding, major organ or body system dysfunction 
such as decompensated liver disease, renal failure, myocardial ischemia, congestive 
heart failure or cerebrovascular disease, major endocrine problems such as uncontrolled 
diabetes, pancreatic or thyroid disease; and 5) people who are infected with the Human 
Immunodeficiency Virus (HIV). 
 Of note, current illicit drug misuse and a positive urine drug screen did not 
preclude any of the subjects for involvement in the protocol or the R/S-SAL analysis. 
 
 
354 
6.3.2b Procedures during detoxification period  
 The screening period included IRB-approved informed consent form discussion, 
comprehension and signing, a complete physical evaluation, blood and CHEM-20 
panel, urinalysis, vital signs assessment, ECG, and chest X-ray.  The DSM-IV/SCID-I 
was used to diagnose the volunteer as an alcohol-dependent patient.  Throughout the 
study, participants underwent various verbal and observational evaluations. Based on 
these assessments, multidisciplinary treatment planning was undertaken by the staff 
with the active participation of the patient.   
 Therapies that were employed to the volunteer were recorded as drug name, 
strength, dose and time drug was given.  Throughout the inpatient detoxification phase 
subjects were scheduled to be seen for clinic visits at admission, day 2, 3, 8 and day 15 
for brief medical and psychiatric check-ups, selected blood and urine tests, as well as 
selected written and computer assessments.   Following subject testing on discharge day 
(day 28), a complete physical exam was given.       
 
6.3.2b-1 Biological measurements 
 Biological sampling for clinical visits took place at 7AM, prior to consumption 
of foodstuffs/beverages and smoking, with the exception of the admission date.  
Sampling time on the day of admission was sporadic, dependent on when the subject 
entered the clinic for detoxification.   Breath alcohol (BrAC) was monitored at 
admission and throughout the inpatient detoxification period.     Patient volunteers with 
positive (BrAC level of ≥ 0.01 g/210L breath) and negative (< 0.01 g/210L breath) 
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results at admission were included in the analysis.  Of note, subjects were required to 
have a negative BrAC throughout subsequent tests.   
 Throughout the detoxification period, a total of five (5) biological samples (e.g., 
plasma) were taken for R/S-SAL and DA concentration assessment on admission, day 
2, 3, 8, and 15.  At all sampling points, a 6-ml plasma sample was collected from the 
non-dominant forearm in a reclined, seated position during the study.  The blood 
samples were centrifuged to obtain plasma.   Briefly, blood samples were centrifuged at 
2915 x g (3800 RPM) for 10 min, 4°C.  An equivalent volume of anti-oxidant/aldehyde 
trapping solution containing 0.6 mol/L, 15 mg ascorbic acid, 6 mg semicarbazide HCl 
in distilled water was added to approximately 3-ml of plasma.  Plasma samples were 
stored at -70°C until analysis for R-SAL, S-SAL and DA concentrations. 
  
6.3.2b-2 Smoking and Alcohol Consumption Assessments 
 For the assessment of smoking dependence and alcohol consumption measures, 
the FTND with Smoking History form, and the Alcohol Timeline-Follow Back (TLFB) 
was administered once during the detoxification period, upon sobriety.    The FTND and 
Smoking History Form were used to classify each subject into a smoking status 
subgroup.  Further discussion may be reviewed in Chapter 5.    The Alcohol TLFB is a 
drinking assessment method that obtains estimates of daily drinking.  Using a calendar, 
subjects provided retrospective estimates of daily drinking over a specified time period 
(Sobell and Sobell, 1992a).   This assessment has been shown to have good 
psychometric characteristics with a variety of drinker groups, and can produce variables 
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that provide a wide array of information about an individual’s drinking. Trained clinical 
staff was responsible for the administration of the TLFB in which the subject recorded 
the total number and type of drinks consumed for the past 90-days into a computer.    
 
6.3.2b-3 Clinical Endpoint Assessment: The CIWA-AR 
 A clinical endpoint characterizing the withdrawal severity during alcohol 
detoxification was administered to each subject.  The Clinical Institute Withdrawal 
Assessment-Alcohol Revised (CIWA-AR) is a validated 10-item assessment tool that 
categorizes the severity of alcohol withdrawal based on symptoms and physical signs 
(Sullivan et al., 1989a).  Scores of 8 points or fewer correspond to mild withdrawal, 9 to 
15 points correspond to moderate withdrawal, and scores of > 15 points correspond to 
severe withdrawal symptoms (maximum score = 67).  Initially, alcohol withdrawal 
assessment was done hourly or every 2-4 hours until the scores were consistently below 
a range of 5-7.  It was also performed on an “as indicated” basis, at the discretion of the 
healthcare team.  This assessment was used primarily to evaluate the withdrawal 
symptoms of the patient and to subsequently administer a benzodiazepine for alleviation 
of withdrawal symptoms.   The CIWA-AR may be reviewed in Appendix I. 
 
6.3.2b-4 Eligibility and Safety Procedures 
 Various safety procedures were conducted to evaluate the health status of the 
volunteer for qualification purposes and during sampling time points.  The Structured 
Clinical Interview for Diagnostics and Statistics Manual-IV (DSM-IV, SCID-I) is a 
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standard clinical procedure to establish criteria for psychiatric diagnoses (First, 2002).  
It is a structured interview consisting of 11 modules with between 35-292 items/module 
that takes about 120-180 minutes.  It was employed for the diagnosis of alcoholism.  
 Blood test panels (BTP) were used throughout the detoxification period to assess 
physiological functions and screen for organ damage, as well as assessment of the 
extent of alcohol and drug exposure, including toxicology and biomarkers. The blood 
tests included Complete blood count with differential, CHEM-20 Panel, thyroid screen, 
Lipid panel, Viral Markers Protocol Screen and Trace Mineral panel.  They were 
performed once in the alcohol-dependent population during screening.   Of importance, 
evaluation of liver function was performed by investigation of markers of liver function 
such as blood aspartate aminotransferase (AST), alanine aminotransferase (ALT), 
albumin, γ-glutamyl transferase (GGT) and total bilirubin.  These measures were 
performed at admission and throughout the detoxification period. 
 Urine drug screens including the qualitative and Drug Profile #1 tests were 
administered to evaluate whether the subject was using other drugs of abuse such as 
benzodiazepines, barbiturates, cocaine, LSD, methamphetamines, opiates, 
phencyclidine, and tetrahydrocannabinol (THC).   It was performed at baseline and 
throughout inpatient detoxification for subject characterization and to appraise whether 
the subject required additional treatment for other drugs of abuse besides alcohol.   
Subjects who had tested positive for a drug of abuse, at any time other than admission, 
was not included in the primary analysis.   
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 Other procedures used to screen for medical diseases and abnormalities were 
incorporated at baseline and throughout the study to test for abnormalities that may 
prevent study participation.  
 
6.3.2b-5 Diet and Smoking  
 Dietary intake for each of the subjects undergoing alcohol detoxification was not 
based on a specific restrictive diet (e.g., low monoamine diet).  The TIQ/BC food and 
beverage inventory was administered to assess average weekly intake of dietary SAL 
(Appendix D).   Further discussion about the food inventory may be viewed in the 
preceding chapter.      
 Cigarette use of the subjects was carefully monitored to assess any influences of 
these factors on R/S-SAL levels, at baseline and throughout the study.  Subject 
participants who were in the LS and HS groups were permitted to smoke ad-libitum 
throughout the inpatient period.    Of importance, biological sampling was conducted 
pre-prandially and prior to smoking the initial cigarette of the day, with the exception of 
on admission day.    
 For all tests and procedures, a timeline and study flow chart for the NIAAA-
NHP is presented below in figure 6-1 and table 6-1, respectively. 
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6.3.3 Blood Sample Analysis 
 The samples containing TIQ’s were kept at -70°C until analysis.  TIQ samples 
were analyzed and assayed for S-SAL, R-SAL and DA by the investigator using 
resources and equipment with generous permission granted from the Laboratory of 
Molecular Signaling, National Institute on Alcohol Abuse and Alcoholism-NIH, 
Rockville, MD.   The assay procedure incorporated the use of 1-ml of patient plasma 
sample in addition to the equivalent volume of 1-ml antioxidant solution (total volume 
of 2-ml).   Details have been described earlier (see Chapter 4). 
 
6.3.4 Statistical Analysis 
6.3.4a Descriptive statistics 
 Descriptive statistics, including mean, standard deviation, and coefficient of 
variation were calculated for each endpoint.    In addition, intra-individual variability 
(e.g., COV%) was calculated for all measured endpoints, i.e., R/S-SAL and DA 
concentrations along with and CIWA-AR, for each volunteer.   
 In the case that assumptions of normal distribution and equal variance was not 
met, raw data were log-transformed to comply with the parametric assumptions of equal 
variance across groups and normal distribution of the residuals.   Appropriate summary 
statistics, using the log-transformed data, such as, median, COV%, percentiles and 
ranges were computed.  
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6.3.4b Inferential statistics 
 The data obtained from this investigation were used to compare prespecified 
factors of smoking status and gender responses to detoxification on the pertinent 
endpoints, including exposure levels of R/S-SAL, DA and CIWA-AR scores.  To 
evaluate the effects of time on R/S-SAL and DA concentrations and the clinical 
endpoint, CIWA-AR, regression analysis was conducted across all subjects.   In the case 
that assumptions of normal distribution and equal variance was not met, raw data was 
log-transformed to comply with the parametric assumptions and the analysis was 
conducted on the log-transformed concentrations.    
 Inter-individual variability (i.e., COV% and range) was calculated for the above 
endpoints as well as all the rating scale scores and CIWA-AR for each of the three 
groups and across all groups via two-way ANOVA, incorporating comparison of 
smoking history and gender factors.  Specifically, R/S-SAL individual concentrations 
were evaluated using the model descried in section 5.3.4b.  The two-way ANOVA was 
performed on the grand total mean (GTM) concentrations, and concentrations obtained 
from admission (day 1) and day 15.   GTM concentrations consisted of the mean of the 
individual subjects concentrations obtained across time. 
 Moreover, R/S-SAL and DA concentrations were correlated with the measures 
dietary intake (TIQ/BC Food Inventory) and alcohol consumption (TLFB) using 
Pearson’s product-moment correlation and linear regression to evaluate if these are 
significant covariates that need to be implemented into the full model.  Associations 
were considered significant with a p-value of <0.05 and a coefficient of determination > 
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0.2.   Multiple covariate analysis was performed on SAL and DA exposure if we have 
more than one significant covariate.  Exploratory analyses using these procedures were 
performed on clinical variables, such as liver function, to evaluate their effects on the 
analyte concentrations on the GTM, day 1, or day 15.   The clinical endpoint, CIWA-
AR, was assessed for a relationship with SAL concentrations during the first three days 
of patient observation.  
 To evaluate differences between the healthy (Clinical study #1) and alcoholic 
populations, an unpaired t-test was employed for all log-transformed biological 
endpoints between smoking status groups in each cohort.   The baseline control from 
Clinical study #1 will be compared to the admission and discharge levels of the 
alcoholic population.   
 All endpoints were tested and compared across all groups in S-PLUS 8.0 
(Insightful Corporation, Seattle, WA).  The full statistical model was implemented 
incorporating covariates, if required.    The residuals were tested for normality using 
Quantile-Quantile (Q-Q) plots and further tested using the Shapiro-Wilk test, where α 
was set to 0.05 such that any p-values > 0.05 indicated that the data was normally 
distributed.  If the data were not normally distributed, the data were log-transformed 
and the full model was repeated.   The level of significance was set a-priori at 0.05.  
Any statistically significant differences found via ANCOVA were further investigated 
via Scheffé test to isolate factor differences.  All ANCOVAS performed are included in 
Appendix O. 
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6.4 Results 
6.4.1 Clinical Results 
6.4.1a Subject Demographics 
 Out of 115 subjects who were enrolled and completed the detoxification 
protocol, a total of thirty-six (36) subjects were chosen for the SAL investigation using 
the aforementioned criteria. Upon plasma concentration analysis, one subject 
disqualified for the study due to a positive HIV testing (subject #13).  Therefore, a total 
of thirty-five subjects were included in the analysis.   Into each smoking status group, 
12 NS, 11 LS and, 12 HS were included, with seventeen females and eighteen males 
comprising the gender distribution within the entire population.   The distribution of 
gender and smoking status for subjects who completed the protocol and met the 
selection criteria is as follows: 6 NS females, 6 NS males, 5 LS females, 6 LS males, 6 
HS females and 6 HS males.  Final subject demographics are included in Table 6-2.  
The subjects incorporated in the analysis were of a mean age of 41.1 years old, ranging 
from 28-58 years.   No statistically significant differences in weight and age were found 
between smoking groups.  Twenty-four Caucasians, seven African-Americans, two 
Hispanics and two subjects of unknown origin completed the study. 
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Table 6-2:  Clinical Study #2 Demographics 
Nonsmokers
Subject # Race Gender Age (yrs) W eight (kg) FTND # Cig/day
1 White F 56 74.1 0 0
2 White F 53 80.2 0 0
3 White F 32 54.1 0 0
4 White F 32 63.7 0 0
5 White F 46 47.2 0 0
6 Black F 40 69.8 0 0
7 Hispanic M 36 78.7 0 0
8 Hispanic M 31 98.9 0 0
9 White M 41 98.8 0 0
10 Black M 38 72.5 0 0
11 Unknown M 46 71.8 0 0
12 White M 48 103 0 0
Total Mean 41.6 76.1 0.0 0.0
Total SD 8.3 17.4 0.0 0.0
Mean Female 43.2 64.9 0.0 0.0
SD 10.3 12.4 0.0 0.0
Mean Male 40.0 87.3 0.0 0.0
SD 6.4 14.5 0.0 0.0
  
Light-smokers
Subject # Race Gender Age (yrs) Weight (kg) FTND # Cig/day
14 White F 34 63.4 5 10
15 White F 45 75.2 1 10
16 White F 31 70.0 4 10
17 Black F 28 99.2 2 5
18 Black F 50 76.6 6 12.5
19 Unknown M 41 89.5 4 10
20 White M 58 87.9 6 10
21 White M 45 91.2 4 6
22 White M 29 116.1 3 10
23 Black M 43 100.2 6 12
24 Black M 30 75.2 5 13
Total Mean 39.5 85.9 4.2 9.9
Total SD 9.8 15.5 1.7 2.5
Mean Female 37.6 76.9 3.6 9.5
SD 9.4 13.5 2.1 2.7
Mean Male 41.0 93.4 4.7 10.2
SD 10.7 13.7 1.2 2.4  
 
 Information regarding therapies utilized during detoxification and other drugs of 
abuse present in drug screen at admission was obtained is supplied in table 6-3.   
 Additional clinical variables were obtained from each of the subjects during 
admission such as information regarding liver function (AST, ALT, albumin, GGT, and 
total bilirubin).  Information about clinical variables is supplied in table 6-3 below and 
divided according to smoking status (NS, LS, and HS) and gender (male or female). 
Clinically significant anomalies were not present amongst the subjects chosen for the 
analysis.  Liver function tests such as AST, ALT, and GGT were all less than three-
times normal values of healthy liver function.   The majority of subjects possessed 
albumin, and total bilirubin within normal ranges. 
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Heavy-smokers
Sub ject # Race Gender Age (yrs) W eigh t (kg) FT ND # C ig/day
25 W hite F 33 48.8 8 20
26 W hite F 57 44.1 8 20
27 W hite F 40 63.1 10 20
28 W hite F 40 69.6 10 50
29 W hite F 35 70.0 8 20
30 Black F 40 52.1 9 31
31 W hite M 33 87.2 8 35
32 W hite M 52 85.3 7 40
33 W hite M 56 105.0 10 40
34 W hite M 53 92.0 8 30
35 W hite M 28 89.4 5 28
36 W hite M 39 78.0 6 20
T otal Mean 42.2 73.7 8.1 29.5
1 1.6 10.1
0 8.8 26.8
1 1.0 12.2
5 7.3 32.1
1.8 7.8
Table 6-2:  Clinical Study #2 Demographics (continued) 
 
T otal SD 9.9 19.
Mean Female 40.8 58.
SD 8.5 11.
Mean Male 43.5 89.
SD 11.7 9.0  
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 It is important to note that 13 of 35 subjects (37%) that were evaluated showed a 
positive urine drug screen at admission for various drugs of abuse (ADM drug screen).  
Moreover, acamprosate (ACAMP) was administered to 9 of the 35 subjects (26%) 
accrued, with all of the subjects being smokers.   All patients were administered various 
therapies throughout the course of detoxification, including benzodiazepines.  
Consideration of these clinical and therapeutic observations is necessary, as their effects 
on R/S-SAL concentrations have not been established.   
  
6.4.1b Smoking, alcohol and dietary exposure variables  
 
 With respect to smoking status and frequency of cigarette smoking, figures 6-2 
and 6-3 report FTND scores and mean cigarette consumption per day, respectively.  
Both NS males and females scored a mean of 0 (± 0 SD) on the FTND and self-reported 
mean number of cigarettes smoked per day.  LS females scored a mean FTND of 3.6 (± 
2.1 SD) while LS males scored a slightly higher value of 4.2 (± 1.7 SD).    HS females 
scored 8.8 (± 1.0 SD) compared to HS males who scored on average 7.3 (± 1.8 SD).  Of 
note, the FTND difference between the genders was not significantly different (two-
tailed unpaired t-test, p-values > 0.073 for LS and HS status).    For the number of 
cigarettes smoked per day, LS females and LS males had similar results with averages 
of both groups being 9.5 (± 2.7 SD) and 10.2 (± 2.4 SD) cigarettes smoked per day, 
respectively.   HS subjects smoked on average a three-fold more number of cigarettes 
per day than the LS counterparts.    In this group, male smokers smoked more cigarettes 
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Figure 6-2:  Mean (± SD) Fagerström Test for Nicotine Dependence (FTND) Score vs. 
Smoking Status (F: female, M: male) 
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Figure 6-3:  Mean (±SD) Cigarettes smoked per day vs. Smoking Status (F: female, M: 
male) 
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per day on average than that of females with an average number of cigarettes smoked 
per day of 32.1 (± 7.8 SD) for males and 26.8 (± 12.2 SD) for females.  Although a 
significant difference was observed with the number of cigarettes smoked per day 
between smoking statuses, a gender difference within each smoking status was not 
detected. 
 In addition to the demographic and R/S-SAL and DA plasma measurements, 
additional information including alcohol intake and weekly exposure to dietary total 
SAL, was recorded via the TLFB and TIQ/BC Food Inventory.  As intake of ethanol 
has been reported to influence the exposure of SAL enantiomers, a measurement of the 
past ninety (90) days of alcohol intake was reported by a validated measure of alcohol 
consumption, the TLFB.  The TLFB assessment was administered to each subject on a 
single occasion during the detoxification period.  The total amount of alcohol 
consumed, in terms number of drinks in the past 90 days, was calculated upon self-
report on the number of alcoholic beverages consumed.   Evaluation of the daily 
frequencies all different types of alcoholic beverages including, wine, beer, wine 
coolers, and spirits were reported by the subject and tallied to calculate the total number 
of drinks within the time period, prior to detoxification.  Of primary note, this is a self-
report measure of overall estimate of total ethanol consumption for the past three 
months. The raw data for the TLFB can be viewed in table 6-4 while the descriptive 
results can be viewed in the table 6-5 reported as total number of ethanol containing 
beverages consumed in the past ninety days prior to inpatient abstinence. 
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 Breath alcohol (BrAC) was measured for each subject upon admission to the 
clinical center.  Subjects who possessed no measureable BrAC were classified as 
negative (neg) while persons who yielded a positive BrAC, as defined by > 0.01 g/210L 
breath, were classified as positive (pos).   If positive, the level of BrAC was reported for 
each subject.  The information with respect to BrAC may be seen in the table 6-4 below  
 Ethanol exposure estimated by the TLFB resulted in substantial differences 
between genders within smoking groups and between smoking groups.   Results here 
are reported as mean, median and range.   NS males and females showed a similar 
median number of drinks of 657 drinks/90 days and 621 drinks/90 days, respectively.    
Conversely, LS and HS possessed significantly higher TLFB scores.  The median 
number of alcoholic drinks estimated in LS males and females was 1381 drinks/90 days 
and 666 drinks/90 days while in HS males and females resulted in 1504 drinks/90 days 
(range: 610 – 2445) and 629 drinks/90 days (range: 75 – 1890), respectively.   In both 
smoking groups, males drank more alcoholic beverages in the past ninety days 
compared to females.  Nonsmokers had a median of 617 drinks/90 days (range: 105 – 
1819) while the estimated LS and HS alcoholic beverage intake was 1112 drinks/90 
days (range: 167 – 2191) and 1134 (range: 75 – 2445).     
 A systematic trend was observed between smoking groups and gender for the 
total amount of alcoholic beverages consumed per last 90 days.  On average, females 
had a lower estimated intake compared to males as a whole and across smoking groups.   
Smoking status showed a significant trend with a resultant increase in estimated 
alcoholic beverage consumption with increasing level of smoking status.  Formal  
372 
Table 6-4:  Individual reports for TLFB and % BrAC on admission   
 
Subject # SS GEN TLFB (90 days) BrAC BrAC level (%)
1 NS F 655.4 neg 0.00
2 NS F 579 neg 0.00
3 NS F 105 neg 0.00
4 NS F 361 neg 0.00
5 NS F 731 pos 0.29
6 NS F 1295 pos 0.08
7 NS M 385.3 neg 0.00
8 NS M 337.7 neg 0.00
9 NS M 327 neg 0.00
10 NS M 1819 neg 0.00
11 NS M 930 neg 0.00
12 NS M 1268 neg 0.00
14 LS F 666.6 neg 0.00
15 LS F 167 neg 0.00
16 LS F 242 neg 0.00
17 LS F 837 pos 0.11
18 LS F 2191 pos 0.31
19 LS M 1272 neg 0.00
20 LS M 1122 neg 0.00
21 LS M 683 neg 0.00
22 LS M 1818.5 pos 0.30
23 LS M 2011 pos 0.10
24 LS M 1491 pos 0.10
25 HS F 75 neg 0.00
26 HS F 366 neg 0.00
27 HS F 354 neg 0.00
28 HS F 1560 pos 0.48
29 HS F 891 pos 0.15
30 HS F 1890 pos 0.07
31 HS M 1104.8 neg 0.00
32 HS M 1164 neg 0.00
33 HS M 1705 neg 0.00
34 HS M 610 pos 0.05
35 HS M 1999 pos 0.18
36 HS M 2445 pos 0.06  
  pos :  positive BrAC 
  neg :  negative BrAC 
  % :  g/210L of breath 
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evaluation of TLFB as a significant covariate will be explored further as the history 
alcohol intake prior to detoxification may affect the exposure of plasma SAL.  
 With respect to admission BrAC, 13 out of 35 subjects (37%) showed a positive 
measureable breath alcohol.  While two of these subjects were part of the NS smoking 
status group, 5 subjects were part of LS and 6 subjects out of HS groups.  If a 
significant effect of positive BrAC was present with respect to admission R/S-SAL 
concentrations, further analysis was employed for correlation between the numeric 
value obtained vs.  SAL concentration.    Formal evaluation of BrAC as a significant 
covariate was also explored.   
 
Table 6-5:  Descriptive results for the TLFB measurement by SS and GEN 
 
GRAND
Mean 1249
Median 1216
Range 327 - 2445
Mean 762
Median 655
Range 75 - 2191
Mean 1013
Median 891
Range 75 - 2445
%COV 66.2
Non-smoker Light-smoker Heavy-smoker
TL
FB
   
   
   
   
  
(#
 d
rin
ks
 in
 p
as
t 9
0 
da
ys
)
Male
844 1399 1434
657 1381 1504
327 - 1819 683 - 2011 610 - 2445
Female
617 820 856
621 666 629
105 - 1295 167 - 2191 75 - 1890
Overall
732 1136 1180
617 1122 1134
105 - 1819 167 - 2191 75 - 2445
69.5 60.4 63.4  
 
 In regard to dietary exposure of SAL, the food survey incorporated 
measurements of type of food, average frequency and average portion size of each 
known food source to have significant quantities of total SAL.   Similar calculations 
used in the Clinical study #1 were used to assess the average nanograms of weekly total 
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SAL consumed from dietary intake (see section 5.4.1b).    The amount of dietary intake 
of these SAL containing food and beverages were not reported for the foods consumed 
during the detoxification period.    The descriptive results of the TIQ/BC Food 
Inventory can be viewed table 6-6 below in average nanograms of average weekly total 
SAL consumed. 
 
Table 6-6:  Descriptive results for the dietary total SAL by SS and GEN 
 
GRAND
Mean 3286
Median 2844
Range 1004 - 4520
Mean 2471
Median 3088
Range 1032 - 5136
Mean 2857
Median 2952
Range 1004 - 5209
%COV 71.8
Non-smoker Light-smoker Heavy-smoker
D
ie
ta
ry
 to
ta
l S
A
L 
(n
g/
w
ee
k)
Male
3112 2977
2871 3099
1134 - 4520 1996 - 4005
Female
3098
3769
2563
1004 - 4296
1872 2444
4562 2031 2671
2091 - 5029 1032 - 5136 1562 - 4010
Overall
3291 2544 2736
3455 2781 2620
75.2 85.4 56.7
1134 - 5209 1032 - 5136 1004 - 4296
 
 
 With the exception of the NS status group, a gender difference was not observed 
within smoking status groups.    Overall, the NS group possessed a higher median 
intake of dietary SAL (3455 ng/week) than that of the LS (2781 ng/week) and HS (2620 
ng/week) groups.  The variability (%COV) within each smoking status group was > 
56%.   As dietary intake of SAL containing foods may affect the overall exposure, the 
food inventory measurement may provide clues into the variability associated with the 
plasma measurement of enantiomeric SAL.    If dietary exposure was found to 
significantly correlate with SAL exposure, average nanograms of total dietary SAL per 
375 
week was considered as a significant covariate and implemented into the statistical 
model. 
 
6.4.2 Primary Analysis for R/S-SAL and DA – Effects of Smoking and Gender 
6.4.2a R/S-SAL and DA – Within Subject Variability 
 Preceding the statistical assessment of the effects of time, and the factors of 
smoking status and gender on R/S-SAL and DA concentrations, within subject 
variability was evaluated.   This analysis was conducted to assess the fluctuation of 
concentrations over fifteen days of early alcohol abstinence. The intra-subject 
variability (median, inter-quartile ranges, %COV) for S-SAL, R-SAL and DA can be 
seen in the tables 6-7, 6-8 and 6-9 below.   
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Table 6-7:  Within Subject Variability for Plasma S-SAL (pg/ml), n =5 timepoints.  
Subject # GEN S-SAL avg stdev %COV median 25% IQR 75% IQR
Nonsmokers
1 F 236 146 62 263 113 321
2 F 290 451 156 145 31 164
3 F 181 196 108 93 74 199
4 F 77 40 53 61 52 105
5 F 117 78 67 95 79 181
6 F 207 178 86 153 134 211
7 M 30 11 37 30 20 38
8 M 136 237 174 36 26 38
9 M 146 90 61 189 61 21
10 M 86 120 139 8 5 141
11 M 20 28 143 9 7 11
12 M 75 34 46 72 48 105
Light Smokers
14 F 108 122 113 92 17 104
15 F 35 18 52 26 22 50
16 F 217 196 90 144 114 154
17 F 40 49 120 33 6 40
18 F 31 43 136 14 5 26
19 M 68 29 43 55 51 72
20 M 71 102 144 24 18 46
21 M 22 16 72 24 8 31
22 M 136 145 107 85 26 179
23 M 31 13 41 28 26 30
24 M 90 82 91 79 26 106
Heavy Smokers
25 F 38 21 55 31 30 41
26 F 73 53 73 40 39 124
27 F 189 222 117 102 82 147
28 F 313 443 142 113 71 217
29 F 40 18 44 38 34 43
30 F 50 27 54 41 39 43
31 M 135 191 141 65 29 91
32 M 111 87 79 61 48 169
33 M 58 7 12 61 51 61
34 M 287 368 128 175 14 337
35 M 128 203 158 32 18 90
36 M 92 74 80 59 37 125
6
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Table 6-8:  Within Subject Variability for Plasma R-SAL (pg/ml), n =5 timepoints. 
Subject # GEN R-SAL avg stdev %COV median 25% IQR 75% IQR
Nonsmokers
1 F 322 266 83 303 155 322
2 F 594 1007 169 243 45 274
3 F 185 257 139 70 40 216
4 F 112 81 72 76 74 198
5 F 181 137 76 133 103 322
6 F 285 258 90 242 174 297
7 M 27 16 58 30 15 31
8 M 200 382 191 30 26 47
9 M 218 141 65 293 96 311
10 M 123 169 137 12 5 217
11 M 27 51 189 4 3 10
12 M 129 67 52 125 71 170
Light Smokers
14 F 423 589 139 146 21 524
15 F 42 25 60 29 22 66
16 F 313 309 99 166 158 238
17 F 69 76 111 65 17 67
18 F 57 74 129 27 10 57
19 M 95 48 51 77 69 103
20 M 105 150 142 25 22 92
21 M 28 25 87 27 10 35
22 M 241 268 111 150 50 313
23 M 16 15 89 11 9 18
24 M 113 119 105 88 23 119
Heavy Smokers
25 F 77 49 64 64 48 96
26 F 69 55 80 51 30 99
27 F 226 281 125 120 96 157
28 F 567 919 162 168 85 300
29 F 42 27 64 33 24 46
30 F 49 33 68 36 35 42
31 M 187 284 152 95 36 107
32 M 143 128 89 77 50 268
33 M 67 27 41 60 45 78
34 M 452 641 142 240 11 456
35 M 178 318 179 32 9 98
36 M 98 102 105 45 30 150  
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Table 6-9:  Within Subject Variability for Plasma DA (ng/ml), n =5 timepoints. 
Subject # GEN DA avg stdev %COV median 25% IQR 75% IQR
Nonsmokers
1 F 8.3 1.5 19 8.3 8.2 9.3
2 F 10.3 6.4 61 8.1 6.1 12.7
3 F 6.9 2.0 29 6.5 5.5 7.9
4 F 6.7 0.9 14 6.7 5.7 7.4
5 F 3.7 1.7 46 3.0 2.9 3.7
6 F 9.8 2.8 28 10.6 8.4 11.5
7 M 3.0 0.5 18 2.8 2.6 3.5
8 M 2.8 1.5 53 3.1 2.8 3.3
9 M 5.5 0.9 17 5.3 5.2 6.2
10 M 3.2 1.3 42 2.8 2.6 3.5
11 M 3.4 0.9 27 3.5 2.5 4.0
12 M 7.0 1.2 18 6.3 6.3 7.8
Light Smokers
14 F 4.8 2.2 46 4.2 3.6 4.4
15 F 5.5 1.3 24 6.2 4.2 6.4
16 F 4.9 1.0 21 4.6 4.3 5.1
17 F 2.4 1.2 52 2.1 1.4 3.3
18 F 3.2 0.9 29 2.8 2.6 3.8
19 M 3.2 0.5 15 3.2 2.8 3.6
20 M 4.2 1.2 29 3.7 3.6 4.4
21 M 5.4 1.1 21 5.2 5.1 5.4
22 M 5.6 3.4 60 4.5 3.7 5.7
23 M 3.8 1.3 35 3.4 2.9 4.2
24 M 8.2 2.2 26 8.4 6.4 9.1
Heavy Smokers
25 F 5.2 0.8 16 5.0 5.0 5.8
26 F 5.4 2.0 38 4.2 4.1 5.8
27 F 5.4 2.7 49 4.4 3.3 6.5
28 F 20.1 24.6 122 7.9 7.5 14.6
29 F 5.2 1.8 35 5.4 4.4 5.8
30 F 7.3 1.0 14 7.4 6.7 8.1
31 M 4.3 2.3 52 3.7 3.4 4.1
32 M 7.8 4.6 59 5.7 5.1 8.4
33 M 5.2 2.0 37 5.3 3.7 6.5
34 M 15.9 12.6 79 16.6 4.9 27.8
35 M 11.9 13.7 115 5.9 4.9 8.0
36 M 5.7 3.2 56 4.5 4.3 5.7  
 
 
 
379 
 For S-SAL and R-SAL concentrations, it is apparent that the within-subject 
variability was large ranging from a %COV 12 to 174% for S-SAL and %COV 41 to 
191% for R-SAL, suggesting that concentrations of these analytes fluctuate throughout 
detoxification.   For non-smokers, %COV ranged from 37 – 174% for S-SAL and 52 – 
191% for R-SAL.  For the LS population, a range of %COV’s of  41 – 144% for S-SAL 
and 51 – 142% for R-SAL were observed, while the HS population possessed %COV 
12 – 158% and %COV 41 – 179% for S-SAL and R-SAL, respectively.     As the 
subjects who were smokers were allowed to smoke ad-libitum throughout the 
detoxification period, it was expected that the intra-individual variability within the LS 
and HS groups would be larger than that of NS.   However, this observation was not 
apparent from the analysis, as the intra-subject variability was not affected by smoking 
status or gender.  In other words, the variability associated with the measurements was 
large, regardless of smoking status or gender. 
 In the case of DA concentrations within-subject variability was relatively 
smaller compared to that of the SAL enantiomers.   DA concentrations ranged from 
%COV 14 to 122%, suggesting that concentrations of DA are more stable throughout 
detoxification.   For non-smokers %COV ranged from 14 – 53%, while for the LS and 
HS populations, a range of %COV’s of 15 – 60% and 14 – 122% were observed, 
respectively.    An interesting note is that the HS populations possessed larger intra-
subject variability than that of the LS and NS smoking status groups.  An effect of 
gender was not observed with DA concentrations. 
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   As biological sampling of the analytes were pre-prandial and before the initial 
cigarette of the day, it is hypothesized that the intra-subject variability is not due to 
consumption of SAL containing foods or from acute inhalation of SAL precursors.   
Rather, the large fluctuation in R/S-SAL concentrations may be a consequence of the 
physiological effects of alcohol detoxification upon early abstinence.  Moreover, several 
factors such as pharmacological therapies and alcohol exposure and/or other drugs of 
abuse used prior to admission may contribute to the variability.  These variables will be 
formally addressed in the subsequent analyses within this chapter.    An interesting 
observation was that the SAL precursor, DA, fluctuated less over sampling periods for 
each subject, relative to R/S-SAL.  This is suggestive that, regardless of the DA 
precursor, the R/S-SAL concentrations between sampling occasions vary and may be a 
consequence of different endogenous sources/precursors or from exogenous 
contribution to overall exposure. Moreover, the biosynthetic pathway of SAL may be 
affected via pathophysiological effects during alcohol detoxification. 
 
6.4.2b Effect of time on R/S-SAL and DA concentrations 
 Prior to evaluation of time and the major study design factors of smoking status 
and gender, correlation analysis was performed between S-SAL, R-SAL and DA.   Of 
note, in order to meet the assumptions of normal distribution and equal variance across 
smoking groups, all data were log-transformed.   Separate evaluation of the effects of 
time, smoking-status and gender were performed on both SAL enantiomers and DA.  
Although the correlation analysis between the analytes suggest that the association 
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between the two SAL enantiomers is very strong (r = 0.933), separate statistical 
analyses for the two enantiomers was conducted.   In addition, associations between DA 
and SAL enantiomers were relatively weak with DA vs. S-SAL possessing a correlation 
coefficient of 0.390 and DA vs. R-SAL was 0.352.  Correlation results from this study 
were similar to those seen in Clinical study #1.  A matrix evaluating the correlation can 
be seen in Figure 6-4 below. 
 
log.S.SAL
log.R.SAL
log.DA
  
Figure 6-4:  Correlation between log S-SAL vs. log R-SAL (r = 0.933), log DA vs. log 
S-SAL (r = 0.390) and log DA vs. log R-SAL (r = 0.352). 
 
  
 As it was expected that time would be a major influence on the concentration of 
the SAL enantiomers, statistical evaluation was conducted on the analytes over the 
detoxification period.    In figures 6-5, 6-6, and 6-7, spaghetti plots of concentration vs. 
382 
time for S-SAL, R-SAL, and DA, respectively, are presented for all subjects.  Plots are 
depicted on a logarithmic scale with average concentrations, for each time point, 
denoted by the solid line.  Individual plots of concentration vs. time may be viewed in 
Appendix M. 
 Upon visual inspection of the plots on logarithmic scale, the concentrations of S-
SAL and R-SAL within and between subjects were quite variable.  Baseline admission 
concentrations varied approximately 1000-fold between patients for both SAL 
enantiomers.   A well defined, systematic trend in concentrations is not observed within 
subjects with concentrations fluctuating throughout the detoxification period.  
Moreover, the trend of concentration vs. time profiles for both enantiomers reveals that 
subjects mat either increase or decrease in concentration over the sampling period.   At 
each time point, at least a 100-fold variability in R/S-SAL concentration is observed 
between subjects. 
 In the case of the DA precursor, concentrations within- and between-subjects 
was less variable.   Moreover, the concentration time profiles are relatively stable 
throughout the detoxification period.    The majority of the inter-individual variability is 
observed during the baseline and approximately a 10-fold difference is seen between 
subjects at all time points.   
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 Regression analysis was performed on all subjects to evaluate the effects of time 
on log S-SAL, log R-SAL and log DA concentrations over the detoxification period.  
Furthermore, the factors of SS and GEN were incorporated in the full model to assess 
whether the design variables have an influence on the time course of the log analyte 
concentrations.  If the effects were considered insignificant, exploratory analyses 
involving individual time points, including admission day, day 15 and GTM, were 
assessed for design factor effects.  Statistical data are presented as F test for the 
regression (df for factors, df for residuals = F-statistic, p-value).  
 A statistically significant effect of time was observed with respect to log S-SAL 
concentrations with F (1, 170) = 21.7, p-value = 6.3 x 10-6.   The coefficient of 
determination (R2) for the entire model was 0.113.  Thus, the factor of time accounts for 
approximately 11.3% of the variability associated with the log S-SAL concentration 
measurements.    On average, a slight increase in log S-SAL concentrations was 
observed throughout the detoxification period across all subjects.   For every day spent 
abstinent from alcohol in the clinical center, an average increase of 0.033 log S-SAL 
concentration was observed from admission day to day 15.     
 The full linear model output for log S-SAL can be seen in figure 6-8 below 
along with the residual plot of the model fit.   Upon visual evaluation, the residuals 
show an even spread of the distribution of data suggesting the lack of unequal variance.   
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*** Linear Model *** 
 
Call: lm(formula = log.S.SAL ~ Day, data = 
NIAAA.d.14.SAL.DA.time.assess.041108, 
 na.action = na.exclude) 
 
Coefficients: 
              Value Std. Error t value Pr(>|t|)  
(Intercept)  1.5513  0.0563    27.5628  0.0000  
        Day  0.0334  0.0072     4.6606  0.0000  
 
Multiple R-Squared: 0.1133  
 
Fitted : Day
R
es
id
ua
ls
1.6 1.7 1.8 1.9 2.0
-1
.5
-1
.0
-0
.5
0.
0
0.
5
1.
0
131
51
74
   
Figure 6-8:  Regression output for log S-SAL concentrations for all subjects as a factor 
of time along with the residual plot of the model fit. 
 
 With regard to R-SAL concentrations, a statistically significant effect of time 
was observed with the model fit resulting in F (1, 170) = 19.2, p-value = 2.1 x 10-5.   
The R2 for the entire model was 0.101.  Thus, the factor of time accounts for 
approximately 10.1% of the variability associated with the log R-SAL concentration 
measurements.    On average, a slight increase in log R-SAL concentrations was 
observed throughout the detoxification period across all subjects.   For every day spent 
abstinent from alcohol in the clinical center, an average increase of 0.04 log R-SAL 
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concentration was observed from admission day to day 15.  The full linear model output 
for Log R-SAL can be seen in figure 6-9 below along with the residual plot of the 
model fit.   As in the case of log S-SAL, the residuals for log R-SAL show an even 
spread of the distribution of data suggesting the lack of unequal variance.   
 
 
*** Linear Model *** 
 
Call: lm(formula = log.R.SAL ~ Day, data = 
NIAAA.d.14.SAL.DA.time.assess.041108, 
 na.action = na.exclude) 
 
Coefficients: 
              Value Std. Error t value Pr(>|t|)  
(Intercept)  1.5674  0.0717    21.8645  0.0000  
        Day  0.0400  0.0091     4.3792  0.0000  
 
Multiple R-Squared: 0.1014  
 
Fitted : Day
R
es
id
ua
ls
1.6 1.7 1.8 1.9 2.0 2.1
-2
-1
0
1
53
74
51
   
Figure 6-9: Regression output for log R-SAL concentrations for all subjects as a factor 
of time along with the residual plot of the model fit.  
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 Converse to log S- and R-SAL concentrations, a significant effect of time was 
not observed with log DA concentrations across all subjects throughout the 
detoxification period (F (1, 170) = 1.6, p-value = 0.208).   The R2 for the entire model 
was 0.009.   For every day spent abstinent from alcohol in the clinical center, an 
average of 0.68 log DA concentration was observed from admission day to day 15.  The 
full linear model output for log DA can be seen in figure 6-10 below along with the 
residual plot of the model fit.    
 
 
 
*** Linear Model *** 
 
Call: lm(formula = log.DA ~ Day, data = NIAAA.d.14.SAL.DA.time.assess.041108,  
 na.action = na.exclude) 
 
Coefficients: 
              Value Std. Error t value Pr(>|t|)  
(Intercept)  0.6834  0.0309    22.0835  0.0000  
        Day  0.0050  0.0039     1.2625  0.2085  
 
Multiple R-Squared: 0.009289  
 
Fitted : Day
lo
g.
D
A
0.70 0.72 0.74 0.76
-0
.5
0.
0
0.
5
1.
0
1.
5
  
 
Figure 6-10:  Regression output for log DA concentrations for all subjects as a factor of 
time along with the residual plot of the model fit. 
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 In essence, a significant effect of time was observed for the R- and S-SAL 
enantiomers while DA concentrations were stable throughout the detoxification period.   
On average across all subjects, a slight increase in concentrations was observed from 
day 1 to day 15, although time was only able to explain 11.3% and 10.1% of the 
variability associated with log S-SAL and log R-SAL concentrations, respectively.   Of 
note, regression analysis on the individual concentration–time profiles for the log R-
SAL and S-SAL analytes yielded significant effects of time with p-values for all 
subjects < 0.046.   The direction of the trend-in-time effect varied between subjects with 
increase and decreases being seen in concentrations over the detoxification period.   
Further assessment of the variability associated with time was further scrutinized upon 
evaluation of concentrations between different smoking status and gender groups.   
 
6.4.2c Effect of Smoking Status and Gender on R/S-SAL and DA concentrations 
 The average concentration vs. time plots for S-SAL, R-SAL and DA for 
smoking status and gender are shown in Figures 6-11 through 6-16 below.  The plots 
are depicted as average concentrations within each factor group (smoking status or 
gender) with corresponding standard deviation for each time point.  Individual 
concentration-time profiles may be viewed in Appendix M. 
 With respect to S-SAL and R-SAL concentrations, a systematic trend (i.e., 
increase or decrease) in concentrations was not observed within and between each 
smoking status group.  Regardless of smoking status, concentrations of S-SAL fluctuate 
with all subjects over the detoxification period.        
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Figure 6-11:  Plot of S-SAL over time on logarithmic scale for subjects within each 
smoking status group (pg/ml).  Each time point represents an average concentration 
within each group with corresponding + SD. 
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Figure 6-12:  Plot of S-SAL over time on logarithmic scale for subjects within each 
gender group (pg/ml).  Each time point represents an average concentration within each 
group with corresponding + SD. 
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Figure 6-13:  Plot of R-SAL over time on logarithmic scale for subjects within each 
smoking status group (pg/ml).  Each time point represents an average concentration 
within each group with corresponding + SD. 
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Figure 6-14:  Plot of R-SAL over time on logarithmic scale for subjects within each 
gender group (pg/ml).  Each time point represents an average concentration within each 
group with corresponding + SD. 
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 Incorporation of the factors of SS and GEN into the full statistical model found 
insignificant effects of both factors on the time course of log S-SAL.   Although a 
significant effect of time was observed, neither SS nor GEN had an influence on the 
time-course of log S-SAL.  Moreover an interaction was not observed between time and 
SS or GEN.  The full statistical model output for the regression analysis may be shown 
in figure 6-15 below.   The factors of time, SS and GEN were able to account for 13.1% 
of the variability associated with log S-SAL concentrations over the detoxification 
period. 
   
 
Call: 
   lm(formula = log.S.SAL ~ Day + SS + GEN + Day:SS + Day:GEN, data =  
 NIAAA.d.14.SAL.DA.time.assess.041108, na.action = na.exclude) 
 
  Coefficients: 
               Value Std. Error  t value Pr(>|t|)  
(Intercept)   1.5718   0.1571    10.0037   0.0000 
        Day   0.0241   0.0202    21.1908   0.0000 
         SS  -0.0478   0.0680    -0.7039   0.4825 
        GEN   0.1535   0.1129     1.3604   0.1756 
     Day:SS   0.0060   0.0087     0.6909   0.4906 
    Day:GEN  -0.0050   0.0144    -0.3477   0.7285 
 
Residual standard error: 0.4915 on 166 degrees of freedom 
Multiple R-Squared: 0.1312  
F-statistic: 5.015 on 5 and 166 degrees of freedom, the p-value is 0.0002637  
 
        
Figure 6-15:  Regression output for the factors of SS, GEN and time on log S-SAL 
concentrations throughout detoxification. 
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 The rank order of average concentrations between each smoking status group 
are not consistent throughout time.   For instance, at day 2 of detoxification the rank of 
HS > NS > LS was observed for the average S-SAL concentrations while the rank 
changes the next day (day 3) to HS > LS > NS.    Upon observation of the average 
profiles of both SAL enantiomers for each smoking status group, the variability 
associated with each time point appears to make the effect of smoking status 
indistinguishable.  
 Interestingly, a difference of gender was observed upon visual inspection of the 
profiles (figure 6-12).  For S-SAL, females had on average a higher concentration 
throughout the detoxification period.  The difference was more pronounced on 
admission day and day 2 of detoxification where a 20-fold difference was observed for 
the average S-SAL concentrations.   Including and subsequent to day 3, average S-SAL 
concentrations were similar between genders.   Both genders showed a parallel 
concentration time profile during the detoxification period, with the exception of the 
first two days.   
 Conversely, the concentration disparity for average R-SAL concentrations was 
observed in an opposite manner with respect to gender (figure 6-14).    Throughout 
detoxification, males showed, on average, higher R-SAL concentrations compared to 
their female counterparts.    At each time point, males had at least a five-fold higher 
average R-SAL concentration than females.  The concentration-time profiles between 
genders showed analogous trends for average R-SAL concentrations.  
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 Incorporation of the factors of SS and GEN into the full statistical model found 
insignificant effects of SS and GEN on the time course of log R-SAL.   A significant 
effect of time was observed with the test statistic for the factor of time yielding F (1, 
166) = 19.4, p-value = 1.8 x 10-5.  An interaction was not observed between time and SS 
or GEN.  The full statistical model output for the regression analysis may be shown in 
figure 6-16 below.   The factors of time, SS and GEN were able to account for 13.4% of 
the variability associated with log R-SAL concentrations over the detoxification period. 
   
Call: 
   lm(formula = log.R.SAL ~ Day + SS + GEN + SS:Day + GEN:Day, data =  
 NIAAA.d.14.SAL.DA.time.assess.041108, na.action = na.exclude) 
 
   
Coefficients: 
              Value Std. Error t value Pr(>|t|)  
(Intercept)  1.5275  0.1986     7.6934  0.0000  
        Day  0.0293  0.0255    19.1470  0.0000  
         SS -0.0411  0.0859    -0.4786  0.6328  
        GEN  0.2501  0.1426     1.7536  0.0813  
     Day:SS  0.0065  0.0110     0.5905  0.5557  
    Day:GEN -0.0038  0.0182    -0.2078  0.8356  
 
Multiple R-Squared: 0.1335  
F-statistic: 5.113 on 5 and 166 degrees of freedom, the p-value is 0.0002182  
 
 
Figure 6-16:  Regression output for the factors of SS, GEN and time on log R-SAL 
concentrations throughout detoxification. 
 
 
 Average DA concentration profiles for smoking status and gender are shown in 
figures 6-17 and 6-18, respectively.   Across all time-points, the rank of average DA 
396 
1
10
100
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
days post admission
D
A
 (n
g/
m
l)
HS
LS
NS
       
Figure 6-17:  Plot of DA over time on logarithmic scale for subjects within each 
smoking status group (ng/ml).  Each time point represents an average concentration 
within each group with corresponding + SD. 
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Figure 6-18:  Plot of DA over time on logarithmic scale for subjects within each gender 
group (ng/ml).  Each time point represents an average concentration within each group 
with corresponding + SD. 
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concentrations resulted in NS > HS > LS.   On average, NS possessed higher DA 
concentrations than both smoking groups.    Throughout the detoxification period, no 
more than a five-fold difference was observed between smoking status groups.  
Although the within-group variability at each time point was large, the concentration 
time profile for DA was relatively stable as compared to the SAL enantiomers.    With 
respect to gender, the concentration-time profiles were parallel with the exception of 
admission day, in which males possessed a three-fold higher DA concentration than 
females on average. 
 Incorporation of the factors of SS and GEN into the full statistical model found 
insignificant effects of both factors on the time course of log DA.  An insignificant 
effect of time was observed, with neither SS nor GEN having an influence on the time-
course of log DA.  The full statistical model output for the regression analysis may be 
shown in figure 6-19 below.       
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Call: 
   lm(formula = log.DA ~ Day + SS + GEN + SS:Day + GEN:Day, data =  
 NIAAA.d.14.SAL.DA.time.assess.041108, na.action = na.exclude) 
 
     Coefficients: 
              Value Std. Error t value Pr(>|t|)  
(Intercept)  0.7241  0.0860     8.4211  0.0000  
        Day  0.0089  0.0111     0.8024  0.4235  
         SS -0.0383  0.0372    -1.0292  0.3049  
        GEN  0.0724  0.0618     1.1722  0.2428  
     Day:SS -0.0010  0.0047    -0.2087  0.8349  
    Day:GEN -0.0038  0.0079    -0.4783  0.6331  
 
Multiple R-Squared: 0.03846  
F-statistic: 1.328 on 5 and 166 degrees of freedom, the p-value is 0.2548  
 
 
Figure 6-19:  Regression output for the factors of SS, GEN and time on log DA 
concentrations throughout detoxification. 
 
 For all analytes, an effect of SS was not observed with respect to the time course 
of the R/S-SAL and DA analytes over the detoxification period.  In order to further 
characterize the variability associated with the R/S-SAL enantiomers and DA 
concentrations, further evaluation of smoking status and gender was evaluated on the 
GTM of concentrations over the detoxification period, on the day of admission (day 1) 
and day 15.    Separate analyses for each analyte were performed for each of these time-
periods in order to assess for the effects of smoking status and gender.   
 
6.4.2c-1 Grand total mean of R/S-SAL and DA  
 Tables 6-10, 6-11 and 6-12 show the descriptive statistics for the concentrations 
S-SAL, R-SAL and DA observed for each smoking status and gender, respectively.  
Measures of central tendency, such as mean and median, along with the variability 
including %COV and range is presented for each factor.  With the exception of the LS 
female group, the gender distribution was similar for each smoking status group with  
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Table 6-10:  Descriptive statistics for GTM S-SAL concentrations (pg/ml) divided into 
smoking status and gender. 
 
Mean 132
Stdev 96
%COV 72
Median 108
MIN 31
MAX 313
Mean 97
Stdev 65
%COV 67
Median 90
MIN 20
MAX 287
Mean 113
Stdev 81
%COV 72
Median 90
MIN 20
MAX 313
S-SAL
Non-smoker Light-smoker Heavy-smoker GRAND
   
 F
em
al
e
117 86 184
111 80 78
95 92 42
61 40 194
38 31 77
313 217 290
   
   
M
al
e
135 70 82
79 41 52
59 59 64
120 70 81
58 22 20
287 136 146
   
 G
R
A
N
D
126 77 133
93 59 83
73 76 62
102 68 126
38 22 20
313 217 290      
 
 
Table 6-11:  Descriptive statistics for GTM R-SAL concentrations (pg/ml) divided into 
smoking status and gender. 
 
Mean 213
Stdev 181
%COV 85
Median 181
MIN 42
MAX 594
Mean 136
Stdev 104
%COV 77
Median 118
MIN 16
MAX 452
Mean 173
Stdev 150
%COV 86
Median 123
MIN 16
MAX 594
R-SAL
Non-smoker Light-smoker Heavy-smoker GRAND
   
 F
em
al
e
172 181 280
205 175 172
120 97 61
73 69 235
42 42 112
567 423 594
   
   
M
al
e
187 100 121
138 80 82
73 81 68
160 100 126
67 16 27
452 241 218
   
 G
R
A
N
D
179 137 200
167 132 153
93 96 76
120 95 183
42 16 27
567 423 594      
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Table 6-12:  Descriptive statistics for GTM DA concentrations (ng/ml) divided into 
smoking status and gender. 
 
Mean 6.5
Stdev 3.1
%COV 48
Median 5.4
MIN 2.4
MAX 15.2
Mean 6.1
Stdev 3.4
%COV 57
Median 5.4
MIN 2.8
MAX 15.9
Mean 6.2
Stdev 3.2
%COV 52
Median 5.4
MIN 2.4
MAX 15.9
4.3 2.4 2.8
15.9 8.2 10.3
52 34 46
5.6 4.8 6.1
15.9 8.2 7.0
   
 G
R
A
N
D
7.9 4.7 5.9
4.1 1.6 2.7
6.8 4.8 3.3
4.3 3.2 2.8
   
   
M
al
e
8.5 5.1 4.2
4.5 1.8 1.7
53 35 41
5.2 2.4 3.7
15.2 5.5 10.3
32
5.4 4.8 7.6
GRAND
   
 F
em
al
e
7.3 4.2 7.6
4.0 1.3 2.4
55 31
DA
Non-smoker Light-smoker Heavy-smoker
     
 
 
each group of 6 males and 6 females.  In the LS group, 6 males and 5 females were 
analyzed.   
 The overall averages (mean and %COV), across all patients for S-SAL, R-SAL 
and DA were 113 (72%), 173 pg/ml (86%) and 6.2 ng/ml (52%), suggesting that the 
GTM plasma SAL and DA concentrations are quite variable between all patients. The 
large differences between the median and mean R/S-SAL and DA concentrations 
suggest that the data follow non-normal distribution.    Upon comparison of the median 
concentrations, females were observed to have a slightly higher median S- and R-SAL 
concentrations compared to males.  Median DA concentrations and ranges were similar 
between genders for the GTM throughout detoxification. 
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 With respect to smoking status, the ranking of median S-SAL concentration was 
HS > NS > LS with similar within-group variability observed.  The same ranking was 
observed with median R-SAL concentrations with a higher amount of within-group 
variability.  Within each smoking status group a gender difference in the ranking was 
observed with S-SAL.   Females had the same overall smoking status group ranking 
while males had the ranking of NS > LS > HS for median S-SAL GTM concentrations.     
A discrepancy was also observed with R-SAL GTM concentrations, in which females 
had the similar overall smoking status group ranking, while in males the following 
ranking was observed of the median concentrations: NS > HS > LS.    For DA, the HS > 
NS > LS ranking was observed.  The inconsistency of ranking between genders was 
also observed with males possessing a rank for median concentration of NS > LS > HS, 
while the female counterparts shared the same ranking as the smoking status group.   
 The distribution of the GTM data within each smoking group for R-SAL, S-SAL 
and DA followed a non-normal distribution upon assessment of quantile-quantile (Q-Q) 
plots.   Moreover, unequal variance was present with the data upon visual inspection of 
the residuals.    For these reasons, log-transformed data were used for the primary 
analysis.  Two-way ANOVA was performed on the log transformed R-SAL, S-SAL and 
DA GTM concentrations, evaluating the factors of smoking status and gender.  Box-
plots exemplifying the median and distribution, including outliers for the effects of 
gender and smoking status are presented below for the GTM log S-SAL (figure 6-20) 
and GTM log R-SAL (figure 6-21).    
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Figure 6-20:  Boxplots of the GTM of log S-SAL for smoking status (SS, left plot) and 
gender (GEN, right plot). 
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Figure 6-21:  Boxplots of the GTM of log R-SAL for smoking status (SS, left plot) and 
gender (GEN, right plot). 
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 Observation of the S-SAL and R-SAL box-plots suggests that there was no 
significant difference between gender groups and a lack of a significant trend was 
observed between smoking groups.  Two-way ANOVA was performed to evaluate the 
effects of gender and smoking on GTM log S-SAL and log R-SAL concentrations.   A 
significant effect of smoking status (SS) and gender (GEN) was not observed with 
respect to GTM log S-SAL and R-SAL concentrations.   For both enantiomers, the 
smoking status factor was insignificant with the test statistic resulting in F (2, 29) = 2.0, 
p-value = 0.15 for S-SAL and F (2, 29) = 0.97, p-value = 0.39 for R-SAL.  The effect of 
gender (GEN) was not significant with the test statistic resulting in p-values > 0.22 for 
both enantiomers.    No interaction between the SS and GEN factors was observed, 
therefore, linear contrasts were unnecessary.   The coefficient of determination (R2) for 
the entire model was 0.257 (p-value = 0.107) for S-SAL and 0.095 (p-value = 0.368).  
Abbreviated ANOVA tables may be viewed in figure 6-22 below.    Full two-way 
ANOVA outputs may be viewed in Appendix O along with the residual plots of the 
model fit.   Upon visual evaluation, the residuals show an even spread of the 
distribution of data suggesting the lack of unequal variance.  As significance was not 
found with the main effects, further multiple comparisons were not performed.  
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*** log S_SAL GTM Analysis of Variance Model *** 
 
Short Output: 
Call: 
   aov(formula = Av.Log.S.SAL ~ SS + GEN + SS:GEN, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.041108, na.action = na.exclude) 
 
 
          Df Sum of Sq   Mean Sq  F Value     Pr(F)  
       SS  2  0.386512 0.1932561 1.993205 0.1544943 
      GEN  1  0.084351 0.0843511 0.869980 0.3586619 
   SS:GEN  2  0.504868 0.2524341 2.603555 0.0912186 
Residuals 29  2.811766 0.0969575                    
 
 
Multiple R-Squared: 0.2576  
F-statistic: 2.013 on 5 and 29 degrees of freedom, the p-value is 0.1065  
 
 
 
*** log R_SAL GTM Analysis of Variance Model *** 
 
Short Output: 
Call: 
   aov(formula = Av.Log.R.SAL ~ SS + GEN + SS:GEN, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.041108, na.action = na.exclude) 
 
          Df Sum of Sq   Mean Sq  F Value     Pr(F)  
       SS  2  0.288904 0.1444520 0.969432 0.3912530 
      GEN  1  0.225614 0.2256137 1.514116 0.2284000 
   SS:GEN  2  0.557630 0.2788149 1.871155 0.1720623 
Residuals 29  4.321198 0.1490068                    
 
 
Multiple R-Squared: 0.0954  
F-statistic: 1.09 on 3 and 31 degrees of freedom, the p-value is 0.368  
 
 
 
Figure 6-22:  Two–way ANOVA output for the effects of SS and GEN on GTM log S-
SAL (top) and GTM log R-SAL (bottom) concentrations. 
 
 
 
 
406 
 Contrary to the SAL enantiomers results, GTM log DA box-plots suggest that 
there was a trend observed between smoking groups. (see figure 6-23 below).  Two-way 
ANOVA was performed to evaluate the effects of gender and smoking on GTM log DA 
concentrations.   While a significant effect of GEN was not observed, the factor of SS 
was significant.  The SS factor was significant with the test statistic resulting in F (2, 
29) = 4.1, p-value = 0.026.  The effect of gender (GEN) was not significant with the test 
statistic resulting in a p-value = 0.403.   No interaction between the SS and GEN factors 
was observed, therefore, linear contrasts were unnecessary.   The coefficient of 
determination (R2) for the entire model was 0.346 (p-value = 0.024).   The factor of SS 
and GEN account for approximately 34.6% of the variability associated with the GTM 
log DA concentration. 
 Multiple comparisons via the Scheffé method found the difference to be 
between the NS and LS groups while differences were not observed between the NS-HS 
and LS-HS groups.  The two-way ANOVA output may be viewed below in figure 6-24 
along with the results of the multiple comparison tests.   The residuals of the model fit 
showed a lack of unequal variance.   
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Figure 6-23:  Boxplots of the GTM of log DA for smoking status (SS, left plot) and 
gender (GEN, right plot). 
 
 
Call: 
   aov(formula = Av.Log.DA ~ SS + GEN + SS:GEN, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.041108, na.action = na.exclude) 
 
          Df Sum of Sq   Mean Sq  F Value     Pr(F)  
       SS  2 0.2755988 0.1377994 4.106723 0.0268920 
      GEN  1 0.0241072 0.0241072 0.718446 0.4035956 
   SS:GEN  2 0.2139152 0.1069576 3.187569 0.0560593 
Residuals 29 0.9730832 0.0335546                    
 
Multiple R-Squared: 0.3455  
F-statistic: 3.061 on 5 and 29 degrees of freedom, the p-value is 0.0244 
95 % simultaneous confidence intervals for specified  
linear combinations, by the Scheffé method  
 
intervals excluding 0 are flagged by '****'  
 
      Estimate Std.Error Lower Bound Upper Bound       
HS-LS   0.0825    0.0766      -0.145       0.310      
HS-NS  -0.1370    0.0748      -0.359       0.085      
LS-NS  -0.2190    0.0766      -0.447      -0.008 ****   
 
Figure 6-24:  Two–way ANOVA output for effects of SS and GEN on GTM log DA. 
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6.4.2c-2  Exploratory and Covariate analysis for GTM 
 A statistically significant effect of smoking status was not observed on log R-
SAL and log S-SAL plasma GTM concentrations.   Further evaluation of the variability 
associated with GTM R/S-SAL and DA exposure was performed by using the FTND 
score and number of cigarettes smoked per day as continuous dependent variables to 
explain the individual subjects’ exposures.    
 As in the case for Study #1, the analyses incorporated FTND and the number of 
cigarettes smoked per day in lieu of the SS category for the ANOVA analysis of GTM 
concentrations.    For GTM log S-SAL, neither the FTND nor the number of cigarettes 
smoked per day had a significant influence on the ANOVA fit with resultant p-values 
being 0.591 and 0.844, respectively.    The same observation was seen for GTM log R-
SAL with the FTND fit having a p-value of 0.552 and the number of cigarettes having a 
p-value of 0.774.     Moreover, use of these smoking variables yielded inferior fits as 
compared to the smoking status factor.   Full linear model results may be viewed in 
Appendix O.  Results of the primary analysis, using smoking status as a factor and the 
exploratory analysis, using FTND and the number of cigarettes per day, suggest that 
smoking does not have a significant influence on GTM log S-SAL and log R-SAL 
concentrations.   
 Information including alcohol intake and weekly exposure to dietary total SAL 
and whether or not acamprosate was used in the subject was recorded to evaluate for 
their effects on the GTM of R-SAL, S-SAL and DA.     As dietary intake of ethanol 
and/or SAL containing foods may affect the overall exposure, this covariate 
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assessments may provide information into the variability associated with the plasma 
measurement of GTM log R-SAL and/or S-SAL.   Moreover, it is unknown whether 
acamprosate has an effect on circulating R/S-SAL or DA, therefore it was prudent to 
evaluate whether this drug may have a significant effect.    If alcohol intake, dietary 
exposure, or acamprosate administration were found to significantly correlate with SAL 
exposure, the TLFB, Food Intake and whether or not the subject was taking 
acamprosate was considered a significant covariate and implemented into the statistical 
model. 
 Linear regressions were performed on GTM log R-SAL, log S-SAL as a 
function of number of drinks in the past ninety days (TLFB) or average weekly dietary 
total SAL (Food Inventory) intake.   Similar criteria aforementioned for covariate 
analysis were used for the SAL and DA analysis.     Evaluation of the significance of 
the covariate was additionally assessed upon implementation into a final ANCOVA 
model.  The p-value was evaluated for significance of the covariate.  If considered 
significant, the fit of the entire model was evaluated for goodness of fit, with use of the 
covariate.    A table summarizing the covariate regression analysis for the TLFB, 
dietary SAL intake, and acamprosate administration is shown below (table 6-13).   
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Table 6-13:  Covariate analysis results for GTM log R-SAL, log S-SAL and log DA 
Weekly 
Dietary Intake 
Acamprosate 
administration 
TLFB   
(# of drinks in 
past 90 days) variable (ng SAL) (yes or no) 
R2 0.0551 0.0382 0.002 
p-value 0.175 0.324 0.803 Log R-SAL 
significance NS NS NS 
R2 0.069 0.102 0.006 
p-value 0.128 0.546 0.657 Log S-SAL 
significance NS NS NS 
R2 0.008 N/A 0.006 
p-value 0.611 N/A 0.646 Log DA 
significance NS N/A NS 
NS:   not significant 
N/A: dietary intake of DA was not available   
 
 
 
 
 The covariate analysis revealed a poor association between the TLFB, weekly 
dietary SAL intake, and acamprosate administration on GTM concentrations of SAL 
enantiomers and DA.  As SAL enantiomers are hypothesized to be influenced by 
chronic alcohol exposure, it was expected that influence of the TLFB would contribute 
to the circulating plasma concentrations.  The TLFB was subsequently incorporated into 
the ANCOVA model as a covariate, with the primary factors of smoking status and 
gender, and was found not to be significant for all analytes.   Moreover, the ANCOVA 
model for assessment of the primary factors was not improved upon implementation of 
the TLFB covariate, for all GTM analytes.  
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 Use of the acamprosate or SAL food Intake as a covariate was not significant 
and was not implemented into the full statistical model.    The results of this covariate 
analysis suggest that the number of drinks consumed in the past ninety days, weekly 
dietary intake of total SAL, and administration of acamprosate do not influence the 
GTM levels of R/S-SAL or DA.   
 The GTM concentrations of the SAL enantiomers and DA represent the overall 
average behavior of concentrations throughout the in-patient detoxification period.    
The analysis was utilized to reflect the influence of smoking and gender, rather than 
time, during of circulating SAL levels throughout the abstinence period.  For the SAL 
enantiomers, a significant effect of smoking status or gender was not observed on the 
GTM concentrations.  This was unexpected as patients were able to smoke cigarettes 
throughout the detoxification period.  A trend between the HS and NS was observed 
with HS possessing a higher GTM R/S-SAL concentration than NS, but statistical 
significance was not observed due to the within group variability.    The within-group 
variability associated for the LS group was large for both SAL enantiomers, 
confounding the lack of a significant effect of smoking status.     In addition, smoking 
variables such as the FTND and number of cigarettes smoked per day did not have a 
significant influence. 
 On the other hand, a significant effect of smoking status was observed with 
GTM DA concentrations, with NS possessing higher concentrations than that of both 
the smoking groups.  Assuming that circulating plasma DA is reflective of CNS 
concentrations, this result supports the hypothesis of the reinforcing properties of 
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cigarette exposure.   In other words, the LS and HS groups possess low concentrations 
of circulating DA compared to NS, and smokers require smoking to increase DA levels 
for homeostasis of central DA activity.   Of note, biological sampling was performed 
prior to smoking the first cigarette of the day.   
 It is important to note that smoking behavior throughout the detoxification 
period was not recorded nor was dietary intake of SAL during the inpatient stay, both of 
which may obscure the primary factor analysis on the GTM concentrations.   
Interestingly, speculated influences of SAL exposure such as prior alcohol exposure or 
average dietary intake did not have an effect on GTM concentrations. Correlation 
analyses found no significant association between these variables and GTM 
concentrations. Throughout the inpatient abstinence period, the use of additional 
pharmacotherapies was employed for concomitant disease states other than alcoholism.    
The use of acamprosate did not have an effect on GTM concentrations.  However, 
evaluation of additional therapies was not assessed for their influence on SAL or DA 
concentrations, which may confound the current results.   
 Of primary importance is the time-course and sampling schedule employed for 
the observations.   Rommelspacher and co-workers found that, during an in patient 
detoxification period, the results of the R/S-SAL concentrations on each day observed 
were quite variable across subjects. For the first week R-SAL and S-SAL 
concentrations were statistically similar.  Time-dependence of the SAL concentrations 
was not observed until 3 and 6-months after detoxification center admission.    At these 
time points, the effect of the underlying alcoholism on SAL levels is presumably 
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negligible with similar SAL concentrations to non-alcoholics (Rommelspacher et al., 
1995).   The effect of smoking on SAL levels in alcoholics my not be observed within 
the time period assessed in our investigation, but rather at a later time of alcohol 
abstinence.   
 
6.4.2c-3 Analysis of R/S-SAL and DA on Admission Day  
 Tables 6-14, 6-15 and 6-16 show the descriptive statistics for the admission day 
concentrations S-SAL, R-SAL and DA observed for each smoking status and gender, 
respectively.  
 
Table 6-14:  Descriptive statistics for admission S-SAL concentrations (pg/ml) divided 
into smoking status and gender. 
 
Mean 86
Stdev 130
%COV 151
Median 58
MIN 1
MAX 567
Mean 37
Stdev 27
%COV 74
Median 33
MIN 5
MAX 106
Mean 61
Stdev 95
%COV 156
Median 41
MIN 1
MAX 567
S-SAL
Non-smoker Light-smoker Heavy-smoker GRAND
   
 F
em
al
e
85 130 52
46 245 28
54 189 53
72 15 49
39 1 21
147 567 95
   
   
M
al
e
35 43 32
24 37 22
69 85 68
30 36 33
10 5 5
66 106 61
   
 G
R
A
N
D
60 82 42
44 156 26
73 191 62
51 36 35
10 1 5
147 567 95       
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Table 6-15:  Descriptive statistics for admission R-SAL concentrations (pg/ml) divided 
into smoking status and gender. 
 
Mean 103
Stdev 200
%COV 194
Median 46
MIN 1
MAX 860
Mean 41
Stdev 38
%COV 93
Median 28
MIN 3
MAX 119
Mean 71
Stdev 144
%COV 201
Median 36
MIN 1
MAX 860
R-SAL
Non-smoker Light-smoker Heavy-smoker GRAND
   
 F
em
al
e
86 190 52
43 375 28
50 197 53
91 15 49
36 1 21
157 860 95
   
   
M
al
e
33 47 32
40 44 22
122 94 68
17 30 33
3 4 5
108 119 61
   
 G
R
A
N
D
60 112 45
49 251 40
82 223 88
45 19 31
3 1 4
157 860 133              
 
Table 6-16:  Descriptive statistics for admission DA concentrations (pg/ml) divided 
into smoking status and gender. 
 
Mean 6.2
Stdev 2.9
%COV 47
Median 5.8
MIN 1.4
MAX 13.6
Mean 4.9
Stdev 2.9
%COV 59
Median 4.0
MIN 1.5
MAX 11.2
Mean 5.5
Stdev 2.9
%COV 53
Median 4.6
MIN 1.4
MAX 13.6
DA
Non-smoker Light-smoker Heavy-smoker GRAND
   
 F
em
al
e
7.5 3.9 6.9
3.5 2.1 1.7
47 54 25
7.0 3.6 6.9
4.4 1.4 4.6
13.6 6.7 9.7
   
   
M
al
e
5.0 5.1 4.6
3.5 3.1 2.6
69 60 56
4.3 4.0 3.2
1.5 2.8 2.8
11.2 11.2 8.8
   
 G
R
A
N
D
6.3 4.5 5.7
3.6 2.6 2.4
57 58 42
5.1 3.7 6.2
1.5 1.4 2.8
13.6 11.2 9.7             
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 The overall averages (mean and %COV), across all patients for S-SAL, R-SAL 
and DA were 61 pg/ml (156%), 71 pg/ml (201%) and 5.5 ng/ml (53%), suggesting that 
the admission plasma SAL and DA concentrations were variable between all patients. 
More variability was observed with the admission concentrations than that of the GTM 
concentrations.   Upon comparison of the median concentrations, females were 
observed to have a slightly higher median S-SAL, R-SAL and DA concentrations 
compared to males.    
 With respect to smoking status, the ranking of median S-SAL concentration was 
NS > LS > HS with varying degrees of within-group variability observed.  The NS and 
HS groups possessed similar %COV while the LS group had a much larger variability 
in admission S-SAL concentration.  The ranking of NS > HS > LS was observed with 
median R-SAL concentrations with a highest amount of within-group variability for the 
LS group.  Within each smoking status group, a gender difference in the ranking was 
observed with S-SAL.   Females possessed the same overall smoking status group 
ranking while males had the ranking of  LS > HS > NS.  In addition, the difference in 
males between smoking status groups was observed to be small for median S-SAL 
admission concentrations.     A discrepancy was also observed with R-SAL admission 
concentrations in which females had the similar overall smoking status group ranking, 
while in males the following ranking was observed of the median concentrations: HS > 
LS > NS.    For DA, the HS > NS > LS ranking was observed.  The inconsistency of 
ranking between genders was also observed with males possessing a rank for median 
concentration of NS > LS > HS, while the female counterparts NS ~ HS > LS.   
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 The distribution of the admission data within each smoking group for R-SAL, S-
SAL and DA followed a non-normality and unequal variance. Therefore, log-
transformed data were used for the primary analysis.  Box-plots are presented below for 
the admission log S-SAL (figure 6-25), log R-SAL (figure 6-26) and log DA (figure 6-
27).    
 
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
Lo
g.
S.
SA
L.
d.
1
x
x
x
HS LS NS
SS
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
Lo
g.
S.
SA
L.
d.
1 x
x
F M
GEN
 
Figure 6-25:  Boxplots of admission log S-SAL for smoking status (SS, left plot) and 
gender (GEN, right plot). 
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Figure 6-26:  Boxplots of admission log R-SAL for smoking status (SS, left plot) and 
gender (GEN, right plot). 
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Figure 6-27:  Boxplots of admission log DA for smoking status (SS, left plot) and 
gender (GEN, right plot). 
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 Observation of the S-SAL, R-SAL and DA box-plots suggest that there was no 
significant difference between gender groups and a lack of a significant trend was 
observed between smoking groups.  Two-way ANOVA was performed to evaluate the 
effects of gender and smoking on admission log S-SAL, log R-SAL and log DA 
concentrations.   A significant effect of smoking status (SS) and gender (GEN) was not 
observed with respect to admission concentrations.   No interaction between the SS and 
GEN factors was observed.   Abbreviated ANOVA tables may be viewed in figure 6-28 
below.  Significance was not found with the main effects, thus further multiple 
comparisons were not performed.  
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*** log S_SAL Admission Analysis of Variance Model *** 
 
Short Output: 
Call: 
   aov(formula = Log.S.SAL.d.1 ~ SS + GEN + SS:GEN, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.041108, na.action = na.exclude) 
 
          Df Sum of Sq   Mean Sq  F Value     Pr(F)  
       SS  2  0.404638 0.2023190 0.790651 0.4630836 
      GEN  1  0.357304 0.3573041 1.396324 0.2469397 
   SS:GEN  2  0.531942 0.2659710 1.039400 0.3664710 
Residuals 29  7.420785 0.2558891                    
    
Multiple R-Squared: 0.1485  
F-statistic: 1.011 on 5 and 29 degrees of freedom, the p-value is 0.4289  
 
 
 
*** log R_SAL Admission Analysis of Variance Model *** 
 
Short Output: 
Call: 
   aov(formula = Log.R.SAL.d.1 ~ SS + GEN + SS:GEN, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.041108, na.action = na.exclude) 
 
          Df Sum of Sq   Mean Sq  F Value     Pr(F)  
       SS  2  0.078214 0.0391069 0.118296 0.8888598 
      GEN  1  0.500541 0.5005412 1.514103 0.2284020 
   SS:GEN  2  0.807796 0.4038981 1.221764 0.3094337 
Residuals 29  9.586996 0.3305861                    
 
Multiple R-Squared: 0.1264  
F-statistic: 0.8388 on 5 and 29 degrees of freedom, the p-value is 0.5332  
 
 
 
*** log DA Admission Analysis of Variance Model *** 
 
Short Output: 
Call: 
   aov(formula = Log.DA.d.1 ~ SS + GEN + SS:GEN, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.041108, na.action = na.exclude) 
 
          Df Sum of Sq   Mean Sq  F Value     Pr(F)  
       SS  2  0.196977 0.0984884 1.273453 0.2950514 
      GEN  1  0.195106 0.1951058 2.522713 0.1230619 
   SS:GEN  2  0.333961 0.1669806 2.159055 0.1336306 
Residuals 29  2.242850 0.0773397                    
 
 
Multiple R-Squared: 0.2446  
F-statistic: 1.878 on 5 and 29 degrees of freedom, the p-value is 0.1291 
 
Figure 6-28:  Two–way ANOVA output for the effects of SS and GEN on admission 
log S-SAL (top) log R-SAL (middle) and log DA (bottom) concentrations. 
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6.4.2c-4 Exploratory and Covariate analysis for admission day 
 A statistically significant effect of smoking status was not observed on log R-
SAL and log S-SAL admission day plasma concentrations.   Further evaluation of the 
variability associated with admission day R/S-SAL and DA exposure was performed by 
using the FTND score and number of cigarettes smoked per day as continuous 
dependent variables to explain the individual subjects’ exposures.    
 For admission day log S-SAL, neither the FTND nor the number of cigarettes 
smoked per day had a significant influence on the ANOVA fit with resultant p-values 
being 0.704 and 0.799, respectively.    The same observation was seen for admission log 
R-SAL with the FTND fit resulting in a p-value of 0.801 and the number of cigarettes 
having a p-value of 0.851.    Results of the primary analysis (using smoking status as a 
factor) and the exploratory analysis (FTND or the number of cigarettes per day), 
suggest that smoking does not have a significant influence on admission day log S-SAL 
and log R-SAL concentrations.   
 With respect to admission day concentrations, it is important to note that 
biological sampling was conducted upon admission to the clinic.  The time of day of 
sampling was variable across subjects, which may confound the analysis.  More 
importantly, 13 of the 35 subjects evaluated (37.1%) tested positive for a drug of abuse 
other than alcohol and nicotine (see table 6-3).  It is unknown to what extent drugs of 
abuse such as amphetamines, cocaine, or benzodiazepine influence circulating R/S-SAL 
plasma concentrations.  Moreover, 13 of the 35 subjects entered the detoxification clinic 
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with a positive BrAC.   This is the result of recent exposure to alcohol and therefore 
may influence the admission day concentration of log R/S-SAL.   
 Similar to the GTM analysis, information including alcohol intake and weekly 
exposure to dietary total SAL  was evaluated for their effects on the admission day log 
R-SAL, S-SAL and DA.  If recent alcohol intake (i.e., positive or negative BrAC), 
chronic alcohol intake (i.e., TLFB),  dietary exposure, or drugs of abuse (i.e., positive or 
negative of admission) were found to significantly correlate with log R/S-SAL of DA 
exposure, they were considered a significant covariate and implemented into the 
statistical model. 
 Linear regressions were performed on log R-SAL, log S-SAL as a function of 
TLFB and average weekly dietary total SAL (Food Inventory) intake.  An association of  
positive or negative BrAC, positive or negative admission drug of abuse as used to 
assess an influence of recent alcohol exposure or drug of abuse, respectively.     Similar 
criteria aforementioned for covariate analysis were used for the SAL and DA analysis.     
Evaluation of the significance of the covariate was additionally assessed upon 
implementation into a final ANCOVA model.  The p-value was evaluated for 
significance of the covariate.   If considered significant, the fit of the entire model was 
evaluated for goodness of fit, with use of the covariate.    For the case of BrAC and 
drug of abuse influence, a dummy-regression variable was used for implementation into 
ANCOVA model.  Boxplots of these variables are included in figure 6-29.   A table 
summarizing the covariate regression analysis for the TLFB, dietary SAL intake, BrAC 
and drugs of abuse (table 6-17). 
42
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 No correlation was observed between the TLFB, weekly dietary SAL intake, 
positive BrAC and positive drug of abuse for the admission concentrations of SAL 
enantiomers and DA.  As SAL enantiomers are hypothesized to be influenced by acute 
alcohol exposure, it was expected that influence of the BrAC would contribute to the 
circulating plasma concentrations.  The boxplot in figure 6-29 exemplifies a lack of a 
difference between positive admission BrAC and negative for both enantiomers, 
suggesting that the sole factor of BrAC is not descriptive of SAL concentrations.    
Interestingly, persons with a positive BrAC had a slightly lower average log 
concentration of both S-SAL and R-SAL.  Employment of BrAC as a categorical 
regression variable in the ANCOVA models, accounting for the factors of smoking 
status and gender, found a lack of statistical significance for the potential covariate.   
Moreover, the fit for the primary factors did not show statistical significance with use of 
BrAC as a covariate.     The same case was observed for persons showing positive 
results for the urine drug of abuse (DOA) screen.   
 Use of the TLFB or SAL food intake as a covariate was not significant and was 
not implemented into the full statistical model.    The results of this covariate analysis 
suggest that the number of drinks consumed in the past ninety days, weekly dietary 
intake of total SAL, positive or negative BrAC, and positive or negative drug of abuse 
testing do not influence the admission levels of R/S-SAL or DA.   
 As a separate analysis, liver function as assessed by AST (aspartate 
aminotransferase) had a significant effect on admission SAL concentrations.   While 
AST is considered a marker of acute ethanol exposure and hepatocellular damage, 
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correlation with the SAL enantiomers on day 1 was performed.    Results showed that, 
for both enantiomers, a significant effect of AST was observed.  AST as a predictor of 
day 1 log S-SAL and R-SAL was significant with the test statistic resulting in F (1, 32) 
= 5.98, p-value = 0.02 for log S-SAL and F (1, 32) = 7.42, p-value = 0.01 for log R-
SAL.  The regression plots of admission day log S-SAL and log R-SAL are shown in 
the figures 6-30 and 6-31 below.   
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Figure 6-30:  Admission log S-SAL as a function of AST (p-value = 0.02, R2 = 0.158, 
log S-SAL = -0.0037 AST + 1.74)   
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Figure 6-31:  Admission log R-SAL as a function of AST (p-value = 0.01, R2 = 0.188, 
log R-SAL = -0.0048 AST + 1.76)   
 
 
 
 According to the regression analysis, liver function as deemed by AST, may be 
an important variable when evaluating admission SAL enantiomer concentrations.    As 
liver function declines, an observed decrease in the both enantiomers is present.    For 
every U/L increase in AST a corresponding 0.0037 decrease in log S-SAL and 0.0048 
decrease in log R-SAL concentration is observed.    Of note, analysis of other liver 
function measures (e.g., alanine aminotransferase and albumin) yielded insignificant 
correlations.   Therefore, as the relationship observed between SAL concentrations and 
AST was not strong, and other measures of liver function did not have a significant 
effect, the interpretability of the relationship should be taken with discretion.   
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 The admission concentrations of the SAL enantiomers and DA represent the 
initial concentrations at the beginning of the in-patient detoxification period.    The 
analysis was utilized to assess the influence prior to initial detoxification on circulating 
SAL levels.  It is important to note that the SAL concentrations at the admission time-
point possessed the greatest variability compared to that of the GTM and day 15.    A 
lack of investigational control of the subjects prior to admission may account for this 
variability.   Biological sampling was performed without information regarding the time 
relative to exposure of SAL-containing or aldehyde-containing foods and beverages. 
 A significant effect of smoking status or gender was not observed on the 
admission log SAL enantiomer concentrations.  Knowledge of prior acute tobacco 
smoking exposure, before entrance into the detoxification center and before biological 
sampling, was unavailable and may have influenced the admission concentrations.    In 
addition, smoking variables such as the FTND and number of cigarettes smoked per day 
did not have a significant influence.  With respect to gender, a slight trend was observed 
with females possessing higher concentrations than males, but the difference was 
statistically insignificant.   
  Interestingly, hypothesized influences of SAL exposure, such as prior alcohol 
exposure, average dietary intake or positive drugs of abuse screen, did not have a 
significant influence on admission concentrations. Correlation analyses found no 
significant association between these variables and the admission concentrations.    
 Liver function, as assessed by AST, had an influence on admission R/S-SAL 
concentrations.    For this reason, the applicability of BrAC or TLFB measures of 
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alcohol exposure may not have been reliable covariates.  As the endogenous formation 
of the SAL enantiomer within the body may require consequent metabolism of ethanol, 
liver function may be an important determinant of SAL exposure upon acute ingestion 
of alcohol.    Moreover, some researchers speculate that SAL enantiomers are formed 
via enzymatic routes (Naoi et al., 1996), therefore, hepatocellular function my play a 
role in the synthesis of SAL enantiomers.    
 
6.4.2c-5 Analysis of R/S-SAL and DA on Day 15  
 Tables 6-18, 6-19 and 6-20 show the descriptive statistics for day 15 
concentrations S-SAL, R-SAL and DA observed for each smoking status and gender, 
respectively.  
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Table 6-18:  Descriptive statistics for day 15 S-SAL concentrations (pg/ml) divided into 
smoking status and gender. 
 
Mean 151
Stdev 118
%COV 78
Median 122
MIN 18
MAX 504
Mean 127
Stdev 141
%COV 111
Median 73
MIN 9
MAX 560
Mean 139
Stdev 129
%COV 93
Median 102
MIN 9
MAX 560
S-SAL
Non-smoker Light-smoker Heavy-smoker GRAND
   
 F
em
al
e
104 147 200
66 99 164
64 68 82
99 122 139
18 50 77
217 314 504
   
   
M
al
e
132 78 172
118 88 203
89 113 118
76 41 128
32 26 9
337 253 560
   
 G
R
A
N
D
118 110 186
92 96 176
78 87 95
94 85 136
18 26 9
337 314 560            
 
Table 6-19:  Descriptive statistics for day 15 R-SAL concentrations (pg/ml) divided 
into smoking status and gender. 
 
Mean 210
Stdev 177
%COV 84
Median 166
MIN 25
MAX 704
Mean 180
Stdev 221
%COV 123
Median 92
MIN 4
MAX 883
Mean 195
Stdev 198
%COV 102
Median 149
MIN 4
MAX 883
R-SAL
Non-smoker Light-smoker Heavy-smoker GRAND
   
 F
em
al
e
132 228 274
93 172 235
70 75 86
113 185 236
25 73 42
300 524 704
   
   
M
al
e
162 107 272
165 137 322
102 127 118
92 43 217
32 18 4
456 367 883
   
 G
R
A
N
D
147 162 273
128 159 269
88 98 99
107 150 217
25 18 4
456 524 883  
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Table 6-20:  Descriptive statistics for day 15 DA concentrations (pg/ml) divided into 
smoking status and gender. 
 
Mean 6.1
Stdev 2.6
%COV 43
Median 5.0
MIN 3.7
MAX 12.7
Mean 5.8
Stdev 3.2
%COV 55
Median 5.2
MIN 2.6
MAX 16.6
Mean 5.9
Stdev 2.9
%COV 49
Median 5.2
MIN 2.6
MAX 16.6
3.7 3.5 2.6
16.6 9.1 12.7
55 31 51
5.5 4.5 5.1
16.6 9.1 6.3
   
 G
R
A
N
D
6.6 5.1 5.9
3.6 1.6 3.0
5.1 5.8 4.1
3.7 3.5 2.6
   
   
M
al
e
6.7 5.9 4.3
4.9 1.8 1.3
73 31 30
4.0 3.9 3.7
9.6 4.5 12.7
47
6.1 4.2 6.2
GRAND
   
 F
em
al
e
6.4 4.2 7.4
2.0 0.2 3.5
31 5
DA
Non-smoker Light-smoker Heavy-smoker
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 The overall averages (mean and %COV), across all patients for S-SAL, R-SAL 
and DA were 139 pg/ml (93%), 195 pg/ml (102%) and 5.9 ng/ml (49%). Upon 
comparison of the median concentrations, females were observed to have a slightly 
higher day 15 median S-SAL and R-SAL concentrations compared to males, while DA 
concentrations were similar between genders.    
 With respect to smoking status, the ranking of median S-SAL concentration was 
HS > NS > LS with similar degrees of within-group variability observed.  The ranking 
of HS > LS > NS was observed with median R-SAL concentrations on day 15.  Within 
each smoking status group a gender difference in the ranking was observed with S-SAL.   
Males possessed the same overall smoking status group ranking while females had the 
ranking of  HS > LS > NS.   A discrepancy was also observed with R-SAL admission 
concentrations in which females had the similar overall smoking status group ranking, 
while in males the following ranking was observed of the median concentrations: HS > 
NS > LS.    For DA, the NS > HS > LS ranking was observed, although the differences 
were negligible between NS and HS groups.  The inconsistency of ranking between 
genders was also observed with males possessing a rank for median concentration of LS 
> NS > HS, while the female counterparts HS ~ NS > LS.  Box-plots are presented 
below for the day 15 log S-SAL (figure 6-32), log R-SAL (figure 6-33) and log DA 
(figure 6-34).    
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Figure 6-32:  Boxplots of day 15 log S-SAL for smoking status (SS, left plot) and 
gender (GEN, right plot). 
 
 
 
 
 
 
 
 
 
434 
 
 
0.
4
0.
6
0.
8
1.
0
1.
2
Lo
g.
D
A
.d
.1
5
x
x
x
HS LS NS
SS
0.
4
0.
6
0.
8
1.
0
1.
2
Lo
g.
D
A
.d
.1
5
x
x
F M
GEN
 
Figure 6-33:  Boxplots of day 15 log R-SAL for smoking status (SS, left plot) and 
gender (GEN, right plot). 
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Figure 6-34:  Boxplots of admission log DA for smoking status (SS, left plot) and 
gender (GEN, right plot). 
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 Observation of the S-SAL, R-SAL and DA box-plots suggest that there was no 
significant difference between gender groups and a lack of a significant trend was 
observed between smoking groups on day 15.  Two-way ANOVA was performed to 
evaluate the effects of gender and smoking on admission log S-SAL, log R-SAL and 
log DA concentrations.   A significant effect of smoking status (SS) and gender (GEN) 
was not observed with respect to admission concentrations.   No significant interaction 
between the SS and GEN factors was observed.   Abbreviated ANOVA tables may be 
viewed in figure 6-35 below.  Significance was not found with the main effects, 
therefore further multiple comparisons were not performed.  
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*** log S_SAL day 15 Analysis of Variance Model *** 
 
Call: 
   aov(formula = Log.S.SAL.d.15 ~ SS + GEN + SS:GEN, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.041108, na.action = na.exclude) 
 
          Df Sum of Sq   Mean Sq  F Value     Pr(F)  
       SS  2  0.155235 0.0776174 0.432217 0.6531812 
      GEN  1  0.327546 0.3275460 1.823960 0.1872881 
   SS:GEN  2  0.309619 0.1548093 0.862065 0.4328294 
Residuals 29  5.207807 0.1795795                    
 
Multiple R-Squared: 0.1321  
F-statistic: 0.8825 on 5 and 29 degrees of freedom, the p-value is 0.5052  
 
 
*** log R_SAL day 15 Analysis of Variance Model *** 
 
Call: 
   aov(formula = Log.R.SAL.d.15 ~ SS + GEN + SS:GEN, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.041108, na.action = na.exclude) 
 
          Df Sum of Sq   Mean Sq  F Value     Pr(F)  
       SS  2  0.129790 0.0648950 0.229385 0.7964508 
      GEN  1  0.616341 0.6163408 2.178589 0.1507193 
   SS:GEN  2  0.392646 0.1963232 0.693947 0.5077060 
Residuals 29  8.204339 0.2829082                    
 
Multiple R-Squared: 0.1219  
F-statistic: 0.8051 on 5 and 29 degrees of freedom, the p-value is 0.5554 
 
 
*** log DA day 15 Analysis of Variance Model *** 
 
Call: 
   aov(formula = Log.DA.d.15 ~ SS + GEN + SS:GEN, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.041108, na.action = na.exclude) 
 
          Df Sum of Sq    Mean Sq  F Value     Pr(F)  
       SS  2 0.0369333 0.01846667 0.705681 0.5020544 
      GEN  1 0.0133690 0.01336899 0.510880 0.4804731 
   SS:GEN  2 0.1738083 0.08690416 3.320936 0.0502740 
Residuals 29 0.7588887 0.02616858                    
 
Multiple R-Squared: 0.228  
F-statistic: 1.713 on 5 and 29 degrees of freedom, the p-value is 0.1632  
 
 
Figure 6-35:  Two–way ANOVA output for the effects of SS and GEN on day 15 log 
S-SAL (top) log R-SAL (middle) and log DA (bottom) concentrations. 
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6.4.2c-6 Exploratory and Covariate analysis for day 15 
 A statistically significant effect of smoking status was not observed on log R-
SAL and log S-SAL day-15 plasma concentrations.   For admission day log S-SAL and 
log R-SAL, neither the FTND nor the number of cigarettes smoked per day had a 
significant influence on the ANOVA fit.  Although a statistically significant difference 
was not observed, HS possessed and apparent higher average log S-SAL concentrations 
compared to that of the LS and NS groups on day 15.   Results of the primary analysis 
(using smoking status as a factor) and the exploratory analysis (FTND or the number of 
cigarettes per day), suggest that smoking does not have a significant influence on log S-
SAL and log R-SAL concentrations observed on day 15.   
 With respect to day 15 concentrations, it is important to note that biological 
sampling was conducted pre-prandially and before smoking a cigarette.  The time of 
day of sampling was similar across subjects.  Information including chronic alcohol 
intake and weekly exposure to dietary total SAL was evaluated for their effects on the 
admission day log R-SAL, S-SAL and DA.   If chronic alcohol intake (i.e., TLFB) or 
dietary SAL was found to significantly correlate with log R/S-SAL of DA exposure, 
they were considered a significant and subsequently implemented into the statistical 
model.  A table summarizing the covariate regression analysis for the TLFB and dietary 
SAL intake is shown below (table 6-21).   
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Table 6-21:  Covariate analysis results for log R-SAL, log S-SAL and log DA 
concentrations in day 15. 
 
 
Weekly 
Dietary Intake  
TLFB     (# of drinks in 
past 90 days)  variable (ng SAL) 
 
R2 0.0005 0.034  
 
p-value 0.901 0.221  Log R-SAL 
 
significance NS NS  
 R2 0.001 0.093  
 p-value 0.804 0.349 Log S-SAL  
 significance NS NS 
 
R2 0.032 N/A  
 
p-value 0.301 N/A  Log DA 
 
significance NS N/A  
 
  NS:   not significant 
  N/A: dietary intake of DA was not available   
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 The covariate analysis yielded a lack of association between the TLFB and 
weekly dietary SAL intake for the day 15 concentrations of SAL enantiomers and DA.  
Therefore, use of the TLFB or SAL food intake as a covariate was not significant and 
was not implemented into the full statistical model.    
 A known biomarker of chronic alcohol consumption and liver damage, γ-
glutamyl transferase (GGT), was used to assess its correlation with the SAL 
enantiomers.   Liver function, as assessed by GGT did not have a significant effect on 
day 15  SAL concentrations.     Results showed that, for both enantiomers, a lack of a 
significant effect of GGT was observed.   GGT as a predictor of day 15 log S-SAL and 
R-SAL  was insignificant with the test statistic resulting in F (1, 32) = 1.09, p-value = 
0.302 for log S-SAL and F (1, 32) = 0.774, p-value = 0.385 for log R-SAL.  According 
to the regression analysis, liver function as deemed by GGT, is not a good predictor of 
log SAL enantiomer concentrations on day 15.  The results of this covariate analysis 
suggest that the number of drinks consumed in the past ninety days, weekly dietary 
intake of total SAL, and GGT do not influence the day 15 levels of R/S-SAL.    
 The day 15 concentrations of the SAL enantiomers and DA characterize the 
point during detoxification where, presumably, the subject is not recently exposed to 
any alcohol, and the acute, physiological effects of alcohol withdrawal are complete.    
This analysis assumes that the SAL concentrations reflected on day 15 are 
representative of either the physiological effects of chronic alcohol intake and/or 
continuous smoking throughout the detoxification period.         
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 The analysis was done to assess the influence of smoking and gender on 
circulating SAL levels, two weeks after in-patient detoxification.  It is important to note 
that the SAL concentrations at the day 15 time-point showed less variability than that 
admission day across all subject.   A significant effect of smoking status or gender was 
not observed on the log R/S-SAL enantiomer concentrations on day 15.  In addition, 
smoking variables such as the FTND and number of cigarettes smoked per day did not 
have a significant influence.   Although a statistically significant difference was not 
observed with respect to smoking status, a divergence of median R- and S-SAL 
concentrations was observed with the HS compared to the LS and NS.  For instance, R-
SAL concentrations possessed a median concentration two-fold higher than that of the 
other smoking status groups.   As reported in figure 6-3, the HS group smoked at least a 
two fold more cigarettes, on average than that of the LS group.   This may account for 
the difference seen on median R-SAL concentrations on day 15, albeit statistically 
insignificant.  With respect to gender, no observable or statistically significant 
difference was seen between males and females at day 15.   
 Chronic exposure measurements such as the TLFB and GGT did not show any 
significant influence on SAL exposure on day 15.   This information suggests that 
neither variable is a good predictor of SAL exposure.  It is interesting to note that, upon 
comparison of the known biomarker of chronic alcohol consumption GGT with TLFB, 
a significant relationship was not established (p-value 0.134, R2 = 0.066).   
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6.4.2d   CIWA-AR correlation with R/S-SAL and DA 
 A clinical endpoint, the CIW-AR was evaluated to assess if a relation between 
R-SAL and S-SAL plasma concentrations and withdrawal symptoms.   Information 
regarding the time course of the CIWA-AR was gathered for the first three days during 
the detoxification period, in which coinciding SAL plasma samples were measured.  Of 
note, biological specimen sampling and CIWA-AR scores occurred within 2 hours of 
each other.    Exploratory evaluation of the distribution of day 1 and average CIWA-AR 
scores were assessed between smoking status and gender (see table 6-22 below).   
 
 
Table 6-22:  Descriptive statistics for day 1 and average CIWA-AR score divided into 
smoking status and gender. 
 
GRAND
Mean 5.5
Median 4.0
Range 0 - 14
Mean 6.0
Median 5.0
Range 0 - 18
Mean 5.7
Median 5.0
Range 0 - 18
GRAND
Mean 3.3
Median 2.2
Range 0 - 7.6
Mean 5.8
Median 5.0
Range 0 - 15.3
Mean 4.5
Median 3.6
Range 0 - 15.3
Overall
5.0 3.4 5.1
4.3 2.6 4.2
0 - 12.7 0.6 - 7.6 1 - 15.3 
Non-smoker Light-smoker Heavy-smoker
Male
3.8 4.8 7.8
2.0 3.5
0 - 12 2 - 10 3 - 18
9.0
0 - 12 2 - 12 1 - 14
0 - 12 2 - 12 0 - 18 
Female
5.0 5.0 7.8
5.5 5.0 6.0
Overall
4.4 4.9 7.8
4.0 4.0 8.0C
IW
A
-A
R
 D
A
Y
 1
   
Non-smoker Light-smoker Heavy-smoker
C
IW
A
-A
R
 a
vg
   
   
Male
2.6 2.9
1.7 2.3
0 - 7.6 0.6 - 7.6
Female
7.3
4.3
4.2
1 - 8
4.0 5.9
7.2 3.9 4.2
0 - 12.7 1.5 - 6.6 1.8 - 15.3
 
443 
 Overall, the range of CIWA-AR scores was between 0 and 18.  Of note the 
maximum score for the CIWA-AR is 67, therefore subjects who participated in the 
analysis possessed relatively low scores.   Every individual had a positive score, with 
the exception of two NS who scored a “0” over the three days of initial detoxification. 
For day 1 CIWA-AR, a difference between genders in median scores was not different 
with males and females possessing median scores similar to the overall population.   
Conversely, a two-fold difference in median CIWA-AR scores was seen between HS 
and LS or NS groups.  This is suggestive that HS underwent a more severe withdrawal 
that that of the LS and NS groups upon initiation of alcohol abstinence.   With respect to 
average CIWA-AR scores, the effect of smoking status was not observed while the 
apparent effect of gender was seen.   Females had a two-fold higher average CIWA-AR 
score as compared to males.  This observation implies that females underwent more 
severe withdrawal symptoms than males throughout the detoxification period.     
 Over the initial time period of alcohol abstinence, the withdrawal symptoms in 
chronic alcoholics were suspected to decline.   Of note, no subject possessed a positive 
CIWA-AR score after day three of detoxification. The effect of time was evaluated for 
the individual CIWA-AR scores over the first three days of detoxification for all 
subjects.  Via linear regression, a significant difference in CIWA-AR was seen with the 
test statistic yielding F (1, 98) = 7.78, p-value = 0.006 (R2 = 0.074).    Time was able to 
only account for 7.4% of the variability associated with CIWA-AR scores. The 
regression may be viewed in the figure 6-36 below. 
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 *** Linear Model *** 
 
Call: lm(formula = CIWA ~ DAY, data = CIWA.AR.ANAL.041208, na.action = 
na.exclude) 
Residuals: 
    Min     1Q  Median    3Q  Max  
 -6.295 -3.323 -0.8511 2.149 11.7 
 
Coefficients: 
              Value Std. Error t value Pr(>|t|)  
(Intercept)  7.7389  1.1081     6.9839  0.0000  
        DAY -1.4439  0.5178    -2.7886  0.0064  
 
Residual standard error: 4.205 on 98 degrees of freedom 
Multiple R-Squared: 0.07352  
F-statistic: 7.776 on 1 and 98 degrees of freedom, the p-value is 0.00636 
 
 
Figure 6-36:  Regression of CIWA-AR vs. time (days) for all subjects until day 3 with 
95% confidence bounds, along with full ANOVA output.  
 
 
 
 The effect of time on the CIWA-AR score was significant for each subject upon 
individual analyses.  Of note, the effect of smoking status was not significant with 
respect to the overall CIWA-AR profile resulting in a test statistic F (2, 94) = 1.12, p-
value = 0.329.  On the other hand, gender showed a significant effect with F (1, 94) = 
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4.62, p-value = 0.034.    Females possessed a greater difference in CIWA-AR score 
over time than their male counterpart.  Interaction of time and smoking status or gender 
was not observed.      The entire model, accounting for time, SS and GEN was able to 
account for 13.6% of the variability associated with CIAW-AR scores during the first 
three-days of detoxification. 
 
 
*** Linear Model *** 
 
Call: lm(formula = CIWA ~ DAY + SS + GEN, data = CIWA.AR.ANAL.041208, 
na.action =  
 na.exclude) 
Residuals: 
    Min     1Q Median    3Q   Max  
 -6.638 -2.721 -1.005 2.123 10.42 
 
Coefficients: 
              Value Std. Error t value Pr(>|t|)  
(Intercept)  9.4308  1.2817     7.3581  0.0000  
        DAY -1.3893  0.5083    -2.7330  0.0075  
       SSLS -1.2979  1.0339    -1.2553  0.2124  
       SSNS -1.4035  0.9872    -1.4217  0.1584  
        GEN -1.7750  0.8257    -2.1497  0.0341  
 
 
Multiple R-Squared: 0.1359  
F-statistic: 3.737 on 4 and 95 degrees of freedom, the p-value is 0.007216  
 
 
 
Figure 6-37:  Linear model output for the effects of time, smoking status and gender on 
CIWA-AR scores.  
 
 
 As an effect of time was present in the CIWA-AR scores, exploratory evaluation 
of an association between the SAL enantiomers was performed.    Individual 
correlations were performed for each subject using log SAL concentration as the 
independent variable and CIWA-AR as the dependent variable.  The regressions may be 
seen in Appendix O.     For 28 of the 36 subjects, a significant relation was not observed 
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yielding p -values > 0.05 and R2 ranging from 0.002 – 0.146.   Of the remaining 
subjects, a significant relationship was observed with R2 ranging from 0.532 – 0.924.   
Statistical significance and R2 was not governed by the two factors of smoking status or 
gender.    In addition, the direction of the relationship (negative or positive) varied 
across subjects and was not systematic with respect to smoking status or gender. 
 Day 1 concentrations of log S-SAL, log R-SAL and log DA were compared with 
initial CIWA-AR score to evaluate the admission concentration with severity of 
withdrawal.  The regressions, including all subjects, of Day 1 log S-SAL, log R-SAL 
and log DA may be seen in figures 6-38, 6-39, and 6-40 below.   An insignificant 
relation between admission concentrations was observed for either of the SAL 
enantiomers (p-values:  S-SAL = 0.753, R-SAL = 0.694).     In essence, both log R-SAL 
and log S-SAL were not able to explain any of the variability associated with the 
CIWA-AR scores.    Moreover, a statistically significant association was not observed 
with log DA and CIWA-AR with p-value being 0.227.   
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 Figure 6-38:  Day 1 log S-SAL vs. day 1 CIWA-AR score for all subjects.    
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 Figure 6-39:  Day 1 log R-SAL vs. day 1 CIWA-AR score for all subjects.    
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 Figure 6-40:  Day 1 log DA vs. day 1 CIWA-AR score for all subjects.    
 
 An analysis was performed on the change of CIWA-AR scores as a function of 
admission day concentrations.   This assessment was executed to evaluate if initial SAL 
concentrations had an influence on the decline of CIWA-AR scores during the first 
three days.     If a significant relationship were to be found, it could be deduced that 
recovery of withdrawal symptoms was influenced by circulating SAL concentrations.  
The regressions for each analyte are present in figures 6-41, 6-42 and 6-43 below.   
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 Figure 6-41:  Day 1 log S-SAL vs. change in CIWA-AR scores over three days 
 for all subjects.    
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 Figure 6-42:  Day 1 log R-SAL vs. change in CIWA-AR scores over three days 
 for all subjects.    
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 Figure 6-43:  Day 1 log DA vs. change in CIWA-AR scores over three days 
 for all subjects.    
 
  
 It can be concluded that no significant relationship between admission SAL or 
DA concentrations and a change in CIWA-AR scores exists.  The regression for each 
SAL and DA analyte yielded statistically insignificant p-values for the association (p-
values all greater than 0.467).  In essence, admission SAL concentrations were not 
predictive of the recovery symptoms associated with alcohol withdrawal.    
 An exploratory analysis was performed on the change of CIWA-AR scores as a 
function of a change in analyte concentrations over three days.   This evaluation was 
performed to assess if the change in SAL concentrations had an influence on the change 
of CIWA-AR scores during the first three days.  The regressions for each analyte are 
present in figures 6-44, 6-45 and 6-46 below.   
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 Figure 6-44:  Change in CIWA-AR scores over three days as a function of 
 change of S-SAL for all subjects. 
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 Figure 6-45:  Change in CIWA-AR scores over three days as a function of 
 change of R-SAL for all subjects. 
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 Figure 6-46:  Change in CIWA-AR scores over three days as a function of 
 change of DA for all subjects. 
 
A significant relationship was not found for any of the analytes.  The regression for 
each SAL and DA analyte yielded statistically insignificant p-values for the association 
(p-values all greater than 0.664).  According to theses results, it could be inferred that 
recovery of withdrawal symptoms was not influenced by a change in SAL 
concentrations over the first three days of alcohol detoxification.   
 
6.4.2e  Summary of Primary Analysis 
 Large within-subject variability was observed with the SAL enantiomers over 
the first 15 days of detoxification.  The levels \fluctuated throughout the detoxification 
period with individual subjects possessing both decreases and increases in 
concentrations of both R and S-SAL enantiomers from admission day to day 15.  A 
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small effect of time was observed on the enantiomers with R-SAL and S-SAL 
concentrations, on average, increasing minimally from admission day to day 15 while 
DA concentrations remained constant.  For individuals, covariates, such as smoking 
status or gender, did not explain the direction of increase or decrease in SAL 
concentrations during detoxification period.  Therefore, three different measurements of 
time were evaluated to assess the influence of smoking and gender on SAL 
concentrations, admission day, day 15 and GTM concentrations throughout the in-
patient period.     
 Admission day concentration assessment was to reflect the initial behavior of 
SAL concentrations at the start of alcohol detoxification.  At this point in time, patients 
were expected to have recently consumed alcohol, compared to the rest of the time 
course.    Of note, this time point showed the largest amount of between-subject 
variability as compared to the other time point assessments.  An effect of smoking 
status or gender was not observed at this time point.   Interestingly, recent exposure of 
alcohol or a drug of abuse did not have any bearing on SAL concentrations, which is 
contrary to the hypotheses involved with acute ethanol exposure effects on circulating 
SAL.  Possibly confounding the results on admission day was presumably alcohol 
induced liver dysfunction, as assessed by AST.    A relationship was observed on 
admission S-SAL and R-SAL and AST, suggesting that the degree of acute liver 
impairment has an influence.  Exploratory covariate analysis evaluating the effects of 
the TLFB and food inventory yielded insignificant results.  Grand total mean (GTM) 
concentrations were assessed for the influence of smoking and gender factors.   This 
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assessment was to reflect the overall behavior of SAL and DA throughout the 
detoxification period.  An effect of the primary factors was not seen upon evaluation of 
the GTM concentrations.    Other potential covariates such as TLFB, dietary SAL intake 
and acamprosate administration was not able to explain the variability associated with 
the GTM measurements.  Day 15 concentration evaluation resulted in an insignificant 
effect of the factors of smoking and gender.  This time point was assumed to be a true 
reflection of SAL concentrations after prolonged abstinence of alcohol, and the 
significant withdrawal effects have subsided.  At this time point, accounting for 
covariates such as the TLFB, dietary SAL assessment, a marker of chronic alcohol 
consumption, the GGT, did not explain any of the variability associated with the SAL 
concentrations.   
 The clinical endpoint, CIWA-AR, did not correlate with S-SAL or R-SAL 
concentrations suggesting that neither enantiomer is predictive of the withdrawal 
symptoms associated with alcohol detoxification.  It is important to note that biological 
specimens were not obtained at the exact time point of CIWA-AR assessment.  The 
acute effects of SAL concentrations on the time-course withdrawal symptoms have not 
been formally assessed.   This discrepancy between sampling and CIWA-AR 
administration was a major limitation and may provide some explanation to the lack of 
association between the clinical endpoint and SAL concentrations.   
 Several shortcomings exist in this investigation on the influence of 
detoxification, smoking status and gender on SAL enantiomer concentrations.   Of 
important note, the subject demographics, including age and disease status throughout 
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the detoxification period, are quite variable between and within smoking status groups.  
Moreover, different therapies were administered to each of the subjects including 
antihypertensives and antidepressants, both of which have not been assessed for their 
influence on SAL concentrations.   A large majority of the subjects received thiamine as 
supportive therapy and vitamin supplementation.    The precursor of SAL, acetaldehyde, 
is known to bind to thiamine (Takabe and Itokawa, 1983), which may disturb the 
endogenous synthesis of the analyte.     The administration of daily thiamine at various 
times of the detoxification period may have confounded the assessment of SAL levels 
in these patients.   
 No statistically significant differences were observed at any time point with 
respect to gender or smoking status.  Several short comings in this analysis precluded 
thorough interpretation of the results.  As this was an observational study, a lack of 
investigational control was a major limitation.  Admission concentrations were quite 
variable with patients possessing different exposures to ethanol and other drugs of abuse 
in the system, relative to the initial sampling time.    Patients throughout the 
detoxification period were able to smoke cigarettes ad-libitum.   An assessment of the 
number of cigarettes smoked during the detoxification period, via a self-report smoking 
log, would have been prudent to formally assess the effects of smoking on SAL levels 
during the detoxification period.   Other functions of SAL exposure such as dietary 
intake was not controlled or accounted for throughout the detoxification period, which 
may have influenced the SAL measurements.   Utilization of the Food Inventory 
attempted to capture the dietary intake of SAL but was unable to account for the 
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variability SAL concentrations.  It is important to note that this in not a validated 
measure of SAL dietary intake.  In essence, diet may have affected the measurements of 
SAL throughout the alcohol abstinence period, but may be unlikely as biological 
specimen sampling was primarily performed pre-prandial.     
 Two major validated measures of alcohol consumption, the TLFB and BrAC 
were assessed for possible effects on circulating SAL concentrations.   The TLFB was 
an insufficient measure to characterize SAL concentrations at any of the time points 
assessed.   This suggests that SAL was not influenced by chronic consumption of 
alcohol, which is contrary to other references.  Moreover, the measure of acute alcohol 
consumption, the BrAC measurement, was also unable to provide explanation of the 
variability associated with plasma SAL.    As endogenous SAL biosynthesis requires the 
enzymatic conversion of ethanol to acetaldehyde via alcohol dehydrogenase, liver 
function is presumed to be an important factor in the exposure of plasma SAL.   It was 
found that a measure of acute liver damage, AST, had a significant effect on SAL 
exposure, with a decline in liver function resulting in decreased SAL concentration 
upon entry to the clinical unit.  The correlation of AST with SAL enantiomers at 
different time-points throughout the detoxification period was not assessed, but the 
factor of liver function may have confounded the results associated with the primary 
analysis.   In essence, the varying degrees of AST levels may have been responsible for 
some of the variability associated with SAL at each measurement in time.    The acute 
effects of alcohol intake may have impaired the livers ability to synthesize acetaldehyde 
to yield the SAL product.  
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 Upon further evaluation of the biosynthesis of SAL, both polymorphisms in 
alcohol dehydrogenase (ADH) and aldehydes dehydrogenase (ALDH) may contribute 
to varying exposures of SAL.   The specific polymorphisms at the loci ADH1B, 
ADH1C, and ALDH2 can increase the levels of acetaldehyde more so than other alleles 
(Day et al., 1991).  This can lead to increased circulating acetaldehyde and, in turn, the 
exposure of SAL.   An abnormally high circulating level of SAL caused by a 
polymorphism in an alcohol metabolizing system is equally plausible.  The intriguing 
possibility exists that the ALDH and ADH enzyme, in one or more of its isoforms, 
could partially be responsible for the formation of SAL in humans.  As these 
polymorphisms are present in differing ethnicities, it would be prudent to genotype the 
populations being studied to determine if there is any effect of ALDH and ADH 
polymorphisms on circulating SAL levels.     
 The metabolic fate of the SAL enantiomers has not been addressed in published 
reports.  This investigation principally evaluates exposure of SAL through different 
measures of intake of potential SAL sources such as cigarette smoking and chronic or 
acute alcohol consumption.    However, this study does not evaluate the influence of 
varying degrees of SAL metabolism.   The disposition for the SAL enantiomers have 
not been formally assessed, but according to SAL structural analysis, enzymes such as 
catechol-o-methyl transferase (COMT) and N-methyl transferase may play an important 
role.  These enzymes are known to have major functional polymorphisms in an alcohol 
dependent population (Kauhanen et al., 2000; Oroszi et al., 2005).  Results of both 
studies indicate that COMT and N-methyl transferase polymorphisms may contribute 
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significantly to alcohol intake not only in alcoholics but also in a general male 
population.   As both enzymes are speculated to have a role in the metabolic fate of 
the SAL enantiomers, polymorphisms with these enzymes may explain the variability in 
SAL exposure.    Moreover, as both of these enzymes are present in the liver, 
impairment of liver function may effect the metabolic disposition of SAL.  
  
6.5 R/S-SAL and DA – Alcohol-dependent vs. control subjects 
 All information presented thus far summarizes R/S-SAL and DA exposure 
information obtained from non-alcohol dependent and alcohol-dependent NS, LS, and 
HS.   In essence, the presented information examines the influence of smoking and 
gender within each population of healthy and alcoholic subjects undergoing 
detoxification.     The significant relationship of smoking status and SAL exposure was 
observed from study #1, which may be resultant of acute inhalation of tobacco smoke 
and/or the inherent physiological difference of smokers to that of nonsmokers.  No 
effect of smoking status was observed in the alcohol-dependent subjects at any point in 
time during the detoxification period.   It is speculated that this discrepancy between 
study populations may have been confounded by the influence of alcoholism.  To 
further clarify this relationship, a comparison was made from the subjects who were 
healthy nonsmokers and smokers to those patients who were alcohol dependent 
nonsmokers and smokers.   
 In brief, this analysis compared two different populations of healthy subjects to 
alcoholic subjects on admission day.  The populations included 1) 41 healthy volunteers 
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including 19 NS and 11 LS and HS who smoked within 30 minutes of biological 
specimen sampling (Study #1) and 2) admission day concentrations of 35 alcohol 
dependent subjects undergoing detoxification including 12 NS, 11 LS and 12 HS.   In 
the non smoking groups between populations, an assessment of the influence on 
alcoholism on circulating SAL levels can be performed.  With respect to the smoking 
groups within each population, the comparison would evaluate the effects of recent 
smoking in the healthy population to that of alcoholic smokers who were assumed to 
have recently smoked a cigarette on admission to the detoxification clinic.  For 
reference the subject demographics of both populations are shown in the tables 6-23 and 
6-24 below.  
 
Table 6-23:  Demographic Results of Study #1 (healthy population acute cigarette 
smoking, mean ± SD) 
Demographic 
variable 
Smoking Status Males Females Overall 
N 9 10 19 
Age 24.9 (2.5) 26.0 (3.1) 25.5 (2.8) 
 
FTND 0 (0) 0 (0) 0 (0) NS 
# Cig/day 0 (0) 0 (0) 0 (0) 
N 5 6 11 
Age 25.4 (4.1) 23.3 (3.8) 24.3 (3.9) 
FTND 2.4 (2.3) 1.5 (1.4) 1.9 (1.8) LS 
# Cig/day 9.0 (4.8) 8.3 (4.6) 8.6 (4.5) 
N 5 6 11 
Age 25.6 (3.1) 24.7 (4.0) 25.1 (3.5) 
FTND 6.8 (0.8) 5.5 (1.4) 6.1 (1.3) HS 
# Cig/day 17.4 (2.5) 25.8 (4.9) 22.0 (5.8) 
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Table 6-24:  Demographic Results Study #2 (alcohol dependent population, mean ± 
SD) 
Smoking 
Status 
Demographic 
variable 
Males Females Overall 
N 6 6 12 
Age 40.0 (6.4) 43.2 (10.3) 41.6 (8.3) 
 
 
 With the exception of the number of subjects within each smoking status and 
gender group, the demographics between studies are similar with respect to FTND.   
There existed significant ethnicity differences between the two populations with the 
clinical study #1 having predominately Asian and Caucasian subjects, while subjects in 
clinical study #2 were predominately African American and Caucasian subjects (see 
tables 5-2 and 6-2).  On average, the alcohol-dependent population smoked more 
cigarettes per day compared to the healthy population of smokers. It should be duly 
noted that the alcoholic subjects, on average, were at least twenty-years older than the 
healthy population, precluding a definitive interpretation of the comparative results 
between the populations.   
FTND 0 (0) 0 (0) 0 (0) NS 
# Cig/day 0 (0) 0 (0) 0 (0) 
N 6 5 11 
Age 41.0 (10.7) 37.6 (9.4) 41.0 (10.7) 
FTND 4.7 (1.2) 3.6 (2.1) 4.2 (1.7) LS 
# Cig/day 10.2 (2.4) 9.5 (2.7) 9.9 (2.5) 
N 6 6 12 
Age 43.5 (11.7) 40.8 (8.5) 42.2 (9.9) 
FTND 7.3 (1.8) 8.8 (1.0) 8.1 (1.6) HS 
# Cig/day 32.1 (7.8) 26.8 (12.2) 29.5 (10.1) 
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 A statistical analysis via two-way ANOVA was conducted on the individual 
SAL and DA concentrations between the populations.   Log transformed values were 
compared evaluating the two primary factors of gender and smoking status.   
 Median smoking status concentrations, along with ranges, of the concentrations 
of Study #1 are compared to the median smoking status concentrations obtained from 
the admission concentrations from the alcoholic population in study #2 in table 6-25 
below.    Between studies, it was observed that the healthy population that recently 
smoked had a higher median concentration of all analytes as compared to the alcohol 
dependent population with approximately 2-fold difference seen with S-SAL, R-SAL, 
and DA concentrations.   The discrepancy in concentrations between the studies is 
due, in part, to the smokers of the healthy population, who were exposed to cigarette 
smoking 30 minutes prior to biological specimen sampling.  With respect to the NS 
groups between populations, it was observed that the concentrations were similar 
between the healthy and alcohol-dependent populations.  Comparison via ANOVA 
found the comparison to be statistically insignificant across all analytes for the NS 
population.     In other words, regardless of the dependency on alcohol, concentrations 
of S-SAL, R-SAL and DA are similar.   Conversely, the populations showed a 
divergence when comparing both smoking groups of LS and HS.     Healthy smokers 
who were recently exposed to tobacco had significantly higher median concentrations 
of R/S-SAL and DA than that of the alcoholic population on admission day.    For 
instance, comparison of the S-SAL concentrations between LS populations showed that 
the healthy smokers have a three-fold higher median concentration than that of the LS 
462 
alcoholic population.  This effect was more pronounced with the HS groups with 
healthy smokers, possessing a 9-fold higher median concentration of S-SAL than that of 
the alcoholic HS. Similar statistically significant trends were observed for the R-SAL 
and DA analytes. 
 Upon comparison with healthy patients that abstained from smoking for 15 
hours, the NS group had statistically similar concentrations of all analytes across all 
populations.  This suggests that there are no significant effects with regard to the sole 
factor of alcoholism on SAL concentrations.  Moreover, even after smoking groups 
were abstinent from smoking for 15 hours, they still had higher median SAL 
concentrations as compared to their smoking status group counterparts from the 
alcohol-dependent patients on admission day.  This infers that the effects of alcoholism 
itself may decrease the concentrations of SAL exposure.  Of note, the ANOVA 
performed across all three populations resulted in the significant difference of SAL 
analytes being between the healthy recent smoking population and the alcohol 
dependent population on admission day.   All of the information obtained from this 
comparison implies that alcoholism has no effect on SAL exposure while the acute 
exposure of tobacco smoke has the most significant effect.   
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 It is interesting to note that the NS group amongst the healthy population had a 
higher median concentration than the HS group of the alcoholic population.   This 
observation is conflicting with all reports of SAL measurement between alcoholic and 
control populations (see chapter 1).   The rank observed for all analyte concentrations in 
the comparison between recently-smoking subjects to that of alcohol-dependent 
subjects on admission day yielded the following results:  for S-SAL the HS Alcoholics 
< LS Alcoholics < NS Alcoholics ~ NS Healthy < LS Healthy < HS Healthy; for R-
SAL the LS Alcoholics < HS Alcoholics < NS Alcoholics < NS Healthy < LS Healthy 
< HS Healthy; for DA the LS Alcoholics < NS Alcoholics < NS Healthy < HS 
Alcoholics < LS Healthy < HS Healthy.    
 Recall that the ANOVA analysis for the effects of smoking status resulted in 
significance for the healthy population, but did not yield significance for the alcohol 
dependent patients on admission day for all analytes.    More investigational control was 
implemented in the healthy population from Study #1 as compared to Study #2.    Study 
#1 implemented a requirement for healthy smokers to smoke one complete cigarette 
prior to sampling.    The treatment effect of smoking was seen to significantly affect the 
circulating SAL levels (see table 5-25).  For study #2, several confounding factors were 
present, hindering the interpretability of the results.    For the most part, the alcoholic 
population presented to the clinic with additional factors that may influence circulating 
SAL levels such as recent alcohol exposure and other drugs of abuse.  Moreover, 
opposite to the case for smokers in Study #1, the sampling time point of the admission 
sample, with respect to the subjects’ last cigarette was not recorded.  The variability 
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associated with the admission SAL concentrations within the alcohol dependent 
smoking groups may be due in part to the unknown pharmacokinetic characteristics of 
SAL in this population after smoking a cigarette.   
 The majority of the alcohol-dependent population either had a recent exposure 
to ethanol and/or a drug of abuse.  Therefore, it was expected that SAL concentrations 
in this population would be elevated compared to that of the healthy population.  
Surprisingly, the healthy population, especially the subjects who were recently exposed 
to smoking, had much greater SAL concentrations compared to that of the alcohol- 
dependent population.   From these results, it is concluded that the source of tobacco 
smoking is what influences the concentrations in a healthy population.  In an alcoholic 
population, the SAL levels are comparable to the NS healthy population.     
 It should be noted that a difference in ethnicity distribution was observed 
between the alcohol-dependent and healthy population with majority of the population 
being Asian in the latter group.  It is known that Asians possess polymorphisms in ADH 
and ALDH metabolizing systems (Yamamoto et al, 1993).  The specific polymorphisms 
at the loci ADH1B, ADH1C, and ALDH2 can increase the levels of acetaldehyde more 
so than other alleles.  This can lead to increased circulating acetaldehyde in the Asian 
population from Clinical Study #1 and, in turn, the exposure of SAL.   It is also duly 
noted that alcohol-dependent patients may have induced alcohol and acetaldehyde 
metabolizing systems yielding a decrease in acetaldehyde.  It is equally plausible that 
the decreased SAL concentrations in alcohol dependent patients compared to healthy 
subjects is due to a decrease in acetaldehyde levels due to metabolic induction.    
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 Factors such as polymorphisms in metabolizing enzyme systems responsible for 
ethanol and SAL disposition along with liver pathophysiology in the alcoholic 
population may account for the difference is SAL exposures seen within this study.   
 
6.6  Summary of Clinical Study #2 
 This investigation was designed to test the effects of smoking status and gender 
on plasma concentrations of R/S-SAL and DA in a population of alcohol dependent 
patients undergoing detoxification.   Demographic information and plasma samples, 
along with clinical variables, were obtained from thirty-five subjects undergoing a four- 
week inpatient alcohol abstention program.  Biological samples for R/S-SAL and DA 
measurements were obtained on days 1, 2, 3, 8, and 15 of the inpatient period. With 
respect to subject selection, patients were chosen based on health status, a complete 
sampling schedule over the sampling schedule, and stratification into smoking status 
groups, ensuring adequate distribution of smoking status and gender within each group. 
The observational study utilized a nicotine dependence scale and the number of 
cigarettes smoked per day in order to stratify the subjects into smoking status groups.    
Along with the alleged nicotine dependence difference between groups, all subjects 
were heterogeneous with respect to demographics.    A large portion of subjects that 
participated in the study possessed a positive BrAC and drugs of abuse screen upon 
admission, which may confound results obtained on admission day.  Throughout the 
inpatient detoxification, investigational control with respect to diet and smoking was not 
performed with patients allowing to smoke ad-libitum and consume foods that may 
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contain SAL.  This information was not recorded and may have had influence on the 
SAL levels reported throughout detoxification.    As biological specimen sampling was 
conducted early morning, pre-prandial and before the first cigarette of the day, it is 
unlikely that these variables would have an effect.    Another confounding variable that 
may hinder interpretation of the results obtained from this study are the different 
pharmacotherapies used on the individual subjects.  It is not known whether any of the 
therapies influence the distribution or disposition of the SAL enantiomers.    
Overall, the variability observed within- and between-subjects was pronounced 
across all groups for all analytes tested.    A general effect of time was observed with 
the both SAL enantiomers while DA concentrations were relatively consistent during 
alcohol abstinence.   A slight increase was observed in average concentration across all 
subjects from admission day to day 15 of sampling.   The variability in SAL 
concentrations associated with these time-points was large (> than 93% COV for S-SAL 
and R-SAL for admission day and day 15 across all subjects).  Therefore, separate 
analyses for the factors of gender and smoking status were performed on the grand total 
mean, admission day, and day 15 concentrations for each analyte.   
The effect of smoking status was not significant at any time-point evaluated.    
Although a trend was observed, with HS possessing higher SAL concentrations on day 
15 compared to that of NS and LS groups, a statistically significant difference was not 
noticed.  The effect of smoking status was further characterized into the design 
variables used for smoking status stratification, the FTND and cigarette smoking 
frequency.   Characterization of subjects utilizing these variables did not yield a 
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significant result in explaining the variability associated with the SAL enantiomer 
concentrations.    Further covariate analysis using the TLFB measure of chronic alcohol 
exposure, the BrAC measure of acute alcohol exposure, average dietary SAL intake, 
acamprosate administration throughout the detoxification period and admission drug of 
abuse screen, did not yield significant relation with R/S-SAL exposure.    A measure of 
acute hepatocellular dysfunction, aspartate amino transferase (AST), showed an inverse 
relation to circulating SAL concentrations.  An increase in AST (more hepatic 
impairment) yielded a decrease in plasma R/S-SAL enantiomers, suggesting that liver 
function was an important determinant of SAL exposure.    
An attempt was made to assess a clinical endpoint, the CIWA-AR to SAL 
exposure, which proved unsuccessful.   The lack of association could be due to the 
discrepancies involved with the biological sampling with the CIWA-AR measurement.  
Moreover a significant effect of time was observed with the CIWA-AR over three days 
with a decrease being observed in all patients.  This time effect was not observed with 
the SAL enantiomers in the first three days, further precluding the correlation of these 
analytes with the alcohol withdrawal assessment.   
Upon comparison with a healthy, non alcohol-dependent population, a 
surprising finding was observed.  On average, the SAL concentrations observed in the 
healthy population were higher that that of the alcohol dependent population on 
admission day of detoxification, despite the fact that 37% of the alcohol dependent 
population has been recently exposed to alcohol (as deemed by entrance BrAC).   
Within each smoking status group, NS healthy and alcohol dependent patients showed 
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statistically equivalent concentrations.  On the contrary, the LS and HS groups within 
the healthy population both possessed higher SAL concentrations than their alcohol 
dependent counterparts.   A major limitation of this analysis is that the smoking 
population in the healthy subjects were required to smoke within thirty minutes of SAL 
sampling, while the alcohol dependent sampling was not controlled for this factor of 
recent smoking.  The assessment of the time frame between last cigarette upon entrance 
into the clinic and the SAL sampling was not assessed in the alcohol dependent patients, 
hindering definitive interpretation of the results.     Nevertheless, the results of clinical 
study #1 conclude that recent smoking of a cigarette influences SAL plasma 
concentrations.   Throughout time, this observation was not observed in the alcohol 
dependent population as sampling, with the exception of admission day, occurred 
before the first cigarette of the day.  The observational results from clinical study #2 
may be confounded by several factors such as concurrent pharmacotherapies, other 
disease states, impaired liver function, and lack of rigid investigational control of 
smoking and dietary intake throughout the inpatient period.     
A major critique of this analysis is that the two separate populations were 
compared to assess the circulating SAL differences, one study of a healthy population 
recently smoking and one study involving an alcohol dependent population on 
admission to a detoxification clinic that may or may not have recently smoked a 
cigarette.  Ideally, a study consisting of observations in the same population, sampling 
before and after smoking, in a healthy and alcohol dependent population, with an 
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adequate sampling schedule would be needed to further support the notion of “true” 
smoking status differences.    
  
 
 
 
 
CHAPTER 7  
OVERALL CONCLUSIONS 
 
 
 TIQ and β-carboline exposure has been reported to be influenced by acute 
ethanol intake and chronic alcoholism.    Significant variability within published studies 
has been reported, hindering the ability for these compounds to be an adequate marker 
for alcohol abuse.  As the association of smoking and alcohol abuse is strong, it is 
suspected that the variability in TIQ and β-carboline exposure observed may be 
explained by tobacco smoking.     
 As the variability associated with measurements may be in part to the analytical 
methodology involved in quantification, two separate assays were developed and 
validated to assess biological concentrations of the β-carbolines, harman and 
norharman, and the TIQ’s, R- and S-Salsolinol.    Several of the reported bioanalytical 
methods used for the quantification of theses analytes in a biological matrix possessed 
many shortcomings including lack of internal standard use and unresolved 
chromatographic resolution between analytes of interest, decreasing the reliability of 
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accurate and precise quantification.   Of utmost importance, none of the reported 
methodologies utilized a calibration matrix that was intended for use in actual sample 
analysis, presumably due to the lack of a true blank matrix.   The bioanalytical methods 
developed in this investigation addressed the inadequacies associated with the reported 
methods.  Significant attention of the analytical procedure development involved 
assessment of an appropriate surrogate matrix for calibration purposes.   Using robust 
method development procedures and validation techniques, along with a thorough 
assessment of “surrogacy” of a modified matrix, two analytical methods used for the 
quantification of the β-carbolines and TIQ’s in human plasma was established. 
 A robust, sensitive, selective and reproducible assay was developed for the 
quantification of the endogenous β-carbolines, harman and norharman in human 
plasma. This technique utilized protein precipitation via cold acetonitrile and phenyl 
SPE cartridges to isolate both β-carbolines from 2-ml plasma.  Extraction efficiency 
was evaluated using yohimbine as an internal standard.   Analyte separation was 
achieved via a commercial C8 column with a ternary isocratic mobile phase consisting 
of methanol, acetonitrile and KH2PO4/H3PO4 buffer, resulting in acceptable resolution 
under optimal fluorescence detection conditions.  A modified matrix, using a minimal 
dilution factor, was proven to show similarity in analytical response as that of 
unmodified, plasma sample matrix.    The surrogate matrix was used to decrease the 
response of the observed constitutive harman and norharman concentrations, thus 
providing a “blank” matrix.     Therefore, this modified matrix was used for calibration 
purposes and subsequently used for validation.   
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 At physiologically relevant concentrations, method precision and accuracy were 
found to be acceptable for both inter- and intra-day measurements.  A linear response 
was observed in 2 ml plasma for both analytes from the LLOQ of 6.3 pg/2 ml to the 
ULOQ of 1.0 ng/2 ml for each analyte, yielding acceptable linear model fits.  The 
evaluation of endogenous plasma concentrations in healthy humans yielded vales that 
were consistent with literature values. 
 The current developed method for the β-carbolines, harman and norharman, has 
maintained resolution between analytes, utilized a novel internal standard to assess 
sample loss from extraction and was fully validated using and appropriate surrogate 
matrix. Moreover, this new method has maintained adequate sensitivity for 
physiological studies. The chromatographic separation conditions along with the 
optimized extraction technique and surrogate matrix calibration was used to support 
clinical investigation for the quantification if the β-carbolines in human plasma.     
 In the case of the TIQ’s, a robust, sensitive, selective and reproducible assay was 
developed for the quantification of the endogenous, S- and R-SAL, along with their 
precursor DA, in human plasma.  A direct single-step pentafluorobenzyl derivatization 
scheme in an aqueous media, without extractive alkylation using phase transfer 
catalysts, was devised for the enantioseparation of SAL with simultaneous detection of 
DA.   In brief, this technique utilized phenylboronic acid cartridges to isolate the 
analytes from 1-ml plasma.  An elution aliquot of acidified methanol was pH adjusted 
for subsequent, optimized, analyte derivatization with pentafluorobenzyl bromide.  The 
final product was hexane extracted, evaporated to dryness, and the residue was 
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dissolved in methanol for the analysis by HPLC-ESI-MS/MS.  Chiral separation was 
obtained via a commercial amylose-derivate based stationary phase HPLC column with 
a binary mixture of isopropanol and methanol as mobile phase.  Deuterium-labeled 
individual SAL enantiomers along with deuterium labeled dopamine were used as 
internal standards.  Detection was carried out via tandem mass-spectrometry and ESI 
mass spectra were acquired in positive ion mode with selected reaction monitoring.  The 
resultant derivatives were stable and base-line resolved both SAL enantiomers as well 
as the DA precursor.  A modified matrix involving destruction of constitutive SAL and 
DA was proven to be surrogate and subsequently used for calibration purposes.  
 At physiologically relevant concentrations, method precision and accuracy were 
found to be acceptable for both inter- and intra-day measurements.  A linear response 
was observed in 1-ml plasma for both SAL enantiomers from the LLOQ of 20 pg to the 
ULOQ of 4 ng for each racemate, yielding acceptable correlation coefficients.    For the 
DA precursor the range observed was between the LLOQ of 100 pg to the ULOQ of 10 
ng, resulting in adequate linear calibration fits.  For both SAL enantiomers, the average 
extraction recovery was 56 ± 5% within the concentration range.  Evaluation of 
endogenous concentrations in healthy, human plasma yielded results that were in the 
reported physiological range for R/S-SAL and DA. 
 In comparison to reported methodologies for the quantification of R/S-SAL and 
DA in human plasma, this procedure has surmounted the limitations aforementioned.  
The optimized chromatography has preserved the baseline resolution of the both 
enantiomers throughout the concentration range, improving the reliability of 
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quantification.   Quantification with the isotopically labeled internal standards of R- and 
S-SAL with DA yielded suitable assay performance results for the quantitative 
bioanalytical HPLC-MS/MS assay.   
 Employment of both of the sensitive and reproducible assays was suspected to 
circumvent any variability associated with the quantification of the β-carbolines and 
TIQ’s in human plasma.  Therefore, these assays were subsequently used to support the 
two separate clinical investigations.   
 Clinical Study #1 was a pilot study in forty-one male and female volunteers to 
study the effects of gender smoking on TIQ and β-carboline exposure.  The outpatient 
study was non-interventional, designed to evaluate measurements of plasma TIQ’s and 
β-carbolines in nonsmokers and in a smoking population who had just recently smoked 
a cigarette.   Subjects were stratified into groups of non-smokers (NS), light-smokers 
(LS) and heavy smokers (HS), based on the number of cigarettes smoked per day and 
the Fagerström Test for Nicotine Dependence (FTND).     Subject participation involved 
two morning outpatient visits in which a single blood sample was taken on each visit for 
the quantification of plasma TIQ’s and β-carbolines.   
 Overall, the variability observed between subjects was pronounced across all 
groups for both β-carbolines and the SAL enantiomers.     The effect of smoking status 
was significant within this study with the primary difference being between nonsmokers 
and smokers.    Although a trend was observed, a statistically significant difference was 
not noticed between the two LS and HS smoking groups.   The difference in exposures 
of the β-carbolines between smokers and nonsmokers are presumed to be resultant of 
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the acute inhalation of β-carbolines from tobacco smoke. Along with the inhaled β-
carbolines, the endogenous formation of the β-carbolines via condensation of 
acetaldehyde biogenic amines may also contribute to the overall exposure.    On the 
other hand, the SAL enantiomers and dopamine are not known to be constituents of 
tobacco smoke.   It is presumed that the acute exposure of acetaldehyde from the 
tobacco smoke, along with the subsequent condensation with dopamine, is responsible 
for the divergence of SAL concentrations between nonsmokers and smokers.    It was 
also observed that there were inherent dopamine differences between smoking status 
groups.   This effect was presumed to be caused by induction of a stress response upon 
smoking, thereby releasing dopamine.   
An attempt was made to characterize true baseline differences between smoking 
status groups with evaluation of a population of smokers who abstained from smoking 
for 15 hours.    A significant baseline difference was observed for both salsolinol 
enantiomers and norharman within this study with the primary difference being between 
the heavy-smokers and nonsmokers.    This is presumed to be a function of a true 
constitutive difference between smokers and nonsmokers or an additive accumulation of 
SAL enantiomer and norharman concentrations within the body.   When compared to 
the study involving smoker’s recent exposure to tobacco smoke, the difference between 
nonsmokers and smokers was more pronounced.   This suggests that, in addition to a 
supposed baseline difference, inhalation of tobacco smoke provides additional exposure 
to circulating TIQ and β-carbolines contributing to the incongruity of concentrations 
between smoking status groups.    As the difference between the smoking status groups 
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was much greater after smoking a cigarette, it was concluded that the effect on the 
analyte concentrations are due to recent tobacco smoke inhalation. 
The design of the investigation of baseline difference between smoking status 
groups possessed few shortcomings. The primary study was not balanced with respect 
to gender and smoking status.     Moreover a strong correlation was observed between 
the smoking status groups and measures of annual ethanol intake, hindering 
interpretability of the resultant smoking status effect.  For all analytes, a large inter-
occasion variability was observed between observational periods.  The sampling 
schedule, with respect to inhalation of tobacco smoke, required more rigid control to 
minimize variability associated with the separate sampling occasion.  A formal 
conclusion with respect to this study cannot be deduced without full understanding of 
the pharmacokinetics of the analytes in question.   These insufficiencies confound the 
results and variability associated between smoking status groups.  Of note, a gender 
difference was not observed but the true difference may have been masked due to the 
unbalanced design for this factor.        
The interrelationship between smoking and alcoholism is strong and has been 
exemplified by several researchers.  As smoking status had a significant effect on TIQ 
and β-carboline exposure in a healthy population, it is expected that this effect would be 
observed in an alcoholic population.    Therefore, a comparison was made to a second 
study involving an alcohol-dependent cohort undergoing detoxification treatment at the 
National Institutes of Health - National Institute on Alcohol Abuse and Alcoholism.  
This investigation evaluated detoxification-induced changes in plasma TIQ 
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concentrations in n = 35 alcoholics undergoing a four-week, inpatient alcohol 
abstinence program.   Using the same criteria used from study #1, subjects were 
stratified with respect to smoking status of NS, LS and HS.   Converse to the study 
involving healthy patients this analysis was balanced for gender.     
Plasma samples were collected during the first two weeks of detoxification: on 
admission, day 2, 3, 8, and 15 days after enrollment.  A clinical endpoint, the Clinical 
Institute Withdrawal Assessment-Alcohol Revised (CIWA-AR), was used to assess a 
possible correlation of these levels to withdrawal symptoms.  Plasma TIQ levels were 
assessed along with CIWA-AR, smoking history and exposure, and alcohol dependence 
measurements in order to assess their feasibility as a clinical biomarker for smoking and 
alcohol dependence.   Importantly, the time-course of these compounds during early 
abstinence in an alcohol-dependent cohort was assessed.  Evaluation of the contribution 
of smoking to levels of these compounds and, ultimately, the time-course was the 
primary objective of this study. 
Overall, the variability observed within- and between-subjects was pronounced 
across all groups for both SAL enantiomers.    A slight increase was observed in 
average R- and S-Salsolinol concentrations across all subjects from admission day to 
day 15 of sampling, while DA concentrations were relatively consistent during alcohol 
abstinence. Separate analyses for the factors of gender and smoking status were 
performed on the grand total mean, admission day, and day 15 concentrations for each 
analyte.   
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At every time point assessed, the effect of smoking status or gender was not 
significant.    Further covariate analysis using the a measure of chronic alcohol exposure 
the TLFB, the BrAC measure of acute alcohol exposure, average dietary SAL intake, 
acamprosate administration throughout the detoxification period and admission drug of 
abuse screen, did not yield significant relation with R/S-SAL exposure.    It is 
interesting to note that measures of alcohol intake such as the TLFB and acute ethanol 
intake, the BrAC did not yield a significant correlation.    These results refutes majority 
of the published literature with regard to SAL concentrations and ethanol intake.  A 
measure of acute hepatocellular dysfunction, aspartate amino transferase (AST), 
showed an inverse relation to circulating SAL concentrations at admission day 
suggesting that SAL exposure may be dependent on liver pathophysiology.   It was 
concluded in the investigation that the discrepancies observed may have been due, in 
part, to liver dysfunction. 
 Upon comparison with a healthy, non alcohol-dependent population, the SAL 
concentrations observed in the healthy population were higher that that of the alcohol 
dependent population on admission day of detoxification.    These results may have 
been due to the fact that the healthy subjects were required to smoke within thirty 
minutes of SAL sampling, while the alcohol dependent sampling was not controlled for 
this factor of recent smoking.  The assessment of the time frame between last cigarette 
upon entrance into the clinic and the SAL sampling was not assessed in the alcohol 
dependent patients, hindering definitive interpretation of the results.    The observational 
results from clinical study #2 may be confounded by several factors such as concurrent 
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pharmacotherapies, other disease states, impaired liver function, and lack of rigid 
investigational control of smoking and dietary intake throughout the inpatient period, 
other drugs of abuse and the heterogeneity of the subject demographics.     
 It was found that, in a healthy population, a noteworthy trend was observed 
between smoking status and TIQ and β-carboline exposure.   This trend is hypothesized 
to be a product of a combination of constitutive endogenous differences between 
smoking status groups and exposure via the inhalation of the analytes themselves and/or 
inhalation of precursors required for endogenous synthesis, acetaldehyde.  Moreover, 
TIQ exposure has been reported to be influenced by acute ethanol intake and chronic 
alcoholism.    Significant variability within these studies has been reported, hampering 
the ability for these compounds to be an adequate marker for alcohol abuse.  As the 
association of smoking and alcohol abuse is strong, it is suspected that the variability in 
TIQ exposure observed may be explained by tobacco smoking.    In the investigation 
with alcohol dependent subjects smoking status or gender was not significant with 
respect to TIQ levels, at any point during detoxification.   Moreover, our study 
concluded that alcohol-dependent patients did not have higher concentration of 
circulating TIQ’s compared to the healthy patients, which contests all published reports. 
 From the information provided from this investigation, SAL enantiomers do not 
seem to be viable biomarker candidates for alcoholism.  The specificity of these 
compounds as state markers of alcoholism is compromised by factors such as liver 
dysfunction.  Moreover, other factors such as other drugs of abuse or additional 
pharmacotherapies may further complicate the use for SAL as a biomarker.    Of most 
481 
importance, the use of the SAL measurement was unable to discriminate between a 
healthy population and an alcohol dependent population, further negating the use of 
SAL and an alcoholism marker.  It was observed that smoking does influence SAL and 
β-carboline concentrations in a healthy population.  Further research is warranted in the 
evaluation of the pharmacokinetics of these compounds to support additional smoking 
biomarker studies.  
The plasma concentrations of TIQ and β-carboline exposure are assumed to be 
reflective of central dopaminergic activity.    The concentration difference between 
smokers and nonsmokers suggest that nicotine dependent subjects may require 
maintenance of these higher concentrations in order to experience feelings of pleasure, 
simultaneously circumventing negative symptoms of nicotine withdrawal.   In the case 
of alcohol dependent subjects, concentrations of TIQ’s were actually lower than that of 
healthy subjects.   This difference between the populations infers that the alcohol-
dependent person may drink in order to attain higher concentrations of TIQ’s for 
feelings of pleasure and reward.   Further studies evaluating the acute cravings of 
alcoholics and smokers need to be conducted in order to substantiate these hypotheses.  
 Behavioral studies do indicate that nicotine and alcohol are addictive and that 
these drugs reinforce self-administration.  This phenomenon is reported to be governed 
by the mesolimbic dopamine system.   A major assumption in this investigation was 
that central TIQ and β-carboline concentrations reflect to those observed in plasma.  
Further investigations, including pharmacokinetic and central nervous system 
concentration assessment, would help corroborate the plasma TIQ and β-carboline 
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concentrations within the presumed in-vivo effects within the mesolimbic dopaminergic 
system.  TIQ and β-carboline exposure within this “reward pathway” may play a 
synergistic role, along with the pharmacological actions of nicotine and alcohol, in the 
reinforcing aspects of tobacco smoking and chronic alcoholism.  
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Appendix A
 
Fagerström Test for Nicotine Dependence 
Heatherton R, Kozlowski L, Frecker R and Fagerström K.   
Br. J. Addiction. 1991; 86, 1119-1127. 
 
1. How soon after you wake up do you smoke your first cigarette? 
 
 _____ After 60 minutes   
 
 _____ 31 – 60 minutes 
  
 _____ 6 – 30 minutes 
 
 _____ Within 5 minutes 
 
2.  Do you find it difficult to refrain from smoking in places where it is forbidden  
(e.g. library, cinema, church?) 
 
 _____ No 
 
 _____ Yes 
 
3.  Which cigarette would you be the most unwilling to give up? 
 
 _____ First one in the morning 
 
 _____ Any other 
 
4.  How many cigarettes a day do you smoke? 
 
 _____ 1 –10 
 
 _____ 11-20 
 
 _____ 21-30 
 
 _____ 30 + 
 
5.  Do you smoke more during the first hours in the morning than during the rest of the day? 
 
 _____ No 
 
 _____ Yes 
 
6.  Do you smoke if you are so ill that you are in bed all day? 
 
 _____ No 
 
 _____ Yes 
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Appendix B 
 
Subject Stratification Criteria 
 
 
 
Subject Group 
 
 
 
Inclusion/Exclusion Criteria 
Nonsmoker (NS) 1. No current tobacco product use 
 2. Not a smoker for the past 5 years 
 3. If previously a smoker, did not smoke more than once a 
year continuously and < 10 cigarettes/year 
 4. FTND score = 0 
 
Light-smoker (LS) 
 
1. Current smoker of cigarettes (No other tobacco products) 
 2. Smokes at least 10 cigarettes/day 
 3. Smoked for at least 1 year continuously 
 4. FTND score 1-7 
 
Heavy-smoker (HS) 
 
1. Current smoker of cigarettes (No other tobacco products) 
 2. At least more than 20 cigarettes/day 
 3. Smoked for at least 1 year continuously 
 4. FTND score > 7 
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Appendix C 
 
Annual Alcohol Intake (AAI) Inventory 
Khavari KA and Farber PD 1978.  J. Stud. Alcohol. 39: 1525-1539. 
 
 
Please answer the following questions as accurately as you can: 
 
1. How often do you drink beer? 
_____ Never had beer 
_____ Tried, but not currently drinking 
_____ Once a year 
_____ Twice a year 
_____ Three or four times a year 
_____ Once a month 
_____ Twice a month 
_____ Three or four times a month 
_____ Once a week 
_____ Twice a week 
_____ Three or four times a week 
_____ Daily 
 
2.  What is the amount of beer that you usually drink per occasion? 
 
 
3. What is the maximum amount of beer you drink on any one occasion? 
 
 
4. How often do you drink this maximum amount of beer? 
_____ Never had beer 
_____ Tried, but not currently drinking 
_____ Once a year 
_____ Twice a year 
_____ Three or four times a year 
_____ Once a month 
_____ Twice a month 
_____ Three or four times a month 
_____ Once a week 
_____ Twice a week 
_____ Three or four times a week 
_____ Daily 
 
 
5. How often do you drink wine? 
 _____ Never had wine 
_____ Tried, but not currently drinking 
_____ Once a year 
_____ Twice a year 
_____ Three or four times a year 
_____ Once a month 
_____ Twice a month 
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_____ Three or four times a month 
_____ Once a week 
_____ Twice a week 
_____ Three or four times a week 
_____ Daily 
 
6. What is the amount of wine that you usually drink per occasion? 
 
 
7. What is the maximum amount of wine you drink on any one occasion? 
 
 
8. How often do you drink this maximum amount of wine? 
_____ Never had wine 
_____ Tried, but not currently drinking 
_____ Once a year 
_____ Twice a year 
_____ Three or four times a year 
_____ Once a month 
_____ Twice a month 
_____ Three or four times a month 
_____ Once a week 
_____ Twice a week 
_____ Three or four times a week 
_____ Daily 
 
 
9. How often do you drink distilled spirits? 
_____ Never had distilled spirits 
_____ Tried, but not currently drinking 
_____ Once a year 
_____ Twice a year 
_____ Three or four times a year 
_____ Once a month 
_____ Twice a month 
_____ Three or four times a month 
_____ Once a week 
_____ Twice a week 
_____ Three or four times a week 
_____ Daily 
 
10. What is the amount of distilled spirits that you usually drink per occasion? 
 
 
 
11. What is the maximum amount of distilled spirits you drink on any one occasion? 
 
 
 
 
 
12. How often do you drink this maximum amount of distilled spirits? 
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_____ Never had distilled spirits 
_____ Tried, but not currently drinking 
_____ Once a year 
_____ Twice a year 
_____ Three or four times a year 
_____ Once a month 
_____ Twice a month 
_____ Three or four times a month 
_____ Once a week 
_____ Twice a week 
_____ Three or four times a week 
_____ Daily 
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Appendix D 
 
TIQ/BC Food Inventory 
 
 
INSTRUCTIONS: Place a check mark in the appropriate column to indicate how frequently you consume each the following foods.   
                             Then place a check mark to indicate your typical serving size when consuming these foods. 
TYPE HOW OFTEN HOW MUCH
OF Never or 1-3 1 2-4 5-6 1 2-3 4 5+ Medium Your 
FOOD less than per per per per per per per per Serving Serving Size
1 per month month week week week day day day day Size Small Medium Large
Tomatoes 1/2 cup
Tomato Sauce 1/2 cup
Tomato Paste 1/2 cup
Bananas 1 Medium Size
Chocolate Covered Doughnuts 1 Doughnut
Chocolate Filled Doughnuts 1 Doughnut
Chocolate Cookie Sandwich 1 Cookie
Chocolate Covered Raisins 10 pieces
Chocolate Syrup 1 T
Chocolate Pie 1/8 pie
Chocolate Cake 1/6 cake
Chocolate Fudge .5 oz piece
Chocolate Cereal 3/4 cup
Chocolate Candy Bar 1 bar (regular size)
Chocolate Chip Cookie 1 medium cookie
Chocolate Candy (M&M, Rolos) 1 pkg
Chocolate Covered Ice Cream Bar 1 bar 
Chocolate Ice Cream/ Yogurt 1/2 cup
Chocolate Pudding/Mousse 1/2 cup
Chocolate Milk 8 fluid oz
Cocoa 8 fluid oz
Hot Chocolate 8 fluid oz
Charred Beef 3 oz
Charred Chicken  3 oz
Charred Fish (specify type) 3 oz
Charred Pork 3 oz
Fish, other than charred (specify type)
 
 
 
TYPE HOW OFTEN HOW MUCH
OF Never or 1-3 1 2-4 5-6 1 2-3 4 5+ Medium Your 
FOOD less than per per per per per per per per Serving Serving Size
1 per month month week week week day day day day Size Small Medium Large
Soy Sauce 3oz
Ketchup 1 T
Fish Supplements/Oils
Instant Caffeinated Coffee 6 fluid oz
Brewed Caffeinated Coffee 6 fluid oz
Cappuccino 6 fluid oz
Mocha 6 fluid oz
Caffeinated Soda 12 fluid oz
Instant Caffeinated Tea 8 fluid oz
Brewed Caffeinated Tea 6 fluid oz
Supplements (Chocolate Flavored) 8 fluid oz
Red Wine 3.5 fluid oz
White Wine 3.5 fluid oz
Beer 12 fluid oz
Distilled spirits (liquor) 1.5 fluid oz
Liqueurs 1.5 fluid oz
Alcohol Coolers 12 fluid oz
Champagne 3.5 fluid oz
Other (please Specify)  
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Appendix E 
 
Protocol and Informed Consent Form – Clinical Study #1 
 
 
 
Project Title: A Pilot Study to Determine Tetrahydroisoquinoline (TIQ) and β-
Carboline Levels in Nonsmokers, Light-Smokers and Heavy 
Smokers 
 
 
Principal Investigator:  Jürgen Venitz, M.D., Ph.D. 
    Associate Professor, Department of Pharmaceutics 
Director, Pharmacokinetic/Pharmacodynamic Research Laboratory 
    Box 980533 
    Virginia Commonwealth University 
    Richmond, VA 23298-0533 
    (804) 828-6249 
    jvenitz@vcu.edu
 
 
Co-Investigator:   Satjit Brar, B.S., Pharm.D./Ph.D. candidate 
Department of Pharmaceutics 
    Box 980533 
    Virginia Commonwealth University 
    Richmond, VA 23298-0533 
    (804) 828-6136 
    ssbrar@vcu.edu
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A Pilot Study to Determine Tetrahydroisoquinoline (TIQ) and β-Carboline Levels in                                   
Nonsmokers, Light-Smokers and Heavy Smokers 
 
 
 
Abstract  
 
 Nicotine dependence is a complex biological and behavioral problem that can be extremely 
difficult to overcome.  An improved overall understanding of drug dependence, coupled with the 
identification of nicotine as a drug with dependence potential, has been instrumental in the development 
of medications and behavioral treatments for nicotine dependence.  Researchers are beginning to find out 
that there may be chemical ingredients other than nicotine in cigarette smoke that contribute to tobacco's 
addicting potential. 
Two classes of endogenously formed compounds, tetrahydroisoquinolines (TIQ) and β-
carbolines, have been involved in adaptive brain mechanisms that may advance to drug dependence.   
These substances have been found to react with specific CNS neuro-receptor system activity (notably 
dopaminergic and serotonergic receptors, see below).  Of primary importance is that TIQ’s and β-
carbolines may activate the brain circuitry that regulates feelings of pleasure, the so-called “reward 
pathways”.  In turn, both of these substances might be responsible in nicotine seeking behavior and 
dependence.  The anticipated results of the proposed pilot study are essential to assess a possible 
relationship between blood TIQ’s and β-carbolines with smoking history and dependence, if it is likely to 
exist.  The study is also intended to evaluate statistically the inter- and intra-individual variability in the 
TIQ and β-carbolines levels as well as the smoking history/nicotine dependence scores of nonsmokers, 
light-smokers, and heavy-smokers. 
 In the proposed study, sixty (60) healthy young volunteers (twenty nonsmokers, twenty light-
smokers, and twenty heavy-smokers) will supply blood samples for determination of baseline levels of 
TIQ’s and β-carbolines.  During outpatient visits, nicotine and cotinine plasma concentrations will also be 
measured from the urine collected to evaluate systemic self-exposure.  An evaluation of their smoking 
history and nicotine dependence score will be used along with the baseline levels of TIQ’s and β-
carbolines to determine any correlation between the compounds of interest and the degree of nicotine 
exposure and dependence. 
If such a relationship can be revealed, future, more detailed, interventional studies will be 
designed to assess the suitability of these endogenous compounds as possible biomarkers of nicotine 
dependence. 
 
Background 
 
 In the search for an explanation for the mechanism in which drug dependence develops, 
researchers have explored possible theories for why individuals become addicted to specific drugs 
including alcohol, nicotine, opiates and other drugs of abuse.  Of note, two classes of endogenously 
formed compounds, tetrahydroisoquinolines (TIQ) and β-carbolines, have been indicted as chemicals that 
may mediate mechanisms thought to be involved in dependence. 
TIQ's are a class of partially aromatic alkaloids that include salsolinol, 1-carboxysalsolinol, 
tetrahydropapaveroline, and salsoline.  TIQ's are compounds that are formed as a result of the 
condensation reaction between dopamine and acetaldehyde or pyruvate (1) and are natural metabolites of 
dopamine produced in the brain as well as other organs (2).  TIQ's also occur naturally such as in wine 
and bananas (3).   Tetrahydropapaveroline (THP) is the dopamine - 3,4, -dihydroxyphenyl acetaldehyde 
condensation product whereas salsolinol (SAL) is the dopamine-acetaldehyde condensation product (4).  
It is known that SAL exists in two chemical conformations, the S-enantiomer and the R-enantiomer (2).  
Previous studies have found that the R-enantiomer or racemic mixture of SAL predominates in the urine 
of normal healthy subjects whereas the S-enantiomer predominates in the urine of alcoholics (3). 
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β-carbolines are another class of compounds such as noreleagnine, harman and norharman. β-
carbolines are aromatic alkaloids that are formed via the condensation of tryptophan or indolealkylamines 
with aldehydes (5).  These compounds exist endogenously in humans under normal conditions, however 
some are also formed after the ingestion of alcohol and further more have been shown to increase ethanol 
consumption in rats (6).  These compounds also exist in plants that have psychotropic properties as well 
in food such as in charred meat and fish as well as in cigarette smoke (5).  Studies have shown that 
norharman may interact with several receptor systems including benzodiazepines as well as serotonin and 
dopamine in higher concentrations (7). 
Interestingly, previous studies have found that upon chronic injection of TIQ's and β-carbolines 
causes an increase in alcohol intake (4, 6, 8).  Specifically, rats infused intraventricularly with 4.0 μg of 
salsolinol increased alcohol intake from 0.74 to 4.9 gm/kg/day (8).  Additionally, 4 rats that were infused 
with 4.0 μg of noreleagnine also had an increase in alcohol consumption from 0.75 to 6.0 gm/kg/day (8).  
In another study, single infusions of THP ranging from a dose of 0.1 - 1.0 μg increased alcohol 
consumption from 0.62 to 4.38 g/kg/day in the non-alcohol-preferring strain of Sprague-Dawley rats (6).  
Furthermore, when unanesthetized rats were infused with THP and tryptoline (TLN), a β-carboline, the 
release of C-dopamine in the caudate nucleus and nucleus accumbens was significantly increased (9).  A 
later study (7) involving injections of a range of doses on norharman showed that administration of doses 
of 2.44 μmol/kg and 43.97 μmol/kg induced an increase of dopamine efflux by 70% and 160%, 
respectively; however, with the administration of 7.33 μmol/kg there was a 72% decrease in dopamine 
efflux from baseline (7).  This was thought to indicate that norharman must influence the mesolimbic 
dopaminergic neurons in a U-shaped dose-response curve, and the authors suggest that norharman is 
affecting the dopaminergic system via different receptors, namely MAO-A, MAO-B and non-MAO 
binding site. 
As it has been noted in the literature, the modulation of drinking behavior and the consequent 
interaction of TIQ's and β-carbolines with the dopaminergic system demonstrate that these compounds 
may have a role in alcohol and drug dependence.  The dopaminergic system has been well established as 
the "reward system" in the brain.  Therefore, compounds that interact with the nucleus accumbens and the 
dopaminergic neurons could have a significant role in drug dependence.  Furthermore, as the 
dopaminergic system has a significant role in the drug-seeking behavior, it is possible that other drugs of 
dependence such as nicotine or other ingredients of cigarette smoke may also interact with the TIQ's and 
β-carbolines.  Additionally, these compounds could possibly mediate smoking behavior. 
In this study, we seek to collect preliminary data on the endogenous baseline levels of TIQ's and 
β-carbolines in nonsmokers, light-smokers and heavy-smokers to assess if there are any gross differences 
between the three groups.  This information may aid the development of further interventional studies 
where the administration of these compounds could be performed to investigate if there is an effect on 
cigarette smoking behavior. 
 
Objectives 
 
 The objective of this study is to obtain preliminary information on the baseline levels of TIQ’s 
and β-carboline concentrations in the blood of non-, light-, and heavy-smokers.  Additionally, venous 
nicotine and cotinine plasma levels will be determined as a measure of systemic exposure due to 
smoking.  Specific aims of this study include: 
1. Assessment of a possible association between the levels of blood TIQ’s and β-carbolines with 
the smoking history and dependence of the volunteers to determine if the line of research in 
smokers should be continued; 
2. Statistical measurement of inter- and intra-individual variability in the levels and smoking 
history/nicotine dependence scores, which would permit formal sample size calculations in 
future studies. 
3. Classification of volunteers according to smoking history and nicotine dependence with the 
Fagerström Scale (Appendix I) in nonsmokers, light smokers, and heavy smokers; further 
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classification by personality type using the TCI personality survey (Temperament and Character 
Inventory). 
  
 The anticipated follow-up study would involve a larger sample size along with possible 
interventions to further characterize plasma levels of TIQs and β-carbolines in order to: 
1. establish TIQs and β-carbolines as biomarkers of nicotine dependence.  
2. be able to predict treatment success of nicotine-replacement and cessation therapies for 
individuals of varying degrees of nicotine dependence. 
 
Methods 
 
Study Design 
 
 Sixty young healthy male and female volunteers, aged 21-35, will be recruited, including 20 
nonsmokers, 20 light-smokers, and 20 heavy-smokers as follows: 
 Male 10 Nonsmoker  
Female 10  
Male 10  Light-Smoker 
Female 10  
 Male 10 Heavy-Smoker  Female 10 
 
The study will involve two visits in which the volunteer will present to the Clinical Research 
Center.  Prior to participation, the subject will be required to take a telephone interview for qualification 
purposes (Appendix VI).  Upon qualification, the subject will be notified of any abstentions required 
before each visit.  The abstentions include: no prescription/OTC/herbal medications or caffeinated 
products for 72 hours prior to each visit (with exception of oral contraceptives prescription for females) 
and no alcoholic beverages 12 hours prior to each visit.  The subject will be given a chance to decline 
participation in the study or, if necessary, to seek his/her personal physician's advice as to whether to 
discontinue any medications he/she may be on.  During the first visit, the volunteer will complete forms 
including:  Medical History (Appendix. V), Subject Entry Probe (Appendix. IV), Smoking History 
(Appendix. II), Annual Alcohol Intake (AAI, Appendix. IX), and Zuckerman's Sensation Seeking Scale 
(Appendix. VIII).  Additionally, during the first visit, the subject will take a Breathalyzer and carbon 
monoxide test as well as give a 60-ml blood sample for estimation of TIQ and β-carbolines levels.  The 
volunteer will also provide a urine sample for drugs of abuse screen and nicotine/cotinine levels.  During 
the second visit, only the breath tests, blood and urine sample will be repeated.  Additionally, the 
Temperament and Character Inventory (TCI) (App. X) will be administered as a computer test.  A 
pregnancy test will be given to female subjects and repeated if the time elapsed between the two visits 
exceeds one week.   
 
 
Inclusion/Exclusion Criteria 
 Potential subjects will be screened over telephone for inclusion/exclusion criteria.  A general 
health questionnaire will be administered over the telephone regarding their medical history, substance 
use, medications, and patient characteristics such as height and weight (Appendix VII).  In addition to the 
general health questionnaire, the Fagerström Test of Nicotine Dependence, (FTND) (10,11, Appendix I) 
will be administered to determine their dependence on nicotine in order to classify potential subjects into 
three groups:  Nonsmokers, Light-smokers, and Heavy-smokers.  The following criteria must be met for 
subjects in each group: 
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Subject Group Inclusion/Exclusion Criteria 
Nonsmoker 1. No current tobacco product use 
 2. Not a smoker for the past 5 years 
 3. If previously a smoker, did not smoke 
more than once a year continuously and no 
more than 10 cigarettes/year 
 4. FTND score = 0 
Light-smoker 1. Current smoker of cigarettes (No other 
tobacco products) 
 2. Smokes at least 10 cigarettes/day 
 3. Smoked for at least 1 year continuously 
 4. FTND score 1-7 
Heavy-smoker 1. Current smoker of cigarettes  (No other 
tobacco products) 
 2. At least more than 20 cigarettes/day 
 3. Smoked for at least 1 year continuously 
 4. FTND score > 7 
 
In the situation that the smoking history and FTND scores put them in two different categories 
(specifically for light- and heavy-smokers), preference will be given to the smoking history (number of 
cigarettes/day) over the FTND score. 
 
Along with the Fagerström Test for Nicotine Dependence scores, personality surveys will be 
administered in order to characterize the study population in terms of their personality traits and alcohol 
use.  Personality surveys including the Temperament and Character Inventory, TCI (17,18, App. X), 
Zuckerman’s Sensation Seeking Scale, ZSSS (12, App. VIII).  In addition, the Annual Alcohol Intake, 
AAI (13, App. IX), will be administered to all subjects to assess concomitant alcohol intake as a potential 
major covariate for TIQ's. 
 
Cloninger et al. (17, 18, 19) developed a Temperament and Character Inventory (TCI) designed 
to assess personality traits that may be associated with activity of central neurotransmitter systems.  The 
TCI (App. X) consists of 240 true/false questions that will  
provide the basis for determining specific personality traits.  The personality characteristics measured 
incorporate: 1) novelty seeking, 2) harm avoidance, 3) reward dependence, 4) persistence, 5) self-
directedness, 6) cooperativeness and 7) self transcendence (17, 18).  This inventory was originally based 
on the concept that each factor is a function of brain neurochemical transmitter systems, i.e., dopamine, 
serotonin, and/or norepinephrine.  The original research suggested that three of the characteristics 
evaluated were a function of one of these neurotransmitters: novelty seeking to dopamine; harm 
avoidance to serotonin; and reward dependence to norepinephrine (17,18).  Human research suggests that 
there is a correlation between personality and neurochemistry but the data are not overwhelming (19). 
  
The ZSSS (12, App VIII) is designed to characterize subjects according to their interests and 
preferences.  The survey features 40 questions of two choices of answers. 
  
The AAI (13, App. IX) survey will be primarily used to assess a potentially significant covariate 
for TIQs:  Several human studies have noted that norharman (a β-carboline) levels are significantly 
elevated in chronic alcoholics (15).  Furthermore, chronic alcoholics who have undergone controlled 
abstinence have shown two-fold higher levels of norharman compared to control subjects at the beginning 
of the abstinence period, with a gradual decline in levels at the end of the 3-week abstinence period (16). 
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The results of these surveys will allow for better characterization of the study population and 
permit comparison with other clinical studies. 
 
 Female subjects must not be pregnant during the clinical study and must be using acceptable 
methods of contraception (abstinence, barrier methods, or oral contraceptives).  However, females that 
are not using oral contraceptives must have regular menstrual cycles of 28-32 days on average and must 
not have dysmenorhea.  Subjects who satisfactorily pass the screening exam will be enrolled in the study. 
 
 Volunteers who have passed the initial telephone screening will be invited to the General 
Clinical Research Center (GCRC) for an out patient visit including medical history (particularly personal 
or family history of psychiatric disorders and/or drug dependence other than smoking), blood pressure, 
and vital signs in order to ensure the health of the subject.  Urine test for drugs of abuse, breath alcohol 
and breath carbon monoxide tests will be done to ensure that the subject does not abuse other drugs, is 
abstinent from alcohol, and to measure nicotine exposure, respectively.  Personality surveys including the 
Temperament and Character Inventory (TCI) (17,18, App. X), Zuckerman’s Sensation Seeking Scale (12, 
Appendix. VIII), and AAI (Annual Alcohol Intake (13, Appendix IX) will be administered to all subjects.  
The results of these surveys will allow for better characterization of the study population and permit 
comparison with other clinical studies. 
 
Endpoints and Measurements 
 For each visit period, the subject will be admitted as an outpatient to the GCRC between 8 AM-
10AM.  During this time, subjects classified as smokers will smoke a cigarette, and blood and urine 
samples will be collected within 30 minutes of smoking.  Upon entrance to the GCRC, a breath carbon 
monoxide test and Breathalyzer test will be administered.  A subject entry probe will also be given to 
determine their adherence to the 12-hour abstention from alcohol and caffeinated products in addition to 
the 72-hours abstention from medications. 
 
Before the blood samples are collected from the subject, Annual Alcohol Intake and 
Zuckerman’s Sensation Seeking Scale are administered (Appendices VIII and IX).  Subsequently, a urine 
specimen will be taken to evaluate drugs of abuse test and nicotine/cotinine levels.  A 60-ml blood 
sample will be collected from the non-dominant forearm in a reclined, seated position during the study.  
Sitting blood pressure, heart rate, and body temperature will be measured as safety precautions.  The 
blood samples will be centrifuged to obtain plasma and serum, and plasma samples will be stored at -
70°C until analysis.  Nicotine and cotinine plasma and urine concentrations will be determined by gas 
chromatography/mass spectroscopy method developed and validated by the Biopharmaceutical Analysis 
Laboratory at the Virginia Commonwealth University Department of Pharmaceutics (14).   A blood 
sample will be sent to Dr. H. Rommelspacher at Freie Universität Berlin in Berlin, Germany to determine 
levels of tetrahydroisoquinolines and β-carbolines (1,2); this sample will not have any identifying 
information about the subject to ensure confidentiality. 
The subject will discharged in approximately two hours pending an evaluation by the nursing 
staff for lack of adverse events. 
The second visit will consist of all of the aforementioned with exception of the medical history, 
smoking history, and personality survey, Annual Alcohol Intake, and Zuckerman’s Sensation Seeking 
Scale).  The Temperament and Character Inventory (TCI, App. X) will also be administered during this 
period.  
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Data Analysis 
 Intra-individual variability (e.g., COV%) will be calculated for all measured endpoints, i.e., TIQ 
and β-carboline concentrations, nicotine and cotinine urine concentrations for each volunteer.  
Appropriate summary statistics such as mean, median, COV%, percentiles and range will be computed. 
Inter-individual variability (i.e., COV% and range) will be calculated for the above endpoints as 
well as all the rating scale scores for each of the three groups and across all groups (see ANOVA, below).  
These variability measures will allow formal sample size calculations for future crossover or parallel-
group studies. 
 Both TIQ and β-carboline mean concentrations will be correlated with the measures of cigarette 
exposure (nicotine and cotinine mean urine concentrations) and dependence (Fagerström rating scale 
scores) using Spearman's rank sum correlation coefficient. 
 All the above endpoints will be compared with smoking history and gender by means of two-
way ANOVA.  If the overall ANOVA is significant at the p<0.05 level, this will followed by a Scheffé 
test to isolate group differences. 
For all tests and statistics, the raw data may be log- or rank-transformed to comply with the 
parametric assumptions of equal variance across groups and normal distribution of the residuals. If 
necessary, appropriate nonparametric tests, e.g., Wilcoxon U-test, will be performed. 
 
Description of Human Subject Protection 
Subject Selection 
 Subjects participating in the study will have passed outpatient screening including past medical 
history and drug screen.  This will exclude participation of subjects with significant disease states 
including renal, hepatic, neurological, cardiovascular, gastrointestinal, pulmonary, neurological and 
psychiatric diseases.   Female subjects must not be pregnant during the clinical study and must be using 
acceptable methods of contraception. 
 Prior to enrollment, all subjects will be explained the objectives, methods, benefits, risks, and 
inconveniences of the study: they will be required to sign the VCU IRB-approved Informed Consent 
Form.  They will be paid an honorarium for the time commitment and inconveniences that the study may 
entail. 
 
Inclusion of Children 
 Children (defined as individuals under the age of 21 years) are to be excluded from the study. 
For this particular study, it would be inappropriate to recruit smoking adolescents since it may reward 
their smoking habits, which should be discouraged.   
 
Risks and Safety Monitoring 
 This investigation does not require the introduction of a study drug or device.  Therefore, any 
risks or side effects associated with a therapeutic drug or device should not be observed. 
A total of one (1) blood sample will be drawn during each study period.  The total amount of 
blood from each session will be 60 ml (about 4 tablespoons) and about a total of 120ml (less than half a 
blood donation) over the entire duration of the study.  Obtaining these blood samples may cause some 
discomfort, pain, or slight bruising around the site of the needle stick.  Sometimes, fainting or infection 
may occur. 
During the two outpatient periods, the subjects’ vital signs will be recorded and will be 
monitored for the appearance of any adverse events by the GCRC nursing staff.  In addition, a Medical 
Monitor will be available to monitor for signs of adverse events associated with blood drawing such as: 
mental confusion, dizziness, and weakness. 
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Risks associated with the aforementioned procedures involving the subject are generally 
minimal to none.  During participation of the study, there is no direct benefit for the subject.   If 
necessary, adverse events will be treated and followed up until resolution. 
 
Confidentiality of Records 
 
Medical records, consent forms, and collected data, which identify the subject, may be looked at 
and/or copied for research or regulatory purposes by: 
 
 the FDA; 
 Department of Health and Human Services (DHHS) agencies; 
 Virginia Commonwealth University (VCU); 
 Governmental and/or regulatory agencies to the extent required by law. 
 
Blood samples will be sent to our collaborator, Dr. Rommelspacher without any identifying 
confidential patient information.  Absolute confidentiality will not be guaranteed because of the need to 
give information to these parties.  The results of this research study may be presented at meetings or in 
publications.  The identity of the subject will not be disclosed in those presentations. 
 
Dose Selection: 
 A therapeutic drug dose or medical device will not be introduced to the subject by the 
investigators or the GCRC staff at any time throughout the study. 
 
Expected Results and Directions for Future Research 
 
 Building on a series of recent scientific findings suggesting that, independent of a drug's initial 
site of action, a number of drugs of abuse appear to increase the levels of the neurotransmitter dopamine 
in a particular brain pathway, TIQ’s and β-carbolines may act as a link between nicotine dependence and 
this common reward producing pathway. 
 
 Several studies have reported that with injection of TIQ’s and β-carbolines, there is an increase 
in alcohol intake (4, 6, 8).  Several human studies have noted that norharman levels are significantly 
elevated in chronic alcoholics (15).  Furthermore, chronic alcoholics who have undergone controlled 
abstinence have shown two-fold higher levels of norharman compared to control subjects at the beginning 
of the abstinence period, with a gradual decline in levels at the end of the 3-week abstinence period (16).  
As nicotine is also a drug of dependence that may interact with the dopaminergic reward pathways, we 
expect that smokers should have higher levels of TIQ’s and β-carbolines compared to nonsmokers.  
Moreover, heavy smokers are expected to have higher levels of TIQ’s and β-carbolines as compared to 
light-smokers. 
 With data from this pilot study, a larger follow-up study will be done to further characterize 
plasma levels of TIQs and β-carbolines in order to establish TIQs and β-carbolines as biomarkers of 
nicotine dependence and consequently be able to predict or identify individuals of varying nicotine 
dependencies.  
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RESEARCH SUBJECT INFORMATION AND CONSENT FORM 
 
Title: Tetrahydroisoquinoline and β-carboline Levels in Healthy 
Nonsmokers, Light-Smokers, and Heavy Smokers 
 
Protocol No.:   VCU IRB #1990 
 
Principal Investigator:  Jürgen Venitz, M.D., Ph.D. 
(804) 828-6249 
    (804) 997-9261 (pager) 
    jvenitz@vcu.edu
 
Co-Investigators:  Satjit Brar, B.S., Pharm.D./Ph.D. candidate 
 
Site:    Virginia Commonwealth University 
    Medical College of Virginia Campus 
    Department of Pharmaceutics 
    Smith Building 
    410 North 12th Street, Room 450-B 
    Richmond, VA 23298-0533 
 
    Virginia Commonwealth University/VCU Health System 
    General Clinical Research Center (GCRC) 
    North Hospital, 8th Floor 
    1300 East Marshall Street 
    Richmond, VA 23298 
 
This consent form may contain words that you do not understand.  Please ask the study doctor or 
the study staff to explain any words or information that you do not clearly understand.  You may take 
home an unsigned copy of this consent form to think about or discuss with family or friends before 
making your decision. 
 
Introduction 
 
 This study is designed to measure the blood and urine levels of chemicals that already exist in 
your body and to study possible differences between nonsmokers, light-smokers, and heavy-smokers.  In 
this study, no drug(s) or medical device(s) will be given.  If you agree to participate, you will have to 
complete paperwork including your medical history, some personality surveys, and give a blood and 
urine sample on two occasions.  Your urine will be tested for drugs of abuse.  If you do not want to get 
involved with the study because of concerns about illicit drug use, please let us know immediately 
and you can opt out of the study.  If you are female, a pregnancy test will be done as well.  
Approximately 60 subjects are expected to participate in this study.  
 
Before coming in for this study, you will not be allowed to take any prescription medications for 
three (3) days before the start of the study.  However, females will be allowed to use oral contraceptives 
throughout the duration of the study.  Prior to discontinuing any medication, you are strongly advised to 
contact your primary care physician.  You will not be allowed to take over-the counter medications or 
drink any beverages containing caffeine for 72 hours, and not permitted to drink any beverages 
containing alcohol for the 12 hours before and during the in-house study periods.  Finally, if you are a 
smoker, you will be allowed to smoke only one cigarette starting from when you enter the General 
Clinical Research Center (GCRC) (i.e., from approximately 8:00am until discharge at 10am). 
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 You will come to the General Clinical Research Center (GCRC) at Virginia Commonwealth 
University / VCU Health System, two times for outpatient visits (spaced at least one week apart from 
each other).  Each time, you will come to the GCRC in the morning (about 8:00 a.m.) and will be released 
around 2 hours later the same morning.  
 
 During the first visit when you come to the GCRC, you will complete several forms including 
your medical history and smoking habits, as well as several personality surveys.  You will also take a 
breath test for carbon monoxide and alcohol.  You will have to give a urine sample of which your urine 
will be tested for drugs of abuse as well as for nicotine.  One (1) blood sample of 60 ml (approximately 4 
tablespoonfuls) will be collected from a vein in your arm by sticking a needle directly into the vein.  For 
your safety, your blood pressure will be taken before and after the blood sample. 
 
 The second visit when you come to the GCRC, everything is the same as the first visit, except 
you do not have to complete the forms on your medical history, smoking history, and personality surveys.  
One additional personality survey will be taken during the second visit in the form of a computer test. 
 
This study is being conducted at the Virginia Commonwealth University / VCU Health System 
by Jürgen Venitz, M.D., Ph.D., Satjit Brar, Pharm.D./Ph.D. candidate, and John Clore, M.D..  Dr. Clore is 
the Medical Monitor for this study and is the first person to be contacted in the case of a medical 
emergency. 
 
Risks, Inconveniences, Discomfort 
 
Since this investigation does not require the introduction of any study drug or device, there 
should be no risks or side effects which might be associated with therapeutic drugs or devices. 
 
A total of one (1) blood sample will be drawn during each study period.  The total amount of 
blood from each session will be 60 ml (about 4 tablespoons) and about a total of 120 ml (less than half a 
blood donation) over the entire duration of the study.  Obtaining these blood samples may cause some 
discomfort, pain, or slight bruising around the site of the needle stick.  Sometimes, fainting or infection 
may occur. 
 
You will report any adverse events after the end of the study up to 30 days after the final 
discharge from the GCRC.  If any undesirable effects occur, you should report them directly to the study 
doctors.  Dr. Clore is the Medical Monitor for this study, and is the person you should contact in the case 
of a medical emergency.  If you cannot reach Dr. Clore, you may contact any of the study doctors. 
 
Pregnancy 
 
There are no effects on pregnancy in this study since there is no drug being given.  However, for 
female subjects of childbearing potential who wish to participate in the study, a negative pregnancy test is 
required for entry into the study.  A pregnancy test will be repeated upon entry to the GCRC, unless a test 
has been performed within seven (7) days prior to admission.  These tests must be negative in order to 
qualify for participation in the study, as there may be an effect of pregnancy on the blood chemicals that 
are being measured.  
Women who are pregnant or nursing a child may not participate in this study.  The use of 
reliable birth control is required for sexually active women to enter this study.  This may include barrier 
methods, intrauterine devices (IUDs) or being surgically sterile; however, no birth control method 
completely eliminates the risk of pregnancy.  Females using birth control pills may be included in the 
study.  Females not using birth control pills may also be included in the study, provided that their periods 
are within 28 to 32 days on average (with no history of abnormal periods).  Before entering this study, 
you and your study doctor must agree on the method of birth control you will use during the entire study.  
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If you suspect that you have become pregnant during the study, you must notify the study doctor 
promptly. 
 
Benefits 
 
You are being asked to participate in this study as a volunteer.  This is not a treatment study, and 
you are not expected to receive any direct medical benefits from your participation in the study.  The 
information from this research study may lead to a better treatment in the future for people with smoking 
dependence.   
 
Costs of Participation 
 
 There will be no charge to you for any laboratory tests, GCRC visits, or other tests related to the 
conduct of this study.  
 
Payment for Participation 
 
 This is a time-consuming study that may interfere with your employment or other activities.  
You will be at the study unit two (2) times in the morning for the study. 
 
 You will be paid $40.00 for the completion of both outpatient visits.  If you withdraw early or 
are discontinued for medical reasons, you will be paid $20.00 for each visit you complete. 
 
 If you decided to withdraw from the study, you may be paid based on the amount of usable 
information that has been collected.  If it is determined that you did not give an accurate history or did not 
follow the guidelines of the study and the regulations of the General Clinical Research Center, you will 
be withdrawn from the study without compensation. 
 
Alternative Treatment 
 
 This is not a treatment study.  You may choose not to participate.  
 
Compensation for Injury 
 
Virginia Commonwealth University and the VCU Health System (formerly known as Medical 
College of Virginia Hospitals) have no plan for providing long-term care or compensation in the event 
that you suffer injury as a result of your participation in this research study. 
 
If you are injured or if you become ill as a result of your participation in this study, contact your 
study doctor immediately.  Your study doctor will arrange for short-term emergency care or referral if it 
is needed. 
 
Fees for such treatment may be billed to you or to appropriate third party insurance.  Your health 
insurance company may or may not pay for treatment of injuries as a result of your participation in this 
study. 
 
Sources of Funding 
 
 Funding for this research study will be provided from ongoing research overhead monies. 
 
Confidentiality of Records 
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Confidentiality of personal information about you – including your medical records and personal 
research data gathered in connection with this study – will be maintained in a manner consistent with 
federal and state laws and regulations. 
 
You should know that research data or medical information about you may be reviewed or 
copied by the sponsor of the research or by Virginia Commonwealth University.  Personal information 
about you might be shared with or copied by authorized official s of the Federal Food and Drug 
Administration, or the Department of Health and Human Services.   
Although results of this research may be presented at meetings or in publications, identifiable 
personal information pertaining to participants will not be disclosed.   
  
Voluntary Participation/Withdrawal 
 
Your participation in this study is voluntary.  You may decide to not participate in this study.  If 
you do participate, you may freely withdraw from the study at any time.  Your decision will involve no 
penalty or loss of benefits to which you are otherwise entitled. 
 
Your participation in this study may be stopped at any time by the study doctor or the sponsor 
without your consent. The reasons might include: 
• the study doctor thinks it necessary for your health or safety; 
• you have not followed study instructions; 
• the sponsor has stopped the study; or 
• administrative reasons require your withdrawal. 
 
If you leave the study before the final regularly scheduled visit, you may be asked by the study 
doctor to make a final visit for some of the end of study procedures. 
 
Questions 
 
 In the future, you may have questions about your study participation.  You may also have 
questions about a possible side effect or a possible research-related injury.  If you have any questions at 
any time concerning the study procedures, contact the study doctors: 
 
      Office   Pager 
Jürgen Venitz, M.D., Ph.D.   (804) 828-6249 (804) 997-9261 
Satjit Brar, Pharm.D./Ph.D. 2006   (804) 828-6136 
John Clore, M.D.     (804) 828-9349  
 
Dr. John Clore is the Medical Monitor for this study.  He is the first person to be contacted in the 
case of an emergency. 
 
If you have any questions regarding your rights as a volunteer in a clinical research study, you 
may contact: 
  
VCU Office of Research Subjects Protection  
Bio-Tech Research Park, Building 1 
800 E. Leigh St., Suite 111 
Richmond, VA 23298=0568 
Telephone: 804-828-0868  
  
 Do not sign this consent form unless you have had a chance to ask questions and have received 
satisfactory answers to all of your questions. 
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Consent 
 
I have been provided with an opportunity to read this consent form carefully.  All of the 
questions that I wish to raise concerning this study have been answered.   
 
By signing this consent form, I have not waived any of the legal rights or benefits, to which I 
otherwise would be entitled.  My signature indicates that I freely consent to participate in this research 
study. 
 
 
Printed         
        (subject name) 
 
 
Signed         Date      
   (subject) 
 
 
Printed          
        (witness name) 
 
 
Signed         Date    
   (witness) 
 
 
Signed         Date     
 (person conducting informed consent discussion) 
 
 
Signed         Date     
     (investigator – if different from above) 
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Appendix F 
 
 Activity Flow Sheet - Clinical Study #1  
 
 
 
 
Outpatient Period 1 Outpatient Period 2 
ICF SEP 
SEP Breathalyzer Test 
Weight and Height Recording CO 
MHx, SH TCI 
ZSSS SMOKE* 
AAI VS 
Breathalyzer Test Blood Sample 
CO VS 
SMOKE* Urine Sample 
VS Drug Screen / PT** 
Blood Sample  
VS  
Urine Sample  
Drug Screen / PT**  
 
*    for smokers only 
**  for female subjects only 
 
 
AAI:  Annual Alcohol Intake 
CO: Breath Carbon Monoxide Test 
ICF: Informed Consent Form 
MHx: Medical History 
PT: Pregnancy Test 
SEP: Subject Entry Probe 
SH: Smoking History 
TCI: Temperament and Character Inventory 
VS: Vital Signs 
ZSSS: Zuckerman’s Sensation Seeking Scale 
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Appendix G 
 
Patient Summary – Clinical Study #1 
 
 
 
   
 
N
o
Init
ID
Screening
R
epeats
C
om
m
ents
R
ace
Sex
Age
W
eight
H
eight
Previous
Sm
oking
D
ate
Abnorm
alities
D
ate
Abnorm
alities
[yrs]
[kg]
[cm
]
Study
FTD
 Score
=
===
=====
=====
==========
===================
===========
===========
===================
==========
===========
=========
===
=========
=========
=========
=========
=========
*
101
AD
S
1980
N
ov-16-01
none
ELIG
IB
LE
W
hite
F
21
68.0
162
none
0
*
102
JK
B
2232
D
ec-17-01
(recent stom
ach cram
ps) -ncs
ELIG
IB
LE
B
lack
F
22
52.7
159
none
0
*
103
H
AG
6554
D
ec-19-01
none
ELIG
IB
LE
W
hite
F
31
86.2
173
none
0
*
104
R
PR
6651
D
ec-19-01
none
ELIG
IB
LE
W
hite
F
21
51.2
153
none
4
*
105
B
AC
6603
D
ec-21-01
(h/o chronic shoulder injury, c/o shoulder pain) -ncs
ELIG
IB
LE
H
ispanic
M
26
70.2
171
none
0
*
106
LG
K
7838
Jan-25-02
ncs
ELIG
IB
LE
Asian
F
26
52.2
151
none
0
*
107
TSL
3465
Feb-22-02
(borderline H
TN
) -ncs
ELIG
IB
LE
W
hite
M
22
88.1
175
none
0
*
108
K
B
R
5471
M
ar-15-02
ncs
ELIG
IB
LE
Asian
M
24
67.7
171
none
6
*
109
LM
D
7823
Jun-06-02
ncs
ELIG
IB
LE
W
hite
F
23
49.5
158
none
4
*
110
JC
D
8124
Jun-12-02
ncs
ELIG
IB
LE
W
hite
F
23
59.0
164
none
5
*
111
TA
T
3529
Jun-14-02
ncs
ELIG
IB
LE
W
hite
F
22
60.9
169
intranasal n
0
*
112
C
D
P
5306
Jul-11-02
ncs
ELIG
IB
LE
W
hite
F
21
48.7
156
none
6
*
113
PR
B
0020
Jul-17-02
ncs
ELIG
IB
LE
W
hite
M
25
71.3
181
none
0
114
SAT
5433
Jul-29-02
D
S: C
ocaine PO
SITIVE
IN
ELIG
IB
LE
W
hite
F
29
45.5
162
none
2
115
M
-G
5263
Jul-30-02
h/o current depression/anxiety; D
S: TH
C
: PO
SITIVE
IN
ELIG
IB
LE
B
lack
F
23
50.3
166
none
0
*
116
P-G
8471
Jul-25-02
ncs
ELIG
IB
LE
Asian
M
24
71.3
157
none
0
*
117
JO
F
2678
Aug-21-02
ncs
ELIG
IB
LE
W
hite
M
32
78.5
177
none
3
*
118
M
R
H
6018
Sep-19-02
ncs
ELIG
IB
LE
W
hite
F
24
79.7
172
intranasal n
7
*
119
JM
K
3716
O
ct-08-02
h/o single m
arijuana use 3 w
eeks prior
ELIG
IB
LE
W
hite
F
21
86.0
176
none
2
*
120
JIM
3916
O
ct-07-02
ncs
ELIG
IB
LE
W
hite
F
26
73.3
171
none
0
*
121
B
M
R
3461
O
ct-14-02
ncs
ELIG
IB
LE
Asian
M
26
81.0
176
none
0
*
122
ZER
6322
Jul-24-03
ncs
ELIG
IB
LE
W
hite
F
21
58.7
160
none
1
*
123
FLW
7447
Jul-25-03
ncs
ELIG
IB
LE
Asian
F
30
65.3
167
none
0
*
124
AJC
5839
Aug-13-03
ncs
ELIG
IB
LE
Asian
M
26
67.5
174
none
0
*
125
JB
H
1461
Sep-17-03
ncs
ELIG
IB
LE
W
hite
M
22
103.6
178
none
0
*
126
C
LM
6562
Feb-24-04
ncs
ELIG
IB
LE
W
hite
F
28
83.6
169
none
7
*
127
K
AB
1800
M
ar-10-04
ncs
ELIG
IB
LE
W
hite
M
23
107.4
188
none
6
*
128
JAG
3606
Sep-25-07
ncs
ELIG
IB
LE
W
hite
F
25
65.1
159
none
0
*
129
N
FL
2060
O
ct-01-07
ncs
ELIG
IB
LE
W
hite
F
31
54.1
157
none
1
*
130
K
AS
2911
O
ct-05-07
ncs
ELIG
IB
LE
Asian
M
26
90.8
178
none
0
*
131
D
SL
4231
O
ct-05-07
ncs
ELIG
IB
LE
Asian
M
30
83.7
173
none
0
*
132
C
N
L
0092
O
ct-22-07
ncs
ELIG
IB
LE
W
hite
F
31
83.6
172
M
igraine s t
4
*
133
C
-M
0000
N
ov-05-07
ncs
ELIG
IB
LE
W
hite
F
22
70.2
174
none
1
*
134
K
D
C
5842
N
ov-21-07
ncs
ELIG
IB
LE
Asian
M
23
72.5
177
none
0
*
135
B
-S
4592
N
ov-27-07
ncs
ELIG
IB
LE
Asian
F
26
52.6
164
none
0
*
136
PSB
9265
N
ov-29-07
ncs
ELIG
IB
LE
Asian
F
28
51.8
156
none
0
*
137
JSS
9263
N
ov-29-07
ncs
ELIG
IB
LE
Asian
F
25
56.8
157
none
0
*
138
AB
B
1255
N
ov-30-07
ncs
ELIG
IB
LE
Asian
M
24
81.1
175
none
2
*
139
G
K
J
4593
N
ov-30-07
ncs
ELIG
IB
LE
W
hite
M
24
78.8
190
none
8
*
140
D
R
D
6917
N
ov-30-07
ncs
ELIG
IB
LE
W
hite
M
25
79.8
170
none
6
*
141
AA
A
2976
D
ec-10-05
ncs
ELIG
IB
LE
Asian
M
25
79.7
167
none
7
*
142
TFP
9482
D
ec-19-07
ncs
ELIG
IB
LE
W
hite
M
31
82.6
175
none
6
*
143
M
-R
6798
Jan-14-08
ncs
ELIG
IB
LE
Asian
M
21
66.5
171
none
1
============================================================================================================================================================================
A Pilot Study To D
eterm
ine TIQ
 and B
eta-C
arboline Levels in N
onsm
oker, Light-Sm
okers And H
eavy Sm
okers
Three groups of N
onsm
okers, Light Sm
okers and H
eavy Sm
okers (n=15 Fem
ales and 15 M
ales per G
roup)
O
bservational, Tw
o-Period Study
Protocol: 07/07/00, 08/21/01, 09/17/01, 06/25/02.
Internal Funding: Personal, J. R
osecrans
VC
U
 IR
B
 #1990: , approved: 08/29/01, 10/16/01, 12/07/02 (advertisem
ent), 02/08/02 (advertisem
ent), 07/25/02, 05/16/03, 04/11/04, 04/28/05 (advertisem
ent *2)
G
C
R
C
: #686; approved 6/28/01.
SC
R
EEN
IN
G
 I
IC
F: 08/21/01, 09/10/02, 05/16/03, 06/23/03, 05/27/04, 04/28/05, 03/23/06, 02/22/07
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N
o
Init
ID
Screening
Preexisting Illnesses
C
oncurrent M
edications
D
ate
=
===
=====
=====
==========
===================
===========
===========
===================
==========
===========
=========
===
=========
=========
=========
=========
*
101
AD
S
1980
N
ov-16-01
(h/o seasonal allergies) -ncs (LM
P: XXX)
O
rthocyclen Q
D
, Fe supplem
ent for 5 days, Flunase PR
N
*
102
JK
B
2232
D
ec-17-01
(h/o seasonal allergies) -ncs (LM
P: XXX)
Excedrin PR
N
, m
ultivitam
in Q
D
*
103
H
AG
6554
D
ec-19-01
(LM
P:12/3-12/9/01)
Ibuprofen PR
N
, m
ultivitam
in Q
D
*
104
R
PR
6651
D
ec-19-01
(LM
P:12/3-12/9/01)
none
*
105
B
AC
6603
D
ec-21-01
(h/o inguinal hernia O
P in 1999) -ncs
Ibuprofen PR
N
, m
ultivitam
in Q
D
*
106
LG
K
7838
Jan-25-02
ncs
N
aproxen 220 m
g, vit. C
 
*
107
TSL
3465
Feb-22-02
(h/o childhood asthm
a, cat allergy) -ncs
Ipratroprium
 and albuterol 110 m
cg puffs B
ID
*
108
K
B
R
5471
M
ar-15-02
ncs
D
ayquil on 3/11/02
*
109
LM
D
7823
Jun-06-02
(h/o U
TI, 1998; asthm
atic bronchitis, 1997; chem
. ind. B
ipolar disorder, 1998) -ncs  (LM
P:5/11/02)
none
*
110
JC
D
8124
Jun-12-02
(h/o bronchitis, 2000; m
inor cyst surgery 2001) -ncs  (LM
P: 6/5/02)
Advil, Tylenol PR
N
; triphasil Q
D
*
111
TAT
3529
Jun-14-02
(h/o interm
ittent insom
nia) -ncs (LM
P: 5/27/02)
Ibuprofen PR
N
, U
nisom
 on 6/9/02
*
112
C
D
P
5306
Jul-11-02
(h/o depression 1998, codeine allergy, interm
ittent m
igraines)-ncs (LM
P: 7/2/02)
N
econ 1 m
g Q
D
, m
etabolife PR
N
, tylenol PR
N
*
113
PR
B
0020
Jul-17-02
(h/o G
ER
D
) -ncs
Pepcid, Inbuprofen PR
N
; m
ultivitam
ines and glucos/chondr. Q
D
114
SAT
5433
Jul-29-02
ncs
none
115
M
-G
5263
Jul-30-02
(h/o current depression/anxiety) -ncs
none
*
116
P-G
8471
Jul-25-02
none
m
ultivitam
ins Q
D
*
117
JO
F
2678
Aug-21-02
(h/o allergies) -ncs
none
*
118
M
R
H
6018
Sep-19-02
(h/o m
iscarriage (D
N
C
) 1996) -ncs
ASA PR
N
, R
obitussin PR
N
, D
epoVera since 2000
*
119
JM
K
3716
O
ct-08-02
(h/o borderline anem
ia, coconut allergy) -ncs (LM
P: 9/21/02)
none
*
120
JIM
3916
O
ct-07-02
(h/o m
itral prolapse) -ncs (LM
P: 9/23/02)
orthocept Q
D
*
121
B
M
R
3461
O
ct-14-02
(h/o m
ild asthm
a, sulfa-allergy) -ncs
TU
M
S PR
N
 (10/12/02), Advil PR
N
*
122
ZER
6322
Jul-24-03
(h/o IB
S, acid reflux, anem
ia, PC
N
 allergy) -ncs (LM
P: XXX)
Advil, R
olaids, Im
m
odium
 PR
N
*
123
FLW
7447
Jul-25-03
(h/o exercise-induced asthm
a, pediatric heart m
urm
ur) -ncs (LM
P:XXX)
Albuterol inhalation, Tum
s PR
N
*
124
AJC
5839
Aug-13-03
ncs
none
*
125
JB
H
1461
Sep-17-03
ncs
Ibuprofen PR
N
*
126
C
LM
6562
Feb-24-04
(h/o asthm
a, seasonal allergies) -ncs
APAP PR
N
, cortisol cream
, D
epo-Provera since 2002
*
127
K
AB
1800
M
ar-10-04
(h/o asthm
a, allergy to erythrom
ycin) -ncs
Ibuprofen PR
N
, N
yquil PR
N
, m
ultivitam
ins Q
D
*
128
JAG
3606
Sep-25-07
(h/o G
ER
D
, depression long tim
e ago) -ncs (LM
P: 9/2/07)
Jonel Q
D
, N
exium
 40 m
g, ranitidine 300 m
g -ncs
*
129
N
FL
2060
O
ct-01-07
(h/o of kidney infection in 2000, recent hepatitis vaccination) -ncs (LM
P: 9/7/07)
ibuprofen PR
N
, O
C
 Q
D
, m
ultivitam
ins
*
130
K
AS
2911
O
ct-05-07
ncs
none
*
131
D
SL
4231
O
ct-05-07
(h/o hyperthyroidosis in 2000; tx w
ith m
etim
azole; recent hepatitis vaccination) -ncs
m
ultivitam
ins Q
D
*
132
C
N
L
0092
O
ct-22-07
(h/o childhood asthm
a; ovarian cysts - surgery) -ncs (LM
P: 10/20/07)
occasional naproxen
*
133
C
-M
0000
N
ov-05-07
(h/o anxiety/public speaking - escitalopran 2/07) (LM
P: 11//07)
M
inerva, N
asonex
*
134
K
D
C
5842
N
ov-21-07
ncs
none
*
135
B
-S
4592
N
ov-27-07
(h/o m
ild anem
ia in 2005; childhood asthm
a) -nca (LM
P: 11/14/07)
occasional ibuprofen
*
136
PSB
9265
N
ov-29-07
(h/o hypothyroidism
 since age 10) - (LM
P: 11/4/07)
carbinizole Q
D
*
137
JSS
9263
N
ov-29-07
(h/o low
 B
P, childhood asthm
a) - (LM
P: 11/27/07)
albuterol inhaler PR
N
; ibuprofen PR
N
*
138
AB
B
1255
N
ov-30-07
ncs
none
*
139
G
K
J
4593
N
ov-30-07
(h/o perforated appendix-A
E in 1990; occas. asthm
a) -ncs
occas. ibuprofen
*
140
D
R
D
6917
N
ov-30-07
(h/o bronchitis, 2002; TE in 1988) -ncs
occas. ibuprofen
*
141
AA
A
2976
D
ec-10-05
(AE in 1997; h/o nephrolithiasis-lithotripsy in 2002) -ncs
ncs
*
142
TFP
9482
D
ec-19-07
(h/o heart m
urm
ur, high cholesterol, G
ER
D
) -ncs
Liptor 20 m
g Q
D
; m
ultivitam
ins; occ. Advil, TU
M
S
*
143
M
-R
6798
Jan-14-08
ncs
Advil PR
N
=
===
=====
=====
==========
===================
===========
===========
===================
==========
===========
=========
===
=========
=========
=========
=========
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V
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D
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=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
=
*
1
A
D
S
1
9
8
0
N
o
v
-1
6
-0
1
W
h
ite
F
2
1
6
8
.0
1
6
2
n
o
n
e
0
N
o
v
-1
6
-0
1
N
o
v
-2
2
-0
1
*
2
J
K
B
2
2
3
2
D
e
c
-1
7
-0
1
B
la
c
k
F
2
2
5
2
.7
1
5
9
n
o
n
e
0
D
e
c
-1
7
-0
1
J
a
n
-0
7
-0
2
*
3
H
A
G
6
5
5
4
D
e
c
-1
9
-0
1
W
h
ite
F
3
1
8
6
.2
1
7
3
n
o
n
e
0
D
e
c
-1
9
-0
1
J
a
n
-1
1
-0
2
*
4
L
G
K
7
8
3
8
J
a
n
-2
5
-0
2
A
s
ia
n
F
2
6
5
2
.2
1
5
1
n
o
n
e
0
J
a
n
-2
5
-0
2
F
e
b
-0
1
-0
2
*
5
J
IM
3
9
1
6
O
c
t-0
7
-0
2
W
h
ite
F
2
6
7
3
.3
1
7
1
n
o
n
e
0
O
c
t-0
7
-0
2
O
c
t-1
4
-0
2
*
6
F
L
W
7
4
4
7
J
u
l-2
5
-0
3
A
s
ia
n
F
3
0
6
5
.3
1
6
7
n
o
n
e
0
J
u
l-2
5
-0
3
A
u
g
-1
8
-0
3
*
7
J
A
G
3
6
0
6
S
e
p
-2
5
-0
7
W
h
ite
F
2
5
6
5
.1
1
5
9
n
o
n
e
0
S
e
p
-2
5
-0
7
O
c
t-0
2
-0
7
*
8
B
-S
4
5
9
2
N
o
v
-2
7
-0
7
A
s
ia
n
F
2
6
5
2
.6
1
6
4
n
o
n
e
0
N
o
v
-2
7
-0
7
N
o
v
-2
9
-0
7
*
9
P
S
B
9
2
6
5
N
o
v
-2
9
-0
7
A
s
ia
n
F
2
8
5
1
.8
1
5
6
n
o
n
e
0
N
o
v
-2
9
-0
7
D
e
c
-0
4
-0
7
*
1
0
J
S
S
9
2
6
3
N
o
v
-2
9
-0
7
A
s
ia
n
F
2
5
5
6
.8
1
5
7
n
o
n
e
0
N
o
v
-2
9
-0
7
D
e
c
-0
4
-0
7
*
1
1
B
A
C
6
6
0
3
D
e
c
-2
1
-0
1
H
is
p
a
n
ic
M
2
6
7
0
.2
1
7
1
n
o
n
e
0
D
e
c
-1
9
-0
1
J
a
n
-1
1
-0
2
*
1
2
T
S
L
3
4
6
5
F
e
b
-2
2
-0
2
W
h
ite
M
2
2
8
8
.1
1
7
5
n
o
n
e
0
F
e
b
-2
2
-0
2
M
a
r-0
1
-0
2
*
1
3
P
R
B
0
0
2
0
J
u
l-1
7
-0
2
W
h
ite
M
2
5
7
1
.3
1
8
1
n
o
n
e
0
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u
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7
-0
2
J
u
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*
1
4
P
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8
4
7
1
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-0
2
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7
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0
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-0
2
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u
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-0
2
*
1
5
A
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3
9
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u
g
-1
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-0
3
A
s
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n
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2
6
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1
7
4
n
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e
0
A
u
g
-1
3
-0
3
A
u
g
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0
-0
3
*
1
6
J
B
H
1
4
6
1
S
e
p
-1
7
-0
3
W
h
ite
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2
2
1
0
3
.6
1
7
8
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o
n
e
0
S
e
p
-1
7
-0
3
S
e
p
-2
5
-0
3
*
1
7
K
A
S
2
9
1
1
O
c
t-0
5
-0
7
A
s
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n
M
2
6
9
0
.8
1
7
8
n
o
n
e
0
O
c
t-0
5
-0
7
O
c
t-2
2
-0
7
*
1
8
D
S
L
4
2
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No Init ID Dosing Labs Vital Signs Adverse Events
Date (Predose)
=== ===== ===== ========== =================== =========== =========== =================== ========== =========== ============= ========= ========= ========= =========
1 ADS 1980 Nov-16-01 DS/HCG: ncs ncs none
2 JKB 2232 Dec-17-01 DS/HCG: ncs ncs none
3 HAG 6554 Dec-19-01 DS/HCG: ncs ncs none
4 LGK 7838 Jan-25-02 DS/HCG: ncs ncs none
5 JIM 3916 Oct-08-02 DS/HCG: ncs ncs none
6 FLW 7447 Jul-24-03 DS/HCG: ncs ncs none
7 JAG 3606 Sep-25-07 DS/HCG: ncs ncs none
8 B-S 4592 Nov-27-07 DS/HCG: ncs (SBP: 97) -ncs none
9 PSB 9265 Nov-29-07 DS/HCG: ncs ncs none
10 JSS 9263 Nov-29-07 DS/HCG: ncs ncs none
11 BAC 6603 Nov-16-01 DS: ncs ncs none
12 TSL 3465 Feb-22-02 DS: ncs ncs none
13 PRB 0020 Jul-17-02 DS: ncs ncs none
14 P-G 8471 Jul-27-02 DS: ncs (asx hypoTN>91 mmHg) -ncs none
15 AJC 5839 Aug-13-03 DS: ncs ncs none
16 JBH 1461 Sep-17-03 DS: ncs ncs none
17 KAS 2911 Oct-05-07 DS: ncs ncs none
18 DSL 4231 Oct-05-07 DS: ncs ncs none
19 KDC 5842 Nov-21-07 DS: ncs ncs none
20
21 LMD 7823 Jun-06-02 DS/HCG: ncs ncs none
22 TAT 3529 Jun-06-02 DS/HCG: ncs ncs none
23 JMK 3716 Oct-08-02 DS/HCG: ncs (asx hypoTN>88 mmHg) -ncs none
24 ZER 6322 Jul-24-03 DS/HCG: ncs ncs none
25 NFL 2060 Oct-01-07 DS/HCG: ncs ncs none
26 C-M 0000 Nov-05-07 DS/HCG: ncs ncs none
27
28
20
30
31 KBR 5471 Mar-15-02 DS: ncs ncs none
32 JOF 2678 Aug-21-02 DS: ncs ncs none
33 BMR 3461 Oct-14-04 DS: ncs ncs none
34 ABB 1255 Nov-30-07 DS: ncs ncs none
35 M-R 6798 Jan-14-08 DS: ncs ncs none
36
37
38
39
40
41 RPR 6651 Dec-19-01 DS/HCG: ncs ncs none
42 JCD 8124 Jun-12-02 DS/HCG: ncs ncs none
43 CDP 5306 Jun-12-02 DS/HCG: ncs (asx hypotn: >91/58) -ncs none
44 MRH 6018 Sep-19-02 DS/HCG: ncs ncs none
45 CLM 6562 Feb-24-04 DS/HCG: ncs ncs none
46 CNL 0092 Oct-22-07 DS/HCG: ncs ncs none
47
48
49
50
51 KAB 1800 Mar-10-04 DS: ncs (HR: 90 bpm) - ncs none
52 GKJ 4593 Nov-30-07 DS: ncs ncs none
53 DRD 6917 Nov-30-07 DS: ncs ncs none
54 AAA 2976 Dec-10-07 DS: ncs ncs none
55 TFP 9482 Dec-19-07 DS: ncs ncs none
56
57
58
59
60
=== ===== ===== ========== =================== =========== =========== =================== ========== =========== ========= === ========= ========= ========= =========
PERIOD 1
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No Init ID Dosing Labs Vital Signs Adverse Events
Date (Predose)
=== ===== ===== ========== =================== =========== =========== =================== ========== =========== ============= ========= ========= ========= =========
1 ADS 1980 Nov-27-01 DS: ncs ncs none
2 JKB 2232 Jan-07-02 DS/HCG: ncs ncs none (took APAP)
3 HAG 6554 Jan-11-02 DS/HCG: ncs ncs none (took biaxin, decongest for sinusitis until 1/7/02)
4 LGK 7838 Feb-01-02 DS/HCG: ncs ncs none
5 JIM 3916 Oct-14-02 DS: ncs ncs none
6 FLW 7447 Aug-18-03 DS: ncs ncs none
7 JAG 3606 Oct-02-07 DS: ncs ncs none (h/a, gastroenteritis)
8 B-S 4592 Nov-29-07 DS: ncs ncs none
9 PSB 9265 Dec-04-07 DS: ncs (105/59, 78) - ncs none
10 JSS 9263 Dec-04-07 DS: ncs ncs none
11 BAC 6603 Jan-16-02 DS: ncs ncs none
12 TSL 3465 Mar-01-02 DS: ncs ncs none
13 PRB 0020 Jul-24-02 (h/o claritin on 7/20) -ncs ncs none
14 P-G 8471 Aug-14-02 DS: ncs ncs none
15 AJC 5839 Aug-20-03 DS: ncs during blood draw: 95/45 mmHg, 50bpm feeling faint (no LOC) during blood draw
16 JBH 1461 Sep-25-03 DS: ncs ncs ncs
17 KAS 2911 Oct-22-07 DS: ncs ncs ncs
18 DSL 4231 Oct-12-07 DS: ncs ncs ncs
19 KDC 5842 Nov-27-07 DS: ncs (HR > 96) -ncs ncs
20
21 LMD 7823 Jun-27-02 DS: ncs ncs none
22 TAT 3529 Jun-21-02 DS: ncs ncs none
23 JMK 3716 Oct-15-02 DS: ncs ncs none
24 ZER 6322 Aug-27-03 DS: ncs (HR prior to blood draw: 112 bpm) -ncs none
25 NFL 2060 Oct-08-07 DS: ncs ncs none
26 C-M 0000 Nov-08-07 DS: ncs ncs none
27
28
20
30
31 KBR 5471 Mar-22-02 DS: ncs ncs ncs
32 JOF 2678 Aug-28-02 DS: ncs ncs ncs
33 BMR 3461 Oct-22-02 DS: ncs ncs ncs
34 ABB 1255 Dec-07-07 DS: ncs ncs ncs
35 M-R 6798 Jan-18-08 DS: ncs ncs ncs
36
37
38
39
40
41 RPR 6651 Jan-09-02 DS/HCG: ncs (SPB>96; HR>96 bpm) -ncs transient mild lightheadedness during blood draw
42 JCD 8124 Jun-21-02 DS/HCG: ncs ncs none
43 CDP 5306 Jul-22-02 DS/HCG: ncs ncs none
44 MRH 6018 Sep-26-02 DS/HCG: ncs ncs none
45 CLM 6562 Mar-02-04 DS/HCG: ncs ncs none
46 CNL 0092 Oct-30-07 DS/HCG: ncs (HR>97) - ncs none
47
48
49
50
51 KAB 1800 Mar-17-04 DS: ncs ncs none
52 GKJ 4593 Dec-03-07 DS: ncs ncs none
53 DRD 6917 Dec-07-072 DS: ncs ncs none
54 AAA 2976 Dec-11-07 DS: ncs ncs none
55 TFP 9482 Dec-21-07 DS: ncs ncs none
56
57
58
59
60
=== ===== ===== ========== =================== =========== =========== =================== ========== =========== ========= === ========= ========= ========= =========
PERIOD 2
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Appendix H
 
Protocol and Informed Consent Form – Clinical Study #2 
 
 
 
Date:    March 13, 2007 
 
To:    Barbara Karp, M.D. Chair, CNS IRB  
 
Recommended by:  __________________ Clinical Director, NIAAA 
    __________________ Chief, LCTS, NIAAA 
 
Protocol title: Assessment and treatment of people with alcohol drinking problems 
 
Abbreviated title: Alcoholism assessment and treatment  
 
Identifying words: Dependence, CIWA, Addiction severity index, CPRS-S-A, combined 
behavioral intervention, medical management 
 
Principal Investigator: David Herion, M.D. 
 
Associate Investigators: Linda Doty, R.N., M.S.W. 
David T. George, M.D. 
Markus Heilig, M.D., Ph.D. 
Debby Hill, M.S.W. 
 Dan Hommer, M.D. 
 Judie Johnson, R.N.  
Tom Lionetti, R.N. 
 Vijay Ramchandani, Ph. D. 
Dave Spero, R.N. 
 John Umhau, M.D. 
 Margaret Weiser, R.N. 
Marjorie Wright, RN 
 
Estimated duration of study: Five years 
 
Participants in study 
 Number  Gender  Age range 
 1000  Male  18 years and older 
 1000  Female  18 years and older 
 
Project uses ionizing radiation:     No 
Project involves use of Durable Power of Attorney   No 
Off-site project:     No 
Multi-institutional project:     No 
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1. Précis  
 The purpose of this protocol is to create a mechanism whereby the intramural program of the 
NIAAA can evaluate and treat a broad range of people with drinking problems at the NIH Clinical Center 
(CC) in Bethesda, MD. Through this program, participants will receive comprehensive, state-of-the-art 
treatment for their alcohol, psychosocial and medical problems and the program will be able to evaluate 
and recruit participants for other, more focused clinical research efforts to advance its research goals. 
Additionally, this will allow investigators and staff to gain broad training experience in alcohol and 
addiction medicine through the clinical care of such patients. The protocol is open to any adult who is 
seeking help for a drinking problem and who is likely to qualify to participate in another NIAAA 
protocol. Participants will be recruited through local media and professional avenues in the Washington, 
DC Metro area. They will be evaluated by a nurse and physician, among others, who will determine the 
need for hospitalization, detoxification and to address other issues. For those needing medically 
supervised detoxification, a standard program of monitoring and treatment with benzodiazepines and 
other medications will be instituted. A standard battery of screening blood, urine and other clinically 
indicated tests, an electrocardiogram, chest x-ray and MRI of the brain will be done as part of the 
comprehensive medical and neurological assessment. Following at least five days of abstinence from 
alcohol, participants will undergo a series of verbal and observational-type assessments designed to 
evaluate psychiatric co-morbidity, psychopathology, psychosocial problems, neurocognitive function, 
personality and other factors relevant to alcoholism treatment. Participants will then be offered a 12-16 
week course of outpatient treatment, consisting of either of two, manual-based therapies used in Project 
COMBINE, a large, NIAAA-sponsored national trial of counseling and medication therapies for alcohol 
dependence(The COMBINE Study Research Group, 2003a; The COMBINE Study Research Group, 
2003b). The first is an intensive counseling approach (12 sessions) called Combined Behavioral 
Intervention (CBI) and the second, Medical Management (MM), is a series of brief counseling sessions 
every 2-4 weeks. At five points during the outpatient phase participants will come to the clinic for 
selected blood and urine tests, interviews and verbal/observational assessments to evaluate abstinence 
from alcohol and identify change in various psychological dimensions. During their participation in this 
protocol, participants will be approached to consider enrolling in other clinical research protocols such as 
imaging studies and drug-treatment trials. For participants willing to participate in these other protocols, 
other appropriate consent(s) will be obtained. 
 
2. Introduction  
     People who have serious problems related to alcohol drinking have heterogeneous historical 
courses, the most serious of which may come to clinical attention (Institute of Medicine, 1990). Some 
people independently experience resolution of their drinking problems, while others go through variable 
cycles of adverse consequences; various non-clinical and clinical treatments and other efforts at 
abstinence or reduced drinking; lapse (first drinking episode); relapse (recurring sustained heavy drinking 
episode); and reemergence of old and new untoward consequences (Institute of Medicine, 1990). It is in 
recognition of this cycle that alcoholism, here equated with alcohol dependence, has been dubbed a 
chronic, relapsing disease, analogous in some respects to diabetes (Institute of Medicine, 1990; O'Brien, 
1994; O'Connor and Schottenfeld, 1998). However, as medical, psychiatric and psychological research 
has advanced, the understanding of how alcohol affects the body’s (brain and other systems) health and 
how coping difficulties maintain problem drinking and, indeed, the concept of disease itself are changing 
(Monti et al., 1989). 
     Against this changing knowledge, treatments for clinically manifest alcohol problems are 
emerging. The most commonly employed psychosocial treatment options, cognitive-behavioral coping 
skills therapy, motivational enhancement therapy, and twelve-step facilitation, are equally effective with 
abstinence rates of 19-35% and relapse rates of 40-46% at one year, under optimal conditions, delivered 
either in inpatient, day treatment, residential or outpatient settings (Project MATCH Research Group, 
1998; Longabaugh and Wirtz, 2001). Neuro-pharmacological treatments are being increasingly studied; 
thus far two drugs, naltrexone and acamprosate, have demonstrated benefit (Kranzler and Van Kirk, 
2001; Anton and Swift, 2003; Soyka and Chick, 2003). Both are to be used in conjunction with 
543 
counseling and supportive approaches, where they yield abstinence rates at one year of (17-47%), with 
most relapse occurring at three months (35-60% relapsed) under typical clinical trial conditions (O'Malley 
et al., 1992; Anton et al., 1999; Kiefer et al., 2003). Furthermore, response to treatment in “real-world” 
care delivery environments is very sparsely documented (O'Malley et al., 2003; The COMBINE Study 
Research Group, 2003a; The COMBINE Study Research Group, 2003b). 
  Given the challenges of understanding and treating clinical problems related to alcohol use, the 
primary thrust of the Laboratory of Clinical and Translational Studies (LCTS) at the intramural research 
program of the NIAAA is to investigate the neurochemistry of alcohol dependence and withdrawal 
(which itself may play a role in relapse), mechanisms of relapse and craving and their possible inter-
relationship and the short-term efficacy of candidate drugs in promoting abstinence. The main approaches 
used by the LCTS are translational research from pre-clinical to clinical models using sensitive 
observational techniques and tools, collaborations with other intramural scientists and scientifically sound 
and relevant clinical research projects. 
     One important tool for the translational studies envisioned by the lab and created within this 
protocol is the evaluation of genes that may underlie processes involved in the more fine-grained 
behavioral and cognitive (so-called “intermediate”) phenotypes seen in clinical populations and relevant 
animal model systems. Among them are neuropeptide and monoaminergic genes. We therefore propose 
to collect genetic information from alcoholics for the purpose of studies of the association of various 
genes with endophenotypes, primarily regional brain volumes and/or functional brain imaging results.   
 For example, due to the well-documented role of dopamine (DA) in drug reinforcement 
processes (Koob and Nestler, 1997), and the role of serotonin (5-HT) in affective psychopathology 
pertinent to substance abuse (Heinz et al., 2001), we propose to obtain allelic data on the following genes: 
1) The 5-HT transporter, the expression of which is reduced in alcoholism (Heinz et al., 1998), and a 
genotype of which has been linked to vulnerability of the brain to excessive alcohol (Heinz et al., 2000), 
2) the 5-HT 2a receptor, which has been linked to impaired impulse control in the context of history of 
psychopathology (Bjork et al., 2002), 3) the DA DR4 receptor, an allelic variant of which has been linked 
to attentional deficits and conduct-disordered behavior (Faraone et al., 2001), 4) the catechol-O-
methyltransferase gene, which has been linked to working memory functioning (Heinz et al., 2001), and 
5) the DA DR2 receptor gene, which has been linked to severity/age of onset of alcoholism (Geijer et al., 
1994), and extraversion in an interaction with presence versus absence of an alcoholic father in the home 
(Ozkaragoz and Noble, 2000). Recently a number of research groups have reported that various genes are 
associated with differences in brain structure as well as function (Mustovic et al., 2005; Wrase et al., 
2005) (Gordon et al., 2005). 
 In addition to the genes discussed above, we will also examine other genes that affect normal 
brain metabolism or development.  In no case will we characterize a gene that has been established to be 
useful in the diagnosis of any medical or psychiatric disorder. In summary, we wish to explore how 
variants of these genes may relate to behavioral, cognitive, neurophysiological and neuroanatomical 
features of subjects, which are ascertained in this and other NIAAA protocols. 
 For this final approach, the NIAAA intramural program needs a steady base of people who are 
seeking treatment for problems related to alcohol drinking and willing to participate in clinical studies. 
Furthermore, a busy and broadly-based alcoholism unit supports another important program goal: to train 
clinicians and investigators in alcohol studies. 
 The evaluation and treatment plan offered in this protocol represents a state-of-the art clinical 
addiction medicine program. Evaluation, including assessments of alcohol use, negative consequences, 
alcohol dependence, co-morbid psychiatric conditions, family history, neuropsychological functioning 
and physical sequelae, has a strong evidence base and has been recommended for clinical use, particularly 
to enhance motivation, plan for treatment and to provide a basis for follow-up(Institute of Medicine, 
1990; Project MATCH Research Group, 1997; O'Connor and Schottenfeld, 1998; Miller et al., 2003). 
Unfortunately, such recommendations have not yet been routinely implemented outside leading treatment 
institutions. However, in accordance with the NIAAA mission and responsibility to lead the community 
not only by performing state-of-the-art, cutting-edge research in alcoholism, but we also plan for the 
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intramural program, in this protocol, to lead by example in the delivery of treatment by offering an 
evaluation and treatment  program that vastly exceeds the standard practice in the community. 
     Because of the evidence-based nature of all assessments used in this protocol, data obtained 
through them can serve at least three purposes: first, to provide a basis for individualizing patient 
treatment, enhancing motivation to change, and following-up such treatment for the sole purpose of 
providing optimal clinical care; second, to provide patient characteristics and outcome data for specific 
research protocols to which the patient may additionally and separately consent; and third, to provide data 
for monitoring the performance and functioning of the program as a whole. 
     To provide the framework for operational management of the LCTS research program and 
conducting clinical trials in coordination with the NIH CC operation as well as to achieve the goal of 
recruiting participants for research, we have written this protocol as a hybrid training and short-term 
natural history protocol. Through it, we offer patients a state-of-the-art clinical work-up that represents a 
research evaluation and a 12-16 week course of standard psychosocial treatment for alcoholism using 
well-documented, effective approaches. Within this framework, we will seek subject participation in 
other protocols focused on more specific questions, including those related to alcohol withdrawal and the 
neuropharmacology of relapse (prevention). The data collected in this protocol may be used in the future 
for research purposes. 
     Subjects enrolled in this protocol may participate in other protocols, including clinical trials or 
mechanism studies using experimental compounds. The data collected in this protocol will be shared and 
used for analysis in those protocols. The protocols whose enrollment is explicitly contingent on prior 
enrollment in this protocol include:    
- 05-AA-0120: Acamprosate for Central Nervous System Hyperexcitability and Neuroadaptation 
in Alcohol Withdrawal 
- 06-AA-0129: NK1 Receptor Antagonism for Treatment of Anxiety and Craving in Anxious 
Alcohol Dependent Subjects During Early Abstinence 
Furthermore, as part of a longitudinal effort to characterize the cohort of subjects seen at the NIAAA, 
data from this protocol will be combined with data from 98-AA-0009, Screening Evaluation for NIAAA 
Protocols, particularly for rating scale information (such as personality factor assessment, mood and 
anxiety scales, etc.), correlation with brain MRI volumes in alcoholics, organ damage and genetic tests. 
 
3. Objectives  
This protocol has several purposes:  
1) It is meant to serve as an entry mechanism to authorize a subject’s admission to the NIH CC in 
Bethesda, Maryland under the care of the NIAAA LCTS and the CC  nursing staff (NIAAA Inpatient 
and Outpatient Care Units). 
2) It authorizes the provision of state-of-the-art care for individuals with alcohol and drug problems, 
including detoxification, assessments, and outpatient counseling approaches. 
3) It provides a high-quality, research-driven venue for training physicians, fellows, residents, medical 
students and other health-care professionals in the diagnosis and management of alcohol use 
disorders. 
4) It provides a set of standard measures, serving a dual purpose: 
a) To provide a basis for optimal treatment planning/matching and follow-up for the benefit of the 
individual patient 
b) To potentially provide patient characteristics and follow-up measures for participants in other 
NIAAA clinical research protocols. 
5) It can serve as a reference document for community facilities that may be interested in referring 
clients to the NIAAA intramural program. 
6) To collect blood samples from alcoholic subjects for the purpose of analyses of DNA and biomarkers 
of alcohol exposure 
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4. Study Design and Methods 
 This protocol does not involve experimental procedures or therapeutics. Rather, it follows the 
typical clinical course of events in people with alcohol dependence and abuse over a brief, intensive time 
period. It therefore consists of a series of phases including: 
- pre-NIH visit gathering of subject information (which generally takes 1 week in our experience), 
- physical evaluation at NIH CC (1-2 days), 
- inpatient alcohol withdrawal and psychosocial management when necessary (5+ days, 2+ weeks, 
respectively), 
- baseline observation (3-5 days) 
- and outpatient treatment (12 weeks).  
     In summary, the planned procedures throughout this protocol involve routine verbal and 
observational procedures, such as “pen-and-paper”-style self-reports and interviews, and minimally 
invasive procedures, such as phlebotomy and urine collection, electrocardiogram (ECG), chest x-ray 
(CXR) and magnetic resonance imagining (MRI) of the brain to provide a comprehensive medical, 
psychiatric and addiction medicine evaluation. The treatment involves standard outpatient counseling-
type therapy for alcohol dependence. 
     Since the NIAAA clinical program also serves to train physicians, nurses and other health 
professionals in the practice of addiction medicine, trainees will be involved in the evaluation of, and 
have direct contact with patients in this protocol. Involvement of trainees will always be under 
supervision of Senior Medical Staff of the Clinical Center, according to the general regulations of clinical 
privileges of the Clinical Center. 
     Following recruitment to the CC, patients will be examined by the medical and nursing staff to 
determine medical and psychiatric stability and to evaluate inclusion and exclusion criteria. Selected 
blood and body fluid tests, among others, will be done as clinically indicated. 
     Patients may need to be hospitalized for monitoring and treatment for problems and certain 
conditions, such as severe alcohol withdrawal, which, when uncomplicated, typically lasts about a week 
(Sullivan et al., 1989b; Kosten and O'Connor, 2003). Currently, the standard care for the treatment of the 
alcohol withdrawal syndrome is to provide close monitoring, supportive care and symptomatic treatment 
with benzodiazepines (diazepam, oxazepam or lorazepam), using the Clinical Institute Withdrawal 
Assessment-Alcohol Revised (CIWA-AR), a validated tool to categorize severity of alcohol withdrawal 
based on symptoms and physical signs (Sullivan et al., 1989b). Which of the three benzodiazepines to use 
and in which dosing regimen, are ultimately clinical decisions, and will be so taught to trainees. 
     Additionally, intravenous fluids and parenteral medications, such as thiamine, haloperidol, and 
antibiotics, may be required. Patients will receive daily folic acid supplements. The successful treatment 
and resolution of the alcohol withdrawal syndrome, for example as measured by consecutive CIWA-Ar 
scores below 7 and a clear sensorium, constitutes the detoxification phase, after which begins the baseline 
period. 
     During the baseline period, participants will undergo various verbal and observational 
assessments (detailed below). Based on these assessments, multidisciplinary treatment planning will be 
undertaken by the staff with the active participation of the patient. They will then be offered an 
opportunity to enroll in a 12-16 week treatment course of counseling that would consist of one of the 
following: CBI or MM, run through the NIAAA/CC outpatient clinic (see 4.C., “Therapy”, below). 
Alternatively, patients may be referred to a suitable non-NIH program for further treatment, depending on 
their preferences and treatment availabilities. 
     During the outpatient follow-up phase they will also be scheduled to be seen for clinic visits at 
weeks 1, 2, 4, 8 and end-of-therapy for brief medical and psychiatric check-ups, and selected blood and 
body fluid tests will be performed, as well as selected verbal assessments (see below). The assessment 
instruments; blood, body fluid and body tests; and therapies, with schedules are: 
 
A. Structured assessments of a subject’s history and internal psychological experiences are performed 
using pen-and-paper and computerized tools after a subject has been abstinent form alcohol for at 
least 5 days. 
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a. The Addiction Severity Index (ASI) is an instrument used extensively in the Addiction Medicine 
field to comprehensively identify problems in multiple dimensions including medical, 
employment, drug and alcohol use, legal, family and social and psychiatric (McLellan et al., 
1980). It is a 200-item interview that takes about 60 minutes. It will be done prior to and at the 
end of the outpatient treatment phase, i.e. baseline and end-of-therapy. 
b. The Structured Clinical Interview for Diagnostics and Statistics Manual-IV (DSM-IV) (SCID-I) 
is another widely-used, standard clinical interview to establish criteria for psychiatric diagnoses 
(First et al., 2002). It is a structured interview consisting of 11 modules with between 35-292 
items/module that takes about 120-180 minutes. It will be done at baseline. DSM-IV diagnoses 
will be established via a consensus, or “blind-rating” process involving trained psychiatrists. 
c. The Alcohol Dependence Scale assesses severity of alcohol dependence in a variety of clinical 
settings (Skinner and Allen, 1982). It consists of 25 questions and takes about 5-10 minutes to 
complete. It will be done at the baseline. 
d. The Obsessive-Compulsive Drinking Scale (OCDS) assesses craving and urges for alcohol 
(Anton et al., 1995). It is a 10-item self-report that takes about 5-10 minutes. It will be done at 
baseline and at each clinic visit during the outpatient treatment phase. 
e. The affective symptoms (anhedonia, depression, anxiety, and dysphoria) following removal of 
alcohol and other drugs, the so-called motivational effects of alcohol, will be assessed with self-
administered subscales derived from the Comprehensive Psychopathological Rating Scale Self-
rating Scale for Affective Syndromes (CPRS-S-A) (Mattila-Evenden et al., 1996; Svanborg, 
1999). It is a 19-item self-report that takes 5-10 minutes to complete. It will be done every three 
days during the admission and baseline phases and during the outpatient phase, at clinic visits. 
f. The Timeline Follow-Back (TLFB) technique collects drinking information using personal 
historical events recounted over a fixed time period (Sobell and Sobell, 1992b; Sobell and 
Sobell, 1996). It is a commonly used technique to assess alcohol drinking patterns and 
quantification in treatment programs. The number of items corresponds to the number of days of 
interest, up to 360 which usually takes about 30 minutes. It will be done at baseline to cover the 
prior 360 days and at each clinic visit during the outpatient treatment phase. 
g. The University of Rhode Island Change Assessment Scale (URICA) is used to indicate a 
subject’s motivation and readiness for treatment. It is URICA is a 32-item self-report that takes 
about 5-10 minutes. It will be done at baseline. 
h. The Neurotocism-Extroversion/Introversion-Openess to Experience (Five Factor) Personality 
Inventory- Revised (NEO PI-R) provides scores on various dimensions of personality (Costa and 
McCrea, 1997; Costa and McCRea, 2002; Costa et al., 2002). It is a 240-item self-report that 
takes up to 35-45 minutes to complete. It will be done at baseline. 
i. The Wechsler Adult Intelligence Scale-Revised (WAIS-R) is the standard technique to 
determine Intelligence Quotient (IQ). We use the Block Design and Vocabulary components to 
measure IQ. In total the tasks comprise 50 items that take about 15-30 minutes to complete. It 
will be done at baseline. 
j. Trails A and B have been extensively used to globally measure executive cognitive performance 
and frontal lobe function. They take about 5 minutes to complete. 
k. The Family Tree Questionnaire (FTQ) is an interview about a subject’s family history of alcohol 
and drug problems (Mann et al., 1985). The duration of the interview depends on the number of 
first- and second-degree relatives, but generally takes about 5-10 minutes. It will be done at 
baseline. 
l. The Important People and Activities Instrument (IPA) is a structured interview about 
interpersonal and social networks, especially as they relate to alcohol drinking (Longabaugh, 
1991; Zywiak et al., 2002). It covers 19 items and takes about 20-30 minutes. It will be done at 
baseline. 
m. The Fagerström nicotine dependence scale is a 5-item self-reported questionnaire about 
smoking. It takes 1-2 minutes to complete. 
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n. The modified Overt Aggression Scale (m-OAS) is a scale to screen for a history of violent 
behavior. It is a single page of questions which takes about a minute to complete. It is an 
interview. 
o. The Lifetime Drinking History estimates the total amount of alcohol consumed over a lifetime. It 
is an interview that takes about 20 minutes to complete. 
 
B. Neurocognitive tests of frontal lobe function: 
     
 Several reports collectively suggest that alcoholism-prone individuals are characterized by 
frontal lobe hypofunction (Ciesielski et al., 1995; Giancola and Moss, 1998), specifically deficits in 
executive cognitive functioning (ECF). These include response inhibition, attention, working memory, 
strategy, and assessment of behavior consequences. Patients need these cognitive abilities, at least to 
some degree, for the successful treatment of their alcohol use disorders. Thus, understanding the specific 
nature and severity of ECF will be helpful in treatment planning for individual patients. 
     We plan to measure and characterize ECF by using four computerized cognitive tests: the 
Wisconsin Card Sorting Task (WCST), The Iowa Gambling Task (IGT), a continuous performance, 
visual working memory task (CPT-WM), and a delay discounting task (DDT). The WSCT and the CPT-
CM both involve attention, working memory and strategy, and both are dependent on functions carried 
out by the lateral surface of the frontal lobes, while the IGT and the DDT both require inhibition and 
assessment of a behavior’s consequences and are thought to depend on the orbital and mesial surfaces of 
the frontal lobe (Bjork et al., in press). 
     We have developed computerized versions of the CPT-WM, IGT and DDT. These three tasks 
have all been used in NIAAA protocol 94-AA-0001, and they successfully discriminate between 
alcoholic and non-alcoholic individuals, as well as measure an individual’s ECF. For the WCST we will 
use a commercially available computerized version of this task. 
     Each of these tasks is performed by interacting with a computer. They are all minimal risk 
procedures and, although demanding, most individuals do not usually consider them unpleasant. The 
WCST is game-like and measures a person’s ability to make strategic changes based on changing 
circumstances. The IGT simulates a gambling game. In neither the WCST nor the IGT do the participants 
actually win money. However, both the CPT-WM and the DDT require that the participants be able to 
win money as part of the task. 
     The CPT-WM requires subjects to press a button in response to a series of letters displayed on a 
computer screen. By manipulating the targets it is possible to access an individual’s ability to focus 
attention as well as inhibit inappropriate responses. In the CPT-WM the amount won is based on a 
participant’s performance. The DDT assesses the degree to which a subject devalues a reward as a 
function of how long the subject must wait to receive it(Mitchell, 1999; Richards et al., 1999). In brief, 
the participant is presented with a series of choices between receiving either a monetary reward (either in 
cash or by mailed check as required) at time-points ranging from immediately to up to one year in the 
future. To enhance the realism of the task, actual reward (selected from a random question) will be 
delivered. A participant’s total winnings in the CPT-WM and DDT typically range from $30.00 - $45.00. 
The maximum amount possible to win from these two games is $80, but it is very unlikely that a 
participant can win this much. 
 
C. Bio-medical evaluations are procedures that physically analyze components of a subject’s body. 
They include: 
a. Breath alcohol analysis is a state measure of alcohol exposure which is also a clinically 
important marker of alcohol intoxication and tolerance and is serially used to correlate with signs 
and symptoms to diagnose the alcohol withdrawal syndrome. It will be done at baseline and each 
clinic visit during the outpatient treatment phase. 
b. Blood test panels to assess physiological functions and screen for organ damage, as well as 
assessment of the extent of alcohol and drug exposure, including toxicology and biomarkers. 
The blood tests (with blood volume) include: 
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i. Complete blood count with differential (CBC with diff) (3 mL, ~ 1 teaspoon). It will be 
done at baseline and each clinic visit during the outpatient treatment phase. 
ii. Chem 20 Panel (Chem 20): Sodium (Na), Potassium (K), Chloride (Cl), Total CO2 
(bicarbonate), Creatinine, Glucose, Urea nitrogen (BUN), Albumin, Calcium total, 
Magnesium total (Mg), Inorganic Phosphorus, Alkaline Phosphatase, ALT/GPT, 
AST/GOT, Total Bilirubin, Direct Bilirubin, LD, Total Protein, Total CK, Uric Acid, 
amylase (4 mL, ~1 teaspoon). It will be done at baseline. 
iii. Thyroid Screen: Thyroid stimulating hormone (TSH), Free thyroxine (FT4), Tri-
iodothyroine (T3) (3.5 mL, ~1 teaspoon)). It will be done at baseline. 
iv. Lipid and essential fatty acid panel: Total Cholesterol, Triglycerides, High-Density 
lipoprotein (HDL) Cholesterol, Low-Density Lipoprotein (LDL) Cholesterol; Lauric 
Acid, Myristic Acid, Hexadecenoic Acid, Palmitoleic Acid, Palmitic Acid, g-Linolenic 
Acid, a-Linolenic Acid, Linoleic Acid, Oleic Acid, Vaccenic Acid, Stearic Acid, EPA 
C20, Eicosapentaenoic Acid, Arachidonic Acid, Mead Acid, Homo-g-Linolenic Acid, 
Arachidic Acid, DHA, Docosahexaenoic Acid, DPA, DTA, C22 5W6, 5W3, C22, 4W6, 
Docosenoic Acid, Nervonic Acid, Triene Tetraene Ratio, Total Saturated Acid, Total 
Monounsaturated Acid, Total Polyunsaturated Acid, Omega 3, Omega 6, Fatty Acids 
(6.0 mL, 1.2 teaspoons). It will be done at baseline. The specimen will be stored in the 
LCTS in the laboratory of Dr. Markus Heilig.” 
v. Viral Markers Protocol Screen: Hepatitis B surface antigen (HBsAg), Hepatitis C Virus 
antibody (anti-HCV), Human Immunodeficiency Virus 1 and 2 (anti-HIV) (8 mL, 1.5 
teaspoons). It will be done at baseline. 
vi. Trace mineral panel: Trace mineral panel and vitamin analysis:  Vitamin C, and 
vitamins B12, homocysteine and methylmalonic acid, copper and ceruloplasmin, iron 
studies (serum iron, transferrin saturation, ferritin) and zinc (25.5 (5.2 teaspoons). It 
will be done at baseline. 
vii. Biomarkers: Currently, there is no clear standard set of blood and body fluid tests that 
clearly indicates relapse to alcohol use. However, guidelines are emerging (Litten and 
Fertig, 2003).  
1. Hepatic Panel (blood, 3.5 mL, ~1 teaspoon). It will be done each clinic visit during 
the outpatient treatment phase. 
2. Gammaglutamyl-transpeptidase (GGT) (blood, 3.5 mL, ~1 teaspoon)  (Conigrave 
et al., 2003). It will be done at baseline and each clinic visit during the outpatient 
treatment phase.  
3. Carbohydrate-deficient transferrin (CDT) (blood, 2.5 mL, ½ teaspoon)  (Javors and 
Johnson, 2003). It will be done at baseline and each clinic visit during the 
outpatient treatment phase.  
4. The ratio of 5-hydroxyindolacetic acid (5-HIAA) to 5-hydroxytryptophol (5HTOL) 
(urine) (Beck and Helander, 2003). It will be done at baseline and each clinic visit 
during the outpatient treatment phase. 
5. Ethyl glucuronide (urine) (Wurst et al., 2003). It will be done at baseline and each 
clinic visit during the outpatient treatment phase. 
6. During the baseline phase, two additional tubes of blood (20 mL) will be collected 
up to a maximum of five times (100 mL). During the outpatient follow-up phase, 
20 mL will be drawn at weeks 2, 4, 8 and 12 (or end of therapy) (80 mL). Various 
blood components (plasma, serum and intracellular proteins) will be assayed using 
experimental tests being developed as biomarkers of alcohol exposure and organ 
damage. The specimens will be stored in the NIAAA LCTS in the laboratory of Dr. 
Markus Heilig. The total amount of blood for the experimental biomarkers is 180 
mL (less than 37 teaspoons). 
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c. Urine tests 
i. Urinalysis to screen for renal and genitourinary abnormalities will be done at baseline 
and during follow-up as clinically indicated. 
ii. Urine drug screens 
1. The Qualitative (DLM) tests for benzodiazepines, cocaine, methamphetamines, 
opiates and tetrahydrocannabinol (THC). It provides a result within hours. It will 
be done at baseline and each clinic visit during the outpatient treatment phase. 
2. The Drug Profile #1 tests for amphetamines, barbiturates, benzodiazepines, 
cocaine, lysergic acid diethylamine, opiates, phencyclidine and THC. It has greater 
sensitivity than the DLM screen and takes about five days to complete. It will be 
done at baseline and each clinic visit during the outpatient treatment phase. 
iii. Pregnancy test. Some medications which may be indicated during routine treatment of 
alcohol related problems are inappropriate for pregnant subjects. For this reason, 
pregnancy tests will be done at baseline and as clinically indicated thereafter. 
iv. Biomarkers (see above) 
1. Ratio of 5-HIAA to 5-HTOL (see above) 
2. Ethyl glucuronide (see above) 
d. Other procedures used to screen for medical diseases and abnormalities. 
i. An electrocardiogram (ECG) is a minimal risk procedure that allows detection of 
cardiac rhythm and structural problems that may be associated with alcoholism. It will 
be performed at baseline. 
ii. The chest x-ray is a minimal risk procedure to allow detection of cardiac, bone and 
pulmonary abnormalities that may be associated with alcoholism and cigarette 
smoking. It will be performed at baseline. 
iii. An MRI of the brain is a minimal risk procedure which allows the diagnosis of brain 
damage associated with alcoholism. It will be performed at least 2 weeks after the last 
drink unless clinically urgent. 
e. Blood sample for collection of DNA (leukocytes) for analysis of polymorphisms in gene loci 
such as the following (other genes known to be involved in brain function and/or alcohol-related 
organ damage may also be examined):  
1) The 44 base-pair repeated element (SLC6A4) of the serotonin (5-HT) reuptake 
transporter (promoter), 
2) The T102C polymorphism of the 5-HT2a receptor  
3) The 48 base-pair repeated element in Exon III of the Dopamine DRD4 receptor 
4) The Val/Met polymorphism of the Catechol-O-Methyl-transferase (COMT),  
5) The Taq1 (A1)-defined polymorphism of the dopamine DRD2 receptor, 
6)  Alleles associated with Brain Derived Neurotrophic Growth Factor (BDNF).  
 
David Goldman, MD, Chief, NIAAA Laboratory of Neurogenetics in collaboration with LCTS will store 
and conduct the genetic analysis.  
 
The alcohol use disorder patients will not be asked to give consent for the blood draw for genetic analysis 
until at least five days after their most recent consumption of alcohol containing beverages. This will 
correspond to when they are asked to sign the “unimpaired subject consent” version of this protocol (05-
AA-0121). 
 
D. Therapy 
a. The assessments listed above are considered to be an important component of treatment 
planning, indicating individual areas of treatment focus and monitoring (Institute of Medicine, 
1990; Donovan, 2003). 
b. CBI is a recently developed form of therapy for alcohol dependence that draws on several 
approaches having reasonable evidence of efficacy. It combines three elements:  
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i. A community reinforcement approach (CRA) that integrates functional analysis of the 
drinking behavior, behavioral skills training (in project MATCH called Cognitive 
Behavioral Coping Skills Therapy, or CBT) and family involvement. Cognitive-
behavioral coping skills therapy (CBT) is an effective treatment approach that basically 
focuses on the training of interpersonal and self-management skills (Monti et al., 1989; 
Kadden et al., 1992; Miller et al., 1995).  
ii. Motivational interviewing and assessment feedback (in Project MATCH called 
Motivational Enhancement Therapy, or MET). MET is a systematic intervention 
approach based on the principles of motivational psychology and designed to produce 
rapid internally motivated change (Miller et al., 1992; Miller et al., 1995). 
iii. CBI will be conducted, as in Project COMBINE, in 4 phases: the first involves 
motivational interviewing and subject assessment (generally 1-2 sessions); phase 2, a 
functional analysis, held jointly with a supportive significant other when available, to 
identify problems in drinking behavior, skills and resources to target specific areas 
where improvement is need (1-2 sessions); phase 3, cognitive behavioral skills group 
therapy (10 sessions). These will be scheduled over a 12 to 16 week time period (The 
COMBINE Study Research Group, 2003b). This arm would be the standard treatment 
for patients not participating in pharmacotherapy trials (protocols) for relapse 
prevention. 
iv. All CBI sessions will be conducted by trained NIH staff: nurses from the CC and/or 
counselors from the NIAAA. Phase 1 and 2 will be conducted at the CC. The current 
plan is that Phase 3 will be conducted at the CC. However, there is initial planning for 
CBI treatment to be conducted at other local facilities that may be more accessible to 
outpatients, as it has been shown that one of the most important variables in retention in 
alcoholism treatment programs is proximity of the treatment to a client’s domicile. 
Also, concern has been raised that the current security circumstances at the NIH’s 
Bethesda facility may be a barrier to treatment retention in our program (personal 
communication, T. K. Li, Director, NIAAA, October 2004). In each such case where an 
outside facility may be considered as a treatment site, the plan would be brought to the 
IRB for discussion, approval and amendment to this protocol as stipulated. 
 
c. Medical Management (MM) is a manual-based behavioral intervention consisting of brief, 
structured counseling sessions to provide strategies for medication adherence and to support 
abstinence through education and referral to support groups (Pettinati et al., 2004). Follow-up 
sessions are used to assess drinking status, overall functioning, medication adherence, and any 
side effects. It is an adaptation of the BRENDA approach (biopsychosocial assessment, reporting 
the assessment results, empathetic understanding, identifying patient needs and priorities, and 
matching needs to treatment options, and adjusting advice to patient response- the “BRENDA” 
approach) developed and used at the Center for Addiction Studies at the University of 
Pennsylvania Health System (http://www.uphs.upenn.edu/trc/index.html).  
d. Under this protocol, pharmacological treatment to prevent relapse will be offered only using 
medications which are approved for this indication (naltrexone and acamprosate). Although 
Antabuse is approved, it will not be offered because of unacceptable safety risks. Other 
treatment options for relapse prevention may be offered if the patient additionally and separately 
consents to participation in treatment trial protocols aimed at evaluating novel candidate 
treatments. These will then be described in the respective clinical trial protocol. 
e. Assignment of subjects to CBI or MM will not be random. Instead, assignment to treatment will 
be based on (a) whether they are in a clinical trial of medication(s) for relapse prevention or 
(Bobo et al.) whether they are taking an approved medication for relapse prevention, such as 
naltrexone or acamprosate, as follows: 
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i. People who participate in approved LCTS drug studies to prevent relapse will be 
treated with MM. A single treatment keeps the study manageable and allows direct 
assessment of the drug’s effect. 
ii. The people who are not on drug studies, but are taking naltrexone or acamprosate off-
study (as they could/should in the real-world) will be offered CBI or MM. 
iii. Anyone not taking a drug for relapse prevention will be offered CBI. 
f. During the outpatient treatment phase participants may experience medical, psychiatric, or 
psychosocial problems. These clinical situations would be handled by trained staff 
(nurse/counselors, physicians, clinical psychologists, and/or social workers) in according to the 
standard of care appropriate for the situation. 
 
5. Inclusion and exclusion criteria  
a. Inclusion 
1) Age greater than 18 years old. 
2) Are seeking help for alcohol drinking-related problems. 
b. Exclusion  
1) People who present with complicated medical problems requiring intensive medical or 
diagnostic management, such as:  
a. Hypertensive emergency 
b. Serious GI bleeding 
c. Major organ or body system dysfunction such as decompensated liver disease, renal 
failure, myocardial ischemia, congestive heart failure or cerebrovascular disease, major 
endocrine problems such as uncontrolled diabetes, pancreatic or thyroid disease. 
2) People who are infected with the Human Immunodeficiency Virus (HIV). 
3) Serious neuro-psychiatric conditions which impair judgment or cognitive function to an extent 
that precludes them from providing informed consent, such as acute psychosis or severe 
dementia (incompetent individuals). 
4) People who are unlikely or unable to complete the treatment program because they become or 
are likely to be incarcerated while on the protocol. 
5) People who are required to receive treatment by a court of law or who are involuntarily 
committed to treatment. 
 
6. Monitoring research participants and criteria for withdrawal of participants from the study 
 Significant events in the natural history of alcohol abuse and dependency can have very serious 
consequences; they include severe depression, harm to self or others, cognitive impairment, medical 
illness and serious legal problems. Such events do have relevance for monitoring and withdrawal of 
participants from this protocol, despite the fact that it is they would very unlikely be related to therapy or 
procedures performed in the protocol. 
 During the hospitalization treatment phase, patients are kept on a secured unit under close nurse 
monitoring. Alcohol withdrawal severity is monitored with frequent vital signs (VS) monitoring and 
CIWA-Ar scoring. In general, during the first few days after stopping alcohol, VS monitoring and CIWA-
Ar scoring is done hourly or every 2-4 hours until the scores are consistently below a range of 5-7. They 
may also be done on an “as indicated” basis, at the discretion of the healthcare team. 
 During the outpatient treatment phase, participants will be examined in clinic (as scheduled 
above) by nurses and physicians with training and experience in the addictions who will specifically 
review symptoms of depression, intent to harm self or others and a history of complications such as 
serious legal or domestic problems. The healthcare professionals will also review the mood ratings scales 
from CPRS-S-A. Participants will be examined in greater detail for cognitive impairment and medical 
illness if either is suggested based on history and/or routine exam. 
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Withdrawal criteria 
- Participants who become incarcerated or who perpetrate harm to self or others. 
- Non-compliance with therapy: Guidelines and strategies for handling absences from therapy 
sessions, lateness, lapse (first instance of drinking) and relapse (first episode of sustained heavy 
drinking) to alcohol and/or drug use have been established and will be used in the context of CBI 
(Miller, 2004). For participants who miss appointments, efforts will be made to establish phone or 
other contact to enquire about the reasons for the absence(s) and to encourage them to return to 
treatment. Indeed, therapists are trained to use non-compliance itself as an area of focus for 
treatment, to the extent that the subject stays engaged. Absolute non-compliance, for example 
exhibited by extensive alcohol or drug use, and repeated absence from therapy will constitute 
grounds for withdrawal from the protocol. This will be at the discretion of the therapists in 
consultation with the Principal Investigator. 
- Participants may withdraw from the protocol at any time for any reason. If they do, NIAAA 
and/or CC staff will make efforts to ensure their safety and well being. 
The following participants will be considered stopped: 
- Those who are withdrawn 
- Those who decide to seek treatment referral elsewhere after the detoxification and assessment 
period 
- Those who successfully complete the outpatient course of therapy 
 
7. Analysis of the study 
     To assess performance of the program, statistics will be cumulatively kept regarding consent, 
screening, enrollment, and withdrawal/stop, including breakdown by timeline period: 
inpatient/stabilization, baseline and outpatient treatment. Specific participant outcomes to be measured 
include attendance at counseling sessions, drop-out, lapse, relapse, and follow-up ASI scores. For 
administrative and regulatory purposes, information such as the demographic composition of the cohort, 
co-morbid conditions and resource utilization (inpatient and outpatient visits, duration of stay, etc.) will 
be kept. This descriptive data will be also used in other protocols of relapse prevention, alcohol 
withdrawal and other studies in which patients may co-participate. The MRI scans collected under this 
protocol may be grouped together with the MRI’s collected under other descriptive protocols assessing 
the effects of heavy alcohol use on the recovering brain and correlating them with outcomes. 
 
8. Data Management Plan 
     Currently, data is collected by paper and entered into application-specific data tables. However, 
a web-based clinical research data management system is currently under development at the LCTS. The 
ultimate goal of this system is to permit point-of-observation data collection through user-friendly 
applications. Additionally, standard operating procedures and documentation for system use, data 
collection, auditing, disaster recovery and security are also being developed.  
     In summary the system consists of a relational database server, an object-oriented middle-tier 
(business model) and a variety of front-end applications. The front-end applications are designed to 
validate out-of-range values and missing key variables at the time of collection. Data will be entered by 
trained personnel such as investigators and staff who are directly engaged in and familiar with clinical 
activities. Self-report data will be audited at the time of capture. Also, data entry personnel without 
clinical research training may be employed at times to enter data from paper-based forms. Access to the 
system will be through authentication mechanisms established for all NIH systems (currently Microsoft® 
Active Directory). Access to data entry screens and reporting modules will be role-based, with oversight 
of the assignment of roles made by the principal investigator and the NIAAA Clinical Director. 
     Data from the CC information system, supplied through agreement with the Division of Clinical 
Research Informatics, is directly imported to the relational database; it includes: biographic and 
demographic data, medical record numbers, CC visits, protocol participation and laboratory test results. 
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9. Human subjects protection 
 
A. Rationale for subject selection 
     Alcohol problems occur in both men and women across all cultures. Thus, participation in our 
program of detoxification, assessment and treatment of alcohol problems will be open to all qualified 
people who can be accommodated. Individuals are recruited primarily from the Washington, D.C. 
metropolitan area through standing newspaper advertisements. A copy of the currently running ad is 
attached to this protocol (Figure). Any changes to it will be subject to IRB approval. Individuals will also 
be recruited through outreach to healthcare organizations, particularly those that see patients with alcohol 
and drug problems throughout Northern Virginia, Maryland, West Virginia and the Washington, D.C. and 
Baltimore metropolitan areas and elsewhere in the US. Increased efforts will be made to recruit 
Hispanics. This will take the form of contacts with treatment programs that serve Hispanic populations, as 
well as through advertising in Spanish language newspapers. Language interpreters are available for non-
English speaking participants. The intramural research program is primarily focused on alcohol-related 
problems in adults, thus patients must be at least 18 years of age to be enrolled. Furthermore, NIH CC 
policy forbids minors (individuals under age 18) to be housed on the same inpatient unit with adults (over 
age 18). 
     This research is covered by a Confidentiality Certificate, issued by the Public Health Service 
under the authority of 42 U.S.C. 241 (d). Under this certificate, NIAAA is authorized to protect the 
privacy of the participants engaged in research by withholding the subject’s name and other identifying 
information from all persons not connected to this research, except under the circumstances specified in 
the consent form under the section: Information on Confidentiality. 
 
B. Evaluation of Benefits and Risks/Discomforts 
  
1. Benefits 
To individual participants: 
1) A thorough medical and psychiatric screening examination, including dental and gynecological 
examinations, as indicated, may prevent long-term illness and deterioration of quality of life and 
identify treatable conditions. 
2) Supervised medical withdrawal from alcohol can prevent the risk of seizures, delirium tremens 
and other neurological and medical complications. It may also help prevent the development of 
long-term CNS damage. 
3) CBT and MET- as in CBI- and brief interventional and medication management approaches- as 
used in MM- among other counseling approaches and brief interventions, and have been shown 
to have a specific beneficial effect on improving outcome in alcohol dependency (Miller et al., 
1995; Carroll, 1996; Project MATCH Research Group, 1998; Burtscheidt et al., 2001). 
Benefit to NIAAA/CC program’s mission: 
1) Improved treatment program performance through feedback and formal analysis of outcomes of 
therapy and program subject factors (dimensions of assessments) 
2) Basis for clinical training of health professionals in the field of addiction medicine, including a 
fellowship program for physicians 
3) Consistent recruiting basis for alcohol clinical research program 
Benefit to community and society 
1) Source of referral and treatment for people with alcohol problems that impact negatively on 
community and society. 
2) Promote the research mission of a national health initiative (NIAAA). 
3) Competently trained addiction medicine specialists 
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2. Risks/Discomforts 
     This research protocol authorizes only routine medical care and proposes no experimental 
therapies and, indeed, carries no more risk than a conventional alcoholism treatment program. It falls 
under the minimal risk category. 
 
Bodily and Psychological 
     Psychological discomfort may derive from a variety of sources, for example during the 
assessment period or in therapy as patients are challenged to discuss personally sensitive issues. To the 
extent that they are appreciated by the patient themselves, the feelings themselves may become the 
subject of therapeutic focus and a target of further monitoring, if they are persistent and compelling. Also, 
some of the results of blood tests may at first create anxiety, such as a positive HIV test. However, 
anxiogenic these test results may be, they never-the-less provide the important assurance of safety of all 
participants and healthcare workers involved in the program. Furthermore, they are a responsible form of 
medical care and widely practiced in the community, and are thus essential. 
     Physical discomfort mainly would derive from the alcohol withdrawal experience, if it occurs, 
which is treated as described above. Phlebotomy entails no serious risk and is a relatively minor 
discomfort, except in individuals (roughly 5% of the population) who faint in response to a phlebotomy 
or anticipation thereof. A total of up to 364 mL (74 teaspoons) will be done over the course of the 
baseline evaluation (up to 178 mL, 36 teaspoons) and outpatient therapy (186 mL, 38 teaspoons). Some 
of the findings from these tests (for example, anti-HCV antibody (+) results) may require other tests for 
further clinical assessment. This research blood volume will be included in calculations in any additional 
protocols in which the subject might participate to ensure maximum allowable limits of blood draws will 
not be exceeded. 
     Since the CPT-WM and DDT neurocognitive tasks require the use of monetary compensation as 
a way of motivating subjects, efforts will be made to reduce the risk that alcoholic subjects will use the 
money they are paid to buy alcoholic beverages. Specifically, the risk of using the money to buy alcoholic 
beverages will be discussed with each alcoholic participant by the alcohol treatment unit staff. If an 
alcoholic subject reports that he or she expects that his/her earnings might be used to buy alcoholic 
beverages, the subject will be urged to make other arrangements for the disposition of the money (e.g., 
have a relative hold it). 
     Confidentiality and information technology standards are in place at the intramural programs of 
the NIH campus, including the NIAAA/LCTS to protect electronic repositories of patient data. It is 
reasonably expected that these safeguards will protect participants’ medical and personal health 
information, ensuring their privacy. 
  
C. Consent process 
     The informed consent process will take place at the NIH Clinical (Research) Center in Bethesda, 
Maryland. It will follow the policies and procedures as described in Manual Transmittal Sheet M77-2 
(rev.), 7 March 2003, “Informed Consent”, from the Medical Administrative Series of The Clinical 
Center. In summary, this policy states that informed consent begins at the time of recruitment of patients, 
involves oral discussions of the protocol with the potential participant, the signature of an IRB-approved 
consent document, and ongoing discussion and education about the protocol for the duration of their 
participation.  
     The determination of impairment is made by the admitting physician and the primary nurse on 
the basis of clinical examination, including factors such as the level of intoxication using breath alcohol 
and urine drug testing; severity of withdrawal (the CIWA has 5 parameters of CNS function); neurologic, 
psychiatric and other functioning. As a matter of standard practice, all subjects, regardless of the clinical 
setting (inpatient or outpatient), sign the Impaired version of the consent at the time of their initial 
protocol evaluation visit. After an extended period of hourly observation, assessment and treatment they 
sign the Unimpaired version. Practically speaking, for inpatients, this is usually sometime after hospital 
day 4; for outpatients, this is at the time of their second protocol visit (usually at least 1 week after the 
initial visit), provided they are not impaired on clinical grounds (see above). 
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     Either the Principal Investigator or an Associate Investigator will conduct the consent process in 
accordance with CC policy. The investigator will first explain that this protocol is primarily designed to 
allow patients to be treated at the NIH for alcohol problems, including alcohol withdrawal and outpatient 
counseling. Also, they will be told of the nature of the research mission at NIAAA and that during their 
participation in this protocol they may be asked about their willingness to participate in other research 
studies. Furthermore, the investigator will explain tests (pen-and-paper type and biomedical procedures) 
that are required and the information that will be sought, and roughly how much time they may take. 
They will be told of the fact that some of the biomedical tests that are performed may have serious 
implications about their future prognosis (life expectancy and well-being) and insurability, such as HIV 
infection. They will further be told that this information will be stored in the CC hospital information 
system as well as a secure centralized computer system maintained by the NIAAA staff. They will also be 
informed of the NIH confidentiality policy. Finally, they will be told of their option to voluntarily 
withdrawal from further participation in the protocol at any time. Signing the consent form will constitute 
enrollment. In keeping with standard good practice, the protocol will be re-explained to participants after 
admission to the program, particularly after the treatment for the alcohol withdrawal syndrome, if it 
occurs, to reassess their understanding of the nature of the protocol and treatment plan. 
 
10. Adverse Event (AE) Reporting 
Adverse events will be reported in accordance with Federal and NIH requirements. 
   
11. Subject Reimbursement Schedule  
 
Compensation 
 
Payment of all participants will conform to Clinical Center Schedules. Subjects will receive payment for 
the MRI Structural Scan as follows:  
 
 Activity     Time (+ICUs)  Cost 
Testing 
 
MRI Structural Scan*    1 hour (1)  20.00 (10.00) 
 
12. Data and Safety Monitoring 
Data and safety will be monitored by the Principal investigator. The medical staff, including other PI’s, 
the head nurse for the inpatient unit and outpatient clinic and the Clinical Director, will review adverse 
events and safety issues on a quarterly basis.  
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Timeline for Training and Natural History Protocol 
 
Phases with usual duration in parentheses 
1) Phone intake/screening (1-2 weeks) 
2) Detox/psychosocial stabilization (if necessary) (2-5 days) 
3) Baseline assessments (1-4 weeks) 
a. Blood and urine tests 
b. ECG, CXR 
c. Interviews/scales, pencil and paper tests 
d. MRI (or may be done during outpatient follow-up) 
e. Neurocognitive tests 
f. Biomarkers 
g. Genetics 
4) Inpatient stabilization, evaluation with treatment (1-30 + days) 
5) Outpatient follow-up (12 weeks): 
 
Week If in CBI group MD visit, if on 
medication 
Blood tests, urine drug 
screen, rating scales 
1 R R R 
2 R R R 
3 R   
4 R R R 
5 R   
6 R   
7 R   
8 R R R 
9    
10 R   
11    
12 R R R 
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Appendix I 
 
Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised  
(CIWA-Ar) 
 
 
Patient:__________________________ Date: ________________ Time: _______________  
(24 hour clock, midnight = 00:00) 
Pulse or heart rate, taken for one minute:_________________________ Blood pressure:______ 
 
NAUSEA AND VOMITING -- Ask "Do you feel sick to your stomach? Have you vomited?"  
 
0 no nausea and no vomiting 
1 mild nausea with no vomiting 
2 
3 
4 intermittent nausea with dry heaves 
5 
6 
7 constant nausea, frequent dry heaves and vomiting 
 
TACTILE DISTURBANCES -- Ask "Have you any itching, pins and needles sensations, any burning, 
any numbness, or do you feel bugs crawling on or under your skin?"  
 
0 none 
1 very mild itching, pins and needles, burning or numbness 
2 mild itching, pins and needles, burning or numbness 
3 moderate itching, pins and needles, burning or numbness 
4 moderately severe hallucinations 
5 severe hallucinations 
6 extremely severe hallucinations 
7 continuous hallucinations 
 
TREMOR -- Arms extended and fingers spread apart. 
 
0 no tremor 
1 not visible, but can be felt fingertip to fingertip 
2 
3 
4 moderate, with patient's arms extended 
5 
6 
7 severe, even with arms not extended 
 
AUDITORY DISTURBANCES -- Ask "Are you more aware of sounds around you? Are they harsh? 
Do they frighten you? Are you hearing anything that is disturbing to you? Are you hearing things you 
know are not there?"  
 
0 not present 
1 very mild harshness or ability to frighten 
2 mild harshness or ability to frighten 
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3 moderate harshness or ability to frighten 
4 moderately severe hallucinations 
5 severe hallucinations 
6 extremely severe hallucinations 
7 continuous hallucinations 
 
PAROXYSMAL SWEATS – 
 
0 no sweat visible 
1 barely perceptible sweating, palms moist 
2 
3 
4 beads of sweat obvious on forehead 
5 
6 
7 drenching sweats 
 
VISUAL DISTURBANCES -- Ask "Does the light appear to be too bright? Is its color different? Does it 
hurt your eyes? Are you seeing anything that is disturbing to you? Are you seeing things you know are 
not there?"  
 
0 not present 
1 very mild sensitivity 
2 mild sensitivity 
3 moderate sensitivity 
4 moderately severe hallucinations 
5 severe hallucinations 
6 extremely severe hallucinations 
7 continuous hallucinations 
 
ANXIETY -- Ask "Do you feel nervous?"  
 
0 no anxiety, at ease 
1 mild anxious 
2 
3 
4 moderately anxious, or guarded, so anxiety is inferred 
5 
6 
7 equivalent to acute panic states as seen in severe delirium or acute schizophrenic reactions 
 
HEADACHE, FULLNESS IN HEAD -- Ask "Does your head feel different? Does it feel like there is a 
band around your head?" Do not rate for dizziness or lightheadedness. Otherwise, rate severity. 
 
0 not present 
1 very mild 
2 mild 
3 moderate 
4 moderately severe 
5 severe 
6 very severe 
7 extremely severe 
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Appendix J 
 
Activty Flow Sheet – Clinical Study #2 
 
 
 
 
 
Step          A      B   C       D              E           F    
          
  
   
 
 Day            1      2  3           8          15      
             
 
 
Step A:   Potential subject contact with NIAAA; Interview and assess whether 
  patient would like to participate. Informed Consent Form discussion, 
  comprehension, and signing; Physical and psychiatric examination  
  including DSM-IV/SCID-I and Drugs of Abuse testing; Inclusion and 
  exclusion criteria evaluation of patient.  
  
Step B:  Admission for detoxification and stabilization at NIAAA/CRC.  BrAC 
  evaluation; Baseline sampling will be performed including: Blood  
  biological sampling, CIWA-AR, and vital signs, urine Drugs of Abuse 
  testing.   
 
Step C:    Day 2 after admission.  BrAC evaluation; Baseline sampling will be 
  performed including: blood biological sampling, CIWA-AR, and vital 
  signs, urine Drugs of Abuse testing;   Biological testing for biomarkers 
  performed in the AM, before smoking and eating.   FTND administration 
  to volunteer for categorization into subgroup (NS, LS, HS). 
 
Steps D-F:  Days 3, 8 and 15 after admission.  Same as step C.  Alcohol TLFB, Food 
  Inventory administration only once any time after sobriety.   
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Appendix K 
 
Patient Summary – Clinical Study #2 
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Appendix L 
 
S-PLUS® ANCOVA and Linear model outputs – Clinical Study #1 
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Table L-1:  ANOVA for main effects of SS and GEN on Log H  
 
 
 
*** Analysis of Variance Model *** 
 
Short Output: 
Call: 
   aov(formula = log.H ~ SS + GEN + visit + SS:GEN, data =  
 SAL.BC..Final.Bioanalysis.Data.VCU.Smoking.031808, na.action =  
 na.exclude) 
 
Terms: 
                      SS      GEN    visit   SS:GEN Residuals  
 Sum of Squares  7.40497  0.02159  0.71119  1.34362  16.63132 
Deg. of Freedom        2        1        1        2        75 
 
Residual standard error: 0.4709044  
Estimated effects may be unbalanced 
 
          Df Sum of Sq  Mean Sq  F Value     Pr(F)  
       SS  2   7.40497 3.702483 16.69658 0.0000010 
      GEN  1   0.02159 0.021590  0.09736 0.7558877 
    visit  1   0.71119 0.711188  3.20715 0.0773521 
   SS:GEN  2   1.34362 0.671812  3.02958 0.0742898 
Residuals 75  16.63132 0.221751                    
 
Residual standard error: 0.4832 on 77 degrees of freedom 
Multiple R-Squared: 0.3116  
F-statistic: 8.715 on 4 and 77 degrees of freedom, the p-value is 7.41e-006 
 
95 % simultaneous confidence intervals for specified  
linear combinations, by the Scheffe method  
 
critical point: 2.86  
response variable: log.H  
rank used for Scheffe method: 3  
 
intervals excluding 0 are flagged by '****'  
 
      Estimate Std.Error Lower Bound Upper Bound       
HS-LS   -0.032     0.143      -0.440       0.376      
HS-NS    0.571     0.127       0.209       0.933 **** 
LS-NS    0.603     0.127       0.241       0.965 **** 
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Table L-2:  ANOVA for main effects of SS and GEN on Log NH  
 
 
 
 
*** Analysis of Variance Model *** 
 
Short Output: 
Call: 
   aov(formula = log.NH ~ SS + GEN + visit + SS:GEN, data =  
 SAL.BC..Final.Bioanalysis.Data.VCU.Smoking.031808, na.action =  
 na.exclude) 
 
Terms: 
                      SS      GEN    visit   SS:GEN Residuals  
 Sum of Squares 13.94415  0.35342  0.01848  1.90789  12.54758 
Deg. of Freedom        2        1        1        2        75 
 
Residual standard error: 0.4090246  
Estimated effects may be unbalanced 
 
          Df Sum of Sq  Mean Sq  F Value     Pr(F)  
       SS  2  13.94415 6.972076 41.67382 0.0000000 
      GEN  1   0.35342 0.353417  2.11246 0.1502757 
    visit  1   0.01848 0.018483  0.11048 0.7405308 
   SS:GEN  2   1.90789 0.953946  2.70197 0.0649521 
Residuals 75  12.54758 0.167301                    
 
Residual standard error: 0.4333 on 77 degrees of freedom 
Multiple R-Squared: 0.4976  
F-statistic: 19.06 on 4 and 77 degrees of freedom, the p-value is 6.246e-011  
 
95 % simultaneous confidence intervals for specified  
linear combinations, by the Scheffe method  
 
critical point: 2.86  
response variable: log.NH  
rank used for Scheffe method: 3  
 
intervals excluding 0 are flagged by '****'  
 
      Estimate Std.Error Lower Bound Upper Bound       
HS-LS    0.276     0.124     -0.0778       0.631      
HS-NS    0.924     0.110      0.6100       1.240 **** 
LS-NS    0.648     0.110      0.3330       0.962 **** 
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Table L-3:  Linear Model for effects of FTND on Log H  
 
 
*** Linear Model *** 
 
Call: lm(formula = log.H ~ GEN + FTND + GEN:FTND, data =  
 SAL.BC..Final.Bioanalysis.Data.VCU.Smoking.032908, na.action =  
 na.exclude) 
Residuals: 
    Min      1Q  Median     3Q    Max  
 -1.212 -0.3671 0.02479 0.4088 0.9894 
 
Coefficients: 
               Value Std. Error  t value Pr(>|t|)  
(Intercept)   1.0875   0.0974    11.1606   0.0000 
        GEN   0.2575   0.1425     1.8074   0.0746 
       FTND   0.1561   0.0310     5.0431   0.0000 
   GEN:FTND  -0.1241   0.0414    -2.9971   0.0037 
 
Residual standard error: 0.4991 on 78 degrees of freedom 
Multiple R-Squared: 0.2558  
F-statistic: 8.939 on 3 and 78 degrees of freedom, the p-value is 0.00003681  
 
 
 
  
Table L-4:  Linear Model for effects of #cig/day on Log H  
 
 
*** Linear Model *** 
 
Call: lm(formula = log.H ~ .cig.day + GEN + .cig.day:GEN, data =  
 SAL.BC..Final.Bioanalysis.Data.VCU.Smoking.032908, na.action =  
 na.exclude) 
Residuals: 
    Min      1Q  Median     3Q   Max  
 -1.206 -0.3661 0.03123 0.3959 1.015 
 
Coefficients: 
                Value Std. Error  t value Pr(>|t|)  
 (Intercept)   1.0810   0.0967    11.1744   0.0000 
    .cig.day   0.0342   0.0067     5.1395   0.0000 
         GEN   0.2159   0.1431     1.5088   0.1354 
.cig.day:GEN  -0.0149   0.0126    -1.1823   0.2407 
 
Residual standard error: 0.4924 on 78 degrees of freedom 
Multiple R-Squared: 0.2757  
F-statistic: 9.896 on 3 and 78 degrees of freedom, the p-value is 0.00001328  
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Table L-5:  Linear Model for effects of FTND on Log NH  
 
 
*** Linear Model *** 
 
Call: lm(formula = log.NH ~ FTND + GEN + FTND:GEN, data =  
 SAL.BC..Final.Bioanalysis.Data.VCU.Smoking.032908, na.action =  
 na.exclude) 
Residuals: 
    Min      1Q Median     3Q    Max  
 -1.054 -0.3148 0.1162 0.2901 0.7051 
 
Coefficients: 
               Value Std. Error  t value Pr(>|t|)  
(Intercept)   1.1142   0.0862    12.9225   0.0000 
       FTND   0.2006   0.0274     7.3253   0.0000 
        GEN   0.2987   0.1261     2.3691   0.0203 
   FTND:GEN  -0.1082   0.0367    -2.9514   0.0042 
 
Residual standard error: 0.4417 on 78 degrees of freedom 
Multiple R-Squared: 0.4712  
F-statistic: 23.16 on 3 and 78 degrees of freedom, the p-value is 8.026e-011  
 
 
 
 
 
Table L-6:  Linear Model for effects of #cig/day on Log NH  
 
 
*** Linear Model *** 
 
Call: lm(formula = log.NH ~ .cig.day + GEN + .cig.day:GEN, data =  
 SAL.BC..Final.Bioanalysis.Data.VCU.Smoking.032908, na.action =  
 na.exclude) 
Residuals: 
    Min      1Q  Median     3Q    Max  
 -1.042 -0.2874 0.07357 0.2893 0.8194 
 
Coefficients: 
                Value Std. Error  t value Pr(>|t|)  
 (Intercept)   1.1027   0.0842    13.0910   0.0000 
    .cig.day   0.0443   0.0058     7.6449   0.0000 
         GEN   0.2711   0.1246     2.1756   0.0326 
.cig.day:GEN  -0.0041   0.0110    -0.3731   0.7101 
 
Residual standard error: 0.4288 on 78 degrees of freedom 
Multiple R-Squared: 0.5016  
F-statistic: 26.16 on 3 and 78 degrees of freedom, the p-value is 8.201e-012  
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Table L-7:  ANCOVA for SS and GEN on Log H, Food and AAI as Covariates 
 
 
*** Analysis of Variance Model *** 
 
Short Output: 
Call: 
   aov(formula = log.H ~ SS + GEN + visit + Food.H + AAI, data =  
 SAL.BC..Final.Bioanalysis.Data.VCU.Smoking.032908, na.action =  
 na.exclude) 
 
Terms: 
                      SS      GEN    visit   Food.H      AAI Residuals  
 Sum of Squares  7.40497  0.02159  0.71119  0.41445  0.37278  17.18772 
Deg. of Freedom        2        1        1        1        1        75 
 
Residual standard error: 0.4787166  
Estimated effects may be unbalanced 
 
          Df Sum of Sq  Mean Sq  F Value     Pr(F)  
       SS  2   7.40497 3.702483 16.15609 0.0000015 
      GEN  1   0.02159 0.021590  0.09421 0.7597453 
    visit  1   0.71119 0.711188  3.10333 0.0822077 
   Food.H  1   0.41445 0.414448  1.80848 0.1827439 
      AAI  1   0.37278 0.372784  1.62667 0.2061005 
Residuals 75  17.18772 0.229170                    
 
 
 
 
 
Table L-8:  ANCOVA for SS and GEN on Log NH, Food and AAI as Covariates 
 
 
*** Analysis of Variance Model *** 
 
Short Output: 
Call: 
   aov(formula = log.NH ~ SS + GEN + visit + Food.NH + AAI, data =  
 SAL.BC..Final.Bioanalysis.Data.VCU.Smoking.032908, na.action =  
 na.exclude) 
 
Terms: 
                      SS      GEN    visit  Food.NH      AAI Residuals  
 Sum of Squares 13.94415  0.35342  0.01848  0.28137  0.14743  14.02668 
Deg. of Freedom        2        1        1        1        1        75 
 
Residual standard error: 0.4324608  
Estimated effects may be unbalanced 
 
          Df Sum of Sq  Mean Sq  F Value     Pr(F)  
       SS  2  13.94415 6.972076 37.27937 0.0000000 
      GEN  1   0.35342 0.353417  1.88971 0.1733284 
    visit  1   0.01848 0.018483  0.09883 0.7541161 
  Food.NH  1   0.28137 0.281367  1.50445 0.2238240 
      AAI  1   0.14743 0.147430  5.78830 0.0774522 
Residuals 75  14.02668 0.187022  
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Table L-9:  ANOVA for main effects of SS and GEN on Log S-SAL  
 
 
 
*** Analysis of Variance Model *** 
 
Short Output: 
Call: 
   aov(formula = log.SAL ~ SS + GEN + visit + SS:GEN, data =  
 SAL.BC..Final.Bioanalysis.Data.VCU.Smoking.031808, na.action =  
 na.exclude) 
 
Terms: 
                      SS      GEN    visit   SS:GEN Residuals  
 Sum of Squares  7.40497  0.02159  0.71119  1.34362  16.63132 
Deg. of Freedom        2        1        1        2        75 
 
Residual standard error: 0.4709044  
Estimated effects may be unbalanced 
 
            Df Sum of Sq  Mean Sq  F Value     Pr(F)  
       SS   2   7.89131 3.945656 15.52240 0.0000012 
      GEN   1   0.14529 0.145293  0.57159 0.4512744 
    visit   1   0.00779 0.007790 0.017859 0.8940485 
   SS:GEN   2   1.52140 0.760699  2.99263 0.0543319 
 Residuals 75  32.71512 0.436202      
 
Multiple R-Squared: 0.1921  
F-statistic: 3.402 on 5 and 75 degrees of freedom, the p-value is 0.007939  
 
95 % simultaneous confidence intervals for specified  
linear combinations, by the Scheffe method  
 
critical point: 2.8393  
response variable: log.S.SAL  
rank used for Scheffe method: 3  
 
intervals excluding 0 are flagged by '****'  
 
      Estimate Std.Error Lower Bound Upper Bound       
HS-LS    0.267     0.128     -0.0969       0.632      
HS-NS    0.623     0.116      0.2930       0.952 **** 
LS-NS    0.355     0.116      0.0252       0.685 **** 
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Table L-10:  ANOVA for main effects of SS and GEN on Log R-SAL 
 
 
 
*** Analysis of Variance Model *** 
 
Short Output: 
Call: 
   aov(formula = log.R.SAL ~ SS + GEN + visit + SS:GEN, data =  
 SAL.BC..Final.Bioanalysis.Data.VCU.Smoking.032908, na.action =  
 na.exclude) 
 
Response: LOG R-SAL 
 
         Df Sum of Sq  Mean Sq  F Value     Pr(F)  
       SS   2   9.62605 4.813024 13.97085 0.0000040 
      GEN   1   0.01798 0.017981  0.05219 0.8197207 
    visit   1   0.00047 0.000468 0.000777 0.9778414 
   SS:GEN   2   1.41383 0.706913  2.05197 0.1334615 
Residuals  75  37.20651 0.344505                    
 
Multiple R-Squared: 0.2571  
F-statistic: 9.156 on 3 and 75 degrees of freedom, the p-value is 0.00001845  
 
95 % simultaneous confidence intervals for specified  
linear combinations, by the Scheffe method  
 
critical point: 2.8401  
response variable: log.R.SAL  
rank used for Scheffe method: 3  
 
intervals excluding 0 are flagged by '****'  
 
      Estimate Std.Error Lower Bound Upper Bound       
HS-LS    0.233     0.147     -0.1840       0.650      
HS-NS    0.676     0.133      0.2990       1.050 **** 
LS-NS    0.443     0.133      0.0656       0.821 **** 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
573 
Table L-11:  ANOVA for main effects of SS and GEN on Log DA 
 
 
 
*** Analysis of Variance Model *** 
 
Short Output: 
Call: 
   aov(formula = log.DA ~ SS + GEN + visit + SS:GEN, data =  
 SAL.BC..Final.Bioanalysis.Data.VCU.Smoking.032908, na.action =  
 na.exclude) 
 
Terms: 
                      SS      GEN    visit   SS:GEN Residuals  
 Sum of Squares 1.165686 0.019696 0.000109 1.426734  7.412780 
Deg. of Freedom        2        1        1        2        75 
 
Residual standard error: 0.3143836  
Estimated effects may be unbalanced 
 
          Df Sum of Sq   Mean Sq  F Value     Pr(F)  
       SS  2  1.165686 0.5828430 5.897008 0.0041824 
      GEN  1  0.019696 0.0196963 0.199280 0.6565887 
    visit  1  0.000109 0.0001090 0.001103 0.9735986 
   SS:GEN  2  1.426734 0.7133668 7.217604 0.0213590 
Residuals 75  7.412780 0.0988371                    
 
R-Squared:  0.2656  
F-statistic: 5.277 on 2 and 75 degrees of freedom, the p-value is 0.0002244 
 
95 % simultaneous confidence intervals for specified  
linear combinations, by the Scheffe method  
 
critical point: 2.86  
response variable: log.DA  
rank used for Scheffe method: 3  
 
intervals excluding 0 are flagged by '****'  
 
      Estimate Std.Error Lower Bound Upper Bound       
HS-LS   0.1980    0.0952     -0.0742       0.470      
HS-NS   0.2650    0.0845      0.0238       0.507 **** 
LS-NS   0.0674    0.0845     -0.1740       0.309      
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Table L-12:  Linear Model for effects of FTND on Log S-SAL 
 
 
*** Linear Model *** 
 
Call: lm(formula = log.S.SAL ~ FTND + GEN + FTND:GEN, data =  
 SAL.BC..Final.Bioanalysis.Data.VCU.Smoking.032908, na.action =  
 na.exclude) 
Residuals: 
    Min      1Q   Median     3Q   Max  
 -1.152 -0.5319 -0.08436 0.5098 1.389 
 
Coefficients: 
               Value Std. Error  t value Pr(>|t|)  
(Intercept)   1.7735   0.1288    13.7686   0.0000 
       FTND   0.1235   0.0409     3.0171   0.0034 
        GEN   0.6218   0.1883     3.3014   0.0015 
   FTND:GEN  -0.1668   0.0548    -3.0472   0.0032 
 
Residual standard error: 0.6598 on 78 degrees of freedom 
Multiple R-Squared: 0.1521  
F-statistic: 4.664 on 3 and 78 degrees of freedom, the p-value is 0.004743  
 
 
 
 
Table L-13:  Linear Model for effects of #cig/day on Log S-SAL 
 
 
 
*** Linear Model *** 
 
Call: lm(formula = log.S.SAL ~ .cig.day + GEN + .cig.day:GEN, data =  
 SAL.BC..Final.Bioanalysis.Data.VCU.Smoking.032908, na.action =  
 na.exclude) 
Residuals: 
    Min      1Q  Median     3Q   Max  
 -1.058 -0.5184 -0.1093 0.5255 1.483 
 
Coefficients: 
                Value Std. Error  t value Pr(>|t|)  
 (Intercept)   1.7999   0.1325    13.5873   0.0000 
    .cig.day   0.0237   0.0091     2.5953   0.0113 
         GEN   0.5011   0.1960     2.5568   0.0125 
.cig.day:GEN  -0.0250   0.0173    -1.4457   0.1523 
 
Residual standard error: 0.6743 on 78 degrees of freedom 
Multiple R-Squared: 0.1143  
F-statistic: 3.354 on 3 and 78 degrees of freedom, the p-value is 0.02307  
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Table L-14:  Linear Model for effects of FTND on Log R-SAL 
 
 
*** Linear Model *** 
 
Call: lm(formula = log.R.SAL ~ FTND + GEN + FTND:GEN, data =  
 SAL.BC..Final.Bioanalysis.Data.VCU.Smoking.032908, na.action =  
 na.exclude) 
Residuals: 
   Min      1Q  Median     3Q   Max  
 -1.67 -0.5535 -0.1323 0.6083 1.506 
 
Coefficients: 
               Value Std. Error  t value Pr(>|t|)  
(Intercept)   1.8309   0.1512    12.1058   0.0000 
       FTND   0.1216   0.0480     2.5308   0.0134 
        GEN   0.5504   0.2211     2.4887   0.0150 
   FTND:GEN  -0.1620   0.0643    -2.5200   0.0138 
 
Residual standard error: 0.7747 on 78 degrees of freedom 
Multiple R-Squared: 0.1016  
F-statistic: 2.94 on 3 and 78 degrees of freedom, the p-value is 0.03829  
 
 
 
 
Table L-15:  Linear Model for effects of #cig/day on Log R-SAL 
 
 
*** Linear Model *** 
 
Call: lm(formula = log.R.SAL ~ .cig.day + GEN + .cig.day:GEN, data =  
 SAL.BC..Final.Bioanalysis.Data.VCU.Smoking.032908, na.action =  
 na.exclude) 
Residuals: 
    Min      1Q  Median     3Q   Max  
 -1.583 -0.6324 -0.1439 0.6064 1.593 
 
Coefficients: 
                Value Std. Error  t value Pr(>|t|)  
 (Intercept)   1.8738   0.1552    12.0761   0.0000 
    .cig.day   0.0215   0.0107     2.0136   0.0475 
         GEN   0.4203   0.2295     1.8312   0.0709 
.cig.day:GEN  -0.0228   0.0202    -1.1279   0.2628 
 
Residual standard error: 0.7899 on 78 degrees of freedom 
Multiple R-Squared: 0.06611  
F-statistic: 1.841 on 3 and 78 degrees of freedom, the p-value is 0.1467  
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Table L-16:  Linear Model for effects of FTND on Log DA 
 
 
*** Linear Model *** 
 
Call: lm(formula = log.DA ~ FTND + GEN + FTND:GEN, data =  
 SAL.BC..Final.Bioanalysis.Data.VCU.Smoking.032908, na.action =  
 na.exclude) 
Residuals: 
    Min      1Q  Median    3Q    Max  
 -1.491 -0.1326 0.01949 0.167 0.6027 
 
Coefficients: 
               Value Std. Error  t value Pr(>|t|)  
(Intercept)   0.7331   0.0590    12.4207   0.0000 
       FTND   0.1049   0.0188     5.5961   0.0000 
        GEN   0.2546   0.0863     2.9499   0.0042 
   FTND:GEN  -0.1122   0.0251    -4.4708   0.0000 
 
Residual standard error: 0.3023 on 78 degrees of freedom 
Multiple R-Squared: 0.2888  
F-statistic: 10.56 on 3 and 78 degrees of freedom, the p-value is 6.65e-006  
 
 
 
 
Table L-17:  Linear Model for effects of #cig/day on Log DA 
 
 
*** Linear Model *** 
 
Call: lm(formula = log.DA ~ .cig.day + GEN + .cig.day:GEN, data =  
 SAL.BC..Final.Bioanalysis.Data.VCU.Smoking.032908, na.action =  
 na.exclude) 
Residuals: 
    Min      1Q    Median     3Q    Max  
 -1.488 -0.1701 -0.008683 0.2211 0.6238 
 
Coefficients: 
                Value Std. Error  t value Pr(>|t|)  
 (Intercept)   0.7519   0.0618    12.1760   0.0000 
    .cig.day   0.0205   0.0042     4.8250   0.0000 
         GEN   0.2147   0.0914     2.3501   0.0213 
.cig.day:GEN  -0.0199   0.0081    -2.4692   0.0157 
 
Residual standard error: 0.3144 on 78 degrees of freedom 
Multiple R-Squared: 0.2311  
F-statistic: 7.815 on 3 and 78 degrees of freedom, the p-value is 0.0001258  
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Table L-18:  ANCOVA for SS and GEN on Log S-SAL, Food and AAI as Covariates 
 
 
*** Analysis of Variance Model *** 
 
Short Output: 
Call: 
   aov(formula = log.S.SAL ~ SS + GEN + visit + Food.SAL + AAI, data =  
 SAL.BC..Final.Bioanalysis.Data.VCU.Smoking.032908, na.action =  
 na.exclude) 
 
Terms: 
                      SS      GEN    visit Food.SAL      AAI Residuals  
 Sum of Squares  1.06763  1.54763  0.00779  0.01073  0.80364  36.60837 
Deg. of Freedom        2        1        1        1        1        75 
 
Residual standard error: 0.6986498  
Estimated effects may be unbalanced 
 
          Df Sum of Sq  Mean Sq  F Value     Pr(F)  
       SS  2   1.06763 0.533813 1.093630 0.3402800 
      GEN  1   1.54763 1.547630 3.170647 0.0790223 
    visit  1   0.00779 0.007790 0.015959 0.8998087 
 Food.SAL  1   0.01073 0.010733 0.021989 0.8825146 
      AAI  1   0.80364 0.803638 1.646422 0.2033975 
Residuals 75  36.60837 0.488112                            
 
 
 
Table L-19:  ANCOVA for SS and GEN on Log R-SAL, Food and AAI as Covariates 
  
 
*** Analysis of Variance Model *** 
 
Short Output: 
Call: 
   aov(formula = log.R.SAL ~ SS + GEN + visit + Food.SAL + AAI, data =  
 SAL.BC..Final.Bioanalysis.Data.VCU.Smoking.032908, na.action =  
 na.exclude) 
 
Terms: 
                      SS      GEN    visit Food.SAL      AAI Residuals  
 Sum of Squares  1.01355  0.94390  0.00047  0.00001  2.06821  48.08055 
Deg. of Freedom        2        1        1        1        1        75 
 
Residual standard error: 0.8006709  
Estimated effects may be unbalanced 
 
          Df Sum of Sq  Mean Sq  F Value     Pr(F)  
       SS  2   1.01355 0.506773 0.790506 0.4573579 
      GEN  1   0.94390 0.943902 1.472376 0.2287788 
    visit  1   0.00047 0.000468 0.000731 0.9785085 
 Food.SAL  1   0.00001 0.000013 0.000020 0.9964389 
      AAI  1   2.06821 2.068209 3.226163 0.0764974 
Residuals 75  48.08055 0.641074                    
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Appendix M 
 
Individual concentration-time profiles – Clinical Study #2 
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Figure M-1:  S/R-SAL (pg/ml) and DA (ng/ml) concentration vs. time profile for 
Subject 1 (HS, F) 
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Figure M-2:  S/R-SAL (pg/ml) and DA (ng/ml) concentration vs. time profile for 
Subject 2 (HS, F) 
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Figure M-3:  S/R-SAL (pg/ml) and DA (ng/ml) concentration vs. time profile for 
Subject 3 (HS, F) 
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Figure M-4:  S/R-SAL (pg/ml) and DA (ng/ml) concentration vs. time profile for 
Subject 4 (HS, F) 
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Figure M-5:  S/R-SAL (pg/ml) and DA (ng/ml) concentration vs. time profile for 
Subject 5 (HS, F) 
 
 
0
100
200
300
400
500
600
700
800
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
day post admission
SA
L 
pg
/m
l
0
2
4
6
8
10
12
14
16
D
A
 n
g/
m
l
S-SAL
R-SAL
DA
 
 
Figure M-6:  S/R-SAL (pg/ml) and DA (ng/ml) concentration vs. time profile for 
Subject 6 (HS, F) 
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Figure M-7:  S/R-SAL (pg/ml) and DA (ng/ml) concentration vs. time profile for 
Subject 7 (HS, M) 
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Figure M-8:  S/R-SAL (pg/ml) and DA (ng/ml) concentration vs. time profile for 
Subject 8 (HS, M) 
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Figure M-9:  S/R-SAL (pg/ml) and DA (ng/ml) concentration vs. time profile for 
Subject 9 (HS, M) 
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Figure M-10:  S/R-SAL (pg/ml) and DA (ng/ml) concentration vs. time profile for 
Subject 10 (HS, M) 
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Figure M-11:  S/R-SAL (pg/ml) and DA (ng/ml) concentration vs. time profile for 
Subject 11 (HS, M) 
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Figure M-12:  S/R-SAL (pg/ml) and DA (ng/ml) concentration vs. time profile for 
Subject 12 (HS, M) 
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Figure M-13:  S/R-SAL (pg/ml) and DA (ng/ml) concentration vs. time profile for 
Subject 13 (LS, F) 
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Figure M-14:  S/R-SAL (pg/ml) and DA (ng/ml) concentration vs. time profile for 
Subject 15 (LS, F) 
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Figure M-15:  S/R-SAL (pg/ml) and DA (ng/ml) concentration vs. time profile for 
Subject 16 (LS, F) 
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Figure M-16:  S/R-SAL (pg/ml) and DA (ng/ml) concentration vs. time profile for 
Subject 17 (LS, F) 
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Figure M-17:  S/R-SAL (pg/ml) and DA (ng/ml) concentration vs. time profile for 
Subject 18 (LS, F) 
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Figure M-18:  S/R-SAL (pg/ml) and DA (ng/ml) concentration vs. time profile for 
Subject 19 (LS, M) 
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Figure M-19:  S/R-SAL (pg/ml) and DA (ng/ml) concentration vs. time profile for 
Subject 20 (LS, M) 
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Figure M-20:  S/R-SAL (pg/ml) and DA (ng/ml) concentration vs. time profile for 
Subject 21 (LS, M) 
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Figure M-21:  S/R-SAL (pg/ml) and DA (ng/ml) concentration vs. time profile for 
Subject 22 (LS, M) 
 
 
0
10
20
30
40
50
60
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
day post admission
SA
L 
pg
/m
l
0
2
4
6
8
10
12
14
16
D
A
 n
g/
m
l
S-SAL
R-SAL
DA
 
 
Figure M-22:  S/R-SAL (pg/ml) and DA (ng/ml) concentration vs. time profile for 
Subject 23 (LS, M) 
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Figure M-23:  S/R-SAL (pg/ml) and DA (ng/ml) concentration vs. time profile for 
Subject 24 (LS, M) 
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Figure M-24:  S/R-SAL (pg/ml) and DA (ng/ml) concentration vs. time profile for 
Subject 25 (NS, F) 
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Figure M-25:  S/R-SAL (pg/ml) and DA (ng/ml) concentration vs. time profile for 
Subject 26 (NS, F) 
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Figure M-26:  S/R-SAL (pg/ml) and DA (ng/ml) concentration vs. time profile for 
Subject 27 (NS, F) 
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Figure M-27:  S/R-SAL (pg/ml) and DA (ng/ml) concentration vs. time profile for 
Subject 28 (NS, F) 
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Figure M-28:  S/R-SAL (pg/ml) and DA (ng/ml) concentration vs. time profile for 
Subject 29 (NS, F) 
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Figure M-29:  S/R-SAL (pg/ml) and DA (ng/ml) concentration vs. time profile for 
Subject 30 (NS, F) 
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Figure M-30:  S/R-SAL (pg/ml) and DA (ng/ml) concentration vs. time profile for 
Subject 31 (NS, M) 
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Figure M-31:  S/R-SAL (pg/ml) and DA (ng/ml) concentration vs. time profile for 
Subject 32 (NS, M) 
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Figure M-32:  S/R-SAL (pg/ml) and DA (ng/ml) concentration vs. time profile for 
Subject 33 (NS, M) 
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Figure M-33:  S/R-SAL (pg/ml) and DA (ng/ml) concentration vs. time profile for 
Subject 34 (NS, M) 
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Figure M-34:  S/R-SAL (pg/ml) and DA (ng/ml) concentration vs. time profile for 
Subject 35 (NS, M) 
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Figure M-35:  S/R-SAL (pg/ml) and DA (ng/ml) concentration vs. time profile for 
Subject 36 (NS, M) 
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Appendix N 
 
Individual Clinical Endpoint (CIWA-AR) vs. time – Clinical Study #2 
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Figure N-1:  CIWA-AR vs. time profile for Subject 1 (HS, F) 
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Figure N-2:  CIWA-AR vs. time profile for Subject 2 (HS, F) 
 
 
0
2
4
6
8
10
12
14
16
18
20
0 1 2 3
day
C
IW
A-
AR
 s
co
re
4
  
 
Figure N-3:  CIWA-AR vs. time profile for Subject 3 (HS, F) 
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Figure N-4:  CIWA-AR vs. time profile for Subject 4 (HS, F) 
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Figure N-5:  CIWA-AR vs. time profile for Subject 5 (HS, F) 
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Figure N-6:  CIWA-AR vs. time profile for Subject 6 (HS, F) 
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Figure N-7:  CIWA-AR vs. time profile for Subject 7 (HS, M) 
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Figure N-8:  CIWA-AR vs. time profile for Subject 8 (HS, M) 
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Figure N-9:  CIWA-AR vs. time profile for Subject 9 (HS, M) 
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Figure N-10:  CIWA-AR vs. time profile for Subject 10 (HS, M) 
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Figure N-11:  CIWA-AR vs. time profile for Subject 11 (HS, M) 
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Figure N-12:  CIWA-AR vs. time profile for Subject 12 (HS, M) 
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Figure N-13:  CIWA-AR vs. time profile for Subject 13 (LS, F) 
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Figure N-14:  CIWA-AR vs. time profile for Subject 15 (LS, F) 
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Figure N-15:  CIWA-AR vs. time profile for Subject 16 (LS, F) 
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Figure N-16:  CIWA-AR vs. time profile for Subject 17 (LS, F) 
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Figure N-17:  CIWA-AR vs. time profile for Subject 18 (LS, F) 
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Figure N-18:  CIWA-AR vs. time profile for Subject 19 (LS, M) 
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Figure N-19:  CIWA-AR vs. time profile for Subject 20 (LS, M) 
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Figure N-20:  CIWA-AR vs. time profile for Subject 21 (LS, M) 
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Figure N-21:  CIWA-AR vs. time profile for Subject 22 (LS, M) 
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Figure N-22:  CIWA-AR vs. time profile for Subject 23 (LS, M) 
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Figure N-23:  CIWA-AR vs. time profile for Subject 24 (LS, M) 
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Figure N-24:  CIWA-AR vs. time profile for Subject 25 (NS, F) 
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Figure N-25:  CIWA-AR vs. time profile for Subject 26 (NS, F) 
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Figure N-26:  CIWA-AR vs. time profile for Subject 27 (NS, F) 
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Figure N-27:  CIWA-AR vs. time profile for Subject 28 (NS, F) 
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Figure N-28:  CIWA-AR vs. time profile for Subject 29 (NS, F) 
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Figure N-29:  CIWA-AR vs. time profile for Subject 30 (NS, F) 
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Figure N-30:  CIWA-AR vs. time profile for Subject 31 (NS, M) 
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Figure N-31:  CIWA-AR vs. time profile for Subject 32 (NS, M) 
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Figure N-32:  CIWA-AR vs. time profile for Subject 33 (NS, M) 
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Figure N-33:  CIWA-AR vs. time profile for Subject 34 (NS, M) 
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Figure N-34:  CIWA-AR vs. time profile for Subject 35 (NS, M) 
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Figure N-35:  CIWA-AR vs. time profile for Subject 36 (NS, M) 
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Appendix O 
 
S-PLUS® ANCOVA and Linear model outputs – Clinical Study #2 
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Table O-1:  Linear model for main effects of time, SS and GEN on Log S-SAL  
 
 
 *** Linear Model *** 
 
Call: lm(formula = log.S.SAL ~ Day + SS + GEN, data =  
 NIAAA.d.14.SAL.DA.time.assess.041108, na.action = na.exclude) 
Residuals: 
    Min      1Q   Median     3Q   Max  
 -1.579 -0.2889 -0.01269 0.2943 1.182 
 
Coefficients: 
               Value Std. Error  t value Pr(>|t|)  
(Intercept)   1.5160   0.1125    13.4803   0.0000 
        Day   0.0337   0.0072     4.7046   0.0000 
         SS  -0.0125   0.0451    -0.2780   0.7814 
        GEN   0.1234   0.0748     1.6497   0.1009 
 
Residual standard error: 0.4895 on 168 degrees of freedom 
Multiple R-Squared: 0.128  
F-statistic: 8.218 on 3 and 168 degrees of freedom, the p-value is 0.00003901  
 
 
 
 
Table O-2:  Linear model for main effects of time, SS and GEN on Log R-SAL  
 
 
*** Linear Model *** 
 
Call: lm(formula = log.R.SAL ~ Day + SS + GEN, data =  
 NIAAA.d.14.SAL.DA.time.assess.041108, na.action = na.exclude) 
Residuals: 
    Min      1Q    Median     3Q   Max  
 -2.537 -0.4059 0.0004769 0.4087 1.407 
 
Coefficients: 
               Value Std. Error  t value Pr(>|t|)  
(Intercept)   1.4628   0.1420    10.3005   0.0000 
        Day   0.0404   0.0090     4.4732   0.0000 
         SS  -0.0031   0.0569    -0.0538   0.9572 
        GEN   0.2270   0.0944     2.4043   0.0173 
 
Residual standard error: 0.6182 on 168 degrees of freedom 
Multiple R-Squared: 0.1313  
F-statistic: 8.467 on 3 and 168 degrees of freedom, the p-value is 0.00002852  
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Table O-3:  Linear model for main effects of time, SS and GEN on Log DA  
 
 
 *** Linear Model *** 
 
Call: lm(formula = log.DA ~ Day + SS + GEN, data =  
 NIAAA.d.14.SAL.DA.time.assess.041108, na.action = na.exclude) 
Residuals: 
   Min      1Q   Median     3Q   Max  
 -1.14 -0.1661 -0.02412 0.1347 1.046 
 
Coefficients: 
               Value Std. Error  t value Pr(>|t|)  
(Intercept)   0.7457   0.0615    12.1299   0.0000 
        Day   0.0051   0.0039     1.3100   0.1920 
         SS  -0.0439   0.0246    -1.7798   0.0769 
        GEN   0.0505   0.0409     1.2348   0.2186 
 
Residual standard error: 0.2676 on 168 degrees of freedom 
Multiple R-Squared: 0.03693  
F-statistic: 2.148 on 3 and 168 degrees of freedom, the p-value is 0.09615  
 
 
 
Table O-4:  ANOVA model for main effects of SS and GEN on Log S-SAL Day 1 
 
 
*** Analysis of Variance Model *** 
 
Short Output: 
Call: 
   aov(formula = Log.S.SAL.d.1 ~ SS + GEN + SS:GEN, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.041108, na.action = na.exclude) 
 
Terms: 
                      SS      GEN   SS:GEN Residuals  
 Sum of Squares 0.404638 0.357304 0.531942  7.420785 
Deg. of Freedom        2        1        2        29 
 
Residual standard error: 0.5058548  
Estimated effects may be unbalanced 
 
          Df Sum of Sq   Mean Sq  F Value     Pr(F)  
       SS  2  0.404638 0.2023190 0.790651 0.4630836 
      GEN  1  0.357304 0.3573041 1.396324 0.2469397 
   SS:GEN  2  0.531942 0.2659710 1.039400 0.3664710 
Residuals 29  7.420785 0.2558891                    
 
Residual standard error: 0.5059 on 29 degrees of freedom 
Multiple R-Squared: 0.1485  
F-statistic: 1.011 on 5 and 29 degrees of freedom, the p-value is 0.4289  
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Table O-5:  ANOVA model for main effects of SS and GEN on Log R-SAL Day 1 
 
 
*** Analysis of Variance Model *** 
 
Short Output: 
Call: 
   aov(formula = Log.R.SAL.d.1 ~ SS + GEN + SS:GEN, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.041108, na.action = na.exclude) 
 
Terms: 
                      SS      GEN   SS:GEN Residuals  
 Sum of Squares 0.078214 0.500541 0.807796  9.586996 
Deg. of Freedom        2        1        2        29 
 
Residual standard error: 0.5749662  
Estimated effects may be unbalanced 
 
          Df Sum of Sq   Mean Sq  F Value     Pr(F)  
       SS  2  0.078214 0.0391069 0.118296 0.8888598 
      GEN  1  0.500541 0.5005412 1.514103 0.2284020 
   SS:GEN  2  0.807796 0.4038981 1.221764 0.3094337 
Residuals 29  9.586996 0.3305861                    
 
Residual standard error: 0.575 on 29 degrees of freedom 
Multiple R-Squared: 0.1264  
F-statistic: 0.8388 on 5 and 29 degrees of freedom, the p-value is 0.5332  
 
  
 
Table O-6:  ANOVA model for main effects of SS and GEN on Log DA Day 1 
 
 
*** Analysis of Variance Model *** 
 
Short Output: 
Call: 
   aov(formula = Log.DA.d.1 ~ SS + GEN + SS:GEN, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.041108, na.action = na.exclude) 
 
Terms: 
                      SS      GEN   SS:GEN Residuals  
 Sum of Squares 0.196977 0.195106 0.333961  2.242850 
Deg. of Freedom        2        1        2        29 
 
Residual standard error: 0.2781001  
Estimated effects may be unbalanced 
 
          Df Sum of Sq   Mean Sq  F Value     Pr(F)  
       SS  2  0.196977 0.0984884 1.273453 0.2950514 
      GEN  1  0.195106 0.1951058 2.522713 0.1230619 
   SS:GEN  2  0.333961 0.1669806 2.159055 0.1336306 
Residuals 29  2.242850 0.0773397                    
 
Residual standard error: 0.2781 on 29 degrees of freedom 
Multiple R-Squared: 0.2446  
F-statistic: 1.878 on 5 and 29 degrees of freedom, the p-value is 0.1291 
614 
Table O-7:  ANOVA model for main effects of SS and GEN on Log S-SAL Day 15 
 
 
*** Analysis of Variance Model *** 
 
Short Output: 
Call: 
   aov(formula = Log.S.SAL.d.15 ~ SS + GEN + SS:GEN, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.041108, na.action = na.exclude) 
 
Terms: 
                      SS      GEN   SS:GEN Residuals  
 Sum of Squares 0.155235 0.327546 0.309619  5.207807 
Deg. of Freedom        2        1        2        29 
 
Residual standard error: 0.4237683  
Estimated effects may be unbalanced 
 
          Df Sum of Sq   Mean Sq  F Value     Pr(F)  
       SS  2  0.155235 0.0776174 0.432217 0.6531812 
      GEN  1  0.327546 0.3275460 1.823960 0.1872881 
   SS:GEN  2  0.309619 0.1548093 0.862065 0.4328294 
Residuals 29  5.207807 0.1795795                    
 
Residual standard error: 0.4238 on 29 degrees of freedom 
Multiple R-Squared: 0.1321  
F-statistic: 0.8825 on 5 and 29 degrees of freedom, the p-value is 0.5052  
 
 
Table O-8:  ANOVA model for main effects of SS and GEN on Log R-SAL Day 15 
 
 
*** Analysis of Variance Model *** 
 
Short Output: 
Call: 
   aov(formula = Log.R.SAL.d.15 ~ SS + GEN + SS:GEN, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.041108, na.action = na.exclude) 
 
Terms: 
                      SS      GEN   SS:GEN Residuals  
 Sum of Squares 0.129790 0.616341 0.392646  8.204339 
Deg. of Freedom        2        1        2        29 
 
Residual standard error: 0.5318912  
Estimated effects may be unbalanced 
 
          Df Sum of Sq   Mean Sq  F Value     Pr(F)  
       SS  2  0.129790 0.0648950 0.229385 0.7964508 
      GEN  1  0.616341 0.6163408 2.178589 0.1507193 
   SS:GEN  2  0.392646 0.1963232 0.693947 0.5077060 
Residuals 29  8.204339 0.2829082                    
 
Residual standard error: 0.5319 on 29 degrees of freedom 
Multiple R-Squared: 0.1219  
F-statistic: 0.8051 on 5 and 29 degrees of freedom, the p-value is 0.5554 
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Table O-9:  ANOVA model for main effects of SS and GEN on Log DA Day 15 
 
 
*** Analysis of Variance Model *** 
 
Short Output: 
Call: 
   aov(formula = Log.DA.d.15 ~ SS + GEN + SS:GEN, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.041108, na.action = na.exclude) 
 
Terms: 
                       SS       GEN    SS:GEN Residuals  
 Sum of Squares 0.0369333 0.0133690 0.1738083 0.7588887 
Deg. of Freedom         2         1         2        29 
 
Residual standard error: 0.161767  
Estimated effects may be unbalanced 
 
          Df Sum of Sq    Mean Sq  F Value     Pr(F)  
       SS  2 0.0369333 0.01846667 0.705681 0.5020544 
      GEN  1 0.0133690 0.01336899 0.510880 0.4804731 
   SS:GEN  2 0.1738083 0.08690416 3.320936 0.0502740 
Residuals 29 0.7588887 0.02616858                    
 
Residual standard error: 0.1618 on 29 degrees of freedom 
Multiple R-Squared: 0.228  
F-statistic: 1.713 on 5 and 29 degrees of freedom, the p-value is 0.1632  
 
 
Table O-10:  ANOVA model for main effects of SS and GEN on Log S-SAL GTM 
 
 
*** Analysis of Variance Model *** 
 
Short Output: 
Call: 
   aov(formula = Av.Log.S.SAL ~ SS + GEN + SS:GEN, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.041108, na.action = na.exclude) 
 
Terms: 
                      SS      GEN   SS:GEN Residuals  
 Sum of Squares 0.386512 0.084351 0.504868  2.811766 
Deg. of Freedom        2        1        2        29 
 
Residual standard error: 0.3113799  
Estimated effects may be unbalanced 
 
          Df Sum of Sq   Mean Sq  F Value     Pr(F)  
       SS  2  0.386512 0.1932561 1.993205 0.1544943 
      GEN  1  0.084351 0.0843511 0.869980 0.3586619 
   SS:GEN  2  0.504868 0.2524341 2.603555 0.0912186 
Residuals 29  2.811766 0.0969575                    
 
Residual standard error: 0.3114 on 29 degrees of freedom 
Multiple R-Squared: 0.2576  
F-statistic: 2.013 on 5 and 29 degrees of freedom, the p-value is 0.1065  
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Table O-11:  ANOVA model for main effects of SS and GEN on Log R-SAL GTM 
 
 
*** Analysis of Variance Model *** 
 
Short Output: 
Call: 
   aov(formula = Av.Log.R.SAL ~ SS + GEN + SS:GEN, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.041108, na.action = na.exclude) 
 
Terms: 
                      SS      GEN   SS:GEN Residuals  
 Sum of Squares 0.288904 0.225614 0.557630  4.321198 
Deg. of Freedom        2        1        2        29 
 
Residual standard error: 0.386014  
Estimated effects may be unbalanced 
 
          Df Sum of Sq   Mean Sq  F Value     Pr(F)  
       SS  2  0.288904 0.1444520 0.969432 0.3912530 
      GEN  1  0.225614 0.2256137 1.514116 0.2284000 
   SS:GEN  2  0.557630 0.2788149 1.871155 0.1720623 
Residuals 29  4.321198 0.1490068                    
 
Residual standard error: 0.3967 on 31 degrees of freedom 
Multiple R-Squared: 0.0954  
F-statistic: 1.09 on 3 and 31 degrees of freedom, the p-value is 0.368  
 
 
Table O-12:  ANOVA model for main effects of SS and GEN on Log DA GTM 
 
 
*** Analysis of Variance Model *** 
 
Short Output: 
Call: 
   aov(formula = Av.Log.DA ~ SS + GEN + SS:GEN, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.041108, na.action = na.exclude) 
 
Terms: 
                       SS       GEN    SS:GEN Residuals  
 Sum of Squares 0.2755988 0.0241072 0.2139152 0.9730832 
Deg. of Freedom         2         1         2        29 
 
Residual standard error: 0.1831791  
Estimated effects may be unbalanced 
 
          Df Sum of Sq   Mean Sq  F Value     Pr(F)  
       SS  2 0.2755988 0.1377994 4.106723 0.0268920 
      GEN  1 0.0241072 0.0241072 0.718446 0.4035956 
   SS:GEN  2 0.2139152 0.1069576 3.187569 0.0560593 
Residuals 29 0.9730832 0.0335546                    
 
Residual standard error: 0.1832 on 29 degrees of freedom 
Multiple R-Squared: 0.3455  
F-statistic: 3.061 on 5 and 29 degrees of freedom, the p-value is 0.0244  
617 
Table O-13:  Linear model: FTND or #cig/day and GEN on Log S-SAL GTM 
 
 
*** Linear Model *** 
 
Call: lm(formula = Av.Log.S.SAL ~ GEN + FTND, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.040508, na.action = na.exclude) 
Residuals: 
     Min      1Q  Median     3Q    Max  
 -0.5998 -0.3068 0.03356 0.2557 0.6058 
 
Coefficients: 
               Value Std. Error  t value Pr(>|t|)  
(Intercept)   1.9577   0.1057    18.5170   0.0000 
        GEN  -0.1054   0.1143    -0.9225   0.3632 
       FTND   0.0087   0.0160     0.5434   0.5906 
 
Residual standard error: 0.3379 on 32 degrees of freedom 
Multiple R-Squared: 0.03532  
F-statistic: 0.5859 on 2 and 32 degrees of freedom, the p-value is 0.5625  
 
 
 
*** Linear Model *** 
 
Call: lm(formula = Av.Log.S.SAL ~ GEN + ..cig, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.040508, na.action = na.exclude) 
Residuals: 
     Min      1Q Median     3Q    Max  
 -0.6023 -0.3328 0.0426 0.2562 0.5828 
 
Coefficients: 
               Value Std. Error  t value Pr(>|t|)  
(Intercept)   1.9837   0.0970    20.4443   0.0000 
        GEN  -0.1085   0.1150    -0.9436   0.3525 
      ..cig   0.0008   0.0042     0.1987   0.8438 
 
Residual standard error: 0.3392 on 32 degrees of freedom 
Multiple R-Squared: 0.02762  
F-statistic: 0.4545 on 2 and 32 degrees of freedom, the p-value is 0.6388  
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Table O-14:  Linear model: FTND or #cig/day and GEN on Log R-SAL GTM 
 
 
*** Linear Model *** 
 
Call: lm(formula = Av.Log.R.SAL ~ GEN + FTND, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.040508, na.action = na.exclude) 
Residuals: 
     Min      1Q  Median     3Q    Max  
 -0.8089 -0.2907 0.04535 0.2861 0.7036 
 
Coefficients: 
               Value Std. Error  t value Pr(>|t|)  
(Intercept)   2.1172   0.1248    16.9681   0.0000 
        GEN  -0.1659   0.1349    -1.2295   0.2278 
       FTND   0.0113   0.0189     0.6010   0.5521 
 
Residual standard error: 0.3988 on 32 degrees of freedom 
Multiple R-Squared: 0.05634  
F-statistic: 0.9553 on 2 and 32 degrees of freedom, the p-value is 0.3954  
 
 
 
*** Linear Model *** 
 
Call: lm(formula = Av.Log.R.SAL ~ GEN + ..cig, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.040508, na.action = na.exclude) 
Residuals: 
     Min      1Q  Median     3Q    Max  
 -0.7832 -0.3127 0.07042 0.2845 0.6785 
 
Coefficients: 
               Value Std. Error  t value Pr(>|t|)  
(Intercept)   2.1470   0.1146    18.7418   0.0000 
        GEN  -0.1705   0.1358    -1.2559   0.2182 
      ..cig   0.0014   0.0050     0.2901   0.7736 
 
Residual standard error: 0.4005 on 32 degrees of freedom 
Multiple R-Squared: 0.04819  
F-statistic: 0.8101 on 2 and 32 degrees of freedom, the p-value is 0.4537  
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Table O-15:  Linear model: FTND or #cig/day and GEN on Log DA GTM 
 
 
*** Linear Model *** 
 
Call: lm(formula = Av.Log.DA ~ GEN + FTND, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.040508, na.action = na.exclude) 
Residuals: 
     Min     1Q   Median     3Q    Max  
 -0.4196 -0.124 -0.07247 0.1278 0.4732 
 
Coefficients: 
               Value Std. Error  t value Pr(>|t|)  
(Intercept)   0.8290   0.0651    12.7259   0.0000 
        GEN  -0.0604   0.0704    -0.8580   0.3973 
       FTND  -0.0125   0.0099    -1.2687   0.2137 
 
Residual standard error: 0.2082 on 32 degrees of freedom 
Multiple R-Squared: 0.06688  
F-statistic: 1.147 on 2 and 32 degrees of freedom, the p-value is 0.3304  
 
 
 
*** Linear Model *** 
 
Call: lm(formula = Av.Log.DA ~ GEN + ..cig, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.040508, na.action = na.exclude) 
Residuals: 
     Min     1Q   Median     3Q    Max  
 -0.4184 -0.133 -0.04882 0.1359 0.4816 
 
Coefficients: 
               Value Std. Error  t value Pr(>|t|)  
(Intercept)   0.8207   0.0593    13.8505   0.0000 
        GEN  -0.0517   0.0702    -0.7367   0.4667 
      ..cig  -0.0036   0.0026    -1.3966   0.1721 
 
Residual standard error: 0.2072 on 32 degrees of freedom 
Multiple R-Squared: 0.07625  
F-statistic: 1.321 on 2 and 32 degrees of freedom, the p-value is 0.2811  
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Table O-16:  Linear model: FTND or #cig/day and GEN on Log S-SAL Day 1 
 
 
 
 
*** Linear Model *** 
 
Call: lm(formula = Log.S.SAL.d.1 ~ GEN + FTND, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.040508, na.action = na.exclude) 
Residuals: 
    Min      1Q Median     3Q   Max  
 -1.583 -0.2234 0.1005 0.3107 1.119 
 
Coefficients: 
               Value Std. Error  t value Pr(>|t|)  
(Intercept)   1.6712   0.1593    10.4925   0.0000 
        GEN  -0.2112   0.1722    -1.2263   0.2290 
       FTND  -0.0092   0.0241    -0.3832   0.7041 
 
Residual standard error: 0.5091 on 32 degrees of freedom 
Multiple R-Squared: 0.04842  
F-statistic: 0.8142 on 2 and 32 degrees of freedom, the p-value is 0.452  
 
 
 
*** Linear Model *** 
 
Call: lm(formula = Log.S.SAL.d.1 ~ GEN + ..cig, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.040508, na.action = na.exclude) 
Residuals: 
    Min      1Q Median     3Q   Max  
 -1.575 -0.2275 0.1261 0.3069 1.117 
 
Coefficients: 
               Value Std. Error  t value Pr(>|t|)  
(Intercept)   1.6524   0.1458    11.3348   0.0000 
        GEN  -0.2066   0.1728    -1.1960   0.2405 
      ..cig  -0.0016   0.0063    -0.2565   0.7992 
 
Residual standard error: 0.5097 on 32 degrees of freedom 
Multiple R-Squared: 0.04602  
F-statistic: 0.7718 on 2 and 32 degrees of freedom, the p-value is 0.4706  
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Table O-17:  Linear model: FTND or #cig/day and GEN on Log R-SAL Day 1 
 
 
*** Linear Model *** 
 
Call: lm(formula = Log.R.SAL.d.1 ~ GEN + FTND, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.040508, na.action = na.exclude) 
Residuals: 
    Min      1Q  Median     3Q   Max  
 -1.408 -0.4111 0.01098 0.3415 1.314 
 
Coefficients: 
              Value Std. Error t value Pr(>|t|)  
(Intercept)  1.6481  0.1787     9.2217  0.0000  
        GEN -0.2430  0.1932    -1.2574  0.2177  
       FTND -0.0069  0.0270    -0.2548  0.8005  
 
Residual standard error: 0.5712 on 32 degrees of freedom 
Multiple R-Squared: 0.0485  
F-statistic: 0.8155 on 2 and 32 degrees of freedom, the p-value is 0.4514  
 
 
 
*** Linear Model *** 
 
Call: lm(formula = Log.R.SAL.d.1 ~ GEN + ..cig, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.040508, na.action = na.exclude) 
Residuals: 
    Min      1Q  Median     3Q   Max  
 -1.403 -0.4092 0.02338 0.3539 1.312 
 
Coefficients: 
               Value Std. Error  t value Pr(>|t|)  
(Intercept)   1.6357   0.1635    10.0073   0.0000 
        GEN  -0.2393   0.1937    -1.2356   0.2256 
      ..cig  -0.0013   0.0071    -0.1889   0.8514 
 
Residual standard error: 0.5715 on 32 degrees of freedom 
Multiple R-Squared: 0.04763  
F-statistic: 0.8002 on 2 and 32 degrees of freedom, the p-value is 0.458  
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Table O-18:  Linear model: FTND or #cig/day and GEN on Log DA Day 1 
 
 
 
*** Linear Model *** 
 
Call: lm(formula = Log.DA.d.1 ~ GEN + FTND, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.040508, na.action = na.exclude) 
Residuals: 
     Min      1Q   Median    3Q   Max  
 -0.6615 -0.1592 -0.01597 0.112 1.002 
 
Coefficients: 
              Value Std. Error t value Pr(>|t|)  
(Intercept)  0.8020  0.0917     8.7459  0.0000  
        GEN -0.1560  0.0992    -1.5733  0.1255  
       FTND -0.0047  0.0139    -0.3363  0.7389  
 
Residual standard error: 0.2931 on 32 degrees of freedom 
Multiple R-Squared: 0.07417  
F-statistic: 1.282 on 2 and 32 degrees of freedom, the p-value is 0.2914  
 
 
*** Linear Model *** 
 
Call: lm(formula = Log.DA.d.1 ~ GEN + ..cig, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.040508, na.action = na.exclude) 
Residuals: 
     Min      1Q   Median    3Q   Max  
 -0.6591 -0.1536 -0.01238 0.121 1.008 
 
Coefficients: 
              Value Std. Error t value Pr(>|t|)  
(Intercept)  0.7956  0.0839     9.4876  0.0000  
        GEN -0.1532  0.0994    -1.5418  0.1330  
      ..cig -0.0011  0.0036    -0.2952  0.7698  
 
Residual standard error: 0.2932 on 32 degrees of freedom 
Multiple R-Squared: 0.07343  
F-statistic: 1.268 on 2 and 32 degrees of freedom, the p-value is 0.2952  
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Table O-19:  Linear model: FTND or #cig/day and GEN on Log S-SAL Day 15 
 
 
 
*** Linear Model *** 
 
Call: lm(formula = Log.S.SAL.d.15 ~ GEN + FTND, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.040508, na.action = na.exclude) 
Residuals: 
     Min      1Q  Median     3Q    Max  
 -0.9397 -0.2655 0.01889 0.2384 0.8188 
 
Coefficients: 
               Value Std. Error  t value Pr(>|t|)  
(Intercept)   1.9870   0.1296    15.3343   0.0000 
        GEN  -0.1942   0.1401    -1.3863   0.1752 
       FTND   0.0195   0.0196     0.9957   0.3269 
 
Residual standard error: 0.4141 on 32 degrees of freedom 
Multiple R-Squared: 0.08527  
F-statistic: 1.492 on 2 and 32 degrees of freedom, the p-value is 0.2402  
 
 
 
*** Linear Model *** 
 
Call: lm(formula = Log.S.SAL.d.15 ~ GEN + ..cig, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.040508, na.action = na.exclude) 
Residuals: 
     Min     1Q    Median     3Q    Max  
 -0.9868 -0.215 -0.001007 0.2376 0.7486 
 
Coefficients: 
               Value Std. Error  t value Pr(>|t|)  
(Intercept)   2.0075   0.1185    16.9349   0.0000 
        GEN  -0.2067   0.1405    -1.4715   0.1509 
      ..cig   0.0050   0.0051     0.9703   0.3392 
 
Residual standard error: 0.4145 on 32 degrees of freedom 
Multiple R-Squared: 0.08389  
F-statistic: 1.465 on 2 and 32 degrees of freedom, the p-value is 0.2461  
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Table O-20:  Linear model: FTND or #cig/day and GEN on Log R-SAL Day 15 
 
 
 
*** Linear Model *** 
 
Call: lm(formula = Log.R.SAL.d.15 ~ GEN + FTND, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.040508, na.action = na.exclude) 
Residuals: 
    Min      1Q  Median     3Q    Max  
 -1.339 -0.2579 0.04198 0.3555 0.9668 
 
Coefficients: 
               Value Std. Error  t value Pr(>|t|)  
(Intercept)   2.1039   0.1616    13.0219   0.0000 
        GEN  -0.2651   0.1747    -1.5172   0.1390 
       FTND   0.0200   0.0244     0.8191   0.4188 
 
Residual standard error: 0.5164 on 32 degrees of freedom 
Multiple R-Squared: 0.08666  
F-statistic: 1.518 on 2 and 32 degrees of freedom, the p-value is 0.2345  
 
 
 
*** Linear Model *** 
 
Call: lm(formula = Log.R.SAL.d.15 ~ GEN + ..cig, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.040508, na.action = na.exclude) 
Residuals: 
    Min     1Q  Median     3Q    Max  
 -1.395 -0.267 0.04639 0.3433 0.8795 
 
Coefficients: 
               Value Std. Error  t value Pr(>|t|)  
(Intercept)   2.1178   0.1474    14.3662   0.0000 
        GEN  -0.2789   0.1747    -1.5967   0.1202 
      ..cig   0.0057   0.0064     0.8924   0.3789 
 
Residual standard error: 0.5154 on 32 degrees of freedom 
Multiple R-Squared: 0.09015  
F-statistic: 1.585 on 2 and 32 degrees of freedom, the p-value is 0.2206  
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Table O-21:  Linear model: FTND or #cig/day and GEN on Log DA Day 15 
 
 
 
*** Linear Model *** 
 
Call: lm(formula = Log.DA.d.15 ~ GEN + FTND, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.040508, na.action = na.exclude) 
Residuals: 
     Min      1Q   Median     3Q    Max  
 -0.2844 -0.1342 -0.02744 0.0747 0.4999 
 
Coefficients: 
               Value Std. Error  t value Pr(>|t|)  
(Intercept)   0.7631   0.0544    14.0380   0.0000 
        GEN  -0.0416   0.0588    -0.7075   0.4844 
       FTND  -0.0023   0.0082    -0.2783   0.7826 
 
Residual standard error: 0.1737 on 32 degrees of freedom 
Multiple R-Squared: 0.01746  
F-statistic: 0.2843 on 2 and 32 degrees of freedom, the p-value is 0.7544  
 
 
 
*** Linear Model *** 
 
Call: lm(formula = Log.DA.d.15 ~ GEN + ..cig, data =  
 LOG.SAL.Data.NIAAA.Detox.d1.d15.AVG.040508, na.action = na.exclude) 
Residuals: 
    Min      1Q  Median      3Q    Max  
 -0.268 -0.1356 -0.0329 0.06635 0.4918 
 
Coefficients: 
               Value Std. Error  t value Pr(>|t|)  
(Intercept)   0.7685   0.0495    15.5263   0.0000 
        GEN  -0.0390   0.0587    -0.6641   0.5114 
      ..cig  -0.0012   0.0021    -0.5723   0.5711 
 
Residual standard error: 0.1731 on 32 degrees of freedom 
Multiple R-Squared: 0.02506  
F-statistic: 0.4113 on 2 and 32 degrees of freedom, the p-value is 0.6662 
 
 
 
 
 
 
 
 
 
 
 
 
 
626 
Table O-22:  Linear model: TLFB on Log S-SAL GTM 
 
 
*** Linear Model *** 
 
Call: lm(formula = Av.Log.S.SAL ~ TLFB..90., data = COV.ANALYSIS.41208, 
na.action = na.exclude) 
 
Residuals: 
     Min      1Q  Median     3Q    Max  
 -0.6332 -0.2766 0.05041 0.2253 0.6245 
 
Coefficients: 
               Value Std. Error  t value Pr(>|t|)  
(Intercept)   2.0715   0.1014    20.4327   0.0000 
  TLFB..90.  -0.0001   0.0001    -1.5593   0.1285 
 
Residual standard error: 0.327 on 33 degrees of freedom 
Multiple R-Squared: 0.06862  
F-statistic: 2.431 on 1 and 33 degrees of freedom, the p-value is 0.1285 
 
 
 
Table O-23:  Linear model: TLFB on Log R-SAL GTM 
 
 
*** Linear Model *** 
 
Call: lm(formula = Av.Log.R.SAL ~ TLFB..90., data = COV.ANALYSIS.41208, 
na.action = na.exclude) 
 
Residuals: 
     Min      1Q  Median    3Q    Max  
 -0.7282 -0.2831 0.04199 0.271 0.6894 
 
Coefficients: 
               Value Std. Error  t value Pr(>|t|)  
(Intercept)   2.2199   0.1219    18.2181   0.0000 
  TLFB..90.  -0.0001   0.0001    -1.3868   0.1748 
 
Residual standard error: 0.393 on 33 degrees of freedom 
Multiple R-Squared: 0.05507  
F-statistic: 1.923 on 1 and 33 degrees of freedom, the p-value is 0.1748  
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Table O-24:  Linear model: TLFB on Log DA GTM 
 
 
*** Linear Model *** 
 
Call: lm(formula = Av.Log.DA ~ TLFB..90., data = COV.ANALYSIS.41208, na.action 
= na.exclude) 
 
Residuals: 
     Min     1Q   Median     3Q    Max  
 -0.3673 -0.132 -0.03049 0.1246 0.5372 
 
Coefficients: 
               Value Std. Error  t value Pr(>|t|)  
(Intercept)   0.7751   0.0656    11.8238   0.0000 
  TLFB..90.   0.0000   0.0001    -0.5137   0.6109 
 
Residual standard error: 0.2114 on 33 degrees of freedom 
Multiple R-Squared: 0.007932  
F-statistic: 0.2638 on 1 and 33 degrees of freedom, the p-value is 0.6109  
 
 
 
Table O-25:  Linear model: ACAMP on Log S-SAL GTM 
 
 
*** Linear Model *** 
 
Call: lm(formula = Av.Log.S.SAL ~ ACAMP, data = COV.ANALYSIS.41208, na.action 
= na.exclude) 
 
Residuals: 
     Min      1Q  Median     3Q    Max  
 -0.6062 -0.2748 0.01026 0.2228 0.5399 
 
Coefficients: 
              Value Std. Error t value Pr(>|t|)  
(Intercept)  1.8986  0.1068    17.7754  0.0000  
      ACAMP  0.0565  0.1264     0.4471  0.6577  
 
Residual standard error: 0.3378 on 33 degrees of freedom 
Multiple R-Squared: 0.00602  
F-statistic: 0.1999 on 1 and 33 degrees of freedom, the p-value is 0.6577  
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Table O-26:  Linear model: ACAMP on Log R-SAL GTM 
   
 
*** Linear Model *** 
 
Call: lm(formula = Av.Log.R.SAL ~ ACAMP, data = COV.ANALYSIS.41208, na.action 
= na.exclude) 
 
Residuals: 
     Min      1Q   Median    3Q    Max  
 -0.8786 -0.2586 0.002235 0.257 0.6849 
 
Coefficients: 
              Value Std. Error t value Pr(>|t|)  
(Intercept)  2.0512  0.1277    16.0601  0.0000  
      ACAMP  0.0379  0.1511     0.2509  0.8035  
 
Residual standard error: 0.4039 on 33 degrees of freedom 
Multiple R-Squared: 0.001904  
F-statistic: 0.06294 on 1 and 33 degrees of freedom, the p-value is 0.8035  
 
 
 
Table O-27:  Linear model: ACAMP on Log R-SAL GTM 
 
 
*** Linear Model *** 
 
Call: lm(formula = Av.Log.DA ~ ACAMP, data = COV.ANALYSIS.41208, na.action =  
 na.exclude) 
 
Residuals: 
     Min      1Q  Median     3Q    Max  
 -0.3362 -0.1452 -0.0249 0.1158 0.5449 
 
Coefficients: 
              Value Std. Error t value Pr(>|t|)  
(Intercept)  0.7207  0.0669    10.7719  0.0000  
      ACAMP  0.0367  0.0792     0.4631  0.6463  
 
Residual standard error: 0.2116 on 33 degrees of freedom 
Multiple R-Squared: 0.006458  
F-statistic: 0.2145 on 1 and 33 degrees of freedom, the p-value is 0.6463  
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Table O-28:  Regression and ANCOVA: TLFB on Log S-SAL Day 1 
 
 
*** Linear Model *** 
 
Call: lm(formula = Log.S.SAL.d.1 ~ TLFB..90., data = COV.ANALYSIS.41208, 
na.action 
  = na.exclude) 
Residuals: 
    Min    1Q Median    3Q  Max  
 -1.489 -0.31 0.1064 0.296 1.08 
 
Coefficients: 
               Value Std. Error  t value Pr(>|t|)  
(Intercept)   1.7201   0.1541    11.1623   0.0000 
  TLFB..90.  -0.0002   0.0001    -1.5114   0.1402 
 
Residual standard error: 0.497 on 33 degrees of freedom 
Multiple R-Squared: 0.06474  
F-statistic: 2.284 on 1 and 33 degrees of freedom, the p-value is 0.1402  
 
 
*** Analysis of Variance Model *** 
 
Short Output: 
Call: 
   aov(formula = Log.S.SAL.d.1 ~ SS + GEN + SS:GEN + TLFB..90., data =  
 COV.ANALYSIS.41208, na.action = na.exclude) 
 
Terms: 
                      SS      GEN TLFB..90.   SS:GEN Residuals  
 Sum of Squares 0.404638 0.357304  0.174893 0.597973  7.179861 
Deg. of Freedom        2        1         1        2        28 
 
Residual standard error: 0.5063829  
Estimated effects may be unbalanced 
 
          Df Sum of Sq   Mean Sq  F Value     Pr(F)  
       SS  2  0.404638 0.2023190 0.789003 0.4641389 
      GEN  1  0.357304 0.3573041 1.393413 0.2477607 
TLFB..90.  1  0.174893 0.1748931 0.682048 0.4158642 
   SS:GEN  2  0.597973 0.2989863 1.165986 0.3262898 
Residuals 28  7.179861 0.2564236        
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Table O-29:  Regression and ANCOVA: TLFB on Log R-SAL Day 1 
 
 
 
*** Linear Model *** 
 
Call: lm(formula = Log.R.SAL.d.1 ~ TLFB..90., data = COV.ANALYSIS.41208, 
na.action 
  = na.exclude) 
Residuals: 
    Min      1Q Median     3Q   Max  
 -1.745 -0.2703 0.1181 0.4162 1.292 
 
Coefficients: 
              Value Std. Error t value Pr(>|t|)  
(Intercept)  1.6936  0.1843     9.1893  0.0000  
  TLFB..90. -0.0002  0.0002    -1.3689  0.1803  
 
Residual standard error: 0.5944 on 33 degrees of freedom 
Multiple R-Squared: 0.05374  
F-statistic: 1.874 on 1 and 33 degrees of freedom, the p-value is 0.1803  
 
 
 
*** Analysis of Variance Model *** 
 
Short Output: 
Call: 
   aov(formula = Log.R.SAL.d.1 ~ SS + GEN + SS:GEN + TLFB..90., data =  
 COV.ANALYSIS.41208, na.action = na.exclude) 
 
Terms: 
                      SS      GEN TLFB..90.   SS:GEN Residuals  
 Sum of Squares  0.13377  0.38933   0.31112  1.15898  10.32713 
Deg. of Freedom        2        1         1        2        28 
 
Residual standard error: 0.6073106  
Estimated effects may be unbalanced 
 
          Df Sum of Sq   Mean Sq  F Value     Pr(F)  
       SS  2   0.13377 0.0668843 0.181344 0.8351204 
      GEN  1   0.38933 0.3893300 1.055592 0.3130170 
TLFB..90.  1   0.31112 0.3111247 0.843554 0.3662269 
   SS:GEN  2   1.15898 0.5794899 1.571174 0.2255764 
Residuals 28  10.32713 0.3688261                    
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Table O-30:  Regression and ANCOVA: TLFB on Log DA Day 1 
 
 
 
*** Linear Model *** 
 
Call: lm(formula = Log.DA.d.1 ~ TLFB..90., data = COV.ANALYSIS.41208, 
na.action =  
 na.exclude) 
Residuals: 
     Min      1Q   Median     3Q    Max  
 -0.5607 -0.1329 -0.01419 0.1573 0.4198 
 
Coefficients: 
              Value Std. Error t value Pr(>|t|)  
(Intercept)  0.7313  0.0743     9.8376  0.0000  
  TLFB..90.  0.0000  0.0001    -0.7656  0.4494  
 
Residual standard error: 0.2397 on 33 degrees of freedom 
Multiple R-Squared: 0.01745  
F-statistic: 0.5861 on 1 and 33 degrees of freedom, the p-value is 0.4494  
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Table O-31:  Regression and ANCOVA: BrAC on Log S-SAL Day 1 
 
 
*** Linear Model *** 
 
Call: lm(formula = Log.S.SAL.d.1 ~ BrAC, data = COV.ANALYSIS.41208, na.action 
= na.exclude) 
 
Residuals: 
    Min      1Q Median     3Q   Max  
 -1.275 -0.3314 0.1402 0.2413 1.122 
 
Coefficients: 
               Value Std. Error  t value Pr(>|t|)  
(Intercept)   1.6316   0.1052    15.5050   0.0000 
       BrAC  -0.2874   0.1727    -1.6647   0.1054 
 
Residual standard error: 0.4936 on 33 degrees of freedom 
Multiple R-Squared: 0.07747  
F-statistic: 2.771 on 1 and 33 degrees of freedom, the p-value is 0.1054  
 
 
  
*** Analysis of Variance Model *** 
 
Short Output: 
Call: 
   aov(formula = Log.S.SAL.d.1 ~ SS + GEN + BrAC + SS:BrAC, data =  
 COV.ANALYSIS.41208, na.action = na.exclude) 
 
Terms: 
                      SS      GEN     BrAC  SS:BrAC Residuals  
 Sum of Squares 0.404638 0.357304 0.563675 0.055005  7.334047 
Deg. of Freedom        2        1        1        2        28 
 
Residual standard error: 0.5117912  
Estimated effects may be unbalanced 
 
          Df Sum of Sq   Mean Sq  F Value     Pr(F)  
       SS  2  0.404638 0.2023190 0.772416 0.4714887 
      GEN  1  0.357304 0.3573041 1.364119 0.2526742 
     BrAC  1  0.563675 0.5636746 2.152003 0.1535270 
  SS:BrAC  2  0.055005 0.0275026 0.105000 0.9006774 
Residuals 28  7.334047 0.2619302                    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
633 
Table O-32:  Regression and ANCOVA: BrAC on Log R-SAL Day 1 
 
 
 
*** Linear Model *** 
 
Call: lm(formula = Log.R.SAL.d.1 ~ BrAC, data = COV.ANALYSIS.41208, na.action 
= na.exclude) 
 
Residuals: 
    Min      1Q  Median     3Q   Max  
 -1.515 -0.3028 0.05519 0.3786 1.338 
 
Coefficients: 
               Value Std. Error  t value Pr(>|t|)  
(Intercept)   1.5964   0.1261    12.6584   0.0000 
       BrAC  -0.3077   0.2069    -1.4870   0.1465 
 
Residual standard error: 0.5915 on 33 degrees of freedom 
Multiple R-Squared: 0.0628  
F-statistic: 2.211 on 1 and 33 degrees of freedom, the p-value is 0.1465 
 
 
 
*** Analysis of Variance Model *** 
 
Short Output: 
Call: 
   aov(formula = Log.R.SAL.d.1 ~ SS + GEN + BrAC + SS:BrAC, data =  
 COV.ANALYSIS.41208, na.action = na.exclude) 
 
Terms: 
                      SS      GEN     BrAC  SS:BrAC Residuals  
 Sum of Squares  0.13377  0.38933  0.78504  0.15329  10.85890 
Deg. of Freedom        2        1        1        2        28 
 
Residual standard error: 0.6227502  
Estimated effects may be unbalanced 
 
          Df Sum of Sq   Mean Sq  F Value     Pr(F)  
       SS  2   0.13377 0.0668843 0.172463 0.8424764 
      GEN  1   0.38933 0.3893300 1.003899 0.3249496 
     BrAC  1   0.78504 0.7850445 2.024261 0.1658507 
  SS:BrAC  2   0.15329 0.0766467 0.197636 0.8218036 
Residuals 28  10.85890 0.3878178                    
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Table O-33:  Regression and ANCOVA: BrAC on Log DA Day 1 
 
 
*** Linear Model *** 
 
Call: lm(formula = Log.DA.d.1 ~ BrAC, data = COV.ANALYSIS.41208, na.action =  
 na.exclude) 
Residuals: 
     Min      1Q   Median     3Q    Max  
 -0.5407 -0.1342 -0.03163 0.1595 0.4436 
 
Coefficients: 
               Value Std. Error  t value Pr(>|t|)  
(Intercept)   0.6905   0.0515    13.4012   0.0000 
       BrAC  -0.0186   0.0845    -0.2205   0.8268 
 
Residual standard error: 0.2417 on 33 degrees of freedom 
Multiple R-Squared: 0.001471  
F-statistic: 0.04863 on 1 and 33 degrees of freedom, the p-value is 0.8268 
 
 
*** Analysis of Variance Model *** 
 
Short Output: 
Call: 
   aov(formula = Log.DA.d.1 ~ SS + GEN + BrAC + SS:BrAC, data =  
 COV.ANALYSIS.41208, na.action = na.exclude) 
 
Terms: 
                      SS      GEN     BrAC  SS:BrAC Residuals  
 Sum of Squares 0.114532 0.107844 0.001429 0.011235  1.695221 
Deg. of Freedom        2        1        1        2        28 
 
Residual standard error: 0.2460561  
Estimated effects may be unbalanced 
 
          Df Sum of Sq   Mean Sq  F Value     Pr(F)  
       SS  2  0.114532 0.0572659 0.945863 0.4004042 
      GEN  1  0.107844 0.1078437 1.781256 0.1927473 
     BrAC  1  0.001429 0.0014292 0.023606 0.8789927 
  SS:BrAC  2  0.011235 0.0056176 0.092786 0.9116676 
Residuals 28  1.695221 0.0605436                    
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Table O-34:  Regression and ANCOVA: Admit Drug of Abuse on Log S-SAL Day 1 
 
 
*** Linear Model *** 
 
Call: lm(formula = Log.S.SAL.d.1 ~ Admit.DOA, data = COV.ANALYSIS.41208, 
na.action 
  = na.exclude) 
Residuals: 
    Min      1Q  Median     3Q   Max  
 -1.394 -0.2919 0.05191 0.3164 1.192 
 
Coefficients: 
               Value Std. Error  t value Pr(>|t|)  
(Intercept)   1.5613   0.1091    14.3149   0.0000 
  Admit.DOA  -0.0980   0.1790    -0.5479   0.5875 
 
Residual standard error: 0.5116 on 33 degrees of freedom 
Multiple R-Squared: 0.009014  
F-statistic: 0.3002 on 1 and 33 degrees of freedom, the p-value is 0.5875  
 
 
*** Analysis of Variance Model *** 
 
Short Output: 
Call: 
   aov(formula = Log.S.SAL.d.1 ~ SS + GEN + Admit.DOA + SS:Admit.DOA, data =  
 COV.ANALYSIS.41208, na.action = na.exclude) 
 
Terms: 
                      SS      GEN Admit.DOA SS:Admit.DOA Residuals  
 Sum of Squares 0.404638 0.357304  0.057277     0.334592  7.560858 
Deg. of Freedom        2        1         1            2        28 
 
Residual standard error: 0.5196447  
Estimated effects may be unbalanced 
 
             Df Sum of Sq   Mean Sq  F Value     Pr(F)  
          SS  2  0.404638 0.2023190 0.749245 0.4819652 
         GEN  1  0.357304 0.3573041 1.323198 0.2597487 
   Admit.DOA  1  0.057277 0.0572768 0.212112 0.6486740 
SS:Admit.DOA  2  0.334592 0.1672958 0.619544 0.5454048 
   Residuals 28  7.560858 0.2700306                    
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Table O-35:  Regression and ANCOVA: Admit Drug of Abuse on Log R-SAL Day 1 
 
 
 
*** Linear Model *** 
 
Call: lm(formula = Log.R.SAL.d.1 ~ Admit.DOA, data = COV.ANALYSIS.41208, 
na.action 
  = na.exclude) 
Residuals: 
   Min     1Q  Median     3Q   Max  
 -1.61 -0.377 0.06613 0.4493 1.394 
 
Coefficients: 
               Value Std. Error  t value Pr(>|t|)  
(Intercept)   1.5404   0.1292    11.9223   0.0000 
  Admit.DOA  -0.1569   0.2120    -0.7402   0.4644 
 
Residual standard error: 0.606 on 33 degrees of freedom 
Multiple R-Squared: 0.01633  
F-statistic: 0.5478 on 1 and 33 degrees of freedom, the p-value is 0.4644  
 
 
 
*** Analysis of Variance Model *** 
 
Short Output: 
Call: 
   aov(formula = Log.R.SAL.d.1 ~ SS + GEN + Admit.DOA + SS:Admit.DOA, data =  
 COV.ANALYSIS.41208, na.action = na.exclude) 
 
Terms: 
                      SS      GEN Admit.DOA SS:Admit.DOA Residuals  
 Sum of Squares  0.13377  0.38933   0.17225      0.29998  11.32501 
Deg. of Freedom        2        1         1            2        28 
 
Residual standard error: 0.6359754  
Estimated effects may be unbalanced 
 
             Df Sum of Sq   Mean Sq   F Value     Pr(F)  
          SS  2   0.13377 0.0668843 0.1653650 0.8484060 
         GEN  1   0.38933 0.3893300 0.9625807 0.3349394 
   Admit.DOA  1   0.17225 0.1722461 0.4258619 0.5193487 
SS:Admit.DOA  2   0.29998 0.1499889 0.3708330 0.6934981 
   Residuals 28  11.32501 0.4044647                     
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Table O-36:  Regression and ANCOVA: Admit Drug of Abuse on Log DA Day 1 
 
 
 *** Linear Model *** 
 
Call: lm(formula = Log.DA.d.1 ~ Admit.DOA, data = COV.ANALYSIS.41208, 
na.action =  
 na.exclude) 
Residuals: 
     Min      1Q   Median     3Q    Max  
 -0.5689 -0.1256 -0.03078 0.1596 0.4603 
 
Coefficients: 
              Value Std. Error t value Pr(>|t|)  
(Intercept)  0.6738  0.0515    13.0865  0.0000  
  Admit.DOA  0.0264  0.0845     0.3119  0.7571  
 
Residual standard error: 0.2415 on 33 degrees of freedom 
Multiple R-Squared: 0.002939  
F-statistic: 0.09729 on 1 and 33 degrees of freedom, the p-value is 0.7571  
 
 
 
 *** Analysis of Variance Model *** 
 
Short Output: 
Call: 
   aov(formula = Log.DA.d.1 ~ SS + GEN + Admit.DOA + SS:Admit.DOA, data =  
 COV.ANALYSIS.41208, na.action = na.exclude) 
 
Terms: 
                      SS      GEN Admit.DOA SS:Admit.DOA Residuals  
 Sum of Squares 0.114532 0.107844  0.007380     0.040886  1.659619 
Deg. of Freedom        2        1         1            2        28 
 
Residual standard error: 0.2434586  
Estimated effects may be unbalanced 
 
             Df Sum of Sq   Mean Sq  F Value     Pr(F)  
          SS  2  0.114532 0.0572659 0.966153 0.3928709 
         GEN  1  0.107844 0.1078437 1.819468 0.1881854 
   Admit.DOA  1  0.007380 0.0073800 0.124510 0.7268365 
SS:Admit.DOA  2  0.040886 0.0204431 0.344903 0.7112561 
   Residuals 28  1.659619 0.0592721                    
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Table O-37:  Regression: AST on Log S- and R-SAL Day 1 
 
 
*** Linear Model *** 
 
Call: lm(formula = Log.S.SAL.d.1 ~ AST.U.L, data = COV.ANALYSIS.41208, 
na.action =  
 na.exclude) 
Residuals: 
    Min      1Q Median     3Q  Max  
 -1.309 -0.1192 0.1088 0.2266 1.07 
 
Coefficients: 
               Value Std. Error  t value Pr(>|t|)  
(Intercept)   1.7380   0.1205    14.4206   0.0000 
    AST.U.L  -0.0037   0.0015    -2.4455   0.0202 
 
Residual standard error: 0.4788 on 32 degrees of freedom 
Multiple R-Squared: 0.1575  
F-statistic: 5.98 on 1 and 32 degrees of freedom, the p-value is 0.02015  
1 observations deleted due to missing values  
 
 
 
 *** Linear Model *** 
 
Call: lm(formula = Log.R.SAL.d.1 ~ AST.U.L, data = COV.ANALYSIS.41208, 
na.action =  
 na.exclude) 
Residuals: 
    Min      1Q Median     3Q   Max  
 -1.524 -0.3227 0.1268 0.3586 1.241 
 
Coefficients: 
               Value Std. Error  t value Pr(>|t|)  
(Intercept)   1.7650   0.1407    12.5456   0.0000 
    AST.U.L  -0.0048   0.0017    -2.7232   0.0104 
 
Residual standard error: 0.5589 on 32 degrees of freedom 
Multiple R-Squared: 0.1881  
F-statistic: 7.416 on 1 and 32 degrees of freedom, the p-value is 0.01038  
1 observations deleted due to missing values  
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Table O-38:  Regression model for main effects of time on CIWA-AR 
                 
 
*** Linear Model *** 
 
Call: lm(formula = CIWA ~ DAY, data = CIWA.AR.ANAL.041208, na.action = 
na.exclude) 
Residuals: 
    Min     1Q  Median    3Q  Max  
 -6.295 -3.323 -0.8511 2.149 11.7 
 
Coefficients: 
              Value Std. Error t value Pr(>|t|)  
(Intercept)  7.7389  1.1081     6.9839  0.0000  
        DAY -1.4439  0.5178    -2.7886  0.0064  
 
Residual standard error: 4.205 on 98 degrees of freedom 
Multiple R-Squared: 0.07352  
F-statistic: 7.776 on 1 and 98 degrees of freedom, the p-value is 0.00636 
 
 
 
 
 
Table O-39:  Regression model for main effects of SS and GEN on CIWA-AR 
 
 
*** Linear Model *** 
 
Call: lm(formula = CIWA ~ DAY + SS + GEN, data = CIWA.AR.ANAL.041208, 
na.action =  
 na.exclude) 
Residuals: 
    Min     1Q Median    3Q   Max  
 -6.638 -2.721 -1.005 2.123 10.42 
 
Coefficients: 
              Value Std. Error t value Pr(>|t|)  
(Intercept)  9.4308  1.2817     7.3581  0.0000  
        DAY -1.3893  0.5083    -2.7330  0.0075  
       SSLS -1.2979  1.0339    -1.2553  0.2124  
       SSNS -1.4035  0.9872    -1.4217  0.1584  
        GEN -1.7750  0.8257    -2.1497  0.0341  
 
 
Multiple R-Squared: 0.1359  
F-statistic: 3.737 on 4 and 95 degrees of freedom, the p-value is 0.007216  
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